Document:

EX-10.3

Exhibit 10.3

EXECUTION COPY

Confidential portions of this exhibit have been omitted and filed separately with the Securities
and Exchange Commission with a request for confidential treatment pursuant to Rule 24b-2 under the
Securities Exchange Act of 1934, as amended. The location of an omitted portion is indicated by an
asterisk within brackets (“[*]”).

MASTER AGREEMENT

BY AND AMONG

MSP TECHNOLOGY (U.S.) COMPANY LLC,

MSP SINGAPORE COMPANY, LLC,

SCHERING CORPORATION,

SCHERING-PLOUGH CORPORATION,

AND

MERCK & CO., INC.

DATED AS OF

DECEMBER 18, 2001

 

 

Table
of Contents

	 	 	 	 	 
	 	 	Page	 
	 
	ARTICLE I DEFINED TERMS
	 	 	1	 
	 
	 	 	 	 
	Section 1.1. Interpretation
	 	 	1	 
	Section 1.2. Definitions
	 	 	1	 
	Section 1.3. Headings
	 	 	19	 
	Section 1.4. Intent of the Parties
	 	 	19	 
	 
	 	 	 	 
	ARTICLE
II THE ECLAFE TRANSACTIONS
	 	 	19	 
	 
	 	 	 	 
	Section 2.1. The EMEA
	 	 	19	 
	Section 2.2. Canada
	 	 	27	 
	Section 2.3. Latin America
	 	 	30	 
	Section 2.4. Far East
	 	 	30	 
	Section 2.5. Amendment of Prior Agreements and S-P ECLAFE License Agreements
	 	 	34	 
	Section 2.6. Certain Contract Manufacturing Agreements
	 	 	37	 
	Section 2.7. Toll Packaging Rights
	 	 	37	 
	 
	 	 	 	 
	ARTICLE
III MANAGEMENT
	 	 	39	 
	 
	 	 	 	 
	Section 3.1. Worldwide Oversight Committee
	 	 	39	 
	Section 3.2. Management of the EMEA
	 	 	40	 
	Section 3.3. Management of Canada
	 	 	47	 
	Section 3.4. Management of Latin America
	 	 	47	 
	Section 3.5. Management of the Far East – Co-Marketing Countries
	 	 	49	 
	Section 3.6. Management of the Far East Board Countries
	 	 	51	 
	 
	 	 	 	 
	ARTICLE
IV GOOD FAITH EFFORTS; OTHER MATTERS
	 	 	55	 
	 
	 	 	 	 
	Section 4.1. Commercially Reasonable Good Faith Efforts
	 	 	55	 
	Section 4.2. Certain Expenses
	 	 	55	 
	Section 4.3. Trademarks
	 	 	56	 
	Section 4.4. Non-Compete
	 	 	61	 
	Section 4.5. Unilateral Termination of Board Country Agreements
	 	 	61	 
	 
	 	 	 	 
	ARTICLE V DISPUTE RESOLUTION, TERMINATION, DISSOLUTION AND LIQUIDATION
	 	 	61	 
	 
	 	 	 	 
	Section 5.1. Dispute Resolution
	 	 	61	 
	Section 5.2. Termination
	 	 	61	 
	Section 5.3. Consequences of Termination
	 	 	63	 
	Section 5.4. Treatment of Master Agreement and Related Agreements
	 	 	68	 
	Section 5.5. Incorporation by Reference
	 	 	72	 

i

 

	 	 	 	 	 
	 	 	Page	 
	 
	ARTICLE
VI REPRESENTATIONS, WARRANTIES, COVENANTS AND INDEMNIFICATION
	 	 	72	 
	 
	 	 	 	 
	Section 6.1. Representations and Warranties of the Parties
	 	 	72	 
	Section 6.2. Certain Representations
	 	 	73	 
	Section 6.3. Certain Covenants
	 	 	73	 
	Section 6.4. Certain Obligations
	 	 	74	 
	Section 6.5. Indemnification
	 	 	75	 
	 
	 	 	 	 
	ARTICLE
VII MISCELLANEOUS
	 	 	77	 
	 
	 	 	 	 
	Section 7.1. Confidentiality
	 	 	77	 
	Section 7.2. Publicity
	 	 	79	 
	Section 7.3. Further Assurances
	 	 	79	 
	Section 7.4. Notices
	 	 	79	 
	Section 7.5. Failure to Pursue Remedies
	 	 	80	 
	Section 7.6. Cumulative Remedies
	 	 	80	 
	Section 7.7. Assignment; Binding Effect
	 	 	80	 
	Section 7.8. Severability
	 	 	80	 
	Section 7.9. Counterparts
	 	 	80	 
	Section 7.10. Integration
	 	 	80	 
	Section 7.11. Governing Law
	 	 	81	 
	Section 7.12. Amendments
	 	 	81	 
	Section 7.13. Judicial Proceeding
	 	 	81	 
	Section 7.14. Enforcement of Certain Rights
	 	 	82	 
	Section 7.15. No Third Party Beneficiaries
	 	 	82	 
	Section 7.16. Survival
	 	 	82	 
	Section 7.17. Sanctioned Countries
	 	 	82	 

ii

 

     This Master Agreement is dated as of December 18, 2001 (the “Effective Date”), by and
among MSP Technology (U.S.) Company LLC (“MSP Technology”), MSP Singapore Company, LLC (the
“Singapore Partnership”), Schering Corporation, Schering-Plough Corporation

(“S-P”), and Merck & Co., Inc. (“M”).

RECITALS

     WHEREAS, S-P and M have entered into a Cholesterol Governance Agreement (the “Governance
Agreement”), and certain related agreements, each dated as of May 22, 2000, with respect to the
research, development and commercialization in the United States of the Cholesterol Products; and

     WHEREAS, S-P and M desire to expand the research, development and commercialization of the
Cholesterol Products to the EMEA, Canada, Latin America and the Far East (other than Japan).

     NOW, THEREFORE, in consideration of the agreements and obligations set forth herein and for
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows:

ARTICLE I

DEFINED TERMS

     Section 1.1. Interpretation. Throughout this Agreement, nouns, pronouns and verbs
shall be construed as masculine, feminine, neuter, singular or plural, whichever shall be
applicable. All references herein to “Articles,” “Sections” and clauses shall refer to
corresponding provisions of this Agreement, unless otherwise specified.

     Section 1.2. Definitions. The terms defined for the purposes of this Agreement, have
the meanings herein specified.

     “Affiliate” means, with respect to a specified Person, any Person that directly or
indirectly controls, is controlled by, or is under common control with, the specified Person;
provided that (i) the Existing M JVs shall be deemed not to be Affiliates of M, so long as they
continue to carry on their respective businesses as presently conducted and (ii) the Existing S-P
JVs shall be deemed not to be Affiliates of S-P, so long as they continue to carry on their
respective businesses as presently conducted. As used in this definition, the term “control” means
the possession, directly or indirectly, of the power to direct or cause the direction of the
management and policies of a Person, whether through ownership of voting securities, by contract or
otherwise.

     “Agency” means any governmental regulatory authority in ECLAFE responsible for
granting or giving approvals, pricing or reimbursement with respect to a Cholesterol Product.

     “Agreement” means this Master Agreement, as it may be amended from time to time.

1

 

     “Amended Agreements” means those Agreements executed and delivered in connection with
the Governance Agreement which have been modified and amended pursuant to Section 2.5.1 of the
Agreement, and the S-P licensing Agreements relating to ECLAFE executed and delivered pursuant to
section 2.5.2.

     “Board Country Agreement” means the EMEA Board Country Agreements and the Far East
Board Country Agreements.

     “Board Country Supply Agreements” means those Supply and Distribution Agreements and
Sub-Distribution Agreements referred to in Sections 2.1(e), and (g), 2.2(a)(3), 2.4(b)(2), (3),
(4), (5) and (6) of this Agreement.

     “Board Country Subsidiary” means any subsidiary of M or S-P that is a party to (or, in
the case of a single presence Affiliate of M or S-P, subject to the provisions of) an EMEA Board
Country Agreement, a Far East Board Country Agreement or the Canada Co-Promotion Agreement (as
referenced in Section 2.2(a)(2)).

     “Calendar Quarter” means each of following three (3) month periods: (i) the period
beginning on January 1st of a given year and ending on March 31st of such
year; (ii) the period beginning on April 1st of a given year and ending on June
30th of such year; (iii) the period beginning on July 1st of a given year and
ending on September 30th of such year; and (iv) the period beginning on October
1st of a given year and ending on December 31st of such year.

     “Calendar Year” means each one year period beginning January 1st of a given
year and ending December 31st of such year.

     “Call” means a face-to-face meeting in an individual or group practice setting,
between a professional sales representative (including Specialty Representatives or Hospital
Representatives) of M or S-P or their respective Affiliates, during which a Primary Position
Detail, a Secondary Position Detail or a Tertiary Position Detail is made to a Prescriber relating
to a Cholesterol Product, provided that such meeting is consistent with and in accordance with the
procedures and policies customarily employed by such Party’s sales force responsible for performing
such activities for the majority of its other major marketed pharmaceutical products, consistently
applied.

     “Call Notice” has the meaning set forth in Section 5.3(d)(ii).

     “Call Party” has the meaning set forth in Section 5.3(d).

     “Call Price” has the meaning set forth in Section 5.3(d).

     “Canadian Agreements” means those referred to in Section 2.2(a) of the Agreement other
than Section 2.2(a)(3).

     “Canadian Partnership” has the meaning set forth in Section 2.2(a)(1).

     “Canadian Board” has the meaning set forth in Section 3.3.1.

2

 

     “Canadian General Manager” has the meaning set forth in Section 3.3.2.

     “Canadian Partnership Agreement” has the meaning set forth in Section 2.2(a)(1).

     “Central and Eastern Europe Region” means, unless otherwise determined by the EMEA
Operating Board, the following countries (and any other countries that result from the division or
consolidation of such countries): Austria, Poland, Czech Republic, Slovak Republic, Hungary,
Turkey, Lithuania, Estonia, Latvia, Croatia, Romania, Bosnia and Herzegovina, Serbia and
Montenegro, Albania, Bulgaria, Macedonia, Russia, Ukraine, Slovenia, Turkmenistan, Georgia,
Azerbaijan, Armenia, Belarus, Moldova, Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan and Mongolia.

     “Change of Control” has the meaning set forth in the Governance Agreement.

     “Cholesterol Absorption Inhibitor” means a product whose primary clinical effect is
through inhibition of the absorption of cholesterol from the diet into the plasma. [*]

     “Cholesterol Product” means the Z/E Combination Product, the Ezetimibe Monotherapy
Product or the M/E Combination Product, as appropriate. “Cholesterol Products” means all of the
foregoing.

     “Claim Notice” has the meaning set forth in Section 6.5.5.

     “C-O-C Notice” has the meaning set forth in Section 5.3(d).

     “C-O-C Party” has the meaning set forth in Section 5.3(d).

     “Co-Marketing” means, with respect to a country, the separate marketing and sale of
the Cholesterol Products under separate brands by both M and S-P (or their respective professional
sales representatives) in the country, including those activities normally undertaken by a
pharmaceutical company’s professional sales representatives of a Cholesterol Product or similar
prescription pharmaceutical product to implement marketing and educational plans and strategies
aimed at encouraging the appropriate use of a prescription pharmaceutical product. When used as a
verb, “Co-Market” shall mean to engage in such activities.

     “Co-Marketing Supply Agreements” means those Supply and Distribution Agreements
referred to in Sections 2.3(a) and 2.4(a)(1) of this Agreement.

     “Combination Product” means either or both of the Z/E Combination Product and/or the
M/E Combination Product, as appropriate.

     “Compensation Auditor” has the meaning set forth in Section 3.2.5.

     “Confidential Information” has the meaning set forth in Section 7.1(a)(1).

     “Consultant’s Report” has the meaning set forth in Section 3.2.4(b).

3

 

     “Contract Sales Force” means one or a group of independent professional sales
representatives (whether or not employed by a Third Party) and retained by M, S-P or their
respective Affiliates for the purpose of detailing pharmaceutical products; provided,
however, that independent professional sales representatives who are not employed by a Third Party
will not be treated as a member of a Party’s Contract Sales Force, (x) in countries where M or S-P
(or their Affiliates), as the case may be, generally engages independent professional sales
representatives who are not employed by a Third Party, (y) with respect to individuals who have
received substantially identical sales force training as provided to sales force employees of M or
S-P, as the case may be, and (z) with respect to individuals who are paid comparable salaries and
are eligible for comparable bonuses, in each case, as the comparable sales force employees of S-P
or M, as the case may be.

     “Co-Promotion” means, with respect to a country, the marketing of the Cholesterol
Products by both M and S-P, or their respective Affiliates, under the same brand, and the sale of
the Cholesterol Products by only one of M or S-P, or their respective Affiliates, in the country,
including those activities normally undertaken by a pharmaceutical company’s professional sales
representatives of a Cholesterol Product or similar prescription pharmaceutical product to
implement marketing and educational plans and strategies aimed at encouraging the appropriate use
of a prescription pharmaceutical product. When used as a verb, “Co-Promote” shall mean to engage
in such activities.

     “Co-Promotion Countries” means the EMEA Co-Promotion Countries and the Far East
Co-Promotion Countries.

     “Core Countries” means France, the United Kingdom, Germany, Netherlands, Spain, Italy,
Sweden and Norway.

     “Country Marketing Committee” means, (i) with respect to a Co-Promotion Country or
EMEA Co-Branding Country, the country marketing committee created pursuant to the applicable EMEA
Co-Venture Agreement, EMEA Co-Branding Agreement or Far East Co-Venture Agreement, or the
equivalent Entity Agreement, which committee shall be composed of an equal number of
representatives of S-P on the one hand and M on the other, and (ii) with respect to a Single
Presence Country, the Person that performs the equivalent Country Marketing Committee functions
under the applicable Single Presence Country Exhibit.

     “Default Marketing Plan” has the meaning set forth in Section 3.2.4(d) hereof.

     “Development Agreement” means the amended and Restated Development Agreement
(Cholesterol Combination) dated as of the date hereof, by and among the Parties, as amended from
time to time.

     “Disadvantaged Party” has the meaning set forth in Section 2.1(a).

     “Disclosing Party” has the meaning set forth in Section 7.2.

4

 

     “Distribution LLC” means MSP Distribution Services (C) LLC.

     “Distribution Party” shall have the meaning set forth in Section 3.4.1.

     “E Monotherapy ECLAFE Business” means the research, development, registration,
manufacture and/or procurement, distribution, promotion and marketing of a pharmaceutical product
which is comprised of Ezetimibe as its sole active ingredient in the Field in ECLAFE, as and to the
extent contemplated by this Agreement and any Related Agreements.

     “E Monotherapy U.S. Trademark” means the trademark used or to be used by the Parties
with respect to the registration, distribution, promotion and marketing of the Ezetimibe
Monotherapy Product in the United States.

     “ECLAFE” means the EMEA, Canada, Latin America and the Far East, and all other
countries in the world other than Japan and the U.S. Territory.

     “ECLAFE Cholesterol Business” means the Z/E ECLAFE Business, the E Monotherapy ECLAFE
Business and the M/E ECLAFE Business as conducted in or with respect to a particular territory.

     “ECLAFE Material Breach” has the meaning set forth in Section 5.2.1(a).

     “ECLAFE Termination Assets” has the meaning set forth in Section 5.3(a).

     “Effective Date” has the meaning set forth in the Recitals.

     “EMEA” means the following countries (and any other countries that result from the
division or consolidation of such countries): (i) Austria, United Kingdom, France, Germany, Italy,
Spain, Norway, Denmark, Finland, Sweden, Switzerland, Portugal, Andorra, Belgium, Greece, Holy See,
Iceland, Ireland, Liechtenstein, Luxembourg, Monaco, Netherlands, San Marino, (ii) Turkey, Poland,
Hungary, Czech Republic, Russia, Albania, Slovak Republic, Armenia, Azerbaijan, Belarus, Bosnia and
Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania,
Macedonia, Moldova, Romania, Serbia and Montenegro, Slovenia, Tajikistan, Turkmenistan, Ukraine,
Uzbekistan, and (iii) Algeria, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon,
Libya, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates, Yemen, Angola,
Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad,
Comoros, Congo, Cote d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea,
Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia,
Madagascar, Malawi, Mali, Malta, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria,
Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, Sudan,
Swaziland, Tanzania, Togo, Uganda, Zambia, Zimbabwe.

     “EMEA Board Countries” means EMEA Co-Promotion Countries, EMEA Co-Branding Countries
and EMEA Single Presence Countries.

5

 

     “EMEA Board Country Agreement” means an EMEA Co-Venture Agreement, EMEA Co-Branding
Agreement or the EMEA Single Presence Country Exhibit, as applicable.

     “EMEA Co-Branding Agreement” has the meaning set forth in Section 2.1(b)(1).

     “EMEA Co-Branding Countries” means Italy (including the Holy See and San Marino) and
countries in the EMEA where Co-Promotion is not legally permitted or which the EMEA Operating Board
designates as EMEA Co-Branding Countries, and other than EMEA Single Presence Countries and EMEA No
Presence Countries. The Parties acknowledge that the EMEA Operating Board will consider whether or
not Greece will become an EMEA Co-Branding Country. In the event the Parties desire to amend the
list of countries comprising EMEA Co-Branding Countries, such list shall be amended upon approval
of the EMEA Operating Board.

     “EMEA Co-Promotion Countries” means all countries in the EMEA, other than the EMEA
Co-Branding Countries, the EMEA Single Presence Countries and the EMEA No Presence Countries.

     “EMEA Co-Venture Agreement” has the meaning set forth in Section 2.1(a)(1).

     “EMEA Executive Sponsors” means (i) a senior executive of M or any of its Affiliates
(who shall also serve as a member of the EMEA Operating Board), designated by M to serve as M’s
“Executive Sponsor” in the EMEA to champion interactions between the M members of the EMEA
Operating Board and the S-P members of the EMEA Operating Board and (ii) a senior executive of S-P
or any of its Affiliates (who shall also serve as a member of the EMEA Operating Board), designated
by S-P to serve as S-P’s “Executive Sponsor” in the EMEA to champion interactions between the S-P
members of the EMEA Operating Board and the M members of the EMEA Operating Board, in each case,
with respect to the ECLAFE Cholesterol Business in the EMEA.

     “EMEA General Manager” has the meaning set forth in Section 3.2.2(a).

     “EMEA Marketing Committee” has the meaning set forth in Section 3.2.3(a).

     “EMEA Marketing Director” has the meaning set forth in Section 3.2.2(b).

     “EMEA No Presence Countries” means each of the following countries in the EMEA:
Albania, Algeria, Angola, Benin, Bosnia and Herzegovina, Botswana, Burkina Faso, Cape Verde,
Central African Republic, Chad, Comoros, Congo, Democratic Republic of the Congo, Djibouti,
Equatorial Guinea, Eritrea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Iraq, Kyrgyzstan, Lesotho,
Liberia, Libya, Macedonia, Malawi, Mali, Mauritania, Mauritius, Moldova, Namibia, Niger, Nigeria,
Rwanda, Sao Tome & Principe, Seychelles, Sierra Leone, Somalia, Sudan, Swaziland, Tajikistan, Togo,
Zambia and Zimbabwe.

     “EMEA Operating Board” has the meaning set forth in Section 3.2.1(a).

6

 

     “EMEA Operating Board Chair” has the meaning set forth in Section 3.2.1(b).

     “EMEA Regional Representatives” means each of the persons designated by M with the
written consent of S-P (such consent not to be unreasonably withheld) to be the regional
representatives with respect to the following regions of the EMEA: Scandinavian Region, Mid-Europe
Region, Central and Eastern Europe Region and Middle East Africa Region. S-P shall have the right
to cause the removal of an EMEA Regional Representative (subject to the written consent of M, not
to be unreasonably withheld), provided that (i) such right shall be exercisable no more than once
every two years and (ii) M shall have the right to designate a replacement for any removed EMEA
Regional Representative with the written consent of S-P (such consent not to be unreasonably
withheld).

     “EMEA Single Presence Countries” means countries in the EMEA which the EMEA Operating
Board designates as EMEA Single Presence Countries; provided, however, that (i)
Burundi, Cameroon, Cote D’Ivoire (Ivory Coast), Cyprus, Iran, Madagascar, Morocco, Mozambique,
Senegal, Tanzania, Tunisia and Uganda will be deemed to be EMEA Single Presence Countries in which
M is the party deemed to have the single presence, and (ii) Armenia, Azerbaijan, Kazakhstan, Syria,
Turkmenistan, Uzbekistan and Yemen will be deemed to be EMEA Single Presence Countries in which S-P
is the Party deemed to have the single presence.

     “EMEA Single Presence Country Exhibit” has the meaning set forth in Section 2.1(c)(1).

     “Entity Agreement” has the meaning set forth in Section 2.1(a)(1).

     “EU Agency” means a marketing authorization Agency in the European Union or any member
state of the European Union.

     [*]

     “European Economic Area” shall mean the following countries that comprise the European
Economic Area as of the Effective Date (and any countries that result from the division or
consolidation of such countries): Austria, Belgium, Denmark, Finland, France, Germany, Greece,
Iceland, Ireland, Italy, Liechtenstein, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden
and The United Kingdom.

     “European Union” shall mean the following countries that comprise the European Union
as of the Effective Date (and any countries that result from the division or consolidation of such
countries): Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy,
Luxembourg, Netherlands, Portugal, Spain, Sweden and The United Kingdom.

     “Existing M JVs” means those Persons listed on Schedule 1.2(ii).

     “Existing S-P JVs” means those Persons listed on Schedule 1.2(iii).

7

 

     “Ezetimibe” means the chemical compound
1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone.

     “Ezetimibe Monotherapy Product” means a pharmaceutical product consisting of Ezetimibe
as the sole active ingredient.

     “Far East” means the following countries (and any other countries that result from the
division or consolidation of such countries): Afghanistan, Australia, Bangladesh, Bhutan, Brunei,
Burma, Cambodia, China (including Hong Kong, Special Administrative Region and Macao Special
Administrative Report), Fiji, India, Indonesia, Kirbati, Laos, Malaysia, Maldives, Marshall
Islands, Federated States of Micronesia, Mongolia, Nauru, Nepal, New Zealand, North Korea,
Pakistan, Palau, Papua New Guinea, Philippines, Samoa, Singapore, Solomon Islands, South Korea, Sri
Lanka, Taiwan, Thailand, Tonga, Tuvalu, Vanuatu and Vietnam (but not including Japan).

     “Far East Board Countries” means Far East Co-Promotion Countries and Far East Single
Presence Countries.

     “Far East Board Country Agreement” means a Far East Co-Venture Agreement or a Far East
Single Presence Country Exhibit, as applicable.

     “Far East Co-Marketing Countries” means all countries in the Far East, other than Far
East Co-Promotion Countries and Far East Single Presence Countries.

     “Far East Co-Promotion Countries” means (i) Malaysia, Singapore, Hong Kong and Taiwan,
and (ii) such countries in the Far East where the Far East Operating Board designates such
countries as Far East Co-Promotion Countries.

     “Far East Co-Venture Agreement” has the meaning set forth in Section 2.4(b)(1).

     “Far East Operating Board” has the meaning set forth in Section 3.6.1(a).

     “Far East Single Presence Country” means countries in the Far East which the Far East
Operating Board designates as Far East Single Presence Countries, provided,
however, that (i) Korea and New Zealand will be deemed to be Far East Single Presence
Countries in which M is the party deemed to have the single presence, and (ii) Thailand, Indonesia
and the Philippines will be deemed to be Far East Single Presence Countries in which S-P is the
Party deemed to have the single presence.

     “Far East Single Presence Country Exhibit” has the meaning set forth in Section
2.4(c)(1).

     “Field” means use as a human pharmaceutical product for lipid management and other
uses that could reasonably be associated with lipid management, including, but not limited to,
lipid related vascular disease management, available only by prescription from a Prescriber.

     “Five-Year Strategic Business Plan” has the meaning set forth in Section 3.2.4(a).

8

 

     “Governance Agreement” has the meaning set forth in the Recitals.

     “Hospital Representatives” means professional sales representatives employed by M or
S-P or their respective Affiliates who focus on the promotion of multiple products in hospital and
other institutional settings, with key account personnel, hospital staff, fellows and residents,
and specialists with institutional affiliation, and who are trained in and provide special program
execution and offer promotion materials, Samples and educational programs.

     “Interests” means, with respect to a Terminated Party, (i) all of the Terminated
Party’s (or its Affiliates’) rights, title and interests in any or all of the Venture Companies, as
applicable, and (ii) all of the Terminated Party’s (or its Affiliates’) rights and obligations
under any or all of the Venture Agreements, as applicable, and (iii) all of the goodwill associated
with the Terminated Party’s Co-Marketing activities. For purposes of this Agreement, “Interests”
shall not include (i) the Interests (as defined in the Governance Agreement) of the Terminated
Party with respect to any or all of the U.S. Related Companies, and (ii) in the event the
Governance Agreement has been terminated prior to, and not simultaneously with, this Agreement, the
U.S. Termination Assets (as defined in the Governance Agreement), if any.

     “JV Entity” has the meaning set forth in Section 7.1(a).

     “LAFE” means Latin America and the Far East.

     “LAFE Co-Marketing Countries” means all countries in LAFE, other than Far East
Co-Promotion Countries and Far East Single Presence Countries.

     “Latin America” means the following countries (and any other countries that result
from the division or consolidation of such countries): Argentina, Mexico, Brazil, Uruguay,
Paraguay, Bolivia, Chile, Columbia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras,
Nicaragua, Panama, Peru, Venezuela, Anguilla, Antigua & Barbuda, Aruba, Bahamas, Barbados, Belize,
Bermuda, Cayman Islands, Cuba, Curacao, Dominica, Dominican Republic, French Guiana, Grenada,
Guadeloupe, Guyana, Haiti, Jamaica, Martinique, Monserrat, Netherlands Antilles, St. Kitts & Nevis,
St. Lucia, St. Maarten, St. Vincent and the Grenadines, Suriname, Trinidad & Tobago, Virgin Islands
and British Virgin Islands.

     “Latin America Executive Sponsors” means (i) a senior executive of M or any of its
Affiliates, designated by M to serve as M’s “Executive Sponsor” in Latin America to champion
interactions between the M and S-P in Latin America, and (ii) a senior executive of S-P or any of
its Affiliates, designated by S-P to serve as S-P’s “Executive Sponsor” in Latin America to
champion interactions between S-P and M in Latin America, in each case, with respect to the ECLAFE
Cholesterol Business in Latin America.

     “Launch” means, with respect to a Cholesterol Product in a country, the first
commercial sale in the Field of the Cholesterol Product to a Third Party in such country after all
regulatory approvals, and pricing and reimbursement within the guidelines

9

 

provided by the EMEA
Operating Board or Far East Operating Board, as applicable, have been obtained or received from the
applicable Agency with respect to the applicable Cholesterol Product in the applicable country.

     “Launch Period” means, with respect to a Cholesterol Product, the three (3) year
period immediately following the Launch of such Cholesterol Product.

     “License Agreements” means the License Agreements listed in Sections 2.5.1 [(3)
through (8)] and Section 2.5.2.

     “Licensor” has the meaning set forth in Section 7.14.

     “Local Affiliate” means, with respect to M or S-P in any country in ECLAFE, an
Affiliate of M or S-P, as the case may be, located in the country, or if there is no local
Affiliate of M or S-P, as the case may be, located in such country, the Affiliate (or Affiliates)
of M or S-P which is (or are) responsible for the marketing, distribution or sale of the
Cholesterol Products in the Field in such country.

     “Local Bankruptcy” means the occurrence of any of the following:

     (i) a Board Country Subsidiary in a country in ECLAFE makes a general assignment for the
benefit of creditors;

     (ii) a Board Country Subsidiary in a country in ECLAFE either (i) is unable to pay its debts
as and when they become due, or (ii) becomes insolvent and is unable to cure such insolvency within
forty-five (45) days of becoming insolvent;

     (iii) a Board Country Subsidiary in a country in ECLAFE files any application or petition in
any tribunal for the appointment of a trustee or receiver;

     (iv) a Board Country Subsidiary in a country in ECLAFE commences any proceeding leading
towards the adjudication of such Board Country Subsidiary as insolvent under any bankruptcy or
reorganization statute, or under any provision of the United States Bankruptcy Code, or under any
insolvency law in a relevant jurisdiction, whether now or hereafter in effect; or

     (v) any petition or application of the types described in clauses (i) through (iv) above is
commenced against such Board Country Subsidiary and is not dismissed within sixty (60) days after
filing, or an order is entered appointing a trustee, receiver, or custodian for such Board Country
Subsidiary, or an order for a relief is issued in any bankruptcy proceeding.

     “Losses” has the meaning set forth in Section 6.5.4.

     “M” has the meaning set forth in the Preamble hereof.

     “M Indemnified Parties” means M, its Affiliates and each of their respective officers,
directors, partners, shareholders, members, agents, representatives, successors

10

 

and assigns.

     “M Sales Force” means those professional sales representatives employed or retained by
M, that engage in Pre-Launch Activities, Co-Promotion, Co-Marketing and/or Marketing Support
Activities in support of the Cholesterol Products in an EMEA Board Country, Far East Board Country
or Canada, subject to the limitation that with respect to each Cholesterol Product (i) in the case
of Canada, Australia, France, the United Kingdom, Germany, Netherlands, Spain, Italy, Sweden and
Norway, no more than 10% of the PDEs required of M in each such country by the Marketing and
Educational Plan in any given Calendar Quarter may be delivered by a Contract Sales Force and (ii)
in the case of all other such countries other than Single Presence Countries, (x) no more than 15%
of the PDEs required of M in each such country by the Marketing and Educational Plan in any given
Calendar Quarter may be delivered by a Contract Sales Force during the period beginning on the date
on which M is first required to deliver PDEs in such country and ending on the last day of the
eighth Calendar Quarter following the Calendar Quarter in which such Cholesterol Product is
Launched in such country and (y) thereafter, no more than 10% of the PDEs required of M by the
Marketing and Educational Plan may be delivered by a Contract Sales Force, in each case, without
approval of the EMEA Operating Board or the Far East Operating Board, as applicable.

     “MAH” has the meaning set forth in Section 2.1(d)(1).

     “Marketing Presence” means, with respect to a country in the EMEA, that, as of the
Effective Date, a Party or its Affiliates has full-time employees (not employed on a temporary
basis) engaged in intra-country detailing, promotional and/or marketing activities. Subject to
Section 3.2.7, [*] shall be deemed to provide [*] with a Marketing Presence in [*].

     “Marketing and Educational Plan” means, with respect to a Co-Promotion Country, EMEA
Co-Branding Country or a Single Presence Country, the annual marketing and educational plan for the
Co-Promotion Country, EMEA Co-Branding Country or a Single Presence Country, as the case may be,
such Marketing and Educational Plan to include the matters referenced in Section 3.2.4, or 3.6.3,
as applicable.

     “Marketing LLC” means MSP Marketing Services (C) LLC.

     “Marketing Support Activities” means those activities normally undertaken by a
pharmaceutical company, other than by its professional sales representatives, in the development,
implementation and monitoring of a Marketing and Educational Plan (other than Pre-Launch
Activities).

     “Material Adverse Effect” has the meaning set forth in Section 5.2.1(a).

     “M/E ECLAFE Business” means the research, development, registration, manufacture
and/or procurement, distribution, promotion and marketing of a
pharmaceutical product in the Field in ECLAFE that shall be a combination product

11

 

comprising,
but not limited to, [*], as and to the extent contemplated by this Agreement and any Related
Agreements.

     “M/E Combination Product” means a pharmaceutical product consisting of a fixed single
combination of pharmacologically active ingredients comprising, but not limited to, [*].

     “M/E Combination Product U.S. Trademark” means the trademark used or to be used by the
Parties with respect to the registration, distribution, promotion and marketing of the M/E
Combination Product in the United States.

     “Mid-Europe Region” means, unless otherwise determined by the EMEA Operating Board,
the following countries (and any other countries that result from the division or consolidation of
such countries): Switzerland, the Netherlands, Belgium, Luxembourg, Portugal, Liechtenstein,
Greece, Israel, South Africa, Botswana, Lesotho, Malawi, Namibia, Swaziland, Zambia and Zimbabwe.

     “Middle East Africa Region” means, unless otherwise determined by the EMEA Operating
Board, the following countries (and any other countries that result from the division or
consolidation of such countries): Algeria, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan,
Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, United Arab Emirates,
Yemen, Angola, Benin, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad,
Comoros, Congo, Cote d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea,
Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Liberia, Madagascar, Mali,
Malta, Mauritania, Mauritius, Niger, Nigeria, Réunion Island, Rwanda, Sao Tome and Principe,
Senegal, Seychelles, Sierra Leone, Somalia, Sudan, Tanzania, Togo, Uganda.

     [*]

     “MSDAPS” means Merck Sharp & Dohme Asia Pacific Services Pte. Ltd., a Singapore
corporation.

     “MSDIL” means Merck Sharp & Dohme (International) Limited, a Bermuda corporation.

     “MSDIS” means Merck Sharp & Dohme International Services, B.V., a Dutch company.

     “MSP Technology” has the meaning set forth in the Preamble hereof.

     “New Agreements” has the meaning set forth in Section 5.3(f).

     “Non-Distribution Party” means, with respect to a distributor or sub-licensee
appointed under Section 3.4.1 or 3.5.1 of this Agreement in a LAFE Co-Marketing Country, whichever
of M or S-P is not the Distribution Party.

12

 

     “Non-Packager” has the meaning set forth in Section 2.7.

     “Non-Representative Educational and Promotional Activities” means all measurable and
reported educational and promotional activities including (where applicable), without limitation
and to the extent permitted by the laws of the applicable country, activities relating to market
research costs, detailing aids, third party fees relating to advertising, marketing and other
promotional activities, media (and any other press materials and interactions), print, internet
programs, direct-to-customer advertising, other advertising, meetings, symposia and congresses,
trade programs, Launch meetings, Cholesterol Product-related special sales force incentive
programs, Phase V studies, Cholesterol Product-specific programs for managed care/private health
plan customers, fees paid directly to a customer for administration of a contract, uninsured losses
of product, product and disease therapy area specific training materials, but not including (i)
activities directly related to detailing efforts, or (ii) Phase IV studies. All such activities
will comply with all applicable Agency regulations including without limitation, those with respect
to advertising and promotion, legally permissible support for physicians, and all other laws and
regulations.

     “Non-Representative Educational and Promotional Spending” means all measurable and
reported educational and promotional expenditures including (where applicable), without limitation
and to the extent permitted by the laws of the applicable country, expenditures relating to market
research costs, detailing aids, third party fees relating to advertising, marketing and other
promotional activities, media (and any other press materials and interactions), print, internet
programs, direct-to-customer advertising, other advertising, meetings, symposia and congresses,
trade programs, Launch meetings, Cholesterol Product-related special sales force incentive
programs, Phase V studies, Cholesterol Product-specific programs for managed care/private health
plan customers, fees paid directly to a customer for administration of a contract, uninsured losses
of product, product and disease therapy area specific training materials, but not including (i)
expenditures directly related to detailing efforts or (ii) Phase IV studies.

     “Obligations” has the meaning set forth in Section 2.1(a).

     “Packager” has the meaning set forth in Section 2.7(1).

     “Party” means a party to this Agreement.

     “PDE Requirements” shall have the meaning set forth in Section 3.2.4(b).

     “Person” means any individual, corporation, trust, association, unincorporated
association, estate, partnership, joint venture, limited liability company, governmental entity or
other legal entity.

     “Phase IV” means post-Launch studies that are intended to result in an added
indication or other label change.

     “Phase V” means post-Launch studies that are not intended to result in an added
indication or other label change.

13

 

     “Pre-Launch Activities” means those activities undertaken by M or its Affiliates, or
the M Sales Force, or S-P or its Affiliates, or the S-P Sales Force, as the case may be, prior to
the Launch of a Cholesterol Product in a country, including, without limitation, conduct of
educational seminars and programs, patient education programs, pre-approval clinical trials, market
research and appropriate educational activities for targeted audiences. All such activities will
comply with all applicable laws, rules and regulations of such country.

     “Prescriber” means a medical or health care professional having authority to prescribe
human prescription pharmaceutical products under the laws of the jurisdiction where such medical or
health care professional is practicing.

     “Pre-Termination Substances” means any Cholesterol Absorption Inhibitor and any
Statin, or any rights thereto, owned or held (by license or otherwise) by the Terminated Party or
any entity that was an Affiliate of the Terminated Party prior to the date determined by clause (i)
or clause (ii) hereafter, regardless of the stage of development (i.e., whether
pre-clinical, clinical or in any other stage) prior to (i) the consummation of a Business
Combination, in the case of termination pursuant to Section 5.2.2(iii) as a result of a Change of
Control described in paragraphs (c), (e) or (f) of the definition of Change of Control or (ii) the
termination of this Agreement, in the case of termination pursuant to Section 5.2.1(a) [ECLAFE
Material Breach], 5.2.1(c) [Bankruptcy], 5.2.2(i) [Bankruptcy], 5.2.2(ii) [Material Breach –
Standstill], 5.2.1(d) [Change of Control] or 5.2.2(iii) [Change of Control] as a result of the
acquisition of 50% of Outstanding Common Stock or Outstanding Voting Securities, change in board
composition or stockholder approval described in paragraphs (a), (b) or (d) of the definition of
Change of Control.

     “Primary Care Representatives” means a professional sales representative other than a
Specialty Representative or a Hospital Representative.

     “Primary Detail Equivalents” or “PDEs” means, either: (a) [*] Primary
Position Detail, (b) [*] Secondary Position Details or (c) [*] Tertiary Position Details.
Notwithstanding the foregoing, during the Launch Period with respect to a Cholesterol Product, PDEs
provided by each of M and S-P with respect to a Cholesterol Product in a given Calendar Year shall
be composed of (x) no less than [*] Primary Position Details and (y) no more than [*] Tertiary
Position Details. To the extent that a party’s (i) Tertiary Position Details comprise greater than
[*] of its PDEs or (ii) Secondary Position Details and Tertiary Position Details, in the aggregate,
comprise greater than [*] of its PDEs, such excess Secondary Position Details and/or Tertiary
Position Details (as applicable) will not be credited towards a Party’s obligation to provide the
level of PDEs provided for under Section 3.1 of the EMEA Board Country Agreements. For purposes of
determining the number of PDEs delivered pursuant to Section 3.1 of the EMEA Board Country
Agreements, a Primary Position Detail or a Secondary Position Detail by a Specialty Representative
shall be equivalent to [*] (as the case may be) of a Primary Care Representative and a Primary
Position Detail or a Secondary Position Detail by a Hospital Representative shall be equivalent to
[*] (as the case may be)
of a Primary Care

14

 

Representative. The Parties shall from time to time reassess these PDE weightings in relation
to a Cholesterol Product’s life cycle and the competitive marketplace.

     “Primary Position Detail” means a full product presentation during a Call by a Party’s
professional sales representative in which key product messages and benefits are verbally presented
in the first position and in a balanced manner, consistent with the terms of the EMEA Board Country
Agreements and Far East Board Country Agreements and equivalent Entity Agreements, and
approximately [*] of the total time of the Call is spent on such presentation.

     “Product Marketing Authorization” shall mean, with respect to each Cholesterol Product,
simvastatin and [*] in a country in ECLAFE, as applicable, all authorizations issued by the
relevant Agency in such country for the manufacturing (where necessary), marketing and sale of such
Cholesterol Product in the Field in such country, and/or supplements thereto, including pricing and
reimbursement approvals where applicable.

     “Regulatory Costs” means costs incurred to assure that the Cholesterol Products comply
with applicable regulatory requirements during the term of this Agreement, including, without
limitation, (i) amounts paid to governments or other third parties for filing and maintenance of
health registrations and (ii) the direct cost of personnel responsible for regulatory matters,
including, without limitation, filings, label updates, regulatory compliance, adverse experience
reporting, safety update submissions and any other activities required so that the Cholesterol
Products comply with applicable regulatory requirements during the term of the ECLAFE Cholesterol
Business in ECLAFE. The direct cost of personnel responsible for regulatory matters will be
charged based on approved budgets and agreement on an FTE (full time equivalent) basis.

     “Regulatory Expenses Cap” shall have the meaning set for in Section 4.2(b).

     “Related Agreements” means any or all of the agreements listed in Article II or
subsequently entered into pursuant to the terms of Article II, and all other agreements executed
and delivered contemporaneously therewith, as such agreements may be amended from time to time and
to the extent such agreement is an amendment to an existing agreement, the existing agreement as
amended. When the term “Related Agreements” is used in a Related Agreement, such term shall
include this Agreement.

     “Sample” means a unit of a Cholesterol Product that is not intended to be sold and is
intended to promote the appropriate trial and proper use of such Cholesterol Product in the Field.

     “Scandinavian Region” means, unless otherwise determined by the EMEA Operating Board,
the following countries (and any other countries that result from the division or consolidation of
such countries): Norway, Denmark, Iceland, Finland and Sweden.

     “Secondary Position Detail” means a product presentation during a Call by a Party’s
professional sales representative in which one or more key product messages and

15

 

benefits are verbally presented in the second position and in a balanced manner, consistent
with the terms of the EMEA Board Country Agreements and Far East Board Country Agreements and
equivalent Entity Agreements, and approximately [*] of the total time of the Call is spent on such
presentation.

     “Singapore Partnership” has the meaning set forth in the Preamble hereof.

     “Singapore Partnership Agreement” means the Limited Liability Company Agreement of the
Singapore Partnership, dated as of May 22, 2000 and as may be amended from time to time, by and
among MSD Technology Singapore Pte. Ltd., MSD Ventures Singapore Pte. Ltd., Schering-Plough
(Singapore) Pte. Ltd. and Schering-Plough (Singapore) Research Pte. Ltd.

     “Single Presence Country” means the EMEA Single Presence Countries and the Far East
Single Presence Countries.

     “Single Presence Country Exhibits” means the EMEA Single Presence Country Exhibit and
the Far East Single Presence Country Exhibit.

     “Simvastatin” shall mean the chemical compound
6(R)-[2-(8'(S)-(2,2-dimethylbutyryloxy)-2'(S),6'(R)-dimethyl-1',2',6',7',8',8'a(R)-hexahydronaphthyl
-1'(S))ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one; also known as
[1S-[1a,3a,7b(2S*,4S*),8ab]]-2,2-Dimethylbutanoic acid
1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester.

     “SOL” means SOL, Limited, a Bermuda corporation.

     “Special Damages” has the meaning set forth in Section 6.5.4.

     “Specialty Representatives” means professional sales representatives employed by M or
S-P or their respective Affiliates who focus in each Call on no more than two product details (i.e.
one Primary Position Detail and one Secondary Position Detail) with physician specialists and
thought leaders. Such representatives have specialized training with depth of medical knowledge on
a disease state, are capable of in depth discussion regarding diagnosis, treatment and patient
management, are trained in and provide special program execution, engage in regional advocate
development and offer reprints, slide kits, promotional items, Samples and, in certain
circumstances, disease management tools.

     “S-P” has the meaning set forth in the Preamble hereof.

     “S-P Indemnified Parties” means S-P, its Affiliates and each of their respective
officers, directors, partners, shareholders, members, agents, representatives, successors and
assigns.

     “S-P Sales Force” means those professional sales representatives employed or retained
by S-P, that engage in Pre-Launch Activities, Co-Promotion, Co-Marketing and/or Marketing Support
Activities in support of the Cholesterol Products in an EMEA

16

 

Board Country, Far East Board Country or Canada, subject to the limitation that with respect
to each Cholesterol Product (i) in the case of Canada, Australia, France, the United Kingdom,
Germany, Netherlands, Spain, Italy, Sweden and Norway, no more than 10% of the PDEs required of S-P
in each such country by the Marketing and Educational Plan in any given Calendar Quarter may be
delivered by a Contract Sales Force and (ii) in the case of all other such countries other than
Single Presence Countries, (x) no more than 15% of the PDEs required of S-P by the Marketing and
Educational Plan in any given Calendar Quarter may be delivered by a Contract Sales Force during
the period beginning on the date on which S-P is first required to deliver PDEs in such country and
ending on the last day of the eighth Calendar Quarter following the Calendar Quarter in which such
Cholesterol Product is Launched in such country, and (y) thereafter, no more than 10% of the PDEs
required of S-P in each such country by the Marketing and Educational Plan may be delivered by a
Contract Sales Force, in each case, without approval of the EMEA Operating Board or the Far East
Operating Board, as applicable.

     “Statin” shall mean a product whose primary clinical effect is through the inhibition
of the human enzyme, 3-hydroxy-3-methylglutaryl Coenzyme A Reductase.

     “Targeted Prescribers” means Prescriber groups representing at least seventy-five
percent (75%) of the market potential of such Cholesterol Products.

     “Terminated Party” means whichever of S-P or M is not the Terminating Party, and its
Affiliates.

     “Terminating Party” means the Party that has the right to terminate this Agreement
either pursuant to Section 5.2.1 or an arrangement in a country in ECLAFE pursuant to Section
5.2.3, or the Party that terminated the Governance Agreement for the reasons referred to in Section
5.2.2.

     “Toll Packaging Agreements” means those Toll Packaging Agreements referred to in
Sections 2.1(f), 2.2(b), 2.3(b) and 2.4(d) of this Agreement.

     “Tertiary Position Detail” means a product presentation during a Call by a Party’s
professional sales representative in which one or more key product messages and benefits are
verbally presented in the third position and in a balanced manner, consistent with the terms of the
EMEA Board Country Agreements and the Far East Board Country Agreements and equivalent Entity
Agreements, and approximately [*] of the total time of the Call is spent on such presentation.

     “Third Party” means a Person which is not M, S-P, or any of their Affiliates.

     “Trademark Registrations” has the meaning set forth in Section 4.3.5(a).

     “U.S. Related Companies” means Distribution LLC and Marketing LLC, and in the event
that this Agreement is terminated pursuant to Section 5.2.2 or the Governance Agreement is not
terminated prior to a termination of this Agreement, the Singapore Partnership and MSP Technology.

17

 

     “U.S. Territory” means the United States of America, its territories and possessions
(including but not limited to Puerto Rico).

     “Venture Agreements” means those Related Agreements setting forth the rights and
obligations of the Parties to market, distribute and sell the Cholesterol Products in the EMEA, Far
East Co-Promotion Countries and Single Presence Countries, including those Agreements and other
documents referred to in Sections 2.1(a), (b), (c) and (d), 2.4(b)(1), and 2.4(c)(1) of the
Agreement.

     “Venture Cholesterol Product” means the Cholesterol Products as developed and marketed
for sale in the Field in ECLAFE by the Parties, or their Affiliates, either individually or as a
group.

     “Venture Companies” means (i) the entities established pursuant to any Entity
Agreement, if any, (ii) the Canadian Partnership, (iii) MAH, in each case, and (iv) to the extent
the Governance Agreement has been terminated and the Interests (as defined in the Governance
Agreement), in Marketing LLC and Distribution LLC and the U.S. Termination Assets (as defined in
the Governance Agreement) have been transferred to the Non-Terminated Party (as defined in the
Governance Agreement), if any, the Singapore Partnership and MSP Technology.

     [*] means [*], a company organized and existing under the laws of [*] and, as of the Effective
Date, having its head office at [*].

     “Worldwide Cholesterol Business” means the Z/E ECLAFE Business, the E Monotherapy
ECLAFE Business, the M/E ECLAFE Business and the Cholesterol Business (as defined in the Governance
Agreement) as conducted in or with respect to the entire world, excluding Japan, including, without
limitation, the ECLAFE and the United States.

     “WWOC” has the meaning set forth in Section 3.1(a).

     “WWOC Chairs” has the meaning set forth in Section 3.1(b).

     “WWOC Representatives” has the meaning set forth in Section 3.1(b).

     “Z/E ECLAFE Business” means the research, development, registration, manufacture
and/or procurement, distribution, promotion and marketing of a pharmaceutical product in the Field
in ECLAFE that shall be a combination product comprising, but not limited to, Simvastatin and
Ezetimibe, as and to the extent contemplated by this Agreement and any Related Agreements.

     “Z/E Combination Product” shall mean a pharmaceutical product consisting of a fixed
single combination of pharmacologically active ingredients comprising, but not limited to,
Simvastatin and Ezetimibe.

18

 

     “Z/E Combination Product U.S. Trademark” means the trademark used or to be used
by the Parties with respect to the registration, distribution, promotion and marketing of the Z/E
Combination Product in the United States.

     Section 1.3. Headings. The headings and subheadings in this Agreement are included
for convenience and identification only and are in no way intended to describe, interpret, define
or limit the scope, extent or intent of this Agreement or any provision hereof.

     Section 1.4. Intent of the Parties. It is the intent of the parties hereto that,
without limiting the rights of the parties hereunder, S-P and M be considered equal partners with
respect to all matters relating to governance and decision-making powers and that the parties
intend to manage the operations of the ECLAFE Cholesterol Business in ECLAFE to maximize its
commercial potential. The parties acknowledge that simultaneously herewith the parties are
executing and delivering an amendment to the Governance Agreement, and agree that the Governance
Agreement shall remain unchanged and in full force and effect, except as expressly amended thereby.

ARTICLE II

THE ECLAFE TRANSACTIONS

     Section 2.1. The EMEA.

          (a) EMEA Co-Promotion Countries.

     (1) As soon as reasonably practicable following the execution and
delivery of this Agreement and, with respect to the Core Countries that
are EMEA Co-Promotion Countries, no later than ninety (90) days following
the execution and delivery of this Agreement, an EMEA Co-Venture Agreement
in the form attached hereto as Exhibit 1 (with such variations as may be
necessary to comply with local laws and regulations) covering each of the
EMEA Co-Promotion Countries shall be executed and delivered by Local
Affiliates of M and S-P, except in limited instances where both Parties
agree that an agreement (an “Entity Agreement”), creating a
separate entity through which the activities and governance functions
contemplated by the form of EMEA Co-Venture Agreement will take place, is
required by local laws and regulations of a country, in which case the
Parties will enter into an Entity Agreement based substantially on the
EMEA Co-Venture Agreement (with such variations as may be necessary to
comply with local laws and regulations) no later than ninety (90) days
following the execution and delivery of this Agreement. If any taxes,
duties, discounts, rebates, price reductions or other financial
considerations imposed under the local laws, rules and/or regulations with
respect to an EMEA country, or under an administrative, judicial or other
governmental action with respect

19

 

to an EMEA country, would materially financially disadvantage one
Party and/or its Affiliates (the “Disadvantaged Party”) but not
the other Party and/or its Affiliates (or would cause a material financial
disadvantage to one Party and/or its Affiliates greater than that caused
to the other Party and/or its Affiliates) with respect to such EMEA
country, solely as a result of its entering into or performing the
relevant Board Country Agreement or Entity Agreement (as applicable)
(“Obligations”), and the Parties have first each, separately or
together, used commercially reasonable efforts to mitigate the effect of
the Obligations, then the Parties agree to work together in good faith,
for a reasonable period of time, to structure the local arrangement in a
manner that would result in the Obligations not being imposed in any
material respect (but without altering the treatment of the applicable
country as an EMEA Co-Promotion Country). If after such good faith
efforts the Parties are unable to implement such a structure, then the
Parties shall in good faith agree upon such variations to the applicable
EMEA Co-Venture Agreement or Entity Agreement as would be necessary to put
the Parties in the economic position in the applicable country that they
would have been in under the applicable EMEA Co-Venture Agreement or
Entity Agreement had the Obligations not been imposed. The Country Sales
Amount applicable to certain EMEA Co-Promotion Countries shall be as set
forth on Schedule 2.1(a). M, S-P and their respective Affiliates shall
not (i) engage in any ECLAFE Cholesterol Business in the applicable
country without the approval of the EMEA Operating Board, except for
activities approved and conducted pursuant to the Development Agreement or
required under this Agreement, or (ii) distribute or sell Cholesterol
Products in an EMEA Co-Promotion Country, in each case, until an EMEA
Co-Venture Agreement or Entity Agreement has been executed and delivered
with respect to the EMEA Co-Promotion Country.

          (b) EMEA Co-Branding Countries.

     (1) As soon as reasonably practicable following the execution and
delivery of this Agreement, and, with respect to the Core Countries that
are EMEA Co-Branding Countries, no later than ninety (90) days following
the execution and delivery of this Agreement, an EMEA Co-Branding
Agreement in the form attached hereto as Exhibit 2 (with such variations
as may be necessary to comply with local laws and regulations), covering
each of the EMEA Co-Branding Countries shall be executed and delivered by
Local Affiliates of M and S-P with respect to each EMEA Co-Branding
Country. If any taxes, duties, discounts, rebates, price reductions or
other financial considerations imposed under the local laws, rules and/or
regulations with respect to an

20

 

EMEA country, or under an administrative, judicial or other
governmental action with respect to an EMEA country, would materially
financially disadvantage a Disadvantaged Party but not the other Party
and/or its Affiliates (or would cause a material financial disadvantage to
one Party and/or its Affiliates greater than that caused to the other
Party and/or its Affiliates) with respect to such EMEA country, solely as
a result of its Obligations, and the Parties have first each, separately
or together, used commercially reasonable efforts to mitigate the effect
of the Obligations, then the Parties agree to work together in good faith,
for a reasonable period of time, to structure the local arrangement in a
manner that would result in the Obligations not being imposed in any
material respect (but without altering the treatment of the applicable
country as an EMEA Co-Branding Country). If after such good faith efforts
the Parties are unable to implement such a structure, then the Parties
shall in good faith agree upon such variations to the applicable EMEA
Co-Branding Agreement as would be necessary to put the Parties in the
economic position in the applicable country that they would have been in
under the applicable EMEA Co-Branding Agreement had the Obligations not
been imposed. M, S-P and their respective Affiliates shall not (i) engage
in any ECLAFE Cholesterol Business in the applicable country without the
approval of the EMEA Operating Board, except for activities approved and
conducted pursuant to the Development Agreement or required under this
Agreement, or (ii) distribute or sell Cholesterol Products in an EMEA
Co-Branding Country, in each case, until a Co-Branding Agreement has been
executed and delivered with respect to the EMEA Co-Branding Country.

          (c) EMEA Single Presence Countries.

     (1) Sales of Cholesterol Products in the Field in EMEA Single
Presence Countries shall be governed by the provisions of Section 3.2.8
and the EMEA Single Presence Country Exhibit attached hereto as Exhibit 3.

          (d) EMEA Marketing Authorization Holder.

     (1) As soon as reasonably practicable following the execution and
delivery of this Agreement and in any event within sixty (60) days of the
execution and delivery of this Agreement, the Singapore Partnership will
form within the European Economic Area an entity to serve as marketing
authorization holder with respect to the European Economic Area (the
“MAH”). The MAH’s name shall include the names of both M and S-P
(or their designated Affiliates) and shall be agreed to by M and S-P. As

21

 

soon as practicable after the execution of this Agreement, the MAH
shall enter into agreements with EMEA supply, distribution and promotional
entities in the European Economic Area in the form attached hereto as
Exhibit 4 (with such variations as may be necessary to comply with local
laws and regulations), and any other agreements that the Parties agree are
required or desirable in the EMEA. Such agreements shall include one or
more agreements under which an Affiliate of S-P agrees to serve as the
“Qualified Person” as defined in Directives 2001/83/EC and 91/356/EEC for
the Ezetimibe Monotherapy Product (the “S-P QP”). Under such agreement(s)
the S-P QP shall undertake the general responsibilities of a Qualified
Person for the Ezetimibe Monotherapy Product for the European Economic
Area and its obligations shall include batch release and disposition
decisions, import testing, stability testing and all other
technical/quality investigations, for the European Economic Area as well
as the EMEA. The S-P QP shall be compensated in a manner consistent with
the Toll Fee calculated pursuant to the template of the Toll Packaging
Agreement set forth in Exhibit 6 hereto. An Affiliate of M acting as toll
packager pursuant to paragraph (f) below shall enter into one or more
agreements with the Affiliate of S-P under which the M Affiliate shall
furnish to the S-P QP such data and services regarding its operations as
toll packager for the Ezetimibe Monotherapy Product as the S-P QP may
reasonably require to discharge its responsibilities as a Qualified
Person. For the avoidance of doubt, an Affiliate of M will serve as the
“Qualified Person” as defined in Directives 2001/83/EC and 91/356/EEC for
the Combination Products (the “M QP”). The M QP shall undertake the
general responsibilities of a Qualified Person for the Combination
Products for the European Economic Area and its obligations shall include
batch release and disposition decisions, import testing, stability testing
and all other technical/quality investigations for the European Economic
Area as well as the EMEA. For the avoidance of doubt, for all regions
other than EMEA, the toll packager shall be responsible for the final
batch release and disposition decisions import testing (if any) stability,
testing and all other technical/quality investigations. The Parties agree
that neither Party, nor any director of the MAH appointed by any such
Party, will take any action in any manner with respect to the MAH, other
than as expressly set forth in the foregoing agreements, and that such
agreements will not be interpreted in a manner inconsistent with this
Agreement and/or the Related Agreements. Promptly after the Effective
Date and the formation of the MAH, the Parties will cause MSD SP to apply
for approval as the manufacturing authorization holder. In the event that
MSD SP is unable to obtain approval as the manufacturing authorization

22

 

holder, and it is not permissible for each of an M Affiliate and an
S-P Affiliate to be a manufacturing authorization holder, then the Parties
will work together in good faith to secure alternative arrangements that
are mutually acceptable.

          (e) Supply and Distribution.

     (1) Simultaneously with the execution and delivery of this Agreement,
MSDIS and the Singapore Partnership shall execute and deliver a Supply and
Distribution Agreement in the form attached hereto as Exhibit 5, pursuant
to which MSDIS will acquire finished, unpackaged Cholesterol Products for
packaging and sale to customers in the EMEA.

     (2) In the event that MSDIS, or any Affiliate of MSDIS, has failed,
for any reason (including without limitation an event of force majeure),
to perform, in any material respect, its obligations under the Supply and
Distribution Agreement entered into pursuant to this Section 2.1(e) to
supply and/or distribute Cholesterol Products received from the Singapore
Partnership in the EMEA, such failure to perform is not cured and
performance by MSDIS, or an Affiliate of MSDIS, as applicable, is not
resumed within sixty (60) days of written notice by S-P of such failure,
and S-P (or its designated Affiliate) can demonstrate to the Singapore
Partnership that it has the ability and the facilities and expertise to
assume such obligations, then S-P (or its designated Affiliate) shall have
the right to assume the rights and responsibilities of MSDIS under the
Supply and Distribution Agreement for supply and distribution of
Cholesterol Products in the EMEA. In such event, the Singapore
Partnership, MSDIS (or its Affiliate, as applicable) and S-P (or its
designated Affiliate) shall immediately amend the Supply and Distribution
Agreement and/or perform such other acts as are necessary to substitute
S-P (or its designated Affiliate) for MSDIS (or its Affiliate, as
applicable) as a party to the Supply and Distribution Agreement and to
assign and transfer to S-P (or its designated Affiliate) all of MSDIS’s
(or its Affiliate’s) rights and obligations under the Supply and
Distribution Agreement with respect to supply and distribution of
Cholesterol Products in the EMEA, including without limitation any rights
to receive payment for services performed thereunder. Nothing in Section
2.1(e) shall be construed as a waiver of any other rights or remedies
available to S-P under this Agreement as a result of such failure to
perform by MSDIS.

     (3) In the event that responsibility for supply and distribution of
Cholesterol Products in the EMEA is transferred to S-P (or its designated
Affiliate) pursuant to Section 2.1(e)(2) and

23

 

MSDIS, or an Affiliate of MSDIS, at any time thereafter demonstrates
to the Singapore Partnership that it has the ability and the facilities
and expertise to resume performance of all such obligations, then the
Singapore Partnership shall determine whether or not to return those
responsibilities to MSDIS or its Affiliate. If responsibility for such
activities is to be returned to MSDIS or its Affiliate, the Singapore
Partnership, MSDIS (or its Affiliate) and S-P (or, if applicable, its
designated Affiliate) shall immediately amend the Supply and Distribution
Agreement and/or perform such other acts as are necessary to substitute
MSDIS or its Affiliate for S-P or its Affiliate, as applicable, as a party
to the Supply and Distribution Agreement and to assign and transfer to
MSDIS or its Affiliate all of the rights and obligations under the Supply
and Distribution Agreement with respect to supply and distribution of
Cholesterol Products in the EMEA. In the event that these Sections
2.1(e)(2) and 2.1(e)(3) result in any other assignment or transfer of
rights under Sections 2.1(f)(2) or 2.1(g)(6), such rights shall be
returned to the relevant M Affiliate simultaneously with the assignment
and transfer contemplated in this Section 2.1(e)(3). Upon the return of
such rights and obligations to MSDIS pursuant to this Section 2.1(e)(3),
the costs incurred by M or S-P, or their Affiliates in transferring the
rights and responsibilities for supply and distribution of Cholesterol
Products in the EMEA under Section 2.1(e)(2) and this Section 2.1(e)(3),
and the cost of transferring such other rights under Sections 2.1(f)(2) or
2.1(g)(6), shall be borne as determined by the Singapore Partnership.

          (f) Toll Packaging.

     (1) As soon as reasonably practicable following the execution and
delivery of this Agreement, an Affiliate of M and MSDIS shall enter into a
Toll Packaging Agreement in the form attached hereto as Exhibit 6 (with
such variations as may be necessary to comply with local laws and
regulations), pursuant to which the Affiliate of M will package the
finished Cholesterol Products for sale in the EMEA. The Toll Packaging
Agreement will provide, among other things, that the Affiliate of M may
arrange for one of its Affiliates, a Third Party or an Affiliate of S-P to
toll package any or all of the Cholesterol Products on behalf of the
Affiliate of M.

     (2) In the event that, and for so long as, S-P (or a S-P Affiliate)
is responsible for the supply and distribution of Cholesterol Products in
the EMEA pursuant to Section 2.1(e)(2), then S-P, or its designated
Affiliate, shall also assume all of MSDIS’s rights and responsibilities to
package Cholesterol

24

 

Products in the EMEA as set forth in the Toll Packaging Agreements
entered into pursuant to Section 2.1(f)(1). MSDIS, S-P (or its designated
Affiliate) and the applicable Affiliates of M shall amend the Toll
Packaging Agreements and/or perform such other acts as are necessary to
substitute S-P (or its designated Affiliates) for MSDIS and the M
Affiliates as parties to the Toll Packaging Agreements and to assign and
transfer to S-P (or its designated Affiliate) all of MSDIS’s and the M
Affiliates’ rights and obligations under the Toll Packaging Agreements
with respect to Cholesterol Products in the EMEA.

          (g) Sub-Distribution Agreements.

As soon as reasonably practicable following the execution and delivery of
this Agreement:

     (1) With respect to the EMEA Co-Promotion Countries, the Local
Affiliates of M will enter into Sub-Distribution Agreements in the form
attached hereto as Exhibit 7 (with such variations as may be necessary to
comply with local laws and regulations), with MSDIS pursuant to which each
M Local Affiliate will purchase finished, packaged Cholesterol Products
from MSDIS for sale in the EMEA Co-Promotion Countries.

     (2) With respect to the EMEA Co-Branding Countries, Local Affiliates
of each of M and S-P will enter into separate, identical (except for the
name of the Local Affiliate) Sub-Distribution Agreements in the form
attached hereto as Exhibit 7 (with such variations as may be necessary to
comply with local laws and regulations), with MSDIS pursuant to which such
M and S-P Local Affiliates will purchase finished, packaged Cholesterol
Products from MSDIS for sale in the EMEA Co-Branding Countries.

     (3) With respect to each EMEA Single Presence Country, whichever of M
or S-P is deemed to have the single presence in such country, will arrange
for one of its Local Affiliates to enter into a Sub-Distribution Agreement
in the form attached hereto as Exhibit 7 (with such variations as may be
necessary to comply with local laws and regulations), with MSDIS pursuant
to which such M or S-P Local Affiliate will purchase finished, packaged
Cholesterol Products from MSDIS for sale in that EMEA Single Presence
Country.

     (4) In the event that the M Local Affiliate that enters into the
Sub-Distribution Agreement with MSDIS in an EMEA

25

 

Co-Promotion Country pursuant to Section 2.1(g)(1), or another Local
affiliate, has failed for any reason (including without limitation an
event of force majeure), to perform, in any material respect, its
obligations under the Sub-Distribution Agreement entered into pursuant to
this Section 2.1(g)(1), such failure to perform is not cured and
performance by the M Local Affiliate or any other M Local Affiliate is not
resumed within sixty (60) days of written notice by S-P of such failure
and S-P (or its designated Affiliate) can demonstrate to the Singapore
Partnership that it has the ability and the facilities and expertise to
assume the rights and responsibilities of the applicable M Local
Affiliate, then S-P (or its designated Affiliate) shall have the right to
assume the rights and responsibilities of the applicable M Local Affiliate
under the Sub-Distribution Agreement in such EMEA Co-Promotion Country.
In such event, MSDIS, the applicable M Local Affiliate and S-P (or its
designated Affiliate) shall immediately amend the Sub-Distribution
Agreement and/or perform such other acts as are necessary to substitute
S-P (or its designated Affiliate) for the applicable M Local Affiliate as
a party to the Sub-Distribution Agreement and to assign and transfer to
S-P (or its designated Affiliate) all of such M Local Affiliate’s rights
and obligations under the Sub-Distribution Agreement, including without
limitation any rights to receive payment for services performed
thereunder. Nothing in Section 2.1(g) shall be construed as a waiver of
any other rights or remedies available to 

S-P under this Agreement as a
result of such failure to perform by such M Local Affiliate.

     (5) In the event that responsibility for distribution of Cholesterol
Products in an EMEA Co-Promotion Country is transferred to S-P (or its
designated Affiliate) pursuant to Section 2.1(g)(4) and an M Local
Affiliate at any time thereafter demonstrates to the Singapore Partnership
that it has the ability and the facilities and expertise to resume
performance of all such obligations, then the Singapore Partnership shall
determine whether or not to return those rights and responsibilities for
such activities to such M Local Affiliate. If responsibility for such
activities is to be returned to such M Local Affiliate, the Singapore
Partnership, such M Local Affiliate and S-P (or, if applicable, its
designated Affiliate) shall immediately amend the Sub-Distribution
Agreement and/or perform such other acts as are necessary to substitute
the M Local Affiliate for S-P or its Affiliate, as applicable, as a party
to the Sub-Distribution Agreement and to assign and transfer to the M
Local Affiliate all of the rights and obligations under the
Sub-Distribution Agreement. Upon the return of such rights and
obligations to the M Local Affiliate pursuant to this Section 2.1(g)(5),
the costs incurred by M or S-P,

26

 

or their Affiliates in transferring the rights and responsibilities
for distribution of Cholesterol Products in the EMEA Co-Promotion Country
under Section 2.1(g)(4) and this Section 2.1(g)(5), shall be borne as
determined by the Singapore Partnership.

     (6) In the event that, and for so long as, S-P (or an S-P Affiliate)
is responsible for the supply and distribution of Cholesterol Products in
the EMEA pursuant to Section 2.1(e)(2), then S-P, or its designated
Affiliate, shall also assume all of MSDIS’s rights and responsibilities
under each of the Sub-Distribution Agreements entered into pursuant to
this Section 2.1(g). MSDIS, S-P (or its designated Affiliate) and the
applicable Affiliates of M and S-P shall amend the Sub-Distribution
Agreements and/or perform such other acts as are necessary to substitute
S-P (or its designated Affiliate) for MSDIS as a party to the
Sub-Distribution Agreements and to assign and transfer to S-P (or its
designated Affiliate) all of MSDIS’s rights and obligations under the
Sub-Distribution Agreements with respect to Cholesterol Products in the
EMEA.

     Section 2.2. Canada.

               (a) Simultaneously with the execution and delivery of this Agreement, the following documents
shall be executed and delivered with respect to the sale of the Cholesterol Products in the Field
in Canada:

     (1) Partnership Agreement of Merck Frosst Schering Pharma, GP (the
“Canadian Partnership”), in the form attached hereto as Exhibit 8
(the “Canadian Partnership Agreement”), between Merck Frosst
Canada Ltd. and Schering Canada, Inc. pursuant to which the Canadian
Partnership is created for the purposes of the commercialization of the
Cholesterol Products in the Field in Canada.

     (2) Co-Promotion Agreement in the form attached hereto as Exhibit 9,
by and among the Canadian Partnership, Merck Frosst Canada Ltd. and
Schering Canada, Inc., pursuant to which the parties agree to Co-Promote
the Cholesterol Products in the Field in Canada.

     (3) Supply and Distribution Agreement in the form attached hereto as
Exhibit 10, between the Canadian Partnership and the Singapore
Partnership, pursuant to which the Canadian Partnership purchases
finished, unpackaged Cholesterol Products from the Singapore Partnership
for packaging and sale to customers in Canada.

27

 

     (4) Warehousing and Support Services Agreement in the form attached
hereto as Exhibit 11, between the Canadian Partnership and Merck Frosst
Canada Ltd., pursuant to which Merck Frosst Canada Ltd. will provide
administrative and support services to the Canadian Partnership.

     (5) In the event that Merck Frosst Canada Ltd., or any Affiliate of
Merck Frosst Canada Ltd., has failed for any reason (including without
limitation an event of force majeure) to perform, in any material respect,
its obligations under the Warehousing and Support Services Agreement
entered into pursuant to Section 2.2(a)(4), such failure to perform is not
cured and performance by Merck Frosst Canada Ltd., or an Affiliate of
Merck Frosst Canada Ltd., is not resumed within sixty (60) days of written
notice by Schering Canada, Inc., and Schering Canada, Inc. (or its
designated Affiliate) can demonstrate to the Canadian Partnership that it
has the ability and the facilities and expertise to assume such
obligations, then Schering Canada, Inc. (or its designated Affiliate)
shall have the right to assume the rights and responsibilities of Merck
Frosst Canada Ltd. (or its Affiliate, as applicable) under the Warehousing
and Support Services Agreement. In such event, the Canadian Partnership,
Merck Frosst Canada Ltd. (or its Affiliate, as applicable) and Schering
Canada, Inc. (or its designated Affiliate) shall immediately amend the
Warehousing and Support Services Agreement and/or perform such other acts
as are necessary to substitute Schering Canada, Inc. (or its designated
Affiliate) for Merck Frosst Canada Ltd. (or its Affiliate, as applicable)
as a party to the Warehousing and Support Services Agreement and to assign
and transfer to Schering Canada, Inc. (or its designated Affiliate) all of
the rights and responsibilities of Merck Frosst Canada Ltd. (or its
Affiliate, as applicable) under the Warehousing and Support Services
Agreement, including without limitation any rights to receive payment for
services performed thereunder. Nothing in Section 2.2(a)(5) shall be
construed as a waiver of any other rights or remedies available to S-P
under this Agreement as a result of such failure to perform by Merck
Frosst Canada Ltd.

     (6) In the event that responsibilities referred to in Section
2.2(a)(4) are transferred to Schering Canada, Inc. (or its designated
Affiliate) pursuant to Section 2.2(a)(5) and Merck Frosst Canada Ltd., or
any Affiliate of Merck Frosst Canada Ltd., at any time thereafter
demonstrates to the Canadian Partnership that it is has the ability and
the facilities and expertise to resume performance of all such
obligations, then the Canadian Partnership shall determine whether or not
to return those responsibilities to Merck Frosst Canada Ltd or such
Affiliate of Merck Frosst Canada

28

 

Ltd. The Canadian Partnership, Merck Frosst Canada Ltd. (or, if
applicable, its Affiliate) and Schering Canada, Inc. (or, if applicable,
its designated Affiliate) shall immediately amend the Warehousing and
Support Services Agreement and/or perform such other acts as are necessary
to substitute Merck Frosst Canada Ltd. (or its Affiliate) for Schering
Canada, Inc. or its Affiliate, as applicable, as a party to the
Warehousing and Support Services Agreement and to assign and transfer to
Merck Frosst Canada Ltd (or its Affiliate) all of the rights and
obligations under the Warehousing and Support Services Agreement. Upon
the return of such rights and obligations to Merck Frosst Canada Ltd. (or
its Affiliate) pursuant to this Section 2.2(a)(6), the costs incurred by M
or S-P, or their Affiliates in transferring such rights and
responsibilities under Section 2.2(a)(5) and this Section 2.2(a)(6), shall
be borne as determined by the Canadian Partnership.

               (b) As soon as reasonably practicable following the execution and delivery of this Agreement,
the following documents shall be executed and delivered with respect to the sale of the Cholesterol
Products in the Field in Canada:

     (1) Toll Packaging Agreement (Combination Products) in the form
attached hereto as Exhibit 6 (with such variations as may be necessary to
comply with local laws), between the Canadian Partnership and Merck Frosst
Canada Ltd., pursuant to which the Canadian Partnership arranges for
packaging of the finished Combination Products with Merck Frosst Canada
Ltd. The Toll Packaging Agreement will provide, among other things, that
Merck Frosst Canada Ltd., may arrange for an Affiliate, a Third Party or
an Affiliate of S-P to toll package the Combination Products on behalf of
Merck Frosst Canada Ltd.

     (2) Toll Packaging Agreement (Ezetimibe Monotherapy Product) in the
form attached hereto as Exhibit 6 (with such variations as may be
necessary to comply with local laws), between the Canadian Partnership and
Schering Canada, Inc., pursuant to which the Canadian Partnership arranges
for packaging of the finished Ezetimibe Monotherapy Product with Schering
Canada, Inc. The Toll Packaging Agreement will provide, among other
things, that the Affiliate of S-P may arrange for an Affiliate, a Third
Party or an Affiliate of M to toll package the Ezetimibe Monotherapy
Product on behalf of the Affiliate of S-P.

29

 

     Section 2.3. Latin America.

               (a) Supply and Distribution.

     (1) Simultaneously with the execution and delivery of this Agreement,
the Singapore Partnership shall execute and deliver separate, identical
(except for the name of MSDIL and SOL) Supply and Distribution Agreements
in the form attached hereto as Exhibit 12, with MSDIL and SOL pursuant to
which, in each case, MSDIL and SOL, respectively, will have the right to
acquire finished, unpackaged Cholesterol Products for packaging and sale
to customers in Latin America. MSDIL and SOL will then separately arrange
for warehousing and sale in those countries in Latin America in which M or
S-P, as applicable, has determined to sell the Cholesterol Products.

               (b) Toll Packaging.

     (1) As soon as reasonably practicable following the execution and
delivery of this Agreement, separate Toll Packaging Agreements in the form
attached hereto as Exhibit 6 (with such variations as may be necessary to
comply with local laws and regulations), relating to the packaging of
Cholesterol Products for sale by M and its Affiliates in Latin America
shall be entered into between MSDIL and an M Affiliate and S-P Affiliate,
respectively, pursuant to which (i) the M Affiliate will package the
finished Combination Products, and (ii) the S-P Affiliate will package the
finished Ezetimibe Monotherapy Product, in each case, for sale by M and
its Affiliates in Latin America.

     (2) As soon as reasonably practicable following the execution and
delivery of this Agreement, separate Toll Packaging Agreements in the form
attached hereto as Exhibit 6 (with such variations as may be necessary to
comply with local laws and regulations), relating to the packaging of
Cholesterol Products for sale by S-P and its Affiliates in Latin America
shall be entered into between SOL and an M Affiliate and S-P Affiliate,
respectively, pursuant to which (i) the M Affiliate will package the
finished Combination Products, and (ii) the S-P Affiliate will package the
finished Ezetimibe Monotherapy Product, in each case, for sale by S-P and
its Affiliates in Latin America.

     Section 2.4. Far East.

               (a) Far East Co-Marketing Countries.

     (1) Simultaneously with the execution and delivery of this Agreement,
the Singapore Partnership shall execute and

30

 

deliver separate, identical (except for the name of MSDAPS and SOL)
Supply and Distribution Agreements in the form attached hereto as Exhibit
12, with MSDAPS and SOL, pursuant to which such Affiliate will have the
right to acquire finished, unpackaged Cholesterol Products for packaging
and sale to customers in Far East Co-Marketing Countries. MSDAPS and SOL
will then separately arrange for warehousing and sale in those Far East
Co-Marketing Countries in which M or S-P, as applicable, has determined to
sell the Cholesterol Products.

               (b) Far East Board Countries.

     (1) As soon as reasonably practicable following the execution and
delivery of this Agreement (or if the list of Far East 

Co-Promotion
Countries is amended, upon the approval of such amendment by the Far East
Operating Board), a Far East Co-Venture Agreement in the form attached
hereto as Exhibit 13 (with such variations as may be necessary to comply
with local laws and regulations), covering each of the Far East
Co-Promotion Countries shall be executed and delivered by Local Affiliates
of M and S-P, except in limited instances where both Parties agree that an
Entity Agreement is required by local laws and regulations of a country,
in which case the Parties will enter into an Entity Agreement based
substantially on the Far East Co-Venture Agreement (with such variations
as may be necessary to comply with local laws and regulations), no later
than ninety (90) days following the execution and delivery of this
Agreement. If any taxes, duties, discounts, rebates, price reductions or
other financial considerations imposed under the local laws, rules and/or
regulations with respect to a Far East country, or under an
administrative, judicial or other governmental action with respect to a
Far East country, would materially financially disadvantage a
Disadvantaged Party but not the other Party and/or its Affiliates (or
would cause a material financial disadvantage to one Party and/or its
Affiliates greater than that caused to the other Party and/or its
Affiliates) with respect to such Far East country, solely as a result of
its Obligations, and the Parties have first each, separately or together,
used commercially reasonable efforts to mitigate the effect of the
Obligations, then the Parties agree to work together in good faith, for a
reasonable period of time, to structure the local arrangement in a manner
that would result in the Obligations not being imposed in any material
respect (but without altering the treatment of the applicable country as
an Far East 

Co-Promotion Country). If after such good faith efforts the
Parties are unable to implement such a structure, then the Parties shall
in good faith agree upon such variations to the applicable Far East
Co-Venture Agreement or Entity Agreement as would be necessary to put the

31

 

Parties in the economic position in the applicable country that they
would have been in under the applicable Far East Co-Venture Agreement or
Entity Agreement had the Obligations not been imposed. M, S-P and their
respective Affiliates shall not (i) engage in any ECLAFE Cholesterol
Business in the applicable country without the approval of the Far East
Operating Board, except for activities approved and conducted pursuant to
the Development Agreement or required under this Agreement, or
(ii) distribute or sell Cholesterol Products in a Far East Co-Promotion
Country, in each case, until such Far East Co-Venture Agreement or Entity
Agreement has been executed and delivered with respect to the Far East
Co-Promotion Country.

     (2) As soon as reasonably practicable following the execution and
delivery of this Agreement, MSDAPS and the Singapore Partnership shall
execute and deliver a Supply and Distribution Agreement in the form
attached hereto as Exhibit 5, pursuant to which MSDAPS will acquire
finished, unpackaged Cholesterol Products for packaging and sale to
customers in Far East Co-Promotion Countries (other than China) and Far
East Single Presence Countries in which M has been deemed to have the
single presence.

     (3) As soon as reasonably practicable following the execution and
delivery of this Agreement, SOL and the Singapore Partnership shall
execute and deliver a Supply and Distribution Agreement in the form
attached hereto as Exhibit 5, pursuant to which SOL will acquire finished
unpackaged Cholesterol Products for packaging and sale to customers in
China (if China becomes a Far East Co-Promotion Country in accordance with
Section 3.5.3 of this Agreement), and Far East Single Presence Countries
in which S-P has been deemed to have the single presence.

     (4) As soon as reasonably practicable following the execution and
delivery of this Agreement, with respect to Far East Co-Promotion
Countries, Local Affiliates of M will enter into Sub-Distribution
Agreements in the form attached hereto as Exhibit 14 (with such variations
as may be necessary to comply with local laws and regulations), with
MSDAPS pursuant to which each M Local Affiliate will purchase finished,
packaged Cholesterol Products from MSDAPS for sale in the Far East
Co-Promotion Countries (other than China).

     (5) As soon as reasonably practicable following the execution and
delivery of this Agreement, with respect to Far East Single Presence
Countries in which M has been deemed to have the single presence, a Local
Affiliate of M will enter into Sub-

32

 

Distribution Agreements in the form attached hereto as Exhibit 14
(with such variations as may be necessary to comply with local laws and
regulations), with MSDAPS pursuant to which the M Local Affiliate will
purchase finished, packaged Cholesterol Products from MSDAPS for sale in
the applicable Far East Single Presence Countries.

     (6) As soon as reasonably practicable following the execution and
delivery of this Agreement, with respect to Far East Single Presence
Countries in which S-P has been deemed to have the single presence and
China (if China becomes a Far East Co-Promotion Country in accordance with
Section 3.5.3 of this Agreement), a Local Affiliate of S-P will enter into
Sub-Distribution Agreements in the form attached hereto as Exhibit 14
(with such variations as may be necessary to comply with local laws and
regulations), with SOL pursuant to which each S-P Local Affiliate will
purchase finished, packaged Cholesterol Products from SOL for sale in the
applicable Far East Single Presence Countries and China (if China becomes
a Far East Co-Promotion Country in accordance with Section 3.5.3 of this
Agreement).

     (7) If any party to a Supply and Distribution Agreement referenced in
Sections 2.4(b)(2) or 2.4(b)(3) with respect to Far East 

Co-Promotion
Countries, or a Sub Distribution Agreement referenced in Sections
2.4(b)(4) with respect to Far East Co-Promotion Countries, has failed, for
any reason (including without limitation an event of force majeure), to
perform, in any material respect, its obligations under the Supply and
Distribution Agreement or Sub Distribution Agreement, as the case may be,
then the rights set forth in Sections 2.1(e)(2), (3) and (g)(6) or
Sections 2.1(g)(4) and (5), as the case may be, shall apply with respect
to supply and distribution in the applicable Far East Board Countries in
the same manner as such rights are applicable to the EMEA. In such case,
references to M and S-P shall be deemed to be references to whichever of M
or S-P is, and is not, the responsible party for these Agreements, as
applicable.

               (c) Far East Single Presence Countries.

     (1) Sales of Cholesterol Products in the Field in Far East Single
Presence Countries shall be governed by the provisions of Section 3.6.4.
and the Far East Single Presence Country Exhibit attached hereto as
Exhibit 15.

33

 

               (d) Toll Packaging.

     (1) As soon as reasonably practicable following the execution and
delivery of this Agreement, separate Toll Packaging Agreements in the form
attached hereto as Exhibit 6 (with such variations as may be necessary to
comply with local laws and regulations), relating to the packaging of
Cholesterol Products for sale by (x) M and its Affiliates in Far East
Co-Marketing Countries, and (y) M and its Affiliates in Far East Single
Presence Countries in which M has been deemed to have the single presence,
and (z) the Parties in Far East Co-Promotion Countries (other than China),
shall be entered into between MSDAPS and an M Affiliate and S Affiliate,
respectively, pursuant to which (i) the M Affiliate will package the
finished Combination Products and (ii) the S-P Affiliate will package the
finished Ezetimibe Monotherapy Product, in each case, for sale in the Far
East.

     (2) As soon as reasonably practicable following the execution and
delivery of this Agreement, separate Toll Packaging Agreements in the form
attached hereto as Exhibit 6 (with such variations as may be necessary to
comply with local laws and regulations), relating to the packaging of
Cholesterol Products for sale by (x) S-P and its Affiliates in Far East
Co-Marketing Countries, (y) S-P and its Affiliates in Far East Single
Presence Countries in which S-P has been deemed to have the single
presence, and (z) the Parties in China (if China becomes a Far East
Co-Promotion Country in accordance with Section 3.5.3 of this Agreement),
shall be entered into between SOL and an M Affiliate and S Affiliate,
respectively, pursuant to which (i) the M Affiliate will package the
finished Combination Products and (ii) the S-P Affiliate will package the
finished Ezetimibe Monotherapy Product, in each case, for sale in the Far
East.

     Section 2.5. Amendment of Prior Agreements and S-P ECLAFE License Agreements.

          Section 2.5.1. Amendment of Prior Agreements. Simultaneously with the execution and
delivery of this Agreement, the following agreements shall be amended and/or restated as
hereinafter described:

     (1) The Singapore Partnership Agreement shall be amended and restated
in the form attached hereto as Exhibit 16.

     (2) The Governance Agreement shall be amended in the form attached
hereto as Exhibit 17, to, among other things, (i) expand the
non-competition provisions to cover ECLAFE; (ii) expand the product recall
provisions to cover ECLAFE; and (iii)

34

 

expand certain termination rights, including without limitation,
change of control termination rights, to cover ECLAFE.

     (3) M License Agreement shall be amended and restated in the form
attached hereto as Exhibit 18, to, among other things, expand the
definition of “Territory” to include ECLAFE with respect to the
Combination Products.

     (4) M Formulation Agreement shall be amended and restated in the form
attached hereto as Exhibit 19, to, among other things, expand the
definition of “Territory” to include ECLAFE with respect to the
Combination Products.

     (5) Amended and Restated S-P License Agreement shall be executed and
delivered in the form attached hereto as Exhibit 20.

     (6) Amended and Restated Contribution Agreement Schering Sales
Management, Inc. (Cholesterol), shall be executed and delivered in the
form attached hereto as Exhibit 21.

     (7) Amended and Restated Contribution Agreement Schering MSP
Pharmaceuticals Limited Partnership (Cholesterol) shall be executed and
delivered in the form attached hereto as Exhibit 22.

     (8) Amended and Restated Contribution Agreement Scherico, Ltd.
(Cholesterol), shall be executed and delivered in the form attached hereto
as Exhibit 23.

     (9) Amended and Restated Contribution Agreement Schering-Plough
(Singapore) Pte. Ltd. (Cholesterol), shall be executed and delivered in
the form attached hereto as Exhibit 24.

     (10) Amended and Restated Sublicense Agreement (Existing Ezetimibe
and Cholesterol Combination IP), shall be executed and delivered in the
form attached hereto as Exhibit 25.

     (11) Amended and Restated S-P Formulation Agreement shall be executed
and delivered in the form attached hereto as Exhibit 26.

     (12) Contract Manufacturing Agreement (Simvastatin) shall be amended
and restated in the form attached hereto as Exhibit 27, to expand the
definition of “Territory” to include ECLAFE.

35

 

     (13) Contract Manufacturing Agreement (Ezetimibe) shall be amended
and restated in the form attached hereto as Exhibit 28, to expand the
definition of “Territory” to include ECLAFE.

     (14) Toll Manufacturing Agreement (Zocor Combination) shall be
amended and restated in the form attached hereto as Exhibit 29, to expand
the definition of “Territory” to include ECLAFE.

     (15) Toll Manufacturing Agreement (Ezetimibe Monotherapy Product)
shall be amended and restated in the form attached hereto as Exhibit 30,
to expand the definition of “Territory” to include ECLAFE.

     (16) Development Agreement shall be amended and restated in the form
attached hereto as Exhibit 31, to (i) expand the Cholesterol Development
Committee (as defined in the Development Agreement) to include
representatives to address EMEA development issues related to the
Cholesterol Products and to expand the Cholesterol Task Force (as defined
in the Development Agreement) as needed for specific EMEA and/or LAFE
activities, (ii) expand its mission to cover Canadian development issues,
and (iii) expand drug experience reporting procedures to cover ECLAFE.

     (17) Limited Liability Company Agreement of MSP Technology (US)
Company LLC (“MSP Technology Agreement”) shall be amended and
restated in the form attached hereto as Exhibit 32.

     (18) Guarantee by Schering Corporation shall be amended in the form
attached hereto as Exhibit 33.

          Section 2.5.2. S-P ECLAFE License Agreements. Simultaneously with the execution and
delivery of this Agreement, the following agreements shall be executed and delivered as hereinafter
described:

     (1) ECLAFE S-P License Agreement shall be executed and delivered in
the form attached hereto as Exhibit 34.

     (2) ECLAFE Contribution Agreement Schering Sales Management, Inc.
(Cholesterol), shall be executed and delivered in the form attached hereto
as Exhibit 35.

     (3) ECLAFE Contribution Agreement Schering MSP Pharmaceuticals
Limited Partnership (Cholesterol) shall be executed and delivered in the
form attached hereto as Exhibit 36.

36

 

     (4) ECLAFE Contribution Agreement Scherico, Ltd. (Cholesterol), shall
be executed and delivered in the form attached hereto as Exhibit 37.

     (5) ECLAFE Contribution Agreement Schering-Plough (Singapore) Pte.
Ltd. (Cholesterol), shall be executed and delivered in the form attached
hereto as Exhibit 38.

     (6) ECLAFE Sublicense Agreement (Existing Ezetimibe and Cholesterol
Combination IP), shall be executed and delivered in the form attached
hereto as Exhibit 39.

     (7) ECLAFE S-P Formulation Agreement shall be executed and delivered
in the form attached hereto as Exhibit 40.

     Section 2.6. Certain Contract Manufacturing Agreements.

     In the event that the M/E Combination Product is proposed to be
developed for sale in ECLAFE, then, promptly after such determination, the
Parties will execute and deliver the following amendments to the following
Agreements:

     (1) Contract Manufacturing Agreement [*] shall be amended and
restated to expand the definition of “Territory” to include ECLAFE in the
same manner as Contract Manufacturing Agreement (Simvastatin) is being
amended and restated pursuant to Section 2.5(9).

     (2) Toll Manufacturing Agreement ([*] Combination Product) shall be
amended and restated to expand the definition of “Territory” to include
ECLAFE in the same manner as Toll Manufacturing Agreement (Zocor
Combination) is being amended and restated pursuant to Section 2.5(11).

     Section 2.7. Toll Packaging Rights.

     (1) In the event that M or S-P, or any of their Affiliates, has
failed for any reason (including without limitation an event of force
majeure) to perform, in any material respect, its obligations under any
Toll Packaging Agreement in ECLAFE entered into pursuant to this Section 2
in which M or S-P or their respective Affiliates (such Person, the
“Packager”) package any Cholesterol Products on behalf of the
other Party, or any of its respective Affiliates (the
“Non-Packager”), such failure to perform is not cured and
performance is not resumed within sixty (60) days of written notice by the
Non-Packager, and the Non-Packager (or its designated Affiliate) can
demonstrate to the Singapore Partnership that it has the ability and the
facilities and expertise to assume such

37

 

obligations, then the Non-Packager (or its designated Affiliate)
shall have the right to assume the rights and responsibilities of the
Packager under the Toll Packaging Agreement for packaging is the
applicable countries in ECLAFE. In such event, the Singapore Partnership,
the Packager and the Non-Packager (or its designated Affiliate) shall
immediately amend the Toll Packaging Agreement and/or perform such other
acts as are necessary to substitute the Non-Packager (or its designated
Affiliate) for the Packager as a party to the Toll Packaging Agreement and
to assign and transfer to the Non-Packager (or its designated Affiliate)
all of the Packager’s rights and obligations under the Toll Packaging
Agreement with respect to packaging of Cholesterol Products in the
applicable countries in ECLAFE, including without limitation any rights to
receive payment for services performed thereunder. Nothing in Section 2.7
shall be construed as a waiver of any other rights or remedies available
to the Non-Packager under this Agreement as a result of such failure to
perform by the Packager.

     (2) In the event that responsibility for packaging of Cholesterol
Products in the applicable countries in ECLAFE is transferred to the
Non-Packager (or its designated Affiliate) pursuant to Section 2.7(1) and
the Packager at any time thereafter demonstrates to the Singapore
Partnership that it has the ability and the facilities and expertise to
resume performance of all such obligations, then the Singapore Partnership
shall determine whether or not to return those responsibilities to the
Packager. If responsibility for such activities is to be returned to the
Packager, the Singapore Partnership, the Packager and the Non-Packager
(or, if applicable, its designated Affiliate) shall immediately amend the
Toll Packaging Agreement and/or perform such other acts as are necessary
to substitute the Packager for the Non-Packager or its Affiliate, as
applicable, as a party to the Toll Packaging Agreement and to assign and
transfer to the Packager all of the rights and obligations under the Toll
Packaging Agreement with respect to packaging of Cholesterol Products in
the applicable countries in ECLAFE. Upon the return of such rights and
obligations to the Packager pursuant to this Section 2.7(2), the costs
incurred by M or S-P, or their Affiliates in transferring the rights and
responsibilities for packaging of Cholesterol Products in the applicable
countries in ECLAFE under Section 2.7(1) and this Section 2.7(2), shall be
borne as determined by the Singapore Partnership.

38

 

ARTICLE III

MANAGEMENT

     Section 3.1. Worldwide Oversight Committee.

               (a) Formation; Purposes. Within forty-five (45) days after the Effective Date, M
and
S-P shall establish a worldwide oversight committee (the “WWOC”), which shall advise and
provide guidance with respect to the Worldwide Cholesterol Business. The WWOC shall review and
advise with respect to all worldwide strategic matters, including long range plans, long range
sales and profit targets, supply shortage allocations and research matters that have an impact on
the Worldwide Cholesterol Business.

               (b) Membership. The WWOC shall be composed of an equal number of representatives
appointed by S-P on the one hand and M on the other. The WWOC shall initially be comprised of five
(5) senior executives of S-P or any of its Affiliates, on the one hand and five (5) senior
executives of M or any of its Affiliates on the other (the “WWOC Representatives”). S-P
may, from time to time, replace any of its WWOC Representatives with another representative of S-P
or any of its Affiliates upon written notice to M and M may, from time to time, replace any of its
WWOC Representatives with another representative of M or any of its Affiliates upon written notice
to S-P. One of the WWOC Representatives appointed by M and one of the members of the WWOC
Representatives appointed by S-P shall be designated by M and S-P, respectively, as a chair
(together, “WWOC Chairs”). The WWOC Chairs shall have responsibility for calling meetings
of the WWOC, circulating agendas, allocating responsibilities for keeping minutes of the WWOC, and
performing administrative tasks required to assure efficient operations of the WWOC.

               (c) Meetings of the WWOC. The WWOC shall hold regular meetings no less frequently
than once every quarter, unless the WWOC otherwise determines. Special meetings of the WWOC may be
called upon reasonable written notice by either WWOC Chair. Meetings, in addition to quarterly
meetings, shall be held as necessary to communicate and interact with the Board of Directors of the
Singapore Partnership to review and discuss whether research and development activities are being
coordinated on a worldwide basis consistently with the recommendations of the WWOC. Meetings of
the WWOC may be held in person, or by audio or video teleconference. S-P on the one hand and M on
the other shall be responsible for all of the expenses incurred by their respective WWOC
Representatives, which expenses arise out of such person’s membership in the WWOC.

               (d) Manner of Acting. The WWOC shall meet only if at least two representatives of S-P
on the one hand and two representatives of M on the other are participating. The WWOC shall make
recommendations regarding the Worldwide Cholesterol Business only if all the WWOC Representatives
participating shall approve such recommendation.

39

 

     Section 3.2. Management of the EMEA.

          Section 3.2.1. EMEA Operating Board.

               (a) Formation; Purposes. Within 45 days after the Effective Date, M and S-P shall
establish an operating board (the “EMEA Operating Board”), which shall have overall
responsibility for the management of the Cholesterol Products in the Field in the EMEA. Without
limiting the generality of the foregoing, the responsibilities of the EMEA Operating Board shall be
approving annual Marketing and Educational Plans and Five-Year Strategic Business Plans (each in
the manner described in Section 3.2.4), capital forecasts and budgets (including costs of Phase V
studies), as well as registration strategy and pricing/reimbursement strategy as proposed by the
EMEA General Manager. The EMEA Operating Board shall carry out its responsibilities as set forth
in this Agreement and the Related Agreements, as applicable, and shall have the authority to
approve or disapprove any recommendation of the EMEA General Manager under this Agreement and the
Related Agreements, as applicable. With respect to matters not the subject of recommendation by
the EMEA General Manager under this Agreement or the Related Agreements, as applicable, no business
may be transacted in the EMEA as contemplated by this Agreement and the Related Agreements without
the prior written consent or written authorization of the EMEA Operating Board. The EMEA Operating
Board shall operate with the intent of maximizing the commercialization of the Cholesterol Products
in the Field in the EMEA. The Parties will seek to avoid unnecessary bureaucracy regarding the
EMEA Operating Board and will seek to utilize the existing expertise within M and S-P. The EMEA
Operating Board shall operate independently of M or S-P or their Affiliates and all lawful
determinations, decisions and actions made or taken by the EMEA Operating Board shall be conclusive
and absolutely binding with respect to the ECLAFE Cholesterol Business in the EMEA.

               (b) Membership. The EMEA Operating Board shall be composed of an equal number of
representatives appointed by S-P on the one hand and M on the other. The EMEA Operating Board
shall initially be comprised of three (3) senior executives of S-P or any of its Affiliates, on the
one hand, and three (3) senior executives of M or any of its Affiliates, on the other. S-P and M
may, upon mutual written consent, change the size and/or composition of the EMEA Operating Board
from time to time. S-P may, in its sole discretion, replace any of its EMEA Operating Board
representatives with another senior executive of S-P or any of its Affiliates at any time upon
written notice to M, and M may, in its sole discretion, replace any of its EMEA Operating Board
representatives with another senior executive of M or any of its Affiliates at any time upon
written notice to S-P. One of the members of the EMEA Operating Board appointed by M shall be
designated by M as the initial EMEA Operating Board Chair (the “EMEA Operating Board
Chair”). The initial EMEA Operating Board Chair (or any replacement designated by M) shall
serve until the end of Calendar Year 2002 and the right to designate the EMEA Operating Board Chair
shall then alternate annually on a Calendar Year basis between a representative of the EMEA
Operating Board designated by S-P and a representative of the EMEA Operating Board designated by M.
The EMEA Operating Board Chair shall be responsible for calling meetings of the EMEA Operating
Board, circulating agendas, allocating responsibilities for keeping

40

 

minutes of the EMEA Operating Board, and performing administrative tasks required to assure
efficient operations of the EMEA Operating Board. Except as expressly set forth in the prior
sentence, the EMEA Operating Board Chair shall have no special rights or authority.

               (c) Meetings of the EMEA Operating Board. The EMEA Operating Board shall hold regular
meetings no less frequently than once every quarter, unless the EMEA Operating Board otherwise
determines. Special meetings of the EMEA Operating Board may be called by any EMEA Operating Board
member, upon reasonable written notice. Meetings, in addition to quarterly meetings, shall be held
timely to approve Marketing and Educational Plans submitted for EMEA Operating Board approval in
accordance with this Agreement and the Related Agreements, as applicable. Meetings of the EMEA
Operating Board may be held in person, or by audio or video teleconference. S-P on the one hand
and M on the other shall be responsible for all of the expenses incurred by their representatives
which are EMEA Operating Board members, which expenses arise out of such EMEA Operating Board
member’s membership on the EMEA Operating Board.

               (d) Manner of Acting. Meetings of the EMEA Operating Board shall be effective only if
at least two representatives of S-P on the one hand and at least two representatives of M on the
other are present or participating throughout. The unanimous vote of the members of the EMEA
Operating Board present or participating at any meeting of the EMEA Operating Board shall be
necessary for the passage of any resolution or act of the EMEA Operating Board. Any action
required or permitted to be taken by the EMEA Operating Board may be taken without a meeting if
each member of the EMEA Operating Board consents thereto in writing.

               (e) Dispute Resolution. Except as set forth in Section 3.2.1(f) and 3.2.4(c) and
(d)
of this Agreement, the members of the EMEA Operating Board will use reasonable efforts to resolve
any dispute, claims, controversies or disagreements relating to the ECLAFE Cholesterol Business in
the EMEA. If any matter cannot be resolved by the EMEA Operating Board within a reasonable period
of time, such reasonableness to be considered in view of the urgency and importance of the matter,
and in any event, within thirty (30) days after the representative(s) of S-P on the one hand or M
on the other on the EMEA Operating Board has given written notice of such disagreement to the
representative(s) of the other Party, S-P and M each shall cause to be prepared and circulated to
the other Party a memorandum or other form of statement setting out its position on the matter in
dispute and its reasons for adopting such position. Each such memorandum or statement shall be
considered by the respective EMEA Executive Sponsors of M or S-P, as applicable. The respective
EMEA Executive Sponsors of M and S-P shall use their respective good faith reasonable efforts to
jointly recommend a resolution of such dispute to the EMEA Operating Board as promptly as
practicable but in any event no later than thirty (30) days after submission of such matter to such
EMEA Executive Sponsors. Upon resolution of the matter, the respective EMEA Executive Sponsors
shall jointly execute a written statement setting forth the terms of such recommended resolution.

41

 

               (f) Product Launch Decisions. Cholesterol Products shall be registered, Launched and
sold in the Field [*].

          Section 3.2.2. EMEA General Manager.

               (a) Designation; Purposes. M shall have the right to designate one employee of M,
subject to the written consent of S-P (such consent not to be unreasonably withheld), to serve as
the general manager of the Cholesterol Products and the ECLAFE Cholesterol Business in the EMEA
(the “EMEA General Manager”). M may from time to time, subject to S-P’s written consent
(such consent not to be unreasonably withheld), replace the EMEA General Manager with another
employee of M. S-P shall have the right to cause the removal of the EMEA General Manager (subject
to the written consent of M, not to be unreasonably withheld), provided that (i) such right shall
be exercisable no more than once every two years and (ii) M shall have the right to designate a
replacement for any removed EMEA General Manager subject to S-P’s written consent (such consent not
to be unreasonably withheld). Except as otherwise provided in this Agreement and in any of the
Related Agreements, the EMEA General Manager shall coordinate the activities of the ECLAFE
Cholesterol Business in the EMEA by making recommendations to the EMEA Operating Board with respect
to the operation and management of the Cholesterol Products and the ECLAFE Cholesterol Business in
the EMEA and shall take such other actions as provided in the Related Agreements. The EMEA General
Manager will coordinate EMEA development needs, develop Marketing and Educational Plans and
strategic plans, oversee execution of plans and monitor performance (including receiving quarterly
reports from each Country Marketing Committee in the EMEA regarding the execution of marketing,
sales and promotion efforts) and otherwise be responsible for maximizing commercialization of the
Cholesterol Products in the Field in the EMEA. The EMEA General Manager shall be fully dedicated
to the ECLAFE Cholesterol Business in the EMEA and shall act in the best interests of the ECLAFE
Cholesterol Business in the EMEA and shall not be involved in any activities relating to the
competing products of S-P or M or any of their respective Affiliates (such as ZOCOR or [*]) unless
the EMEA Operating Board agrees otherwise. The EMEA General Manager’s compensation shall be based
on the success of the Cholesterol Products in the Field in the EMEA which, in the period prior to
Launch of the Cholesterol Products in the Field in the EMEA, shall be determined by the EMEA
Operating Board based on the ability to meet development timelines and, in the period following
Launch of the Cholesterol Products in the Field in the EMEA, shall be determined by the EMEA
Operating Board based on meeting projected sales in the EMEA as set forth in the applicable
Marketing and Educational Plans. The EMEA General Manager shall also enter into an appropriate
confidentiality agreement. Such confidentiality agreement shall govern the use or disclosure of
Confidential Information obtained from M, S-P or any of their respective Affiliates.

               (b) Management. The EMEA General Manager will report to the EMEA Operating Board and
on a day-to-day administrative basis to the M Senior Vice President, Worldwide Human Health
Marketing and the EMEA General Manager shall have such duties and responsibilities as provided in
this Agreement and the Related Agreements. The EMEA General Manager shall appoint the members of
his or her staff

42

 

including one S-P employee. The EMEA General Manager will appoint an M employee to serve as
the EMEA marketing director (the “EMEA Marketing Director”) who will chair the EMEA
Marketing Committee. The EMEA Marketing Director will report to the EMEA General Manager. The
EMEA General Manager shall meet with the EMEA Marketing Committee and the EMEA Operating Board as
frequently as necessary, but not less than quarterly, to review and discuss the actual results
compared to the applicable Five-Year Strategic Business Plan, Marketing and Educational Plan or
Default Marketing Plan (as the case may be) for each EMEA Board Country. Each Country Marketing
Committee in the EMEA shall consult with the EMEA General Manager as and to the extent the Country
Marketing Committee believes such consultation is necessary or appropriate or as otherwise required
by this Agreement or the Related Agreements.

               (c) Country Marketing Committee Disputes. All Country Marketing Committee disputes
relating to the ECLAFE Cholesterol Business in the EMEA which cannot be resolved by a Country
Marketing Committee within a reasonable period of time, such reasonableness to be considered in
view of the urgency and importance of the matter, and in any event, within fifteen (15) days after
the representative(s) of S-P on the one hand or M on the other on the Country Marketing Committee
has given written notice of such disagreement to the representative(s) of the other Party, shall be
referred to the EMEA General Manager who will seek to resolve such disputes. In the event the EMEA
General Manager is unable to resolve such a dispute to the satisfaction of both local M and S-P
entities within thirty (30) days after the dispute has been referred to the EMEA General Manager,
the dispute shall be referred to the EMEA Executive Sponsors who shall use their respective good
faith efforts to jointly recommend a resolution of such dispute to the EMEA Operating Board as
promptly as practicable but in no event later than ten (10) days after submission of such matter to
the EMEA Executive Sponsors. Upon resolution of the matter, the respective EMEA Executive Sponsors
shall jointly execute a written statement setting forth the terms of such recommended resolution.
If the EMEA Executive Sponsors cannot reach resolution within such ten (10) day period, the dispute
will be referred to the EMEA Operating Board for resolution pursuant to Section 3.2.1(e).

          Section 3.2.3. EMEA Marketing Committee.

               (a) Formation. Within forty-five (45) days after the Effective Date, S-P and
M  shall
cause to be established a marketing committee (the “EMEA Marketing Committee”). The EMEA
Marketing Committee will be comprised of twenty (20) members, the chair of the EMEA Marketing
Committee, S–P’s senior global marketing representative having responsibility for Cholesterol
Products, as well as one representative from each of M and S-P from each of the following countries
or groups of countries: (i) Germany, (ii) France, (iii) Italy, (iv) Spain, (v) the U.K., (vi)
Scandinavian Region, (vii) Mid-Europe Region, (viii) Central and Eastern Europe Region and (ix) the
Middle East Africa Region.

               (b) Purposes. The EMEA Marketing Committee shall advise the EMEA General Manager and
be responsible for identifying and proposing to the EMEA Operating Board through the EMEA General
Manager operating strategies for

43

 

marketing aspects of the Cholesterol Products in the Field in the EMEA and coordinating
pan-EMEA initiatives and sharing best practices. The EMEA Marketing Committee, through the EMEA
Marketing Director, shall also be responsible for identifying and proposing the specific needs of
the EMEA for the successful commercialization of the Cholesterol Products in the Field. Members of
the EMEA Marketing Committee will act in the best interests of the maximum commercialization of the
Cholesterol Products in the Field. The EMEA Marketing Committee shall have no express or implied
authority to act on behalf of the EMEA Operating Board, EMEA General Manager, or M or S-P or any of
their respective Affiliates.

          Section 3.2.4. Five-Year Plans; Approval of Annual Marketing and Educational Plans;
Default Marketing Plans.

               (a) No later than May 15 of each Calendar Year, each (i) EMEA Regional
Representative, after
consultation and collaboration with, and the endorsement of the applicable Country Marketing
Committee(s) in the EMEA, and (ii) Country Marketing Committee in the EMEA for which no EMEA
Regional Representative has been appointed, will present a five-year strategic business plan (a
“Five-Year Strategic Business Plan”) to the EMEA General Manager. The Five-Year Strategic
Business Plan shall include a comprehensive marketing, sales, pricing, manufacturing, supply, and
distribution strategy (including, without limitation, Phase V and educational activities) and
related profit and loss forecasts for the Cholesterol Products in the Field in the applicable
country or group of countries. The EMEA General Manager will, in consultation and collaboration
with the applicable EMEA Regional Representative or Country Marketing Committee for countries in
which no EMEA Regional Representative has been appointed, prepare a Five-Year Strategic Business
Plan for the EMEA and submit such Five-Year Strategic Business Plan to the EMEA Operating Board for
approval no later than July 31 of each Calendar Year.

               (b) If a Country Marketing Committee in an EMEA Board Country cannot agree on an estimate of
(i) the optimal number of PDEs required to be delivered by each of M and S-P or their respective
Affiliates to Targeted Prescribers, (ii) the positioning of such PDEs for Targeted Prescribers, and
(iii) the frequency of such PDEs for Targeted Prescribers, so as to maximize the commercial
potential of each Cholesterol Product, and to provide for market leadership by a Cholesterol
Product in the Field (collectively, the “PDE Requirements”), in accordance with the
applicable EMEA Board Country Agreement, then M and S-P will agree on a marketing consulting firm
to provide a report (a “Consultant’s Report”) to the EMEA General Manager in a timely
manner having regard to the requirements of Section 3.2.4(c) detailing, with respect to any such
EMEA Board Country, such consulting firm’s estimate of the PDE Requirements. Notwithstanding the
foregoing, no Consultant’s Report shall be sought with respect to an EMEA Board Country if the
Country Marketing Committee for such EMEA Board Country determines that a Consultant’s Report would
not be commercially beneficial.

               (c) No later than September 1 of each Calendar Year, each (i) EMEA Regional Representative,
after consultation and collaboration with, and the

44

 

endorsement of the applicable Country Marketing Committee(s) in the EMEA, and (ii) Country
Marketing Committee in each country in the EMEA for which no EMEA Regional Representative has been
appointed, will submit a preliminary Marketing and Educational Plan with respect to the Cholesterol
Products in the Field in the applicable EMEA Board Country for the following Calendar Year to the
EMEA General Manager for consultation and review. This preliminary Marketing and Educational Plan
will (i) identify the Cholesterol Product which will receive primary emphasis, (ii) seek to
maximize the commercial potential of each Cholesterol Product in the Field within the applicable
country or region, and to provide for market leadership by a Cholesterol Product, (iii) be based on
the Consultant’s Reports, if any, as well as match, where appropriate, the efforts of leading
competitors of the ECLAFE Cholesterol Business in such EMEA Board Country, (iv) identify Targeted
Prescribers, (v) identify the number of PDEs to be delivered by Specialty Representatives, Hospital
Representatives and Primary Care Representatives and (vi) propose spending levels with respect to
Non-Representative Educational and Promotional Activities. Following a review of such preliminary
Marketing and Educational Plans, the EMEA General Manager, in consultation and collaboration with
the EMEA Regional Representative or the Country Marketing Committee in countries in the EMEA for
which no EMEA Regional Representative has been appointed, will submit a written report to the EMEA
Operating Board describing any principle issues, if any, which could reasonably be expected to
result in the implementation of a Default Marketing Plan in such EMEA Board Country. This report
must be submitted to the EMEA Operating Board prior to October 1 of each Calendar Year. The EMEA
General Manager, with the endorsement of the Country Marketing Committee in such EMEA Board
Country, will develop a final Marketing and Educational Plan to be submitted to the EMEA Operating
Board for approval no later than October 15 of each Calendar Year. In the event that such
Marketing and Educational Plan is not approved by the EMEA Operating Board, the EMEA General
Manager will, in close collaboration with the EMEA Regional Representatives and Country Marketing
Committees for such EMEA Board Country, and with the endorsement of the County Marketing Committee
for such EMEA Board Country, endeavor to reach consensus on an appropriate Marketing and
Educational Plan and submit such Marketing and Educational Plan to the EMEA Operating Board, within
thirty (30) days thereof.

               (d) In the event that a Marketing and Educational Plan with respect to the Cholesterol
Product(s) in the Field for a Calendar Year in an EMEA Board Country (other than EMEA Single
Presence Countries) is not approved by the EMEA Operating Board for any reason by the November 15th
immediately prior to such Calendar Year, then a default marketing plan for the Cholesterol
Product(s) in the Field in the applicable EMEA Board Country (a “Default Marketing Plan”)
shall be implemented as set forth below:

     [*]  [Note: Approximately four and one-half pages of text are omitted.]

45

 

          Section 3.2.5. Sales Force Compensation Auditor. Upon the request of either M or S-P
or the EMEA General Manager, each of M and S-P shall provide, to an independent third-party auditor
mutually agreed to by M and S-P (the “Compensation Auditor”), sufficient details on the
target compensation, bonus structure, and benefits expected to be provided to either the M Sales
Force or the S-P Sales Force in a specific EMEA Board Country on the Cholesterol Products and on
other comparable priority cholesterol products promoted by such individuals, upon the Effective
Date and annually thereafter (in the case of reports subsequent to the Effective Date, such reports
will include the achievement rates for the prior Calendar Quarter of such compensation, bonus
structure, and benefits programs), so that the Compensation Auditor may make a reasonable
determination of comparability and effectiveness of the bonus incentives under the preceding
sentence, which determination shall be given to the EMEA General Manager. In the event that, upon
receipt of such determination from the Compensation Auditor, the EMEA General Manager is concerned
that either M’s or S-P’s bonus incentive structure for the M Sales Force or the S-P Sales Force
respectively in a specific EMEA Board Country is not adequate or comparable to the incentive
structure of its other sales force personnel (or with respect to comparable priority cholesterol
products), the EMEA General Manager will seek the assistance of the applicable Country Marketing
Committee in the EMEA and the EMEA Executive Sponsors in a good faith attempt to help resolve any
of the perceived inequities.

          Section 3.2.6. EMEA No Presence Countries. In relation to the EMEA No Presence
Countries, the EMEA General Manager shall make a recommendation to the EMEA Operating Board as to
whether the Cholesterol Products should be sold in such countries and a recommendation as to how
the Cholesterol Products should be marketed in such countries. If such EMEA No Presence Country is
designated by the EMEA Operating Board as an EMEA Co-Promotion Country, EMEA Co-Branding Country or
EMEA Single Presence Country, it shall cease to be an EMEA No Presence Country for the purposes of
this Agreement.

          Section 3.2.7. [*]

          Section 3.2.8. EMEA Single Presence Countries. The Parties acknowledge that the list
of EMEA Single Presence Countries is intended to reflect those countries in which the Parties have
respective Marketing Presences, but that no Party may challenge the definition of EMEA Single
Presence Country after the Effective Date on the basis of such definition. If requested by a
Party, however, the EMEA Operating Board will consider whether the definitions of EMEA Single
Presence Countries should be modified. From the Effective Date (or, if a country in the EMEA is
designated an EMEA Single Presence Country by the EMEA Operating Board after the Effective Date,
from the date of such designation), the Parties agree that the provisions of this Agreement,
including the provisions attached hereto as Exhibit 3, will govern the rights and obligations of
the Parties in the EMEA Single Presence Countries, and whichever of S-P and M has the single
presence in the EMEA Single Presence Country shall ensure that an Affiliate shall comply with the
provisions of this Agreement and the provisions contained in such Exhibit 3.

46

 

          Section 3.2.9. Access to Promotional Materials. S-P and M, and their respective
Affiliates, will have full and equal access, for use in EMEA Co-Branding Countries, to the
marketing and promotional materials developed by S-P and M, or their respective Affiliates, for use
in the Co-Promotion Countries, Single Presence Countries, the U.S. Territory and in Canada.

     Section 3.3. Management of Canada.

          Section 3.3.1. Management by the Canadian Board of Members. The ECLAFE Cholesterol
Business in Canada shall be managed by, and all powers of the Canadian Partnership shall be vested
in, the Canadian Partnership’s Board of Members (the “Canadian Board”). The terms and
provisions governing the Canadian Board shall be as set forth in the Canadian Partnership
Agreement. The Canadian Board shall be responsible for determining the general policies of the
Canadian Partnership and the scope of the Canadian Partnership’s activities and operations.

          Section 3.3.2. Canada General Manager. The Canadian Agreements will provide that
(i) Merck Frosst Canada Ltd., shall have the right to designate one employee of Merck Frosst Canada
Ltd., subject to the written consent of Schering Canada, Inc. (such consent not to be unreasonably
withheld) to serve as the general manager of the Cholesterol Products and the ECLAFE Cholesterol
Business in Canada (the “Canadian General Manager”), (ii) Schering Canada, Inc. shall have
the right to cause the removal of the Canadian General Manager (subject to the written consent of
Merck Frosst Canada Ltd., not to be unreasonably withheld), provided that (x) such right shall be
exercisable no more than once every two years and (y) Merck Frosst Canada Ltd. shall have the right
to designate a replacement for any removed Canadian General Manager subject to the written consent
of Schering Canada, Inc. (such consent not to be unreasonably withheld). The terms and provisions
regarding the Canadian General Manager shall be as set forth in the Canadian Partnership Agreement.

     Section 3.4. Management of Latin America.

          Section 3.4.1. Supply and Distribution. With respect to all countries in Latin
America, to the extent S-P and/or M determines to sell Cholesterol Products in Latin America, the
Singapore Partnership will supply an Affiliate of S-P and/or M, as the case may be, with finished,
unpackaged Cholesterol Products, for sale in those countries in Latin America determined by S-P or
M respectively. Sales from the Singapore Partnership to the S-P Affiliate and to the M Affiliate
will be at the same price. Subject to the provisions of Sections 3.4.1 and/or 3.4.3, S-P and M
will be entitled to commence marketing and selling Cholesterol Products in the Field in any country
in Latin America at any time. S-P or M will market, promote and sell their Cholesterol Products
independent of the other. S-P and M will have the right to introduce multiple brands of each
Cholesterol Product in any country in Latin America. Each of S-P and M (each, a “Distribution
Party”) may sublicense and/or sell Cholesterol Products for sale and distribution in any
country in Latin America to those distributors or sub-licensees, (i) in which a Distribution Party
owns, directly or indirectly, at least [*] of the outstanding equity interests in such distributor
or sub-licensee as of the date in which such distributor

47

 

or sub-licensee commences the marketing and sale of the Cholesterol Products in such country,
or (ii) that the Latin America Executive Sponsors (after consulting with and receiving the advice
and recommendation of the WWOC) have approved as a distributor or sub-licensee of the Distribution
Party, provided, that if the Non-Distribution Party reasonably believes that the
performance of such distributor or sub-licensee in the applicable country is unsatisfactory, then,
the Non-Distribution Party, may request a discussion with the Latin America Executive Sponsors to
consider whether such distributor’s or sub-licensee’s performance in the applicable country is
unsatisfactory. If, following such discussion, the Non-Distribution Party reasonably determines
that the distributor’s or sub-licensee’s performance in the applicable country is unsatisfactory,
then the Non-Distribution Party shall provide the Distribution Party with written notice, setting
forth in reasonable detail the basis for such determination. Thereafter, such distributor or
sub-licensee shall have sixty (60) days to demonstrate to the Non-Distribution Party that it has
cured such unsatisfactory performance. If, during such period, the distributor or sub-licensee
fails to demonstrate to the Non-Distribution Party that it has cured such unsatisfactory
performance, then such distributor or sub-licensee shall cease to be a distributor or sub-licensee
of the Distribution Party for the Cholesterol Products in the Field in such country and shall
thereafter cease marketing and selling the Cholesterol Products in such country.

          Section 3.4.2. Reporting Obligations. M shall ensure that each of the M Local
Affiliates for Latin America shall provide the Singapore Partnership with sufficient information to
calculate any special allocations required to be made pursuant to the Singapore Partnership
Agreement with respect to sales by M in Latin America.

          Section 3.4.3. Registration and Launch. With respect to all countries in Latin
America where S-P and M determine to sell Cholesterol Products, each of an M Local Affiliate and an
S-P Local Affiliate shall undertake the Co-Marketing and sale of the Cholesterol Products in such
countries under its own separate and distinct brands. With respect to each country in Latin America
where: (A) the simultaneous filing of Product Marketing Authorizations and qualifications for the
Cholesterol Products by one Party on behalf of itself and the other Party is permitted by local
law; (B) M and S-P each have a Marketing Presence and (C) M and S-P each notify the Singapore
Partnership, within thirty (30) days after the availability of the Cholesterol Product health
registration packages for the applicable Product for such country, that it intends to sell such
Cholesterol Product, the Latin America Executive Sponsors will authorize either an S-P Affiliate or
an M Affiliate to obtain and maintain all Product Marketing Authorizations and qualifications (e.g.
discounts) for each Cholesterol Product in such country as required under local laws and
regulations to enable both (i) an S-P Local Affiliate to market such Cholesterol Product under one
or more S-P Local Affiliate’s brands as S-P may designate and (ii) an M Local Affiliate to market
such Cholesterol Product under one or more of M Local Affiliate’s brands as M may designate, in the
country. In those countries in Latin America (i) where the requirements referenced in the second
sentence of this Section 3.4.3 are satisfied, or (ii) where the requirements referenced in the
second sentence of this Section 3.4.3 other than part (A) of such requirements are satisfied, then,
to the extent permitted by law, neither M nor S-P, or their respective Affiliates, shall Launch a
Cholesterol Product, or engage in any pre-selling in such country in Latin

48

 

America until each of M and S-P has received all Product Marketing Authorizations and
qualifications (e.g. discounts) required under local laws and regulations to Launch a brand of the
Cholesterol Product in such country. With respect to each country in Latin America where the
preceding sentence does not apply, each Party will independently seek the Product Marketing
Authorization and qualification of its brand(s) of Cholesterol Products in accordance with the
Development Agreement.

          Section 3.4.4. Access to Promotional Materials. S-P and M, and their respective
Affiliates, will have full and equal access for use in Latin America to the marketing and
promotional materials developed by S-P and M, or their respective Affiliates, for use in the
Co-Promotion Countries, Single Presence Countries, the U.S. Territory and in Canada.

          Section 3.4.5. Dispute Resolution in Latin America. The Latin America Executive
Sponsors will use reasonable efforts to resolve any dispute, claims, controversies or disagreements
relating to the ECLAFE Cholesterol Business in Latin America. If any matter cannot be resolved by
the Latin America Executive Sponsors within a reasonable period of time, such reasonableness to be
considered in view of the urgency and importance of the matter, and in any event, within thirty
(30) days after the representative(s) of S-P on the one hand or M on the other has given written
notice of such disagreement to the representative(s) of the other Party, S-P and M each shall cause
to be prepared and circulated to the other Party a memorandum or other form of statement setting
out its position on the matter in dispute and its reasons for adopting such position. The
respective Latin America Executive Sponsors of M and S-P shall use their respective good faith
reasonable efforts to resolve such dispute as promptly as practicable but in any event no later
than ten (10) days after submission of such matter to such Latin America Executive Sponsors. Upon
resolution of the matter, the respective Latin America Executive Sponsors shall jointly execute a
written statement setting forth the terms of such resolution.

     Section 3.5.
Management of the Far East — Co-Marketing Countries.

          Section 3.5.1. Supply and Distribution. With respect to Far East Co-Marketing
Countries, to the extent S-P and/or M determines to sell Cholesterol Products in the Far East, the
Singapore Partnership will supply an Affiliate of S-P and/or M, as the case may be, with finished,
unpackaged Cholesterol Products, for sale in those countries in the Far East determined by S-P or M
respectively. Sales from the Singapore Partnership to the S-P Affiliates and the M Affiliates will
be at the same price. Subject to the provisions of Sections 3.5.1 and/or 3.5.3, S-P and M will be
entitled to commence marketing and selling Cholesterol Products in the Field in any Far East
Co-Marketing Country at any time. S-P or M will market, promote and sell their Cholesterol
Products independent of the other. S-P and M will have the right to introduce multiple brands of
each Cholesterol Product in any Far East Co-Marketing Country. Each Distribution Party may
sublicense and/or sell Cholesterol Products for sale and distribution in any Far East Co-Marketing
Country to those distributors or sub-licensees, (i) in which a Distribution Party owns, directly or
indirectly, at least [*] of the outstanding equity interests in such distributor or sub-licensee as
of the date in which such distributor or sub-licensee

49

 

commences the marketing and sale of the Cholesterol Products in such country, or (ii) that the
Far East Operating Board have approved as a distributor or sub-licensee of the Distribution Party,
provided, that if the Non-Distribution Party reasonably believes that the performance of
such distributor or sub-licensee in the applicable country is unsatisfactory, then, the
Non-Distribution Party, may request a discussion at the Far East Operating Board to consider
whether such distributor’s or Sub-licensee’s performance in the applicable country is
unsatisfactory. If, following such discussion, the Non-Distribution Party reasonably determines
that the distributor’s or sub-licensee’s performance in the applicable country is unsatisfactory,
then the Non-Distribution Party shall provide the Distribution Party with written notice, setting
forth in reasonable detail the basis for such determination. Thereafter, such distributor or
sub-licensee shall have sixty (60) days to demonstrate to the Non-Distribution Party that it has
cured such unsatisfactory performance. If, during such period, the distributor or sub-licensee
fails to demonstrate to the Non-Distribution Party that it has cured such unsatisfactory
performance, then such distributor or sub-licensee shall cease to be a distributor or sub-licensee
of the Distribution Party for the Cholesterol Products in the Field in such country and shall
thereafter cease marketing and selling the Cholesterol Products in such country.

          Section 3.5.2. Reporting Obligations. M shall ensure that each of the M Local
Affiliates for the Far East Co-Marketing Countries shall provide the Singapore Partnership with
sufficient information to enable it to calculate the special allocations required to be made
pursuant to the Singapore Partnership Agreement with respect to sales by M in the Far East.

          Section 3.5.3. Registration and Launch. With respect to all Far East Co-Marketing
Countries where S-P and M determine to sell Cholesterol Products, [*].

          Section 3.5.4. Access to Promotional Materials. S-P and M, and their respective
Affiliates, will have full and equal access, for use in Far East Co-Marketing Countries, to the
marketing and promotional materials developed by S-P and M, or their respective Affiliates, for use
in the Co-Promotion Countries, Single Presence Countries, the U.S. Territory and in Canada.

          Section 3.5.5. Dispute Resolution in Far East Co-Marketing Countries. The members of
the Far East Operating Board will use reasonable efforts to resolve any dispute, claims,
controversies or disagreements in Far East Co-Marketing Countries. If any matter cannot be
resolved by the Far East Operating Board within a reasonable period of time, such reasonableness to
be considered in view of the urgency and importance of the matter, and in any event, within thirty
(30) days after the representative(s) of S-P on the one hand or M on the other on the Far East
Operating Board has given written notice of such disagreement to the representative(s) of the other
Party, S-P and M each shall cause to be prepared and circulated to the other Party a memorandum or
other form of statement setting out its position on the matter in dispute and its reasons for
adopting such position. Thereafter, a representative of S-P on the one hand and M on the other of
the Far East Operating Board shall use their reasonable good faith efforts to resolve any such
dispute as promptly as practicable but in any event no later than ten (10) days after submission of
such matter to such representatives. Upon

50

 

resolution of the matter, such representatives of S-P and M of the Far East Operating Board
shall jointly execute a written statement setting forth the terms of such resolution.

     Section 3.6. Management of the Far East Board Countries

          Section 3.6.1. Far East Board Countries.

               (a) Far East Operating Board; Purposes. Within forty-five (45) days after the
Effective Date, M and S-P shall establish a board for Far East Board Countries (the “Far East
Operating Board”), which shall have overall responsibility for the management of the
Cholesterol Products in the Field in Far East Board Countries, and certain responsibilities
regarding the Cholesterol Products in the Field in Far East Co-Marketing Countries as set forth in
Section 3.5. Without limiting the generality of the foregoing, the responsibilities of the Far
East Operating Board shall include approving annual Marketing and Educational Plans and Five-Year
Strategic Business Plans (each in the manner described in Section 3.6.2), capital forecasts and
budgets (including costs of Phase V studies), as well as registration strategy and
pricing/reimbursement strategy. The Far East Operating Board shall carry out its responsibilities
as set forth in this Agreement and the Related Agreements, as applicable, and shall have the
authority to approve or disapprove any recommendation of a Country Marketing Committee under this
Agreement and the Related Agreements, as applicable. The Far East Operating Board shall operate
with the intent of maximizing the commercialization of the Cholesterol Products in the Field in the
Far East. The Far East Operating Board will coordinate the Far East Board Countries development
needs, develop Marketing and Educational Plans and strategic plans, oversee execution of plans and
monitor performance (including receiving quarterly reports from each Country Marketing Committee in
the Far East regarding the execution of marketing, sales and promotion efforts) and otherwise be
responsible for maximizing commercialization of the Cholesterol Products in the Field in Far East
Board Countries. The Far East Operating Board shall operate independently of M or S-P or their
Affiliates and all lawful determinations, decisions and actions made or taken by the Far East
Operating Board shall be conclusive and absolutely binding with respect to the ECLAFE Cholesterol
Business in the Far East.

               (b) Membership. The Far East Operating Board shall be composed of four (4)
representatives, two (2) appointed by S-P on the one hand, and two (2) appointed by M on the other.
M and S-P shall determine the composition of the Far East Operating Board within forty-five (45)
days after the Effective Date. M and S-P may, upon mutual written consent, change the size and/or
composition of the Far East Operating Board from time to time. S-P may, in its sole discretion,
replace any of its Far East Operating Board representatives at any time upon written notice to M,
and M may, in its sole discretion, replace any of its Far East Operating Board representatives at
any time upon written notice to
S-P. M shall designate a board
member to call meetings of the Far
East Operating Board, circulate agendas, allocate responsibilities for keeping minutes of the Far
East Operating Board, and perform administrative tasks required to assure efficient operations of
the Far East Operating Board until the end of Calendar Year

51

 

2002. Those responsibilities shall thereafter alternate in each subsequent Calendar Year
between a board member designated by S-P and a board member designated by M.

               (c) Meetings of the Far East Operating Board. The Far East Operating Board shall hold
regular meetings no less frequently than once every quarter, unless the Far East Operating Board
otherwise determines. Special meetings of the Far East Operating Board may be called by any Far
East Operating Board member, upon reasonable written notice. Meetings, in addition to quarterly
meetings, shall be held timely to approve plans submitted for Far East Operating Board approval in
accordance with this Agreement and the Related Agreements, as applicable. Meetings of the Far East
Operating Board may be held in person, by audio or by video teleconference. S-P on the one hand
and M on the other shall be responsible for all of the expenses incurred by their representatives
which are Far East Operating Board members, which expenses arise out of such Far East Operating
Board member’s membership on the Far East Operating Board.

               (d) Manner of Acting. Meetings of the Far East Operating Board shall be effective
only if at least one representative of S-P on the one hand and at least one representative of M on
the other are present or participating throughout. The unanimous vote of the members of the Far
East Operating Board present or participating at any meeting of the Far East Operating Board shall
be necessary for the passage of any resolution or act of the Far East Operating Board. Any action
required or permitted to be taken by the Far East Operating Board may be taken without a meeting if
each member of the Far East Operating Board consents thereto in writing.

               (e) Dispute Resolution. Except as set forth in Sections 3.6.1(f) and (g) and
3.6.3(b)
and (c) of this Agreement, the members of the Far East Operating Board will use reasonable efforts
to resolve any dispute, claims, controversies or disagreements relating to the ECLAFE Cholesterol
Business in Far East Board Countries. If any matter cannot be resolved by the Far East Operating
Board within a reasonable period of time, such reasonableness to be considered in view of the
urgency and importance of the matter, and in any event, within thirty (30) days after the
representative(s) of S-P on the one hand or M on the other on the Far East Operating Board has
given written notice of such disagreement to the representative(s) of the other Party, S-P and M
each shall cause to be prepared and circulated to the other Party a memorandum or other form of
statement setting out its position on the matter in dispute and its reasons for adopting such
position. Thereafter, a representative of S-P on the one hand and M on the other of the Far East
Operating Board shall use their reasonable good faith efforts to jointly recommend a resolution of
such dispute to the Far East Operating Board as promptly as practicable but in no event later than
ten (10) days after submission of such matter to such representatives. Upon resolution of the
matter, such representatives of S-P and M of the Far East Operating Board shall jointly execute a
written statement setting forth the terms of such recommended resolution.

               (f) Country Marketing Committee Disputes. All Country Marketing Committee disputes
relating to the ECLAFE Cholesterol Business in Far East Board Countries which cannot be resolved by
the relevant Country Marketing Committee

52

 

within a reasonable period of time, such reasonableness to be considered in view of the
urgency and importance of the matter, and in any event, within thirty (30) days after the
representative(s) of S-P on the one hand or M on the other on the Country Marketing Committee has
given written notice of such disagreement to the representative(s) of the other Party, shall be
referred to the Far East Operating Board which shall recommend a resolution of such dispute to the
Country Marketing Committee as promptly as practicable but in no event later than ten (10) days
after submission of such matter to the Far East Operating Board. Upon resolution of the matter,
representative(s) of S-P on the one hand and M on the other of the Far East Operating Board shall
jointly execute a written statement setting forth the terms of such recommended resolution. If
the Far East Operating Board cannot reach resolution within such ten (10) day period, the dispute
will be resolved pursuant to Section 3.6.1(e).

               (g) Product Launch Decisions. Cholesterol Products shall be registered, Launched and
sold in the Field [*].

          Section 3.6.2. Appointment of a Far East General Manager. The Far East Operating
Board shall discuss in good faith the need for a general manager of the Cholesterol Products and
the ECLAFE Cholesterol Business in the Far East Board Countries. If the Far East Operating Board
determines that there is a need for a general manager, M shall have the right to designate one
employee of M, subject to the written consent of S-P (such consent not to be unreasonably
withheld), to serve as such general manager. Upon such appointment, this person will perform the
same role, and have the same rights and responsibilities in the Far East Board Countries as the
EMEA General Manager has in the EMEA. S-P’s and M’s rights with respect to such general manager
shall be the same as the rights S-P and M have with respect to the EMEA General Manager.

          Section 3.6.3. Five-Year Plans; Approval of Annual Marketing and Educational Plans;
Default Marketing Plans.

               (a) No later than May 15 of each Calendar Year, each Country Marketing Committee in Far
East
Board Countries will present a Five-Year Strategic Business Plan to the Far East Operating Board.
The Five-Year Strategic Business Plan shall include a comprehensive marketing, sales, pricing,
manufacturing, supply and distribution strategy (including, without limitation, Phase V and
educational activities) and related profit and loss forecasts for the Cholesterol Products in the
Field in the applicable country. The Far East Operating Board will prepare and approve a Five-Year
Strategic Business Plan for the Far East Board Countries no later than July 31 of each Calendar
Year.

               (b) No later than September 1 of each Calendar Year, each Country Marketing Committee in the
Far East will submit a preliminary Marketing and Educational Plan with respect to the Cholesterol
Products in the Field in the applicable Far East Board Country for the following Calendar Year to
the Far East Operating Board for consultation and review. This preliminary Marketing and
Educational Plan will contain the PDE Requirements (i) identify the Cholesterol Product which will
receive

53

 

primary emphasis, (ii) seek to maximize the commercial potential of each Cholesterol Product
in the Field, within the applicable country and to provide for market leadership by a Cholesterol
Product, (iii) match, where appropriate, the efforts of leading competitors of the ECLAFE
Cholesterol Business in such Far East Board Country, (iv) identify Targeted Prescribers, (v)
identify the number of PDEs to be delivered by Specialty Representatives, Hospital Representatives
and Primary Care Representatives and (vi) propose spending levels with respect to
Non-Representative Educational and Promotional Activities. The Far East Operating Board and each
Country Marketing Committee in such Far East Board Country will develop a final Marketing and
Educational Plan to be approved by the Far East Operating Board no later than October 15 of each
Calendar Year. In the event that such Marketing and Educational Plan is not approved by the Far
East Operating Board, the Country Marketing Committee will seek to address the issues raised by the
Far East Operating Board and submit such Marketing and Educational Plan to the Far East Operating
Board for approval, within thirty (30) days thereof.

               (c) In the event that a Marketing and Educational Plan with respect to the Cholesterol
Product(s) in the Field for a Calendar Year in a Far East Board Country (other than a Far East
Single Presence Country) is not approved by the Far East Operating Board for any reason by the
November 15th immediately prior to such Calendar Year, then a Default Marketing Plan for the
Cholesterol Product(s) in the applicable country shall be implemented as set forth in Section
3.2.4(d). The provisions of Sections 3.2.4(d), (e), (f), (g), (i) and (j) shall apply to such
country; provided, however, that references therein to an EMEA Board Country, the
EMEA Operating Board and an EMEA Board Country Agreement shall be deemed to be references to a Far
East Board Country, the Far East Operating Board and a Far East Board Country Agreement,
respectively.

               (d) Subsequent to the Launch of a Combination Product in a Far East Board Country (other than
a Far East Single Presence Country), no sales representative of either M or S-P, or their
respective Affiliates shall be responsible for detailing both (x) a Combination Product and (y) a
product of M or S-P or their respective Affiliates (as the case may be) in the Field in such Far
East Board Country, unless agreed to in an approved Marketing and Educational Plan.

54

 

          Section 3.6.4. Far East Single Presence Countries. From the Effective Date (or, if a
country in the Far East is designated a Far East Single Presence Country by the Far East Operating
Board after the Effective Date, from the date of such designation), the Parties agree that the
provisions of this Agreement, including the provisions attached hereto as Exhibit 15, will govern
the rights and obligations of the Parties in the Far East Single Presence Countries, and whoever of
S-P and M has or has been deemed to have the single presence in the Far East Single Presence
Country shall ensure that an Affiliate shall comply with the provisions of this Agreement and the
provisions contained in such Exhibit 15.

ARTICLE IV

GOOD FAITH EFFORTS; OTHER MATTERS

     Section 4.1. Commercially Reasonable Good Faith Efforts. Each of the Parties hereto
agrees to use its commercially reasonable good faith efforts to execute and deliver all of the
agreements and documents referred to in Article II or otherwise contemplated by this Agreement, and
make all necessary filings relating thereto, if any, as promptly as practicable.

     Section 4.2. Certain Expenses.

               (a) Expenses Outside EMEA. Marketing and Educational Expenses as described in
Schedule 4.2(a) incurred by M or its Affiliates, or by S-P or its Affiliates outside the EMEA and
approved by the EMEA Operating Board shall be shared equally by M and S-P; provided that
such expenses incurred by M or its Affiliates will be shared equally by M and S-P up to [*] per
Calendar Year; and provided, further, that promotional expenses shall be shared
equally only to the extent such expenses are incurred with respect to global branding and the
centralized preparation of sales materials for Launch of each Cholesterol Product in the Field in
ECLAFE. To the extent that M’s Marketing and Educational Expenses (as described in Schedule
4.2(a)) exceed [*] million in any Calendar Year or that M incurs promotional expenses other than those
incurred with respect to global branding and the centralized preparation of sales material for the
Launch of each Cholesterol Product, M shall bear [*]% of such costs and S-P shall bear [*]% of
such costs. M will invoice S-P for these costs on a quarterly basis and S-P shall pay such
invoices within 30 days of receipt.

               (b) EMEA Regulatory Costs. Regulatory Costs associated with the EMEA, whether
incurred within or outside the EMEA will be aggregated and will be shared equally between M and
S-P; provided, however, that, notwithstanding anything set forth herein or in any
of the Related Agreements including the provisions of Section 6.2(a) of the EMEA Board Country
Agreements, if Regulatory Costs incurred by M Local Affiliates in the EMEA in a Calendar Year in
the aggregate exceeds $[*] (the “Regulatory Expenses Cap”), then M shall bear [*]% and
S-P shall bear [*]% of such excess. To the extent such proviso applies, there will be no
adjustments made to the payment obligations under the EMEA Co-Venture Agreement or Related
Agreements; however, an allocation pursuant to the Singapore Partnership Agreement will be
made to give effect thereto. If, in a Calendar Year, Regulatory Costs incurred by M Local

55

 

Affiliates are unusually high, the EMEA Operating Board may modify the Regulatory Expenses Cap
to take into account such unusual circumstances.

               (c) Expenses Outside Canada; Expenses Outside Far East Co-Promotion Countries.
Canadian related Marketing and Educational Expenses, as described in Schedule 4.2(a), incurred by M
or S-P or their respective Affiliates outside Canada and approved by the Canadian Board shall be
shared equally by M and S-P. Far East Co-Promotion Country Marketing and Educational Expenses, as
described in Schedule 4.2(a), incurred by M or S-P or their respective Affiliates outside the Far
East Co-Promotion Countries and approved by the Far East Operating Board shall be shared equally by
M and S-P. Each of M and S-P will invoice the other for the costs referred to in the first
sentence of Section 4.2(c) on a quarterly basis and provide the other Party with such documentation
in support thereof as the other Party may reasonably request, and the other Party shall pay such
invoices within thirty (30) days of receipt of such invoice and all such supporting documentation.
In addition, if only one Product Marketing Authorization is required with respect to each
Cholesterol Product in any Co-Marketing country in LAFE, the Regulatory Costs associated with such
registration will be shared equally between M and S-P. An allocation pursuant to the Singapore
Partnership Agreement will be made to give effect to such sharing of Regulatory Costs.

               (d) Phase IV Clinical Trials. The costs associated with Phase IV clinical trials
shall be borne by the Singapore Partnership.

     Section 4.3. Trademarks.

               Section 4.3.1.  EMEA.

               (a) General. The Parties will seek to optimize the use of the E Monotherapy U.S.
Trademark, the Z/E Combination Product U.S. Trademark and the M/E Combination Product U.S.
Trademark in each country in the EMEA, but only to the extent that the applicable Cholesterol
Products are sold by or on behalf of S-P or M or any of their Affiliates in the Field in such
country in the EMEA.

               (b) EMEA Co-Promotion Countries. With respect to EMEA Co-Promotion Countries, the
Singapore Partnership will own and the Affiliates of M and S-P shall have the exclusive right to
use in those countries the E Monotherapy U.S. Trademark, the Z/E Combination Product U.S. Trademark
and the M/E Combination Product U.S. Trademark and any back-up trademarks related thereto.

               (c) EMEA Single Presence Countries. With respect to EMEA Single Presence Countries,
the Singapore Partnership will own and an Affiliate of M or S-P which has the single presence in
that EMEA Single Presence Country shall have the exclusive right to use in those countries the E
Monotherapy U.S. Trademark, the Z/E Combination Product U.S. Trademark and the M/E Combination
Product U.S. Trademark and any back-up trademarks related thereto.

               (d) EMEA Co-Branding Countries — S-P. With respect to the EMEA Co-Branding
Countries,
the Singapore Partnership will own and an S-P Local

56

 

Affiliate will have the exclusive right to use in those countries, the E Monotherapy U.S.
Trademark and, if such use would be commercially impracticable as determined by S-P in its
reasonable good faith judgment or prohibited by regulatory or statutory laws, rules or regulations
in an EMEA Co-Branding Country, a back-up trademark that is not confusingly similar to the E
Monotherapy U.S. Trademark filed in that country; provided, however, that if S-P
elects to use a back-up trademark in respect of the E Monotherapy U.S. Trademark, (i) S-P shall
lose the right to use the E Monotherapy U.S. Trademark and (ii) M may elect either to have the
exclusive use of the E Monotherapy U.S Trademark or the exclusive use of any one other back up
trademark (that is not confusingly similar to the trademark used by S-P) filed in that country. An
M Local Affiliate shall be entitled to use any back-up trademark that is not confusingly similar to
the E Monotherapy U.S. Trademark filed in an EMEA Co-Branding Country, other than any back-up
trademark required to be used by an S-P Local Affiliate in that country.

               (e) EMEA Co-Branding Countries — M. With respect to the EMEA Co-Branding Counties,
the Singapore Partnership will own and the M Local Affiliate will have the exclusive right to use
in those countries, the Z/E Combination Product U.S. Trademark and the M/E Combination Product U.S.
Trademark and, if such use would be commercially impracticable as determined by M in its reasonable
good faith judgment or prohibited by regulatory or statutory laws, rules or regulations in an EMEA
Co-Branding Country, a back-up trademark that is not confusingly similar to the Z/E Combination
Product U.S. Trademark filed in that country; provided, however, that if M elects
to use a back-up trademark in respect of either the Z/E Combination Product U.S. Trademark or the
M/E Combination Product U.S. Trademark, (i) M shall lose the right to use such Z/E Combination
Product U.S. Trademark or M/E Combination Product U.S. Trademark and (ii) S-P may elect either to
have the exclusive use of such Z/E Combination Product U.S. Trademark or M/E Combination Product
U.S. Trademark or the exclusive use of any one other back up trademark (that is not confusingly
similar to the trademark used by M) filed in that country. An S-P Local Affiliate shall be
entitled to use any back-up trademark that is not confusingly similar to the Z/E Combination
Product U.S. Trademark and the M/E Combination Product U.S. Trademark filed in an EMEA Co-Branding
Country, other than any back-up trademark required to be used by an M Local Affiliate in that
country.

               (f) Ownership. Except in the limited circumstances set forth in Section 4.3.5, all
back-up trademarks will be owned by the Singapore Partnership.

          Section 4.3.2. Canada. The Parties will seek to optimize the use of the E Monotherapy
U.S. Trademark, the Z/E Combination Product U.S. Trademark and the M/E Combination Product U.S.
Trademark in Canada, but only to the extent that the applicable Cholesterol Products are sold in
Canada.

          Section 4.3.3. LAFE.

               (a) General. The Parties will seek to optimize the use of the E Monotherapy U.S.
Trademark, the Z/E Combination Product U.S. Trademark and the M/E Combination Product U.S.
Trademark in each country in LAFE, but only to the

57

 

extent that the applicable Cholesterol Products are sold in the Field by or on behalf of S-P
or M or any of their Affiliates in such country in LAFE.

               (b) Far East Co-Promotion Countries. With respect to Far East Co-Promotion Countries,
the Singapore Partnership will own and the Affiliates of M and S-P shall have the exclusive right
to use in those countries the E Monotherapy U.S. Trademark, the Z/E Combination Product U.S.
Trademark and the M/E Combination Product U.S. Trademark and any back-up trademark relating
thereto.

               (c) Far East Single Presence Countries. With respect to Far East Single Presence
Countries, the Singapore Partnership will own and an Affiliate of M or S-P which has been deemed to
have the single presence in that Far East Single Presence Country shall have the exclusive right to
use in those countries the E Monotherapy U.S. Trademark, the Z/E Combination Product U.S. Trademark
and the M/E Combination Product U.S. Trademark and any back-up trademark relating thereto.

               (d) LAFE
Co-Marketing Countries — S-P. With respect to the LAFE Co-Marketing
Countries, the Singapore Partnership will own and the S-P Local Affiliates will have the exclusive
right to use in those countries, the E Monotherapy U.S. Trademark and, if such use would be
commercially impracticable as determined by S-P in its reasonable good faith judgment or prohibited
by regulatory or statutory laws, rules or regulations in a LAFE Co-Marketing Country, a back-up
trademark that is not confusingly similar to the E Monotherapy U.S. Trademark filed in that
country; provided, however, that if S-P elects to use a back-up trademark in
respect of the E Monotherapy U.S. Trademark, (i) S-P shall lose the right to use the E Monotherapy
U.S. Trademark and (ii) M may elect either to have the exclusive use of the E Monotherapy U.S
Trademark or the exclusive use of any one other back up trademark (that is not confusingly similar
to the trademark used by S-P) filed in that country. An M Local Affiliate shall be entitled to use
any back-up trademark that is not confusingly similar to the E Monotherapy U.S. Trademark filed in
a LAFE Co-Marketing Country, other than any back-up trademark required to be used by an S-P Local
Affiliate in that country.

               (e)
LAFE Co-Marketing Countries — M. With respect to the LAFE Co-Marketing Countries,
the Singapore Partnership will own and the M Local Affiliates will have the exclusive right to use
in those countries, the Z/E Combination Product U.S. Trademark and the M/E Combination Product U.S.
Trademark and, if such use would be commercially impracticable as determined by M in its reasonable
good faith judgment or prohibited by regulatory or statutory laws, rules or regulations in a LAFE
Co-Marketing Country, a back-up trademark that is not confusingly similar to the Z/E Combination
Product U.S. Trademark filed in that country; provided, however, that if M elects
to use a back-up trademark in respect of either the Z/E Combination Product U.S. Trademark or the
M/E Combination Product U.S. Trademark, (i) M shall lose the right to use such Z/E Combination
Product U.S. Trademark or M/E Combination Product U.S. Trademark and any back-up trademarks and
(ii) S-P may elect either to have the exclusive use of such Z/E Combination Product U.S. Trademark
or M/E Combination Product U.S. Trademark or the exclusive use of any other back up trademark (that
is not confusingly similar to the trademark used by M) filed in that country. An S-P Local

58

 

Affiliate shall be entitled to use any back-up trademark that is not confusingly similar to
the Z/E Combination Product U.S. Trademark and the M/E Combination Product U.S. Trademark filed in
a LAFE Co-Marketing Country, other than any back-up trademark required to be used by an M Local
Affiliate in that country.

               (f) Ownership. Except in the limited circumstances set forth in Section 4.3.5, all
back-up trademarks will be owned by the Singapore Partnership.

          Section 4.3.4. General.

               (a) All trademarks filed for Cholesterol Products by M or S-P or any of their respective
Affiliates prior to the Effective Date, will be assigned to the Singapore Partnership as promptly
as practicable after the Effective Date and in any event within ninety (90) days after the
Effective Date. Notwithstanding any provisions to the contrary contained in this Agreement, M
shall retain the ownership and the exclusive use of the ZOCOR trademarks and marks similar thereto
including, without limitation, trademarks containing the name ZOCOR, and nothing contained in this
Agreement shall provide the Singapore Partnership or S-P or any of its Affiliates any rights with
respect thereto.

               (b) As soon as reasonably practicable following the execution of this Agreement, M or its
Affiliate and Singapore Partnership shall enter into a trademark license, in form and substance
satisfactory to M, pursuant to which M shall grant to Singapore Partnership a non-exclusive,
royalty free license, for use only in the marketing and/or sale of a Z/E Combination Product in the
Field in ECLAFE, to the ZOCOR trademark to be used only in combination with another term and not
alone.

               (c) All grants of usage by the Singapore Partnership pursuant to this Section 4.3 with
respect
to the E Monotherapy U.S. Trademark, the Z/E Combination Product U.S. Trademark and the M/E
Combination Product U.S. Trademark, and all back-up trademarks, domain names or other appropriate
forms of brand protection relating thereto, are made exclusively for the marketing and sale of the
Cholesterol Products in the Field. Neither M or S-P, nor any of their respective Affiliates, shall
have the right to use any such trademarks or domain name registrations or other forms of brand
protection for the Cholesterol Products outside the Field, other than, in the case of S-P and its
Affiliates, with respect to the E Monotherapy U.S. Trademark, and all back-up trademarks, domain
names or other forms of brand protection relating thereto, in Japan.

          Section 4.3.5. Applications.

               (a) Consequences of Non-Singapore Partnership Registrations. To the extent that S-P
has commenced appropriate trademark and domain name registrations and any other appropriate forms
of brand protection for the Cholesterol Products (“Trademark Registrations”) in the Field
in the U.S. Territory and/or ECLAFE and such registrations and forms of brand protections have not
been obtained prior to the Effective Date in a particular country, then S-P shall continue the
process of procuring

59

 

such Trademark Registrations in such country on behalf of the Singapore Partnership. S-P
shall not without M’s prior written consent make or approve the making of applications to register
trademarks or domain names in the Field in the U.S. Territory and/or ECLAFE that consist of or
include marks, signs or brands that are identical or confusingly similar to marks, signs or brands
belonging to M. All Trademark Registrations with respect to the Cholesterol Products in the U.S.
Territory and/or ECLAFE are to belong to, and wherever possible shall be made in, the name of the
Singapore Partnership. In the event that prior to the Effective Date S-P has made, or procures the
registration of, any Trademark Registration in its name with respect to the Cholesterol Products in
the U.S. Territory or ECLAFE, S-P shall hold such applications or registrations in trust for and
shall assign or procure the assignment of them to the Singapore Partnership as soon as possible
and, in any event, within seven (7) days of the later (i) the Effective Date, and (ii) obtaining
such registration or other form of brand protection. After the Effective Date, neither S-P, nor
its Affiliates shall seek Trademark Registrations in the U.S. Territory or ECLAFE in its name with
respect to any of the Cholesterol Products in the Field unless it had commenced the process prior
to the Effective Date. This Section 4.3.5(a) does not modify, alter or grant to S-P or M any
rights to any trademarks, domain names or any other types of brand protection for use in Japan. In
addition to the foregoing, (i) S-P shall assign or transfer to the Singapore Partnership all
Trademark Registrations for trademarks or tradenames which have previously been disclosed to the
Singapore Partnership or M or its Affiliates and (ii) any Trademark Registrations outside the Field
which are not assigned or transferred to the Singapore Partnership pursuant to this Section
4.3.5(a) shall not be confusingly similar to any trademarks or tradenames owned or used by
Singapore Partnership for use in the Field.

               (b) Back-Up Trademarks in EMEA Co-Branding Countries and LAFE Co-Marketing Countries.
Subject to Section 4.3.1 (d) and (e) or Section 4.3.3(d) and (e), as applicable, Affiliates of S-P
and M in any EMEA Co-Branding Country or LAFE Co-Marketing Country shall be entitled to utilize an
unlimited number of trademarks and/or domain name registrations or any other form of brand
protection for the Cholesterol Products in such countries; provided, however, that
the Singapore Partnership shall have the exclusive right to register and own any such trademark or
domain name or other form of brand protection. Upon the written request of the Affiliate of S-P or
M, the Singapore Partnership shall, with the assistance of such Affiliate of S-P or M, use its
commercially reasonable efforts to register such trademark or domain name or other form of brand
protection. Such Affiliate of M or S-P shall have the exclusive right to use any trademark or
domain name or other form of brand protection registered pursuant to this Section 4.3.5(b).

          Section 4.3.6. Infringement. Any Local Affiliate of M or S-P in any country in ECLAFE
shall promptly advise the Singapore Partnership of all cases of potential infringement of any
patents, trademarks, tradenames or other forms of brand protection owned or used by the Singapore
Partnership that come to such Local Affiliate’s attention, and shall render all assistance
reasonably requested in connection with any action taken by the Singapore Partnership relating
thereto. The control of such
action, including without limitation the determination of whether to initiate action or to
settle, shall be under the sole control of the Singapore Partnership. All costs and

60 

 

expenses
associated with such proceedings shall be borne by the Singapore Partnership.

     Section 4.4. Non-Compete.

[*]

     Section 4.5. Unilateral Termination of Board Country Agreements. Notwithstanding any
other provision of this Agreement, if M or S-P determines to terminate all of its business and
operations (with respect to all products, not just the Cholesterol Products) in an EMEA Board
Country or Far East Board Country (any such country, a “Terminated Country”), then the terminating
Party shall have the right to unilaterally terminate (or cause its Local Affiliate to unilaterally
terminate) any EMEA Board Country Agreement, Far East Board Country Agreement and/or any applicable
Sub-Distribution Agreement, in effect with respect to the Terminated Country, provided that
no such termination shall be effective (i) unless the terminating Party has provided the other
Party with at least 90 days prior written notice of termination, (ii) until all such other business
and operations have been terminated and (iii) with respect to an EMEA Co-Venture Agreement, EMEA
Co-Branding Agreement or Far East Co-Venture Agreement, until the terminating Party has entered
into arrangements reasonably satisfactory to the other Party which provide (x) for the allocation
of profit and loss arising from subsequent Third Party sales in such Terminated Country under the
Singapore Partnership Agreement, [*]% to the terminating Party and [*]% to the other Party from
and after the date of termination and (y) the other Party to have all such rights as may be
necessary to continue selling the Cholesterol Products in the Terminated Country. Any Terminated
Country that was an EMEA Single Presence Country shall, following such termination, be treated as
an EMEA No Presence Country. Any Terminated Country that was a Far East Single Presence Country
shall, following such termination, be treated as a Far East Co-Marketing Country.

ARTICLE V

DISPUTE RESOLUTION, TERMINATION, DISSOLUTION AND

LIQUIDATION

     Section 5.1. Dispute Resolution. Without limiting any dispute resolution procedures
and remedies specifically provided in any of the Related Agreements, any and all disputes, claims,
controversies or disagreements with respect to this Agreement or any of the Related Agreements
shall be resolved pursuant to the procedures set forth in Sections 3.2.1(e), 3.2.1(f), 3.2.2(c),
3.4.5, 3.5.5, 3.6.1(e), 3.6.1(f) and 3.6.1(g), as applicable, and each of S-P, M and the Singapore
Partnership agree that none of them shall, except as contemplated by Section 7.13 [Judicial
Proceeding], resort to any means whatsoever, including litigation, arbitration, dissolution by a
judicial forum or decree, or by operation of law, appointment of a trustee, receiver, custodian or
similar person, or to any other form of proceeding in connection with any such dispute, claim,
controversy or disagreement, including, without limitation, pursuant to Section 18-802 of the
Delaware Limited Liability Company Act and other similar applicable laws.

     Section 5.2. Termination.

61

 

          Section 5.2.1. Right to terminate. This Agreement may be terminated and the
provisions of Section 5.3 and 5.4 shall apply, as follows:

               (a) ECLAFE Material Breach. By M, in the event of an ECLAFE Material Breach (as
defined below) by S-P or one of its Affiliates of its obligations under this Agreement or one or
more of the Related Agreements (to the extent such Related Agreement and such ECLAFE Material
Breach directly relate to the ECLAFE Cholesterol Business in ECLAFE) or, by S-P, in the event of an
ECLAFE Material Breach by M or one of its Affiliates of its obligations under this Agreement or one
of the Related Agreements (to the extent such Related Agreement and such ECLAFE Material Breach
directly relate to the ECLAFE Cholesterol Business in ECLAFE), which breach is not cured by the
breaching party or its Affiliates within thirty (30) days, or such longer period as specifically
provided pursuant to the Related Agreements, after receipt by the breaching party and its ultimate
parent, M or S-P, as the case may be, of written notice of the breach requesting cure of the
breach, with reasonable detail of the particulars of the alleged breach or in the event that the
breach cannot be reasonably cured within such thirty (30) day period, or such longer period as
specifically provided pursuant to the Related Agreements, the other party or its Affiliate has not
initiated actions reasonably expected to cure the cited failure within thirty (30) days of
receiving notice and has not in any event cured such breach within 120 days of receiving notice, or
such longer period as specifically provided pursuant to the Related Agreements. For purposes of
this Section 5.2.1(a), “ECLAFE Material Breach” means a breach of a material provision of
this Agreement or any of the Related Agreements (to the extent such Related Agreements and breach
directly relate to the ECLAFE Cholesterol Business in ECLAFE) that (i) results in a material
adverse effect on the ECLAFE Cholesterol Business in ECLAFE taken as a whole, or the operations or
financial condition of the ECLAFE Cholesterol Business in ECLAFE taken as a whole, or the value of
the ECLAFE Cholesterol Business in ECLAFE taken as a whole, and (ii) materially frustrates the
ability of either S-P or M, as the non-breaching party, as the case may be, to realize the
reasonably anticipated benefits of the ECLAFE Cholesterol Business in ECLAFE (“Material Adverse
Effect”). If the Governance Agreement has been terminated but this Agreement has not been
terminated in connection therewith pursuant to Section 5.2.2, an ECLAFE Material Breach shall also
be deemed to occur upon any breach of Section 9.9 of the Governance Agreement, provided
that if an alleged breach is by a Person that has been determined to be an Affiliate of M or S-P,
as the case may be, such breach will not be deemed an ECLAFE Material Breach if M or S-P, as the
case may be, demonstrates by a preponderance of the evidence each of the following (i) that it did
not cause, assist or encourage such Affiliate to take the action underlying the alleged breach,
(ii) that it did not have the power to prevent such Affiliate from taking such action and (iii)
that it used commercially reasonable efforts to prevent such Affiliate from taking such action.
Notwithstanding the prior sentence, such breach may, however, nevertheless be determined to be an
ECLAFE Material Breach pursuant to the provisions of the next sentence. The determination of
whether an ECLAFE Material Breach has occurred and liability for such breaches shall be made in a
judicial proceeding pursuant to Section 7.13 [Judicial Proceeding]; or

               (b) [*]

62 

 

               (c) Bankruptcy. If the Governance Agreement has been terminated but this Agreement
has not been terminated in connection therewith pursuant to Section 5.2.2, by M, in the event of
the Bankruptcy of S-P or any of its Significant Subsidiaries (as defined in the Governance
Agreement) or, by S-P, in the event of the Bankruptcy of M or any of its Significant Subsidiaries;
or

               (d) Change of Control. If the Governance Agreement has been terminated but this
Agreement has not been terminated in connection therewith pursuant to Section 5.2.2, by S-P, in the
event of a Change of Control of M, or by M, in the event of a Change of Control of S-P, as the case
may be; or

               (e) [*]

          Section 5.2.2. Automatic Termination of Master Agreement. This Agreement shall
terminate automatically and the provisions of Sections 5.3 and 5.4 shall apply upon a termination
of the Governance Agreement pursuant to (i) Section 7.2(b) [Bankruptcy] of the Governance
Agreement, (ii) Section 7.2(c) [Material Breach] of the Governance Agreement due to a breach of
Section 9.9 [Standstill] of the Governance Agreement, (iii) Section 7.2(d) [Change of Control] of
the Governance Agreement, or (iv) [*].

          Section 5.2.3. Local Bankruptcy. In the event of a Local Bankruptcy of a Local
Affiliate of M that is a party to a Venture Agreement (or the Canadian Agreement referred to in
Section 2.2(a)(2)) in a country in ECLAFE, S-P may terminate the arrangements and agreements
between the Parties that apply to such country, and in the event of a Local Bankruptcy of a Local
Affiliate of S-P that is a party to a Venture Agreement (or the Canadian Agreement referred to in
Section 2.2(a)(2)) in a country in ECLAFE, M may terminate the arrangements and agreements between
the Parties that apply to such country and, in each case, Section 5.3(b)(ii) shall apply.

     Section 5.3. Consequences of Termination.

               (a) General. With respect to any event of termination (whether a local termination
pursuant to Section 5.2.3 or termination of this Agreement), each Party shall undertake, during the
pendency of the procedure to determine whether such event of termination has occurred and the
implementation of the consequences of such termination, to maintain the ECLAFE Cholesterol Business
in ECLAFE as a going concern, so that all of the rights, title and interests in the Venture
Companies and the ECLAFE Cholesterol Business in ECLAFE may be conveyed to the extent contemplated
by this Article 5. The parties acknowledge that in the event of a termination of this Agreement
that results in one party acquiring the Interests of another party hereto and ECLAFE Termination
Assets, if any, (i), the acquiring party may determine to continue operating the ECLAFE Cholesterol
Business in ECLAFE, (ii) appropriate adjustments to the Singapore Partnership Agreement will be
made to provide that (A) profit and loss arising from the ECLAFE Cholesterol Business in ECLAFE
shall be specifically
allocated to the Party (or its Affiliates) that acquires the Interests of the other Party and
its Affiliates and (B) to the extent the Governance Agreement has not been terminated or is

63 

 

not
being terminated simultaneously with this Agreement pursuant to Section 7.2(b) [Bankruptcy],
Section 7.2(c) [Material Breach due to a breach of Section 9.9 [Standstill] of the Governance
Agreement], Section 7.2(d) [Change of Control] or [*] of the Governance Agreement, that the assets
and liabilities of the Singapore Partnership, to the extent they relate to the ECLAFE Cholesterol
Business in ECLAFE (“Singapore Termination Assets”), can be sold as set forth in the last
sentence of this Section 5.3(a), or the rights thereto otherwise transferred, to the Terminating
Party or its Affiliates pursuant to this Section 5.3 and (iii) appropriate adjustment to the MSP
Technology Agreement will be made to provide that, to the extent the Governance Agreement has not
been terminated or is not being terminated simultaneously with this Agreement pursuant to Section
7.2(b) [Bankruptcy], Section 7.2(c) [Material Breach due to a breach of Section 9.9 [Standstill] of
the Governance Agreement], Section 7.2(d) [Change of Control] or [*] of the Governance Agreement,
the assets and liabilities of MSP Technology Partnership, to the extent they relate to the ECLAFE
Cholesterol Business in ECLAFE (the “Technology Termination Assets,” and together with the
Singapore Terminations Assets, the “ECLAFE Termination Assets”), can be sold as set forth
in the last sentence of this Section 5.3(a), or the rights thereto transferred, to the Terminating
Party or its Affiliates pursuant to this Section 5.3. In the event of any such termination, the
Parties will enter into such agreements as are necessary or appropriate to provide for the transfer
of the ECLAFE Termination Assets and will endeavor in good faith to arrange for such transfer to be
effected in a manner that is tax efficient, to the maximum extent reasonably practicable, to both
the Terminated Party and the Terminating Party, and any other agreements as may be necessary or
appropriate to effectuate the foregoing.

          (b) Bankruptcy. (i) In the event of termination pursuant to Section 5.2.1(c) or
5.2.2(i), the non-bankrupt party (or its designee) shall be entitled to purchase the bankrupt
party’s Interests in the ECLAFE Cholesterol Business in ECLAFE, and (ii) in the event of
termination pursuant to Section 5.2.3, the non-bankrupt party (or its designee) shall be entitled
to purchase the bankrupt party’s Interest with respect to the ECLAFE Cholesterol Business in the
country in ECLAFE where such bankrupt party engages in the ECLAFE Cholesterol Business in ECLAFE.
If local law prohibits the Parties from enforcing these provisions in a jurisdiction, the Parties
will take all necessary actions to give effect to the intent of this Section 5.3(b)(ii). Any
purchase and sale pursuant to clause (i) or (ii) of this Section 5.3(b) shall be consummated as
soon as practicable, but in any event within 300 days of determination of a Bankruptcy or Local
Bankruptcy of the other, and each of the parties shall execute such documents as are reasonable and
necessary in connection therewith. The purchase price for any such purchase shall be an amount
equal to the fair market value of the particular bankrupt party’s Interests being purchased or
acquired and shall be determined in the manner described in Section 5.3(d)(i).

          (c) ECLAFE Material Breach.

          (i) In the event of termination pursuant to Sections 5.2.1(a), or 5.2.2(ii), the
non-breaching party (or its designee) shall be entitled to purchase the
breaching party’s Interests and the ECLAFE Termination Assets, if any, in the Venture
Companies and the ECLAFE Cholesterol Business in ECLAFE.

64 

 

          (ii) Any purchase and sale pursuant to this Section 5.3(c) shall be consummated as
soon as practicable, but in any event within 120 days of determination of an ECLAFE
Material Breach and the related appraisal and damage proceedings, and each of the parties
shall execute such documents as are reasonable and necessary in connection therewith. The
purchase price for any such purchase shall be an amount equal to the fair market value of
the breaching party’s Interests and the ECLAFE Termination Assets, if any, as determined in
a judicial proceeding as set forth in Section 7.13 [Judicial Proceedings]. In determining
the fair market value of the breaching party’s Interests and the ECLAFE Termination Assets,
if any, the court shall apply the standards applicable in an appraisal proceeding under
Section 262 of the Delaware General Corporation Law as may be amended from time to time,
which value shall not include the value of any goodwill, rights and services not
transferred with the Interests and the ECLAFE Termination Assets, if any (e.g. MSDIS
distribution services).

          (iii) Any termination of this Agreement or any of the Related Agreements pursuant to
this Section 5.3(c) due to a breach of this Agreement or any of the Related Agreements
shall not relieve the breaching party from liability for damages caused by its breaches
(except that the breaching party shall not be liable for punitive, special, consequential,
incidental, indirect or exemplary or other similar damages or lost profits) as a result of
any such breach. Damages shall be determined in the judicial proceeding contemplated by
this Section 5.3(c).

          (d) Change of Control. Within 45 days after the date of a Change of Control of S-P or
Change of Control of M, the party which did not experience the Change of Control (the “Call
Party”) may by written notice (the “C-O-C Notice”) delivered to the other party (the
“C-O-C Party”) request that the fair market value of the C-O-C Party’s Interests (the
“Call Price”) be determined in accordance with paragraph (i) of this Section 5.3(d).

          (i) The Call Price shall be conclusively determined by two internationally recognized
investment banking firms, one of which shall be retained and paid by the Call Party and one
of which shall be retained and paid by the C-O-C Party. The Call Party and the C-O-C Party
shall promptly notify each other of their respective selections. If either such party
fails to deliver such notice to the other party of its selection of an investment banking
firm within thirty (30) days after delivery of a C-O-C Notice, the determination shall be
rendered by the single investment banking firm so selected (whose fees, in such case, shall
be borne equally by S-P and M). The investment banking firms selected in accordance with
the foregoing procedure shall each determine the fair market value of the C-O-C Party’s
Interest, (which value shall be an amount determined assuming that the buyer and seller are
under no compulsion to buy or sell and shall be determined without regard to any minority
or illiquidity discount or the
value of any goodwill, rights and services not transferred with the Interests, e.g.
MSDIS distribution services) and submit their determinations of such value to the Call
Party and the C-O-C Party within 45 days following their selection. The Call

65 

 

Price shall
be the amount equal to the sum of such values determined by each investment banking firm
divided by two, except that if there is more than a twelve percent (12%) difference between
(x) the average of such values and (y) each of such values, the two investment banking
firms shall, within twenty (20) days after their submissions mutually select and appoint a
third investment banking firm, similarly qualified, and give written notice thereof to the
Call Party and the C-O-C Party. If the two investment banking firms fail to appoint a
third investment banking firm within such twenty-day period, the third investment banking
firm shall be selected and appointed, at the request of either party, by the President of
the Association of the Bar of the City of New York or by a person designated by such
President. Within thirty (30) days after the appointment of the third investment banking
firm, the third investment banking firm shall promptly submit in writing to the Call Party
and the C-O-C Party its determination of the fair market value. If the valuation of the
third banker is not between the valuations of the first and second bankers, fair market
value shall be the average of the valuations of the third banker and the next closest
valuation. If the valuation of the third banker is (i) between the valuations of the first
and second bankers and (ii) not more than thirty percent (30%) (calculated as the average
of the first two valuations multiplied by 0.3) higher or lower than the valuations of each
of the first and second bankers, then fair market value shall be the average of the
valuations of all three bankers. If the valuation of the third banker is (x) between the
valuations of the first and second bankers and (y) more than thirty percent (30%)
(calculated as the average of the first two valuations multiplied by 0.3) higher or lower
than one or both of the other two valuations, then fair market value shall be the average
of the third banker’s valuation and the valuation, if any, that is not more than thirty
percent (30%) (calculated as the average of the first two valuations multiplied by 0.3)
higher or lower than the third banker’s valuation. For illustrative purposes only,
Schedule 7.3 of the Governance Agreement sets forth examples of the method of determining
fair market value pursuant to the provisions of this Section 5.3(d). The fair market value
as determined above shall be final and binding upon the Call Party and the C-O-C Party.
The cost of such third investment banking firm shall be borne one-half by the Call Party
and one-half by the C-O-C Party.

          (ii) The Call Party shall have the right, exercisable by delivery of written notice to
the C-O-C Party (a “Call Notice”) within sixty (60) days after the final
determination of the Call Price, to require the C-O-C Party to sell and transfer the C-O-C
Party’s entire Interest to the Call Party (or its designee) at a price equal to the Call
Price. Any such sale shall be made without representations or warranties of the C-O-C
Party other than regarding the authorization of the sale and title to the Interest being
sold. Upon and after the consummation of such sale, the C-O-C Party shall have no
responsibility or liability for any liabilities or obligations arising from the Interests
(whether contingent, absolute, realized or unrealized) that exist as of the date of such
sale or that are incurred with respect to
the Interest thereafter and shall only be obligated to continue performance under any
Related Agreement in accordance with Section 5.4.

66 

 

          (iii) Any purchase and sale of the C-O-C Party’s Interest effected pursuant to this
Section 5.3(d) shall be consummated at a closing at the offices of the Call Party on a
business day within fifteen (15) days following the delivery of the Call Notice (upon at
least five days’ notice by the Call Party); provided that such period shall be extended for
180 additional days, or such shorter period of time, as shall be necessary in order to
obtain requisite governmental or regulatory approvals with respect to such transaction;
provided, further, that such closing may be held at such other time and place as the
parties to the transaction may agree. At such closing, the Call Party shall pay the C-O-C
Party the Call Price by wire transfer of immediately available funds to an account
specified by the C-O-C Party, and the parties to such transaction and the Venture Companies
shall execute any and all documents necessary to effect the full and complete transfer of
the C-O-C Party’s Interest.

          (iv) No investment banking firm selected by a party pursuant to this Section 5.3(d)
shall have represented such party in a significant engagement within the 24-month period
immediately prior to such selection. Any investment banking firm selected in any other
manner shall not have represented either party in a significant engagement within the
24-month period immediately prior to such selection.

          (e) [*]. In the event this Agreement is terminated pursuant to Sections [*], this Agreement
and all the Related Agreements shall immediately terminate (except, in the case of a termination
pursuant to [*], for the Amended Agreements, which will be amended or terminated as required to
terminate the provisions that relate to the ECLAFE Cholesterol Business in ECLAFE) and the assets
and liabilities, to the extent related to the ECLAFE Cholesterol Business in ECLAFE, will be
distributed as follows: (1) all of the assets contributed will solely be returned to the original
party who had contributed them, so as to put the parties back, to the maximum extent possible and
as promptly as practicable, to the position they were in prior to the contribution of such assets
pursuant to this Agreement and the Related Agreements (to the extent such Related Agreements relate
to the ECLAFE Cholesterol Business in ECLAFE), (2) with respect to the Research Results (as defined
in the Development Agreement), each party will have equal ownership and access on a co-exclusive
basis for use in the Field in ECLAFE (except that S-P and/or its Affiliates shall have exclusive
rights to Research Results relating to R&D IP-Ezetimibe Monotherapy for use outside ECLAFE), and
(3) with respect to liabilities and assets, other than those contributed by the parties and the
Research Results, such liabilities and assets will be transferred in a commercially reasonable
manner to S-P and/or its Affiliates and M and/or its Affiliates to the greatest extent possible on
an equal basis. To the extent such assets are necessary for the continued operation of the
Cholesterol Business (as defined in the Governance Agreement), such assets will not be distributed.
The cost of such distribution and dissolution shall be shared equally by S-P and M. Such
distribution and dissolution shall occur within ten (10) business days of the termination event or
if not possible within ten (10) business days, then as soon as
practicable. In the event of such termination, (i) Section 7.1(a)(1) shall survive and
continue to be binding on all of the parties in all respects (and, in addition, the provisions of
Section 7.1 and 7.2 shall be deemed applicable with respect to the information

67 

 

specifically
relating to assets distributed to the parties in connection with such termination) for six years
following such termination and (ii) Sections 6.1, 6.2, 6.4.1 and 6.5 shall survive for two years
following such termination.

          (f) Agreement to Enter into New Agreements. In the event that (i) this Agreement is
terminated pursuant to Sections [*] of this Agreement and (ii) S-P resolves the issues that M believed
constituted [*], as the case may be, S-P will promptly notify M in writing of the resolution of
such issues or completion of such study, as the case may be. Then, if M provides written notice to
S-P within twenty (20) business days of receipt of supporting information reasonably requested by M
and study results, as the case may be, the parties will enter into agreements on substantially
similar terms as the terms set forth in this Agreement and the Related Agreements (the “New
Agreements”) within sixty (60) days of receipt of such notice. M shall reimburse S-P on the
date of execution of the New Agreements for costs incurred by S-P (net of costs reimbursed to S-P
and its Affiliates by any Third Party) relating to the development and marketing of Ezetimibe and
the Z/E Combination Product from the date of termination of this Agreement until the execution date
of the New Agreements that would otherwise have been borne by Singapore Partnership.
Notwithstanding the non-compete provisions of the Governance Agreement, the parties hereto
acknowledge that from the date of termination of this Agreement pursuant to Sections 5.2.1(e),
5.2.2(iv) or 5.2.1(b) of this Agreement until the execution date of the New Agreements, S-P will be
free to enter into any business arrangements of any kind with respect to Ezetimibe and that the New
Agreements will contain such modifications to the non-compete and other provisions as are necessary
to reflect any such business arrangements, as well as changes in law or corporate organization.

          (g) No Double Counting. The Parties agree that in no event shall the value of the
Terminated Party’s Interests determined under this Agreement and the value of the Terminated
Party’s Interests (as defined in the Governance Agreement) determined under the Governance
Agreement include the valuation of the same assets so that such assets are valued twice.

     Section 5.4. Treatment of Master Agreement and Related Agreements.

          (a) General. Notwithstanding any provision to the contrary in this Agreement or any
Related Agreement, (i) no Party will permit any Affiliate to terminate any Related Agreement,
except as provided in the Governance Agreement or this Article 5 and Section 4.5, and (ii) each
Party will cause its Affiliates to amend or terminate the Related Agreements as provided in this
Article 5 and Section 4.5.

          (b) Survival of Certain Provisions of this Agreement. In the event of any termination
of this Agreement pursuant to Section 5.2.1(a) [ECLAFE Material Breach], 5.2.1(c) or 5.2.2(i)
[Bankruptcy], 5.2.2(ii) [Material Breach-Standstill], or 5.2.1(d) or 5.2.2(iii) [Change of
Control]:

          (i) All provisions of Section 7.1 [Confidentiality] shall survive and continue to be
binding on the Terminated Party in all respects for six years

68 

 

     following such termination.

          (ii) All provisions of Section 7.1 (other than Sections 7.1(a)(1) and (a)(3)) shall
survive and continue to be binding on the Terminating Party for six years following such
termination, provided that if the Terminated Party’s Interests and ECLAFE Termination
Assets, if any, are not acquired by the Terminating Party, all provisions of Section 7.1
shall survive and continue to be binding on the Terminating Party for six years following
such termination.

          (iii) [*]

          (iv) All other provisions of Section 4.4 shall survive and continue to be binding on
the Terminated Party and its Affiliates (including any acquiring or surviving entity in the
event of a Change of Control), but only with respect to Pre-Termination Substances, until
the later of (A) four years following such termination or (B) with respect to the Core
Countries, Australia and Canada, four years after the Launch of a Combination Product in
such country, provided that the maximum survival period under this clause (B) shall be five
years after termination of this Agreement.

          (v) All provisions of Sections 6.1, 6.2, 6.4 and 6.5 shall survive for two years
following termination.

          (c) Effect of Certain Terminations. In the event of any termination of this Agreement
pursuant to Section 5.2.1(a) [ECLAFE Material Breach], 5.2.1(c) or 5.2.2(i) [Bankruptcy], 5.2.2(ii)
[Material Breach-Standstill], or 5.2.1(d) or 5.2.2(iii) [Change of Control]:

          (i) The Canadian Agreements and the Venture Agreements entered into by the Terminated
Party or its Affiliates shall, notwithstanding anything to the contrary contained therein,
remain in effect as provided therein following the termination of this Agreement and the
rights and benefits of the Terminated Party or its Affiliates in the Canadian Agreements
and the Venture Agreements entered into by the Terminated Party or its Affiliates shall be
assigned to the Terminating Party or its designee at the closing of the acquisition by the
Terminating Party of the Interests held by the Terminated Party or its Affiliates and the
ECLAFE Termination Assets, if any, and thereafter the Terminated Party shall have no rights
or obligations under such agreements with respect to the ECLAFE Cholesterol Business in
ECLAFE.

          (ii) The Co-Marketing Supply Agreements entered into by the
Terminated Party shall be terminated immediately following the termination of this
Agreement;

          (iii) The Board Country Supply Agreements entered into by the Terminated Party shall
remain in full force and effect for ninety (90) days following the termination of this
Agreement and shall then terminate;

69 

 

          (iv) The Toll Packaging Agreements pursuant to which the Terminated Party or any of
its Affiliates packages for the benefit of the Terminating Party or any of its Affiliates
(or which relates to the packaging of Cholesterol Products comprising the Interests and
ECLAFE Termination assets, if any, acquired under Section 5.3) shall terminate upon the
termination of this Agreement; provided that, the Terminating Party shall have the option
to require by written notice that the Terminated Party or its Affiliate continue to perform
its obligations under such Toll Packaging Agreement for a period of up to two (2) years
after the date of termination of this Agreement. Such written notice shall be provided to
the Terminated Party no later than sixty (60) days prior to the purchase of Interest(s).
In the event such option is exercised, the relevant Toll Packaging Agreement shall remain
in full force and effect for the period of such exercise up to two (2) years and then
terminate. All other Toll Packaging Agreements may be terminated at the discretion of the
Terminating Party.

          (v) The Amended Agreements entered into by the Terminated Party shall, notwithstanding
anything to the contrary contained therein, remain in effect as provided therein following
the termination of this Agreement and shall be amended at the closing of the acquisition by
the Terminating Party of the Interests held by the Terminated Party and the ECLAFE
Termination Assets, if any, in accordance with this Agreement, in order to transfer to such
Terminating Party any rights acquired by the Terminating Party in connection with the
acquisition of the Interests in the ECLAFE Cholesterol Business in ECLAFE and the ECLAFE
Termination Assets, if any, and thereafter the Terminated Party shall have no rights or
obligations under such agreements with respect to the ECLAFE Cholesterol Business in ECLAFE
and the ECLAFE Termination Assets, if any. Nothing in this Section 5.4(c)(v) shall affect
the Terminated Party’s Interests determined under this Agreement, or the value of the
Terminated Party’s “Interests” in the U.S. Related Companies and “U.S. Termination Assets”,
if any, in the “Cholesterol Business” (each, as defined in the Governance Agreement) in the
U.S. Territory determined under the Governance Agreement.

          (d) Effect of Termination Due to Local Bankruptcy. In the event of the exercise of
the termination right pursuant to Sections 5.2.3 [Local Bankruptcy]:

          (i) The relevant Venture Agreement (or Canadian Agreement referred to in Section
2.2(a)(2), if applicable) entered into by the Terminated Party in the relevant country
shall, notwithstanding anything to the contrary contained therein, remain in effect as
provided therein and the rights, benefits and obligations of the Terminated Party in such
Venture Agreement (or Canadian
Agreement) entered into by the Terminated Party shall be assigned to the Terminating
Party or its designee at the closing of the acquisition by the Terminating Party of the
Interests held by the Terminated Party in such country or countries, and thereafter the
Terminated Party shall have no rights or obligations under such Agreements with respect to
the ECLAFE Cholesterol Business in such country or countries.

70 

 

          (ii) The relevant Co-Marketing Supply Agreement(s) entered into by the Terminated
Party or its Affiliates shall be terminated or amended, as necessary immediately following
the termination of this Agreement to exclude the application of such Co-Marketing Supply
Agreement to that country (or countries) and the equivalent Co-Marketing Supply Agreement
entered into by the Terminating Party shall be amended as necessary immediately following
the termination of this Agreement to grant to such Terminating Party any additional rights
required in connection with the acquisition of the Interests held by the Terminated Party
in such country or countries, and thereafter the Terminated Party shall have no rights or
obligations under such Agreements with respect to the ECLAFE Cholesterol Business in such
country or countries.

          (iii) The Board Country Supply Agreement(s) entered into by the Terminated Party or
its Affiliates shall remain in full force and effect for ninety (90) days following the
termination of this Agreement and shall then be terminated or amended, as necessary, to
exclude the application of such Board Country Agreement to that country (or countries), and
thereafter the Terminated Party shall have no rights or obligations under such Agreements
with respect to the ECLAFE Cholesterol Business in such country or countries.

          (iv) The Toll Packaging Agreement(s) pursuant to which the Terminated Party or any of
its Affiliates packages Cholesterol Products for sale in the relevant country (or
countries) shall terminate (or be amended to exclude the relevant country or countries from
such Terminated Party’s or its Affiliates’ packaging obligations therein) upon the local
termination, and thereafter the Terminated Party shall have no rights or obligations under
such Agreements with respect to the ECLAFE Cholesterol Business in such country or
countries; provided that, the Terminating Party shall have the option to require by written
notice that Terminated Party or its Affiliate continue to perform its obligations under
such Toll Packaging Agreement with respect to such country or countries for a period of up
to two (2) years after the date of such local termination. Such written notice shall be
provided to the Terminated Party no later than sixty (60) days prior to the purchase of
Interest(s). In the event such option is exercised, the relevant Toll Packaging Agreement
shall remain in full force and effect for the period of such exercise up to two (2) years
and then terminate.

          (v) The Amended Agreements entered into by the Terminated Party or its Affiliates
shall, notwithstanding anything to the contrary contained therein, remain in effect as
provided therein following exercise of the termination right contained in Section 5.2.3,
and shall be amended at the closing of the
acquisition by the Terminating Party of the Interests held by the Terminated Party
with respect to the country (or countries), in order to transfer to such Terminating Party
any rights acquired by the Terminating Party in connection with the acquisition of the
Interests in such country (or countries) and thereafter the Terminated Party shall have no
rights or obligations under such Agreements with respect to the ECLAFE Cholesterol Business
in such country or countries.

71 

 

     Section 5.5. Incorporation by Reference. The Termination of the Governance Agreement
shall not affect the provisions of the Governance Agreement incorporated by reference and such
provisions will remain in full force and effect as set forth herein until terminated pursuant to
the terms of this Agreement.

ARTICLE VI

REPRESENTATIONS, WARRANTIES, COVENANTS

AND INDEMNIFICATION

     Section 6.1. Representations and Warranties of the Parties. M hereby represents and
warrants to S-P with respect to itself and S-P hereby represents and warrants to M with respect to
itself as of the date hereof as follows:

                    (a) Organization and Good Standing; Power and
Authority; Qualifications. Such Party
(i) is duly organized, validly existing and in good standing under the laws of its jurisdiction of
organization, (ii) has all requisite power and authority to own, lease and operate its properties
and to carry on its business as presently conducted and as proposed to be conducted and (iii) has
all requisite power and authority to enter into and carry out the transactions contemplated by this
Agreement and the Related Agreements to which it is a Party.

                    (b) Authorization of this Agreement and the
Related Agreements. The execution,
delivery and performance of each of this Agreement and the Related Agreements have been duly
authorized by all requisite action on the part of such Party which is a Party hereto and thereto,
and each of this Agreement and the Related Agreements constitutes a legal, valid and binding
obligation of such Party which is a Party hereto and thereto, enforceable against each such Party
in accordance with its terms except to the extent that enforceability may be limited by bankruptcy,
insolvency or other similar laws affecting creditors’ rights generally.

                    (c) No Conflict. The execution and delivery by
such Party of this Agreement and the
Related Agreements to which it is a Party and the consummation by such Party of the transactions
contemplated hereby and thereby and the compliance by such Party with the provisions hereof and
thereof will not (i) violate any material provision of law, statute, rule or regulation, or any
ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other
governmental body applicable to it, or any of its properties or assets, (ii) conflict with or
result in any breach of any of the terms, conditions or provisions of, or constitute (with due
notice or lapse of time, or both) a default under, or result in the creation of any encumbrance
upon any of its properties or assets under, any contract to which it is a Party or (iii) violate
its certificate of incorporation or by-laws or other organizational documents, that in the case of
clause (i) or (ii), would individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, or prevent the consummation of the transactions contemplated hereby.
Without limiting the generality of the foregoing, S-P represents and warrants that neither it nor
any of its Affiliates has any obligation to any Third Party that would require it to contribute or
license to a Third Party the right to manufacture, market or distribute in ECLAFE (i) for the
over-the-counter market, any of the

72 

 

Cholesterol Products or (ii) any Cholesterol Absorption Inhibitor so that such Third Party
could use such Cholesterol Absorption Inhibitor alone or in combination with a Statin. Without
limiting the generality of the foregoing, M represents and warrants that neither it nor any of its
Affiliates has any obligation to any Third Party that would require it to contribute or license to
a Third Party the right to manufacture, market or distribute in ECLAFE (i) for the over-the-counter
market, any of the Cholesterol Products or (ii) Simvastatin for combination use so that such Third
Party could use Simvastatin for combination use in combination with a Cholesterol Absorption
Inhibitor. Notwithstanding the foregoing, M has represented to S-P that there may be restrictions
on M’s rights to contribute Simvastatin (i) for combination use for the over-the-counter market
pursuant to a joint venture with Johnson & Johnson and (ii) for animal health uses pursuant to a
joint venture with Aventis S.A.

     Section 6.2. Certain Representations.

               (a) - (d)[*]

               (e) S-P hereby represents and warrants that the Cholesterol Assignment Documents (as defined
in the Governance Agreement), together with this Agreement and the Related Agreements, provide to
the Singapore Partnership all of the rights and obligations and all of the benefits of all of the
representations, warranties, covenants and agreements provided to Schering Sales Management, Inc.
pursuant to the Schering License Agreement (Existing Cholesterol Combination IP), dated as of the
date of the Governance Agreement and as may be amended from time to time, excluding only the
obligations under Section 7 of that Schering License Agreement.

     Section 6.3. Certain Covenants. Each party hereto, with respect to itself, agrees
that, for so long as this Agreement is in effect:

               (a) Maintenance of Corporate Existence, etc. Such party shall maintain in full force
and effect its corporate existence, rights, governmental approvals, permits, and franchises and all
licenses and other rights material to and necessary in the conduct of its business as currently
conducted and as proposed to be conducted, except to the extent that such failure to preserve and
maintain such existence and qualifications would not reasonably be expected to have a Material
Adverse Effect.

               (b) Compliance with Laws. Each Party shall use reasonable efforts to comply with all
applicable laws, rules regulations and orders, except for violations or failures to so comply, if
any, that, individually or in the aggregate, would not reasonably be expected to have a Material
Adverse Effect. Each of M and S-P shall comply with all applicable laws, rules, regulations and
orders as it relates to such party with respect to the ECLAFE Cholesterol Business in ECLAFE,
except for violations or failures to so comply, if any, that, individually or in the aggregate,
would not reasonably be expected to have a Material Adverse Effect.

73

 

               (c) Insurance. Each Party shall maintain adequate insurance (or have adequate self
insurance) covering all aspects of the ECLAFE Cholesterol Business in ECLAFE . Each party and its
respective Affiliates (as applicable) shall keep its assets that are necessary to perform its
obligations under this Agreement and the Related Agreements and which are of an insurable
character, if any, insured in accordance with such Party’s then applicable insurance program for
its business.

     Section 6.4. Certain Obligations.

          Section 6.4.1. Affiliate Obligations. Each of M and S-P hereby guarantees the
performance by their respective Affiliates of each of such Affiliates’ obligations (i) under this
Agreement, and (ii) as parties to the Related Agreements.

          Section 6.4.2. Amendments to Related Agreements. Any Related Agreement that is solely
between Affiliates of M may not be amended or modified in any manner without the written consent of
S-P. Any Related Agreement that is solely between Affiliates of S-P may not be amended or modified
in any manner without the written consent of M.

          Section 6.4.3. Non-Discrimination. To the extent M or an Affiliate of M is
responsible for the distribution and supply of Cholesterol Products in countries in the EMEA or
LAFE (other than in LAFE Co-Marketing Countries and Far East Single Presence Countries where S-P
has been deemed to have the single presence, each of M and its Affiliates will use commercially
reasonable efforts to perform its obligations to distribute and supply the Cholesterol Products
under the applicable Related Agreements, which efforts shall be at least equivalent to those
employed by M and/or its Affiliate (as applicable) in the supply and distribution of other M
products of comparable stage of development, potential, value and status. In performing such
activities, M and/or its Affiliates (as applicable) shall not favor its other products of
comparable stage of development, potential, value and status over the Cholesterol Products. In
addition, to the extent that M or an M Affiliate is supplying Cholesterol Products to both M (or a
M Affiliate) and S-P (or a S-P Affiliate) for marketing and sale in a country in the ECLAFE, M or
its Affiliate (as applicable) shall not treat either party to which it is supplying Cholesterol
Products in any fashion less favorable than the other party.

          Section 6.4.4. Supply Allocation. To the extent M or an Affiliate of M is responsible
for the distribution and supply of Cholesterol Products in countries in the EMEA or LAFE (other
than in LAFE Co-Marketing Countries, and Far East Single Presence Countries where S-P has been
deemed to have the single presence), each of M and its Affiliates will use commercially reasonable
efforts to ensure that the methods used to allocate the supply of Cholesterol Products are the same
as the methods used to allocate the supply of other pharmaceutical products supplied by M or its
Affiliates in connection with other business in the relevant territory.

          Section 6.4.5. Promotional Disputes. The Parties agree that decisions regarding any
promotional disputes with Third Parties regarding the Cholesterol Products in the Field in ECLAFE
shall be made jointly and that following the Effective Date they

74

 

will work together in good faith to agree on mutually satisfactory procedures to govern the
conduct of any promotional disputes with Third Parties regarding the Cholesterol Products in the
Field in ECLAFE.

     Section 6.5. Indemnification.

          Section 6.5.1. Indemnification by the Singapore Partnership. The Singapore
Partnership shall indemnify, defend and hold harmless the M Indemnified Parties and the S-P
Indemnified Parties from and against all Losses incurred or suffered by any of them as a result of,
arising from, or in connection with any claim, action, proceeding or investigation of any Third
Party relating to:

               (a) the development, testing or use of any of the Cholesterol Products in the Field in ECLAFE;
or

               (b) the marketing, distribution, promotion, supply or sale of the Cholesterol Products in the
Field in the EMEA Board Countries, the Far East Board Countries, the EMEA No Presence Countries or
Canada.

     Notwithstanding the foregoing, no M Indemnified Party and no S-P Indemnified Party shall be
entitled to any indemnification pursuant to this Section 6.5.1 to the extent the Loss for which
indemnification is being sought is caused by the gross negligence or willful misconduct of the
party seeking indemnification.

          Section 6.5.2. Indemnification by M. M shall indemnify, defend and hold harmless the
S-P Indemnified Parties and the Singapore Partnership from and against all Losses incurred or
suffered by any of them as a result of, arising from, or in connection with:

               (a) the breach by M of any of its representations, warranties or covenants in this Agreement,
the Development Agreement, any License Agreements or any Co-Venture Agreement or Entity Agreement,
provided that no claim may be made for indemnification under this Section 6.5.2 for breaches of
representations or warranties until the aggregate dollar amount of all such claims exceeds $2
million;

               (b) the gross negligence or willful misconduct by M or any of its Affiliates in the
performance of any of their obligations under this Agreement or the Related Agreements (other than
manufacturing or packaging agreements);

               (c) the development, testing, use, marketing, distribution, promotion, supply or sale by M or
its Affiliates of the Cholesterol Products outside the Field; or

               (d) the development, testing, use, marketing, distribution, promotion, supply or sale by M or
its Affiliates (or Banyu Pharmaceutical Company, Ltd) of the Cholesterol Products in Japan to the
extent such Cholesterol Products are developed, tested, used, marketed, distributed, promoted,
supplied or sold either (i) under a Product Marketing Authorization that includes, directly or by
reference, data

75

 

comprising “Merck Clinical IP”, “Schering Clinical IP” or “Merck Formulation IP” (each as
defined in the Development Agreement), or (ii) under a trademark, tradename or other form of brand
protection owned or used by the Singapore Partnership.

     Notwithstanding the foregoing, neither any S-P Indemnified Party nor the Singapore Partnership
shall be entitled to any indemnification pursuant to this Section 6.5.2 to the extent the Loss for
which indemnification is being sought is caused by the gross negligence, willful misconduct or
willful violation of law of the party seeking indemnification.

          Section 6.5.3. Indemnification by S-P. S-P shall indemnify, defend and hold harmless
the M Indemnified Parties and the Singapore Partnership from and against all Losses incurred or
suffered by any of them as a result of, arising from, or in connection with:

               (a) the breach by S-P of any of its representations, warranties or covenants in this
Agreement, the Development Agreement, any License Agreements or any Co-Venture Agreements or Entity
Agreements, provided that no claim may be made for indemnification under this Section 6.5.3 for
breaches of representations or warranties until the aggregate dollar amount of all such claims
exceeds $2 million;

               (b) the gross negligence or willful misconduct by S-P or any of its Affiliates in the
performance of any of their obligations under this Agreement or the Related Agreements(other than
manufacturing or packaging agreements);

               (c) the development, testing, use, marketing, distribution, promotion, supply or sale by S-P
or its Affiliates of the Cholesterol Products outside the Field; or

               (d) the development, testing, use, marketing, distribution, promotion, supply or sale by S-P
or its Affiliates of the Cholesterol Products in Japan to the extent such Cholesterol Products are
developed, tested, used, marketed, distributed, promoted, supplied or sold either (i) under a
Product Marketing Authorization that includes, directly or by reference, data comprising “Merck
Clinical IP”, “Schering Clinical IP” or “Merck Formulation IP” (each as defined in the Development
Agreement), or (ii) under a trademark, tradename or other form of brand protection owned or used by
the Singapore Partnership.

     Notwithstanding the foregoing, neither any M Indemnified Party nor the Singapore Partnership
shall be entitled to any indemnification pursuant to this Section 6.5.3 to the extent the Loss for
which indemnification is being sought is caused by the gross negligence, willful misconduct or
willful violation of law of the party seeking indemnification.

          Section 6.5.4. Indemnification Principles. For purposes of this Section 6.5,
“Losses” shall mean each and all of the following items: claims, losses, liabilities,
obligations, payments, damages, charges, judgments, fines, penalties, amounts paid in settlement,
costs and expenses (including, without limitation, interest which may be

76

 

imposed in connection therewith, costs and expenses of investigation, actions, suits,
proceedings, demands, assessments and reasonable fees, expenses and disbursements of counsel,
consultants and other experts). Losses shall not include, and indemnification shall not be
available under this Section 6.5 for, (i) lost profits, punitive, special, indirect, consequential,
incidental, exemplary or other similar damages (collectively, “Special Damages”), other
than Special Damages payable to Third Parties, or (ii) any Obligations which are otherwise subject
to Sections 2.1(a), 2.1(b) and 2.4(b)(1). Notwithstanding any provision in this Agreement or any
Related Agreement, no Party hereto or thereto shall seek or be entitled to receive any Special
Damages from any other Party, or its Affiliates, in connection with such Agreements.

          Section 6.5.5. Claim Notice. A Party seeking indemnification under this Section 6.5
shall, promptly upon becoming aware of the facts indicating that a claim for indemnification may be
warranted, give to the Party from whom indemnification is being sought a claim notice relating to
such Loss (a “Claim Notice”). Each Claim Notice shall specify the nature of the claim, the
applicable provisions of this Agreement under which the claim for indemnity arises, and, if
possible, the amount or the estimated amount thereof. No failure or delay in giving a Claim Notice
and no failure to include any specific information relating to the claim (such as the amount or
estimated amount thereof) or any reference to any provision of this Agreement or other instrument
under which the claim arises shall affect the obligation of the Party from whom indemnity is sought
except to the extent such Party is materially prejudiced by such failure or delay.

ARTICLE VII

MISCELLANEOUS

     Section 7.1. Confidentiality.

               (a) Without limiting the effect of the confidentiality provisions of any of the Related
Agreements, and subject to the exceptions provided in Section 7.1(b), none of S-P or M, their
respective Affiliates, or the Singapore Partnership or any entity created pursuant to an Entity
Agreement (a “JV Entity”) shall, without the prior written consent of S-P or M, as the case
may be, divulge, use or permit its, or its Affiliates’, officers, employees, agents, advisors or
contractors to divulge to any Person or use (other than as provided in Section 7.1(c)):

     (1) the contents of this Agreement or any of the Related Agreements;
(2) any confidential or proprietary information which has been provided to
it (whether before or after the date of this Agreement) by any of the
other parties hereto; or (3) any confidential or proprietary information
relating to the ECLAFE Cholesterol Business in ECLAFE other than the
information covered by this Section 7.1(a)(2); including, in each case,
all financial, marketing and technical information, specifications, ideas,
concepts, technology, processes, knowledge and know-how, together with all
details of customers, suppliers, prices, discounts, margins, information
relating to research and development, current

77

 

trading performance and future business strategy (collectively, the
“Confidential Information”).

          (b) The restrictions imposed by Section 7.1(a) shall not apply to the disclosure of any
information which:

     (1) is or becomes generally available to the public other than as a
result of any breach of the provisions of this Agreement; (2) is lawfully
in the possession of such other Party prior to receipt from the disclosing
Party; (3) is commonly known to Persons engaged in the pharmaceutical
industry other than as a result of any breach of the provisions of this
Agreement; (4) is independently developed by such Party without reference
to the other Party’s or such Party’s Affiliates’ Confidential Information;
or (5) is required to be disclosed by S-P, M, the Singapore Partnership or
any of their Affiliates or any JV Entity under any law applicable to the
conduct of such Party’s business or otherwise or is disclosed upon S-P, M,
the Singapore Partnership or any of their Affiliates or any JV Entity
becoming legally compelled to disclose, if, in any such case, S-P, M, the
Singapore Partnership or any of their Affiliates or any JV Entity under
such legal obligation or compulsion has used its best efforts to afford
the other Party the opportunity to obtain an appropriate protective order
or other satisfactory assurance of confidential treatment for the
information required to be so disclosed.

          (c) Each of S-P and M shall ensure that Confidential Information is disclosed only to those of
its and its Affiliates’ officers, employees, agents, advisors and contractors who need to know it,
and who are bound by written obligations of confidentiality in respect of such information or have
similar duties under their professional ethics code, and each Party hereto takes full
responsibility for all actions of its employees and advisors and those of its Affiliates.

          (d) Each of S-P and M will return all copies of documents containing Confidential Information
to the Party to which such information relates upon request after termination hereof other than one
copy which may be maintained solely for record keeping purposes.

          (e) Notwithstanding any other provision of this Agreement, during the six-year period
following termination of this Agreement pursuant to Section 5.2.2(ii), all Confidential Information
relating to the Cholesterol Products known to, or in the possession of, the Terminated Party and
entities that were Affiliates of the Terminated Party prior to the termination of this Agreement,
shall not be disclosed, provided or otherwise made available, to the Person that acquired the
Terminated Party or to any of such Person’s Affiliates, officers, directors, employees or agents.

78

 

     Section 7.2. Publicity. Neither S-P nor any of its Affiliates on the one hand nor M
or any of its Affiliates on the other hand may use the name of the other or any of their Affiliates
or the Singapore Partnership or any JV Entity in any publicity or advertising except as
specifically provided in any Related Agreements, and may not issue a press release or otherwise
publicize or disclose any information related to the existence or substance of this Agreement or
any of the Related Agreements or the terms or conditions hereof or thereof, without the prior
written consent of the other. S-P and M shall agree on the form, content and timing of the initial
press release or public statement that may be used by either of S-P or M to describe this Agreement
and any of the Related Agreements and any subsequent press release or subsequent public statement
with respect to or relating to the transactions contemplated by this Agreement or any of the
Related Agreements or any of the terms or conditions hereof or thereof. In the event that either
S-P or any of its Affiliates on the one hand or M or any of its Affiliates on the other hand (the
“Disclosing Party”) is requested (by oral questions, interrogatories, requests for
information or documents in legal proceedings, subpoena, civil investigative demand or other
similar process) or required (by applicable federal or state securities laws or any rule or
regulation of any national securities exchange) to make any such disclosure, the Disclosing Party
shall provide the other Party (either S-P or M, as the case may be) with prompt written notice of
any such request or requirement so that such other Party may seek a protective order or other
appropriate remedy and/or, if it also determines that such disclosure is required, waive compliance
with the provisions of this Section 7.2. If, in the absence of a protective order or other remedy
or the receipt of a waiver by such other Party, the Disclosing Party is nonetheless, in the written
opinion of its outside legal counsel, legally compelled to make such disclosure, the Disclosing
Party may disclose only that portion which such counsel advises the Disclosing Party is legally
required to be disclosed, provided that the Disclosing Party shall use its best efforts to avoid
such disclosure including, without limitation, by cooperating with the other Party to obtain an
appropriate protective order or other reliable assurance that, to the extent available,
confidential treatment will be afforded to such information included in the disclosure.

     Section 7.3. Further Assurances. Each of S-P on the one hand and M on the other hand
shall (i) cooperate with each other, (ii) promptly execute, acknowledge and deliver any assurances,
approvals or documents reasonably requested by the other that is necessary for the requesting Party
to satisfy its obligations hereunder or obtain the benefits contemplated hereby and (iii) cause
their respective Affiliates to perform, comply with and abide by the terms of this Agreement.

     Section 7.4. Notices. All consents or other notices provided for in this Agreement
shall be in writing, duly signed by the Party giving such notice, and shall be delivered,
telecopied or mailed by registered or certified mail, as set forth on Schedule 7.4. Notices
delivered to an addressee shall be deemed to have been given upon such delivery. Notices sent by
telecopier shall be deemed to have been given upon confirmation by telecopy answerback (followed
promptly by the mailing of the original of such notice). Notices mailed by registered or certified
mail shall be deemed to have been given upon the expiration of five (5) business days after such
notice has been deposited in the mail.

79

 

     Section 7.5. Failure to Pursue Remedies. The failure of any Party to seek redress for
violation of, or to insist upon the strict performance of, any provision of either this Agreement
or any Related Agreement shall not prevent a subsequent act, which would have originally
constituted a violation, from having the effect of an original violation. No waiver of any breach
of any of the terms of this Agreement or any of the Related Agreements shall be effective unless
such waiver is in writing and signed by the Party or parties against whom such waiver is claimed.

     Section 7.6. Cumulative Remedies. The rights and remedies provided by this Agreement
are cumulative and the use of any one right or remedy by any Party shall not preclude, constitute
an election of remedies or waive its right to use any or all other remedies. Said rights and
remedies are given in addition to any other rights the parties may have by law, statute, ordinance
or otherwise.

     Section 7.7. Assignment; Binding Effect. Except as specifically set forth in the
Related Agreements, without the consent of all of the parties hereto, which consent may be given or
withheld by each Party in its sole discretion, neither this Agreement, any of the Related
Agreements, nor any interest of a Party in the ECLAFE Cholesterol Business in ECLAFE may be
assigned or otherwise transferred, except (i) to wholly-owned subsidiaries of such Party, provided
that any such subsidiary remains at all times directly or indirectly wholly-owned by M or S-P, as
the case may be, or (ii) pursuant to Section 5.3 or 5.4. Subject to the foregoing, this Agreement
shall be binding upon and inure to the benefit of the parties hereto and, to the extent permitted
by this Agreement, their successors, legal representatives and permitted assigns.

     Section 7.8. Severability. In the event of any challenge of the validity or
enforceability of any term, part or provision of this Agreement or any of the Related Agreements,
until a final, unappealable decision is rendered and, pending such final, unappealable decision,
such challenged term, part or provision shall remain in full force and effect. Any term, part or
provision of this Agreement or any of the Related Agreements, which is determined by a court in a
final, unappealable decision to be invalid or unenforceable in any jurisdiction shall, as to that
jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering
in any way invalid or unenforceable the remaining terms, parts and provisions of this Agreement, or
any of the Related Agreements or affecting the validity or enforceability of any of the terms,
parts or provisions of this Agreement or any of the Related Agreements, in any other jurisdiction
and, accordingly, all such other terms, parts and provisions shall remain in full force and effect.
If any provision of this Agreement or any of the Related Agreements, is so broad as to be
unenforceable, the provision shall be interpreted to be only so broad as is enforceable.

     Section 7.9. Counterparts. This Agreement may be executed in any number of
counterparts with the same effect as if all parties hereto had signed the same document. All
counterparts shall be construed together and shall constitute one instrument.

     Section 7.10. Integration. This Agreement and the Related Agreements constitute the
entire agreement among the parties hereto pertaining to the subject matter

80

 

hereof and thereof and supersede all prior agreements and understandings pertaining thereto.
In the event of any inconsistency between the terms and conditions of this Agreement and the terms
and conditions of any of the Related Agreements, the terms and conditions of this Agreement shall
prevail, except as specifically provided herein.

     Section 7.11. Governing Law. This Agreement and the Related Agreements and the rights
of the parties hereunder shall be interpreted in accordance with the laws of the State of Delaware,
and all rights and remedies shall be governed by such laws without giving effect to choice of law
provisions thereof; provided, that, the substantive law governing the Parties’
performance in a given country under a Related Agreement shall continue to govern performance in
such country to the extent provided in such Agreements.

     Section 7.12. Amendments. Any amendment, supplement or waiver to this Agreement shall
be made in writing and shall be adopted and be effective only if signed and approved by each of the
parties hereto.

     Section 7.13. Judicial Proceeding.

               (a) General. Any disputes, claims, controversies or disagreements with respect to
this Agreement or any of the Related Agreements, including whether an ECLAFE Material Breach has
occurred, that cannot be resolved pursuant to the procedures set forth in Sections 3.2.1(e),
3.2.1(f), 3.2.2(c), 3.4.5, 3.5.5, 3.6.1(e), 3.6.1(f), 3.6.1(g) and 5.1, as applicable, such
procedures to be fully complied with, as applicable, shall be finally determined in a judicial
proceeding; provided that (i) no Party shall seek dissolution by a judicial forum or by operation
of law, appointment of a trustee, receiver, custodian or similar person and (ii) the foregoing
shall not limit any remedies specifically provided in any of the Related Agreements.
Notwithstanding the foregoing, no dispute relating solely to business decisions relating to the
operation of the ECLAFE Cholesterol Business in ECLAFE shall be submitted to any judicial
proceeding hereunder.

               (b) Consent to Jurisdiction. Each Party to this Agreement, or to any of the Related
Agreements hereby, consents to the exclusive jurisdiction of the state courts of New York for the
purposes of any action or proceeding arising out of or in connection with this Agreement or any of
the Related Agreements pursuant to Section 7.13(a), and each of the Parties hereto irrevocably
agrees that all claims in respect to such action or proceeding may be heard and determined
exclusively in the New York Supreme Court-Commercial Division. None of the parties to this
Agreement, nor any of their subsidiaries or Affiliates, will raise any objection to proceedings in
New York based on section 1312 of the New York Corporation Law or any similar statute. Each of the
parties hereto agrees that a final judgment in any action or proceeding shall be conclusive and may
be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.
Each of the parties hereto further irrevocably consents to the service of any summons and complaint
and any other process in any other action or proceeding relating to this Agreement or any of the
Related Agreements, on behalf of itself or its property, by the personal delivery of copies of such
process to such Party. Nothing in

81

 

this Section 7.13(b) shall affect the right of any Party hereto to serve legal process in any
other manner permitted by law.

     Section 7.14. Enforcement of Certain Rights. In the event that M or S-P believes that
the other Party or an Affiliate of the other Party is not complying with its obligations as a whole
in a material respect, under any of the Related Agreements to the extent applicable to ECLAFE, any
dispute with respect thereto shall be referred to the EMEA Operating Board, EMEA General Manager,
EMEA Executive Sponsors, Far East Operating Board, Far East General Manager, Latin America
Executive Sponsors, the Canadian General Manager or the Chairmen of M and S-P, as the case may be,
and first be subject to resolution pursuant to the procedures set forth herein, such procedures to
be fully complied with, as applicable. Notwithstanding anything contained herein, if the dispute
cannot be resolved pursuant to such dispute resolution procedures, then the complaining Party shall
have the power and authority to enforce, on behalf of the Person, or to cause the Person to
enforce, the Person’s rights through a judicial remedy in accordance with the provisions of Section
7.13; provided that notwithstanding the foregoing, M shall have the right to immediately
seek on behalf of any Person a judicial remedy in the event it believes that there has been or is
reasonably likely to be a breach of any agreements which require the consent of M for any licensing
of Ezetimibe to any Party, or that prohibits the licensing of Ezetimibe to other parties, or that
any exclusive product rights are being violated or are reasonably likely to be violated. If any of
M, S-P or any of their respective Affiliates agrees to license to an Affiliate manufacturing
technology or know-how pursuant to the terms of a manufacturing agreement (the “Licensor”),
then the parties hereto that are Affiliates of the Licensor shall not take any action (or omit to
take any action) which could materially hinder or frustrate the ability of the Person to enforce
and realize the benefits of such license.

     Section 7.15. No Third Party Beneficiaries. Except as otherwise specifically set
forth in the Related Agreements, neither this Agreement nor any of the Related Agreements shall
confer upon any Person, other than the parties hereto and thereto, any rights or remedies hereunder
or thereunder.

     Section 7.16. Survival. Notwithstanding any other provision herein, if this Agreement
is terminated for any reason, the applicable provisions of Sections 5.3, 5.4, 6.1, 6.2, 6.4, 6.5 ,
7.13 and this Section 7.16, and any applicable definitions set forth or incorporated in Section
1.2, shall survive to the extent necessary to effectuate any Related Agreements that survive such
termination, and Sections 5.3(f) and 5.4(b), 5.4(c) and 5.4(d)(together with the applicable
definitions set forth in Section 1.2) shall survive for the periods respectively set forth in each
such section.

     Section 7.17. Sanctioned Countries. The Parties acknowledge that certain countries in
ECLAFE are subject to sanctions by the United States Government and/or the United Nations. As of
the Effective Date, the following countries are subject to sanctions:

               (a) in the EMEA – Iran, Iraq, Libya, Sudan;

82

 

               (b) in Latin America – Cuba; and

               (c) in the Far East – Afghanistan, North Korea (only with respect to imports to the U.S.).

     The Parties shall comply with all applicable laws, rules and regulations governing commercial
activities involving such countries and shall obtain any required licenses or authorizations prior
to undertaking any activities related to the ECLAFE Cholesterol Business in such countries. In the
event that countries are added to or deleted from the list of sanctioned countries, the provisions
set forth in this Section 7.17 shall apply to such sanctioned countries.

83

 

     IN WITNESS WHEREOF, the parties hereto have executed this Master Agreement as of the date
first above stated.

     [Signatures omitted]

84

 

Schedule 1.2(ii)

Existing M JVs

[*]

S-1

 

Schedule 1.2(iii)

Existing S-P JVs

[*]

S-2

 

Schedule 2.1(a)

Country Sales Amounts for Major Countries in EMEA

($ millions)

[*]

S-3

 

Schedule 4.2(a)

[*] [Note:
Approximately three pages of text are omitted.]

S-4

 

Schedule 7.4

     [*]
[Note:
Approximately two pages of text are omitted.]

S-5EX-10.4

Exhibit 10.4

EXECUTION COPY

Confidential portions of this exhibit have been omitted and filed separately with the
Securities and Exchange Commission with a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The location of an omitted portion is indicated
by an asterisk within brackets (“[*]”).

MASTER MERIAL VENTURE AGREEMENT

DATED as of May 23, 1997, BY AND AMONG:

RHÔNE-POULENC S.A., a société anonyme organized under the laws of France
(“Rhône-Poulenc”),

INSTITUT MÉRIEUX S.A., a société anonyme organized under the laws of France (“IM”),

RHÔNE-MÉRIEUX S.A., a société anonyme organized under the laws of France (“RM”),

MERCK & CO., INC., a corporation organized under the laws of the state of New Jersey (“Merck &
Co.”),

MERCK SH INC., a corporation organized under the laws of the state of Delaware (“Merck SH”),
and

MERIAL LIMITED, an English private company limited by shares (and, after the
domestication contemplated by Section 1.3(a)(B), also a Delaware limited liability
company) (“Merial”).

 

 

RECITALS

     WHEREAS, both the RP Group and the Merck Group are engaged, among other activities, in the
research and development, manufacturing, marketing and sale of Animal Health Products and of
Poultry Genetics Products throughout the world;

     WHEREAS, RP and Merck wish to combine their respective Animal Health Businesses and Poultry
Genetics Businesses into a worldwide venture owned and controlled 50% by each of them and IM has
created Merial as the parent company of the group of companies which will conduct these businesses;

     WHEREAS, IM will contribute the entirety of RM’s share capital to Merial on or prior to the
Closing Date;

     WHEREAS, RP, Merck, and certain of their respective Subsidiaries, on the one hand, and RM or
an RM Subsidiary or Merial, on the other hand, have entered into or will, prior to or concurrently
with the Closing, enter into the Ancillary Agreements, including research and development,
manufacturing and supply, license and various other agreements to enable the Merial Venture to
conduct these combined activities;

     WHEREAS, the terms and conditions of this Agreement and the Ancillary Agreements do not limit
Merial’s (and Merial has) full independence and commercial autonomy, such terms and conditions not
being intended to limit Merial’s independence and commercial autonomy in marketing, selling,
negotiating and determining customers and resale prices for Animal Health Products and Poultry
Genetics Products.

     WHEREAS, prior to or at the Closing, pursuant to the terms of this Agreement and the
applicable Ancillary Agreements, the Parties will take further steps to implement the Merial
Venture, including the domestication of Merial as a limited liability company in the State of
Delaware, and the transfer (by merger or otherwise) to Merial and/or its Subsidiaries of the
entirety of the Merck Contributed Assets; and

2

 

     WHEREAS, upon completion of the Transactions at the Closing, the Merial Venture will commence
the Merial Venture Business and IM and (subject to Section 5.1(a)(iii)) Merck SH will each hold a
50% ownership interest in Merial;

     NOW, THEREFORE, in consideration of the respective representations and covenants of the
Parties as set forth below, the Parties agree as follows:

ARTICLE I

OBJECTIVES AND STRATEGIES, BUSINESS SCOPE 
AND OVERVIEW OF TRANSACTION

SECTION 1.1. Objectives and Strategies

     The Merial Venture is being formed with the following objectives and strategies:

     (a) The principal objective of the Merial Venture is to combine, on the terms and conditions
of this Agreement and the Ancillary Agreements, the complementary strengths of the RP Group and the
Merck Group to create a global leader in the Animal Health Business and Poultry Genetics Business
industries, committed to satisfying the needs of its customers, employees and members worldwide.
Within the Merial Venture, the Animal Health Business and the Poultry Genetics Business will
maintain their own identity and organization.

     (b) While maintaining close links with both Groups, the Merial Venture will function as a
self-contained independent entity with a single globally responsible management and will establish
its own unique identity and culture, built on the best available talents and practices.

     (c) In the Animal Health Business, the Merial Venture will, with the support of the research
and development capacities of the two Groups and/or other persons party to the Ancillary Agreements
(on the terms and conditions of this Agreement and the

3

 

Ancillary Agreements), have a unique blend of biological and pharmaceutical expertise that will
enable it to respond more effectively to new threats to animal health as they arise. In
cooperation with both Groups, which are expected to remain important sources of new compounds and
technologies, the objective of the Merial Venture will be to discover and develop a broad range of
innovative pharmaceutical and biological Animal Health Products.

     (d) The Merial Venture will offer a broad differentiated line of Animal Health Products and
related services in markets around the world. It will target those markets where products for the
prevention and treatment of animal diseases provide the economic opportunity to sustain innovation
and yield sufficient return on investment. The Merial Venture will distribute its products in a
manner which best meets the strategic needs of each market.

     (e) The Merial Venture will maintain its position as a global leader through continued
investment in new markets, technologies, people and facilities with the objective, among other
things, of delivering the highest quality products in the most cost efficient manner.

     (f) In the Poultry Genetics Business, the Merial Venture will be the leader in the development
and production of poultry breeding stock providing full service to the chicken, turkey and egg
market segments.

     (g) The rights, powers, obligations and duties of the Parties with respect to the Merial
Venture are only those set forth in this Agreement (other than this Section 1.1), the Ancillary
Agreements, the Association Documents and the LLC Agreement, each as amended from time to time, and
any Future Agreements.

SECTION 1.2. Business Scope

     (a) The business activities to be conducted by the Merial Venture (the “Merial Venture
Business”) will include:

4

 

	 	•	 	the discovery and development, manufacturing, marketing and sale of Animal
Health Products throughout the world (the “Animal Health Business”); and
	 
	 	•	 	the discovery and development, manufacturing, marketing and sale
of Poultry Genetics Products throughout the world (the “Poultry Genetics
Business”).

     (b) “Animal Health Products” are defined to include all pharmaceutical, biological and
medicinal, including in-feed, products intended to enhance the health or performance of any and all
species of animals (including livestock and companion animals but excluding humans), but to exclude
(i) any products with a different intended utility, (ii) nutritional additives, (iii) chemical
intermediates, and (iv) the inhalational anaesthetics Isoflurane, Halothane, Sevoflurane and
Desflurane.

     (c) “Poultry Genetics Products” are defined to include all products developed using genetic
techniques (including selective breeding) to improve poultry, whether for meat production, egg
production or any other purpose. Such products are commonly, but not exclusively, sold in the form
of hatching eggs or day-old poultry. For the purposes of this definition, “poultry” includes
chickens, turkeys, ducks, geese, guinea fowl, pheasants, partridges and quail.

     (d) Merial shall, and shall cause each Merial Venture Company, to use or sell all bulk
materials or products supplied by the Merck Group or the RP Group only in the Merial Venture
Business.

SECTION 1.3. Overview of Transaction

     The Parties intend to create a viable, independent entity, capable of successfully competing
globally in the Merial Venture Business industries. To that end, and upon the terms and
conditions set forth herein and in the Ancillary Agreements:

5

 

   
  (a) Formation of Merial

     Merial has been formed as an English private company limited by shares for the purpose of
conducting the Merial Venture Business. On the date hereof Merial is wholly owned by IM and
Rhône-Poulenc Finance S.A., a wholly owned Subsidiary of RP (“RP Finance”), with IM owning one
million shares of Merial and RP Finance holding one share of Merial as nominee for IM. Merck SH
has been created as a Delaware corporation, and is wholly owned by Merck and Company Incorporated
(“MACI”).

     (i) On or prior to the Closing Date, the Parties shall cause the
following corporate actions to be taken:

     (A) IM shall (w) form a single member Delaware limited liability company (“IM
LLC”) which satisfies the statutory requirements under French law to be a
shareholder of a société par actions simplifiée (“SAS”), including the requirement
that IM LLC have a share capital of at least the equivalent of FF 1,500,000; (x)
sell one of IM’s shares of RM to IM LLC and contribute the remainder of IM’s shares
of RM to Merial; (y) cause RM to be converted into a SAS with Merial and IM LLC as
its shareholders; and (z) sell (without any net profit to IM from all of the
transactions contemplated by this clause (A)) the entirety of its ownership interest
in IM LLC to Merial for an amount in cash equal to the fair market value of such
ownership interest (equal to the cash held by IM LLC and the cash value of one share
of RM);

     (B) Merck shall (u) cause Merck SH and MACI to form a Delaware limited
liability company (“Merck Transitory LLC”) owned 99% by Merck SH and 1% by MACI; (v)
cause Merck Holdings, Inc. to contribute the entirety of its share capital in
Hubbard Farms, Inc. to MACI; (w) cause MACI to contribute the entirety of the share
capital of Hubbard Farms, Inc. to Merck SH; (x) cause Hubbard Farms, Inc. to be
converted into Hubbard Farms LLC, a Delaware limited liability company;

6

 

(y) cause Merck SH to contribute its interest in Hubbard Farms LLC to Merck Transitory LLC; and (z)
cause Hubbard Farms LLC to be merged with Merck Transitory LLC, with Merck Transitory LLC being the
surviving company; and

     (C) Merck shall, in accordance with Section 5.1(a)(i), transfer (or cause to be
transferred) the remainder of the Merck Contributed U.S. Assets (other than the limited liability
company interests in Hubbard Farms LLC) to MACI (except to the extent MACI already holds any such
assets), and shall cause MACI to transfer all of the Merck Contributed U.S. Assets (other than the
limited liability company interests in Hubbard Farms LLC) to Merck SH, which will in turn transfer
them to Merck Transitory LLC.

     (ii) On the Closing Date, the following steps shall be taken:

     (A) Meetings of the members and directors of Merial at such time shall take place (v) to
amend the memorandum of association and articles of association of Merial so as to adopt a
memorandum of association and articles of association in the form (with certain provisions thereof
to be completed prior to Closing as indicated therein, it being understood that to the extent there
are any inconsistencies between the attached form and the provisions of this Agreement, the
attached form shall be modified to be consistent herewith) provided as Exhibit I hereto (the
“Memorandum of Association” and the “Articles of Association”, respectively), (w) to approve the
domestication of Merial as a limited liability company in the State of Delaware, (x) to approve and
execute the limited liability company agreement of Merial in the form provided as Exhibit II
hereto, (y) to approve the merger of Merck Transitory LLC with and into Merial, and (z) to approve
the transfer by RP Finance of its one share to IM, the increase in the authorized share capital of
Merial, the redesignation of the shares owned by IM as B Ordinary Shares and the issuance of one
million and one A Ordinary Shares to Merck SH in

7

 

consideration for its agreement to transfer the Merck Contributed Assets to Merial, each
such class of Merial shares to be governed by the provisions of the Association Documents,
with the effect that, after all such actions are taken, each Principal shall own, directly
or indirectly, exactly the same number of Ordinary Shares of Merial and have exactly the
same general ownership interest in Merial except for the differences between A Ordinary
Shares and B Ordinary Shares as set forth in the Association Documents;

     (B) Merial shall be domesticated as a limited liability company in the State of
Delaware; and

     (C) Merck Transitory LLC shall merge with and into Merial in accordance with Delaware
Law, with Merial being the survivor company (such that Merial shall own all of the assets,
and be subject to all of the Liabilities, of Merck Transitory LLC, Merck Transitory LLC
thereupon ceasing to exist).

(b) Ancillary Agreements

     (i) The following Ancillary Agreements are being entered into concurrently herewith,
and are conditional upon, and shall come into effect as of, the Closing:

     (A) The Supply Agreement between Merck and Merial, provided as Exhibit III hereto (the
“Merck Supply Agreement”).

     (B) The Research and Future Products License Agreement between Merck, Merial and
RM, provided as Exhibit IV hereto (the “Merck Research Agreement”).

8

 

     (C) The Existing Products License Agreement between Merck and Merial, provided as
Exhibit V hereto (the “Merck License Agreement”).

     (D) The Supply Agreement between Merial and Rhône-Poulenc Agrochimie S.A., provided as
Exhibit VI hereto (the “RP Ag Supply Agreement”).

     (E) The Research and Future Products License Agreement between Merial and Rhône-Poulenc Agrochimie S.A., provided as Exhibit VII hereto (the “RP Ag Research Agreement”).

     (F) The Fipronil and Existing Products License Agreement between Merial and Rhône-Poulenc Agrochimie S.A., provided as Exhibit VIII hereto (the “RP Ag Licence Agreement”).

     (G) The Research and License Agreement between Merial and Rhône-Poulenc Rorer Inc., provided as Exhibit IX hereto (the “RPR Research Agreement”).

     (H) The Research and License
Agreement between Merial and Pasteur Mérieux Sérums
et Vaccins S.A., provided as Exhibit X hereto the “PMSV Research Agreement”).

     (ii) The following Ancillary Agreements shall be negotiated and executed prior to
or at the Closing:

     (A) The RP Transfer Agreement among Merial, RP and IM, to implement the
transactions involving the contribution of RM and its Subsidiaries and assumption of the RM
Contributed Liabilities on the terms and conditions specified in this Agreement (the “RP
Transfer Agreement”).

9

 

     (B) The Merck Transfer Agreement among Merial, Merck, MACI, Merck Transitory
LLC and Merck SH, to implement the transactions involving the contribution of the
Merck Contributed Assets and assumption of the Merck Contributed Liabilities on the
terms and conditions specified in this Agreement (the “Merck Transfer Agreement”).

     (C) The Avermectin and Existing Products Sublicense Agreement between Merial
and RM.

     (D) The Merck Trademark (Dual Use) License Agreement between Merck and
Merial, a form of which is provided as Exhibit XI hereto.

     (E) The Fipronil Sublicense Agreement between Merial and RM.

     (F) The Merck Transition Services Agreement between Merck and Merial,
consistent with the provisions set forth in Section 11.8(b) of this Agreement.

     (G) The RP Transition Services Agreement between RP and Merial,
consistent with the provisions set forth in Section 11.8(b) of this Agreement.

     (H) The Merck Employee Leasing Agreement, substantially in the form
provided as Exhibit XII hereto.

     (c) Contribution of Merck Contributed Non-U.S. Assets. Merck shall, in
accordance with Sections 5.1 (a)(ii) and 5.2(a) and the Merck Transfer Agreement, contribute enough
cash to Merial , and/or accept (or cause its Subsidiaries to accept) a promissory note or notes
issued by Merial or that Merial Venture Company that is purchasing such assets (which promissory
notes constitute part or all of the Debt that Merck is to contribute to the Merial Venture), to
enable Merial or an appropriate Merial

10

 

Subsidiary to purchase each of the Merck Contributed Non-U.S. Assets in accordance with Section
5.1(a)(ii). The Principals may also agree, based on relevant criteria including tax-efficiency,
on another method to transfer certain Merck Non-U.S. Contributed Assets to the Merial Venture,
which method may involve the creation of a new direct or indirect wholly-owned Subsidiary of Merial
which shall purchase such assets or the transfer or merger of one or more Subsidiaries of Merck to
or with Merial or one of its Subsidiaries. In the absence of such agreement in writing, but
subject to Section 5.4, the foregoing provisions of this Section 1.3(c) shall apply.

     (d) Each Party’s obligation to take any of the actions contemplated by this Section 1.3
to occur on or prior to the Closing Date is conditioned upon contemporaneous completion of all such
actions no later than the Closing Date.

11

 

ARTICLE II

DEFINITIONS

     As used in this Agreement, capitalized terms have the meanings set forth below:

     “Action” means any claim, action, suit, arbitration, inquiry, proceeding or
investigation by or before any Public Authority.

     “Affiliate” means, with respect to any Person, (i) a Person which is a Subsidiary of such
Person, (ii) a Person of which such Person is a Subsidiary, or (iii) any other Person which is a
Subsidiary of a third Person of which such Person is also a Subsidiary.

     “Ancillary Agreements” means, collectively, the agreements referred to (and as each is defined
in) Section 1.3(b).

     “Animal Health Business” has the meaning set forth in Section 1.2(a).

     “Animal Health Products” has the meaning set forth in Section 1.2(b).

     “Association Documents” means, collectively, the Memorandum of Association and the Articles of
Association, each as defined in Section 1.3(a)(ii)(A), as the same may be amended, modified,
supplemented or restated from time to time.

     “Avermectin Products” means all those Merial Venture Products containing one of the Avermectin
class of compounds, including, but not limited to, products containing abamectin, ivermectin,
eprinomectin or emamectin.

     “Benefit Plan” means each plan, program, policy, payroll practice, contract, agreement or
other arrangement (including plans maintained both inside and outside of the U.S. and excluding
Governmental Plans) providing for compensation, severance (including termination indemnities, long
service leave obligations and similar obligations), termination pay, performance awards, stock or
stock-related awards, fringe benefits or

12

 

other employee benefits of any kind, whether formal or informal, funded or unfunded, written or
oral and whether or not legally binding, including, without limitation, each “employee benefit
plan,” within the meaning of Section 3(3) of ERISA and each “multi-employer plan” within the
meaning of Sections 3(37) or 4001(a)(3) of ERISA.

     “Biological Products” means all RM Existing or Pipeline Products (other than diagnostic
products, including the products included in the Diagnostic Disposal) that are vaccines, whether
preventive or therapeutic, as well as any immunological products (except the GnRH vaccine),
together with electronic identification products and vaccinating equipment, including injectors and
sprayers.

     “Board of Directors” has the meaning set forth in Section 4.3(a).

     “Business Day” means any day which is not a bank holiday in any of London, New York or Paris.

     “Business Plan” has the meaning set forth in Section 4.4(c).

    
 “Central Biologics” has the meaning set forth in Section 5.1(b)(iii).

     “CEO” has the meaning set forth in Section 4.4(e).

     “CFM Agreement” shall refer to the Consolidation Fiscale Mondiale or worldwide tax
consolidation agreement, dated February 7, 1994, between RP and the French Taxing Authority, as the
same may be supplemented, amended, modified or restated from time to time, or any successor
agreement thereto.

     “Change of Control” means, with respect to either RP or Merck, the acquisition by any Person
or Group, directly or indirectly, beneficially or of record, of shares or options or other rights
to purchase shares representing in the aggregate more than fifty percent (50%) of the aggregate
ordinary voting power represented by the issued and outstanding capital stock of RP or Merck, as
the case may be. Notwithstanding the

13

 

foregoing, the following transactions shall be deemed not to constitute a Change of Control: any
merger or other business combination with another entity (x) solely to reincorporate RP or Merck,
as the case may be, in a different form or under the laws of a different jurisdiction, (y) in
connection with an internal reorganization which results in RP or Merck, as the case may be, being
a direct or indirect wholly-owned Subsidiary of such entity or (z) any other transaction or series
of transactions which results in RP or Merck, as the case may be, being a direct or indirect
wholly-owned Subsidiary of any such entity, only if in the case of clauses (x), (y) or (z): the
shareholders of RP or Merck, as applicable, immediately prior to the consummation of such
transaction(s) own, in the aggregate, immediately after such transaction(s), shares representing
more than fifty percent (50%) of the aggregate ordinary voting power represented by the issued and
outstanding capital stock of such entity (or any parent company thereof). A “Successor Entity”
means any entity which satisfies the conditions set out in any of clauses (x), (y) or (z) of the
preceding sentence and which has executed a deed in the form of Exhibit XIII under which it agrees
to be bound by the obligations of that party in respect of which it is a Successor Entity.
Following any transaction(s) referred to in such clauses (x), (y) or (z), all references to RP or
Merck shall be deemed to refer to the applicable Successor Entity, including the references in
clauses (x), (y) or (z). For purposes of this definition only, “Group” means two or more Persons
who agree to act together for the purpose of acquiring, holding, voting or disposing of equity
securities of an issuer.

     “Closing” means the completion of the merger of Merck Transitory LLC with and into Merial.

     “Closing Date” has the meaning set forth in Section 12.3.

     “Closing Meeting” means the meetings of Merial’s members or board of directors, as
appropriate, held on the Closing Date.

     “Code” means the Internal Revenue Code of 1986, as amended and any regulations
promulgated or proposed thereunder.

14

 

     “Combination” means any Animal Health Product that contains more than one active
ingredient.

     “Companies Act” means the United Kingdom Companies Act of 1985.

     “Control,” whether used as a noun or verb, refers to the possession, directly or indirectly,
of the power to direct, or cause the direction of, the management or policies of a Person, whether
through the ownership of voting securities, by contract or otherwise.

     “Damages” means any liability (whether arising out of fault, strict liability or otherwise),
obligation, loss, fine, damage, judgment, arbitration award, settlement amount, penalty, claim, or
Environmental Liability, and all reasonable costs and expenses related thereto (including
reasonable costs of investigation, fees and expenses payable to outside counsel, independent
accountants and similar professional advisors or consultants, but not including any corporate
allocation for management time or for the use of similar in-house services or facilities), in each
case whether or not incurred in connection with a Third Party Claim.

     “Debt” has the meaning set forth in Section 5.1(c).

    
 “Delaware Act” means the Delaware Limited Liability Company
Act, 6 Del. C. § 18-101,
et seq., as amended from time to time, including, without limitation, any amendments to
Section 18-109 thereof.

     “Delayed Purchase Assets” has the meaning set forth in Section 5.1(a)(ii)(A)(4).

     “Diagnostic Disposal” means the contemplated sale by RM of its diagnostic product
business.

     “Director” has the meaning set forth in Section 4.3(b).

15

 

     “Dissolution” or “Dissolve” or “Dissolved”, as applied to the Merial Venture, means
either (i) the sale of the Merial Venture Interest of one Principal to the other Principal
pursuant to Sections 16.3, 16.4, 16.5, 17.2(c)(ii) or otherwise or (ii) the sale of
all or substantially all of the Merial Venture to a Third Party pursuant to Sections 16.3, 16.4,
17.2(c)(i) or otherwise.

     “Dissolution Date” has the meaning set forth in Section 16.6(a).

     “Distributable Profits” has the meaning set forth in Section 181 of the Companies Act.

     “Economic Effective Date” has the meaning set forth in Section 6.3(a).

     “Encumbrance” means any lien, privilege, mortgage, pledge, third-party claim or right,
charge, restriction of use, defect of title, easement, security interest or encumbrance of any
kind, including, without limitation, obligations resulting from any sublease, tenancy, right
of occupation, easement, preemptive right or privilege in favor of any person or entity.

     “Environmental Laws” means, at any date, all provisions of law (including applicable
principles of common and civil law), statutes, ordinances, rules, regulations, published
standards and directives that have the force and effect of Laws, permits, licenses, judgments,
writs, injunctions, decrees and orders enacted, promulgated or issued by any Public
Authority, and all indemnity agreements and other contractual obligations, as in effect at
such date, relating to (i) the protection of the environment, including the air, surface and
subsurface soils, surface waters, groundwaters and natural resources, and (ii) occupational
health and safety and exposure of persons to Hazardous Materials. Environmental Laws shall
include the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. §§
9601 et seq., and any other Laws imposing or creating liability with respect to Hazardous
Materials.

16

 

     “Environmental Liability” means any liabilities, obligations, costs, losses, payments or
damages, including compensatory and punitive damages, incurred (i) to contain, remove, clean up,
assess, abate or otherwise remedy any actual or alleged release or threatened release of Hazardous
Materials, any actual or alleged contamination (by Hazardous Materials) of air, surface or
subsurface soil, groundwater or surface water, or any personal injury or damage to natural
resources or property resulting from any such release or contamination, pursuant to the
requirements of any Environmental Law or in response to any claim by any Public Authority or other
Third Party under any Environmental Law; (ii) to modify facilities or processes or take any other
remedial action in response to any claim by any Public Authority of non-compliance with any
Environmental Law; (iii) as a result of the imposition of any civil or criminal fine or penalty by
any Public Authority for the violation or alleged violation of any Environmental Law; or (iv) as a
result of any action, suit, proceeding or claim by any Third Party under any Environmental Law.
The term “Environmental Liability” shall include: (i) reasonable fees of counsel and consultants
(but not any corporate allocation for management time or for the use of similar in-house services
or facilities) and (ii) the costs and expenses of any investigation undertaken to ascertain the
existence or extent of any potential or actual Environmental Liability.

     “ERISA” means the Employee Retirement Income Security Act of 1974, as amended and any
regulations promulgated or proposed thereunder.

     “Event of Insolvency,” with respect to any person, shall occur when either:

     (i) such person shall (A) voluntarily commence any proceeding or file any
petition seeking relief under Title 11 of the United States Code, French Law No. 84-148 of
March 1, 1984, French Law No. 85-98 of January 25, 1985 or any other bankruptcy, insolvency
or similar law of the United States, any state thereof, or France, (B) apply for or consent
to the appointment of a receiver, trustee, custodian, sequestrator, conciliator,
administrator or similar official for it or a substantial part of its property, (C) file an
answer admitting the material allegations of a petition filed against or in respect of it in
any such proceeding,

17

 

(D) make a general assignment for the benefit of creditors, (E) become unable generally, or admit
in writing its inability, to pay its debts as they become due, or (F) take corporate action for the
purpose of effecting any of the foregoing; or

     (ii) an involuntary proceeding shall be commenced or any involuntary petition shall be
filed in a court of competent jurisdiction seeking (A) relief in respect of such person, or of a
substantial part of such person’s property, under Title 11 of the United States Code, French Law
No. 84-148 of March 1, 1984, French Law No. 85-98 of January 25, 1985 or any other bankruptcy,
insolvency or similar law of the United States, any state thereof, or France, (B) the appointment
of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for
such person or for a substantial part of such person’s property or (C) the winding-up or
liquidation of such person; and such proceeding or petition shall continue undismissed for sixty
(60) days or an order or decree approving or ordering any of the foregoing shall continue unstayed
and in effect for thirty (30) days;

     (iii) an order is made by a court of competent jurisdiction, or a resolution is passed,
for the winding up, dissolution or administration of such person or the appointment of a
liquidator, manager, receiver, administrator, trustee or other similar officer in respect of, or an
encumbrancer taking possession of or selling, any substantial assets of such person, or such person
makes any arrangement or composition with, or any assignment for the benefit of, its creditors, or
makes an application to a court of competent jurisdiction for protection from its creditors
generally, and such order, resolution, appointment, arrangement, assignment or application is not
withdrawn or cancelled within sixty (60) days of its being made.

     (iv) anything analogous to any of the events specified in (i), (ii) and (iii) above occurs
in respect of such person under the laws of any applicable jurisdiction.

18

 

     “Executive Chairman” has the meaning set forth in Section 4.4(a).

     “Executive Officers” has the meaning set forth in Section 4.4(d).

     “Existing Other JVs” means (a) with respect to RP, those Persons set forth on Schedule 2-2 and
(b) with respect to Merck, those Persons set forth on Schedule 2-3, in either case only so long as
such Persons are Other JVs.

     “Existing Product” means each Animal Health Product or Poultry Genetics Product that is
marketed in any country on the date of this Agreement, by RM or its Subsidiaries (including those
set forth in Schedule 2-4) or by the Merck Group (including those set forth in Schedule 2-5).

     “Fipronil Products” means all those Merial Venture Products containing Fipronil as an active
ingredient.

     “Fiscal Year” has the meaning set forth in Section 11.4.

     “Future Agreement” means any written agreement (other than an Ancillary Agreement) between any
RP Company or Merck Company, on the one hand, and any one or more of the Merial Venture Companies,
on the other hand, which may be entered into at any time after the Closing.

     “Future Product” means any Animal Health Product or Poultry Genetics Product, other than an
Existing Product or a Pipeline Product, as to which any Merial Venture Company has or may at any
time acquire (through internal research and development efforts and/or from other persons) any
Product Rights, Patents or Know-How relating to the manufacture, use or sale thereof.

     “GAAP” means, with respect to any country, such country’s generally accepted accounting
practices or the International Accounting Standards (“IAS”), in either case as in effect from time
to time, consistently applied.

19

 

     “Goubin Book Value” has the meaning set forth in Section 5.1(b)(i).

     “Grandfathered Merck Employees” has the meaning set forth in Section 7.1(b).

     “Governmental Order” means any order, writ, judgment, injunction, decree, stipulation,
determination or award entered by or with any Public Authority.

     “Governmental Plan” means any plan that is sponsored or maintained by a Public Authority to
which either the RP Group or the Merck Group contributes, or is required to contribute, on behalf
of any RM Employee or Merck Employee.

     “Goubin” means Compagnie Jean Goubin S.A.

     “Group” means the Merck Group or the RP Group, as appropriate.

     “Hazardous Material” means any substance regulated by any Environmental Law or which may now
or in the future form the basis for any Environmental Liability.

     “Health Cost” has the meaning set forth in Section 7.1(c).

     “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

     “ICC” means the International Chamber of Commerce.

     “ICE” means the International Centre for Expertise of the ICC.

     “IM” has the meaning set forth in the introduction to this Agreement.

     “IM LLC” has the meaning set forth in Section 1.3(a).

20

 

     “Income Taxes” means income, corporation or franchise taxes or other Taxes measured in
whole or in part by income or by reference to income, together with any interest or penalties
imposed with respect thereto, levied by any Taxing Authority.

     “Indemnified Party” has the meaning set forth in Section 14.7(a).

     “Indemnifying Party” has the meaning set forth in Section 14.7(a).

     “Intellectual Property” of a Person means, collectively, the Product Rights, Patents and
Know-How of such Person.

     “Interim Financing” means the revolving credit facilities provided or arranged by each of RP
and Merck to Merial in accordance with Section 5.2(d).

     “Inventory” or “Inventories” of any Person means all inventory, merchandise, partially
finished and finished products, and raw materials, maintained, held or stored by or for such Person
and any prepaid deposits for any of the same; provided that

     “Inventories” of any of Merck or its Subsidiaries shall mean only such inventories as
constitute Merck Contributed Assets.

     “Investment Bank” means a reputable international investment bank with experience
appraising and selling businesses comparable to the Merial Venture.

  
   “IRS” means the Internal Revenue Service.

   
  “ISA” means Institut de Sélection Animale S.A.

     “Know-How” means, in respect of any product, all technical knowledge, ability, skill or
expertise in the manufacture or commercialization of such product other than knowledge or expertise
covered by a Patent.

21

 

     “Label” means, in respect of any Merial Venture Product, the packaging, product brochure or
product monograph filed with the appropriate Public Authority (or Public Authorities) having
authority to approve the marketing of such Merial Venture Product and the package insert directed
to veterinarians or consumers that has been approved by such Public Authority (or Public
Authorities) for such Merial Venture Product, including, in each case, the indications, claims,
uses and dosages appearing therein.

     “Laws” means any supranational, national, state, local or foreign statute, law, directive,
ordinance, regulation, rule, code, order, requirement or rule of common law.

     “Liabilities” means any and all debts, liabilities and obligations, whether accrued or fixed,
absolute or contingent, matured or unmatured or determined or determinable, including those arising
under any Law (including any Environmental Law), Action or Governmental Order and those arising
under any contract, agreement, arrangement, commitment or undertaking.

     “LIBOR” means, in relation to any unpaid sum, the rate per annum equal to the arithmetic mean
(rounded upwards, if not already such a multiple, to the nearest whole multiple of one-thirty
second of one per cent.) of the offered quotations in the so-called London Interbank loan market as
displayed on Pages 3740 or 3750 (as appropriate) on the Telerate Service for the currency in which
such unpaid sum is to be denominated and for the relevant specified period at or about 11:00 a.m.
(London time) on the second Business Day before the beginning of such specified period.

     “LLC Agreement” means the limited liability company agreement of Merial in the form provided
as Exhibit II hereto, as the same may be amended, modified, supplemented or restated from time to
time.

     “MACI” has the meaning set forth in Section 1.3(a).

22

 

     “Material Adverse Change or Effect” means, with respect to any Person, a change or effect that
materially adversely affects, or (except with respect to Sections 12.6(b)(vi) or 12.6(c)(vi), as
the case may be) is reasonably likely to materially adversely affect,

     (i) if such determination is to be made on or prior to the Closing, (A) in the
case of an RP Company, the assets, liabilities, operations, results of operations or
financial condition of RM and its Subsidiaries, taken as a whole; and (B) in the case of a
Merck Company, the Merck Contributed Assets or the operations, results of operations or
financial condition of the Merck Contributed Business; or

     (ii) if such determination is to be made after the Closing, (A) in the case of a
Merial Venture Company, the assets, liabilities, operations, results of operations or
financial condition of the Merial Venture; and (B) in the case of an RP Company or a Merck
Company, the ability of such company to perform any of its material obligations under this
Agreement or any Ancillary or Future Agreement if such obligations are material to the
assets, liabilities, operations, results of operations or financial condition of the Merial
Venture;

provided that, as used in Articles VIII, IX and X of this Agreement, the terms “Material
Adverse Change”, “Material Adverse Effect”, “material” or any similar terms shall mean having an
adverse impact or effect or potential adverse impact or effect on the value of RM and its
Subsidiaries or the value of the Merck Contributed Assets, as the case may be, or on the aggregate
net income of the Merial Venture, of at least [*].

     “Member” means a shareholder of Merial being either the RP Member or the Merck Member,
which together shall be the “Members”.

     “Members’ Meeting” has the meaning set forth in Section 4.1.

     “Merck” means Merck & Co. or any Successor Entity thereto.

23

 

     “Merck & Co.” has the meaning set forth in the introduction to this Agreement.

     “Merck Accrued Tax Liabilities” has the meaning set forth in Section 5.1(a)(ii)(B).

     “Merck Adjustment Products” has the meaning set forth in Section 6.4(c).

     “Merck Animal Health Executive” means the Merck executive with direct responsibility for
Merial reporting to the Chief Executive Officer of Merck and any duly appointed successor in such
role, notified in writing by Merck to RP and Merial.

     “Merck Benefit Plan” means each Benefit Plan (other than Merck Employee Agreements) which is
now or previously has been sponsored, maintained, contributed to, or required to be contributed to,
or with respect to which any withdrawal liability (within the meaning of Section 4201 of ERISA) has
been incurred, by Merck, any of its Subsidiaries or any Merck ERISA Affiliate for the benefit of
any Merck Employee, and pursuant to which Merck, any of its Subsidiaries or any Merck ERISA
Affiliate has or may have any liability, contingent or otherwise.

   
  “Merck Breach” has the meaning set forth in
Section 14.2(b).

   
  “Merck Company” means any of Merck or its Subsidiaries.

     “Merck Contributed Assets” has the meaning set forth in Section 10.10.

     “Merck Contributed Business” means all the Merck JV Business activities and operations
immediately prior to the Closing, other than those activities or operations (i) that Merck will
continue to conduct pursuant to the Ancillary Agreements to which Merck or any of its Subsidiaries
is a party, (ii) conducted using the assets, properties and rights set forth in Schedule 2-7, and
(iii) relating to “The Merck Veterinary Manual” and the Annual Authorizations Service Repertory
License Agreement between Copyright Clearance Center, Inc. and Merck & Co. Inc. dated December 31,
1995.

24

 

     “Merck Contributed Business Financials” has the meaning set forth in Section 10.5. The Merck
Contributed Business Financials are attached as Exhibit XVI.

     “Merck Contributed Debt” has the meaning set forth in Section 5.2(a).

     “Merck Contributed Liabilities” means all of the obligations or Liabilities of Merck or any of
its Subsidiaries (whether or not reflected on the Merck Contributed Business Financials or the
books and records of Merck or any of its Subsidiaries) arising from, relating to, resulting from or
incurred in connection with, the Merck Contributed Business or any of the Merck Contributed Assets
or the ownership or operation of, or conduct of any activities on or from, any of the foregoing,
including (i) under the agreements, contracts, leases, licenses and other arrangements included
within the Merck Contributed Assets, (ii) accounts and other payables, (iii) Environmental
Liabilities, (iv) Taxes, (v) threatened, pending or settled litigation, (vi) under Merck Benefit
Plans, and (vii) all obligations or Liabilities of the types referred to in the Merck Contributed
Business Financials or that are the subject of any of the representations in Article X.

     “Merck Contributed Non-U.S. Assets” means all the Merck Contributed Assets that are not Merck
Contributed U.S. Assets.

     “Merck
Contributed U.S. Assets” has the meaning set forth in Section 5.1(a)(i).

     “Merck Employee” means each current, former, or retired employee of a Merck Transferred
Subsidiary together with those employees listed in Schedule 10.19H-2.

     “Merck Employee Agreement” means each management, employment, severance, consulting,
non-compete, confidentiality, or similar agreement or contract between Merck or any of its
Subsidiaries and any Merck Employee pursuant to which Merck or any of its Subsidiaries has or may
have any liability, contingent or otherwise.

     “Merck ERISA Affiliate” means each business or entity which is a member of a “controlled group
of corporations,” under “common control” or an “affiliated service

25

 

group” with Merck within the meaning of Sections 414(b), (c) or (m) of the Code, or required to be
aggregated with Merck under Section 414(o) of the Code, or is under “common control” with Merck,
within the meaning of Section 4001(a)(14) of ERISA.

     “Merck Group” means Merck, together with all its Subsidiaries.

     “Merck JV Business” means, from time to time at any time prior to the Closing, all the Merial
Venture Business activities of the Merck Group, including of the Merck Transferred Subsidiaries,
throughout the world.

     “Merck Leased Employees” has the meaning set forth in Section 7.1(a).

     “Merck Manufacturing Supply Price Formula” means the Merck Manufacturing Supply Price Formula
annexed as Exhibit 10 to the Merck Supply Agreement.

     “Merck Member” means the Member that is a Subsidiary of Merck which shall, as of the Closing,
be Merck SH.

     “Merck Negotiated Supply Price” has the meaning set forth in Section 6.7(a).

     “Merck Pre-Closing Taxes” has the meaning set forth in Section 14.12(a).

     “Merck
Product Registrations” has the meaning set forth in
Section 10.13.

     “Merck Proprietary Rights” has the meaning set forth in Section 10.12(b).

     “Merck Restructuring Event” means any transaction or series of related transactions pursuant
to which all or substantially all of the assets of Merck are sold or otherwise transferred to a
Third Party.

     “Merck Retirement Plans” has the meaning set forth in Section 7.1(b).

26

 

     “Merck SH” has the meaning set forth in the introduction to this Agreement.

     “Merck Stock Option Plan” has the meaning set forth in Section 7.1(d).

     “Merck Transferred Benefit Plan” means the Merck & Co., Inc. Employee Savings and
Security Plan and each Merck Benefit Plan sponsored, maintained, or contributed to by a
Merck Transferred Subsidiary.

     “Merck Transitory LLC” has the meaning set forth in Section 1.3(a).

     “Merck Transferred Foreign Pension Plan” means each Merck Transferred Benefit Plan that is an
“employee pension benefit plan” within the meaning of Section 3(2) of ERISA but that is not subject
to Title I or IV of ERISA pursuant to Sections 4(b)(4) and 4021(b)(7) of ERISA.

     “Merck Transferred Pension Plan” means each Merck Transferred Benefit Plan which is an
“employee pension benefit plan” within the meaning of Section 3(2) of ERISA and is subject to Title
IV of ERISA.

     “Merck Transferred Subsidiaries” means each Subsidiary of Merck listed in Schedule 2-8
hereto.

     “Merial” has the meaning set forth in the introduction to this Agreement.

     “Merial Merck Employees” has the meaning set forth in Section 7.1(a).

     “Merial Venture” means the group comprised of all the Merial Venture Companies.

     “Merial Venture Business” has the meaning set forth in Section 1.2(a).

27

 

     “Merial Venture Companies” means collectively Merial and (following its transfer to Merial)
each Transferred Subsidiary and any other Subsidiary of Merial from time to time, and “Merial
Venture Company” means any one of them.

     “Merial Venture Interest” of a Principal means all direct and indirect equity and other
ownership interests of such Principal and any of its Subsidiaries in the Merial Venture.

     “Merial Venture Product” means, from time to time, any one of the Existing Products or
Future Products.

     “Net Reported Sales” means, in respect of any Avermectin, Fipronil or Biological Products, as
the case may be, the sales amount calculated in the same manner as Net Sales, but without deducting
from the gross invoice price of such products the items listed in (iv) and (v) of the definition of
Net Sales and calculated for purposes of Sections 6.4 or 6.5, in the case of sales made in the
currencies set forth therein, based on the exchange rates set forth in Section 6.4(e).

     “Net Sales” means the gross invoice price (which will not include any taxes) of Avermectin,
Fipronil or Biological Products, as the case may be, sold by Merial, its Subsidiaries or
sublicensees to the first independent third party after deducting, if not already deducted in the
amount invoiced:

     (i) the normal or customary trade and/or quantity discounts, excluding cash
discounts, that are actually allowed or granted;

     (ii) returns, rebates and allowances that are actually granted;

     (iii) retroactive price reductions applicable to sales of such products that are
actually allowed or granted;

28

 

     (iv) sales commissions that are actually paid to third party distributors and
selling agents; and

     (v) [*] of the amount invoiced to cover cash discounts, bad debt,
freight or other transportation costs, insurance charges, additional special packaging,
duties, tariffs and other governmental charges.

With respect to sales of Avermectin or Fipronil Products sold in Combinations, Net Sales shall be
calculated in accordance with the provisions of the definition of Net Sales set forth in Exhibit XXI
[Avermectin Products Sales Adjustment] or the RP Ag Research Agreement, respectively.

     “Other JVs” means Persons that are, in substance, joint ventures in which (a) the Merck Group
or the RP Group, as the case may be, owns 50% or less of both (x) the outstanding equity, and (y)
the outstanding equity that has the right to elect or appoint the members of the board of directors
or similar governing body of such Person (the Parties hereby conclusively deem the conditions of
this clause (a) to be satisfied in respect of Banyu Pharmaceutical Co. Ltd., its Subsidiaries and
its and their respective successors), and (b) the principal business of such Person is a business
or businesses other than the Animal Health Business or the Poultry Genetics Business.

     “Other Taxes” means all Taxes which are not Income Taxes, including registration and stamp
duties (even if related to real property); provided, however, that such term shall
not include any real property taxes.

     “Parties” means all the parties to this Agreement and “Party” means any one of them.

     “Patents” means, in respect of any product, any unexpired patents or patent applications in
any jurisdiction necessary to make, have made, use or sell such product.

29

 

     “Person” or “person” means a natural person or any corporation, partnership, company,
limited liability company, association, trust or other entity of any kind whatsoever.

     “Pipeline Products” means, with respect to RM and its Subsidiaries, the products listed under
the caption “Pipeline” on page 1 of the RM base case attached as Exhibit XIV hereto and, with
respect to the Merck Group, the products listed under the caption “Pipeline” of the Merck base case
attached as Exhibit XV hereto.

     “PMSV” means Pasteur Mérieux Sérums et Vaccins S.A.

     “Poultry Genetics Business” has the meaning set forth in Section 1.2(a).

     “Poultry Genetics Products” has the meaning set forth in Section 1.2(c).

     “Pre-Closing Benefit Liabilities” means liabilities incurred, suffered or accrued as of, or
otherwise arising out of events or periods occurring prior to, the Closing Date with respect to a
Merck Transferred Benefit Plan or an RM Transferred Benefit Plan and calculated as follows: (i) the
calculation of liabilities for “employee pension benefit plans” within the meaning of § 3(2) of
ERISA and which are defined benefit plans shall be determined as of the Closing Date using the
January 1, 1997 census data of each such plan (unless there have been significant demographic
changes between January 1, 1997 and the Closing Date, in which case the Closing Date census data of
a particular plan shall be used with respect to such plan) and shall be determined (on an
accumulated benefit obligation basis) based upon actuarial assumptions used by RM (for RM
Transferred Pension Plans) or Merck (for Merck Transferred Pension Plans) for purposes of
determining pension expense pursuant to FAS 87 for each such plan for 1997; (ii) the calculation of
liabilities for retiree medical plans shall be determined as of the Closing Date using the January
1, 1997 census data of each such plan (unless there have been significant demographic changes
between January 1, 1997 and the Closing Date, in which case the Closing Date census data of a
particular plan shall be used with respect to such plan) and shall be determined (on an accumulated
post-retirement benefit obligation basis)

30

 

based upon those actuarial assumptions used by RM (with respect to RM Transferred Benefit Plans
which provide retiree medical benefits) or Merck (with respect to Merck Transferred Benefit Plans
which provide retiree medical benefits) for calculating the expense for purposes of FAS 106 for
1997; (iii) the calculation of liabilities for RM Transferred Benefit Plans and Merck Transferred
Benefit Plans providing post-employment (but pre-retirement) benefits such as salary and health
care continuation, supplemental unemployment benefits, severance benefits and disability-related
benefits (including workers’ compensation) shall be determined as of the Closing Date using the
January 1, 1997 census data of each such plan (unless there have been significant demographic
changes between January 1, 1997 and the Closing Date, in which case the Closing Date census data of
a particular plan shall be used with respect to such plan) and shall be determined based upon those
actuarial assumptions used by RM (with respect to RM Transferred Benefit Plans which provide such
benefits) or Merck (with respect to Merck Transferred Benefit Plans which provide such benefits)
for calculating the expense for purposes of FAS 112 for 1997; provided, however,
that the calculation of liabilities for long-term disability plans shall include liability for any
employee who has commenced or is eligible to commence benefits under a short-term disability plan
maintained by his or her employer as of the Closing Date and becomes eligible to receive, after the
Closing Date, benefits under a long-term disability plan of the Merial Venture as a result of such
pre-Closing disability, provided that such disability is continuous in accordance with the terms of
the applicable plan; (iv) the calculation of other liabilities for RM Transferred Benefit Plans and
Merck Transferred Benefit Plans which are medical or dental plans shall be based on claims for
treatment or services received or other expenses incurred prior to the Closing and reported prior
to December 31, 1997; (v) liabilities for RM Transferred Benefit Plans and Merck Transferred
Benefit Plans which are bonus plans shall be equal to a pro rata portion (based on
the percentage of the bonus period up to and including the Closing Date) of the bonus that is paid
with respect to the full bonus period; and (vi) the liability for any RM Transferred Benefit Plan
or Merck Transferred Benefit Plan not covered by clauses (i) through (v) above including any and
all such plans maintained outside of the U.S., shall be determined using generally accepted
actuarial or accounting principles, and using such actuarial or other assumptions as may be
necessary, and as agreed to by RP and Merck. Pre-Closing Benefit Liabilities shall be calculated by

31

 

the plan actuary for the plan at issue (or if there is no plan actuary, by the actuary or
accountant appointed by the plan sponsor); provided, however, that if Merck or RP
dispute the determination of such liabilities made by such actuary (or accountant, as applicable),
Merck and RP shall jointly choose an actuary or accountant, as applicable, to perform such
calculation and the determination of the jointly chosen actuary or accountant, as applicable, shall
be binding on RP and Merck. Pre-Closing Benefit Liabilities shall exclude RM Pre-Closing Taxes and
Merck Pre-Closing Taxes.

     “Pre-Closing Tax Period” in relation to a Person means all taxable periods of that Person
ending on or before the Closing Date.

     “Principal” means each of RP and Merck, which are together the “Principals.”

     “Product Liability” means any Damages that arise as a result of, or in connection with, the
use by a Third Party of a Merial Venture Product.

     “Product Registration” means, with respect to a product, the product registration (final and
pending) or any other authorizations of Public Authorities necessary to market such product in any
country.

     “Product Rights” means, with respect to a product and its marketing, distribution and sale in
a country, (i) the Product Registrations, and (ii) all product trademarks, service marks, trade
dress and copyrights necessary to market, distribute and sell such product in that country.

     “Public Authority” means any supranational, national, regional, state or local
government, court, tribunal, governmental agency, authority, board, bureau, instrumentality
or regulatory body.

     “Qualified Future Other JVs” means Other JVs for so long as no member or representative of the
Merck Group or the RP Group, as applicable, initiates or takes other affirmative action to cause
such Other JV to commence an Animal Health Business or

32

 

Poultry Genetics Business other than (a) de minimis activities that are incidental to the principal
business or businesses of such Other JV or (b) which result from the exploitation of a product
(including for the Animal Health or Poultry Genetics Business) invented or developed in the
principal business or businesses (i.e. non Animal Health or Poultry Genetics Business) of such
Other JV.

     “Receivables” of any person means any and all accounts receivable of such person and all notes
and other amounts receivable by such person from third parties, including, without limitation,
customers and employees, whether or not in the ordinary course of business, together with any
unpaid financing charges accrued thereon; provided that “Receivables” of any of Merck or its
Subsidiaries shall mean only such receivables as constitute Merck Contributed Assets.

     “Representative” of a Member has the meaning set forth in Section 4.2(d).

     “Research Agreements” means, collectively, the Merck Research Agreement, the RPR Research
Agreement, the RP Ag Research Agreement and the PMSV Research Agreement.

     “Retained Inventory” shall have the meaning set forth in Section 5.1(a)(ii)(C).

     “Retained Receivables” shall have the meaning set forth in Section 5.1(a)(ii)(C).

     “Retirement Cost” shall have the meaning set forth in Section 7.1(b).

     “Retroactive Closing Mechanism” shall have the meaning set forth in Section 6.3(a).

     “Retroactive Closing Financial Statements” shall have the meaning set forth in Exhibit XIX
hereto.

33

 

     “Returns” means all returns, reports, declarations, estimates, information returns, statements
and forms of any nature regarding Taxes, including remittance advice, required to be filed with any
Taxing Authority.

     “Rhône-Poulenc” has the meaning set forth in the introduction to this Agreement.

     “RM” has the meaning set forth in the introduction to this Agreement.

     “RM Accrued Tax Liabilities” has the meaning set forth in Section 5.2(b).

     “RM Benefit Plan” means each Benefit Plan (other than RM Employee Agreements) which is now or
previously has been sponsored, maintained, contributed to, or required to be contributed to, or
with respect to which any withdrawal liability (within the meaning of Section 4201 of ERISA) has
been incurred, by RP, any of its Subsidiaries or any RM ERISA Affiliate for the benefit of any RM
Employee, and pursuant to which RP, any of its Subsidiaries or any RM ERISA Affiliate has or may
have any liability, contingent or otherwise.

     “RM Contributed Liabilities” means all of the obligations or Liabilities of RM or any of its
Subsidiaries (whether or not reflected on the RM Financials or the books and records of RM or any
of its Subsidiaries).

     “RM Employee” means each current, former, or retired employee of an RM Transferred
Subsidiary together with those employees listed on Schedule 8.18A-2.

     “RM Employee Agreement” means each management, employment, severance, consulting, non-compete,
confidentiality, or similar agreement or contract between RP or any of its Subsidiaries and any RM
Employee pursuant to which RP or any of its Subsidiaries has or may have any liability contingent
or otherwise.

     “RM ERISA Affiliate” means each business or entity which is a member of a “controlled
group of corporations,” under “common control” or an “affiliated service

34

 

group” with RP within the meaning of Sections 414(b), (c) or (m) of the Code, or required to
be aggregated with RP under Section 414(o) of the Code, or is under “common control” with RP,
within the meaning of Section 4001(a)(14) of ERISA.

     “RM Financials” has the meaning set forth in Section 8.5. The RM Financials are attached as
Exhibit XVII.

     “RM Intercompany Debt” has the meaning set forth in Section 5.2(b).

     “RM Outstanding Debt” has the meaning set forth in Section 5.2(b).

     “RM Plans” has the meaning set forth in Section 7.1(e).

     “RM Pre-Closing Taxes” has the meaning set forth in Section 14.11(a).

     “RM Proprietary Rights” has the meaning set forth in Section 8.11(b).

     “RM Transferred Benefit Plan” means each RM Benefit Plan sponsored, maintained, or
contributed to by an RM Transferred Subsidiary.

     “RM Transferred Foreign Pension Plan” means each RM Transferred Benefit Plan that is an
“employee pension benefit plan” within the meaning of Section 3(2) of ERISA but that is not subject
to Title I or IV of ERISA pursuant to Sections 4(b)(4) and 4021(b)(7) of ERISA.

     “RM Transferred Pension Plan” means each RM Transferred Benefit Plan which is an “employee
pension benefit plan” within the meaning of Section 3(2) of ERISA and is subject to Title IV of
ERISA.

     “RM Transferred Subsidiaries” means, collectively, RM and each Subsidiary of RM listed in
Schedule 2-11 hereto.

35

 

     “RM U.S. Employees” has the meaning set forth in Section 7.1(e).

     “RM 401(k) Plan” has the meaning set forth in Section 7.1(e).

     “RP” means Rhône-Poulenc S.A. or any Successor Entity thereto.

     “RP Adjustment Products” has the meaning set forth in Section 6.4(b).

     “RP Ag” means Rhône-Poulenc Agrochimie S.A.

     “RP Ag Manufacturing Supply Price Formula” means the Manufacturing Supply Price Formula
annexed as Exhibit 3 to the RP Ag Supply Agreement.

     “RP Animal Health Executive” means the individual named in Schedule 2-12 and any duly
appointed successor to such individual, notified in writing by RP to Merck and Merial.

     “RP Breach” has the meaning set forth in Section 14.2(b).

     “RP Company” means any of RP or its Subsidiaries.

     “RP Contributed Debt” has the meaning set forth in Section 5.2(b).

     “RP Finance” has the meaning set forth in Section 1.3(a).

     “RP Group” means RP, together with all its Subsidiaries.

     “RP Member” means the Member that is a Subsidiary of RP which shall, subject to sections 17.1
and 17.2, be IM.

     “RP Restructuring Event” means any transaction or series of related transactions pursuant to
which (i) any of RP Ag, PMSV or RPR ceases to be a Subsidiary of RP, or

36

 

(ii) all or substantially all of the assets of any of RP Ag, PMSV or RPR are sold or
otherwise transferred to a Third Party.

“RPR” means Rhône-Poulenc Rorer S.A.

“SAS” means société par actions simplifiée.

“Special Dividend” has the meaning set forth in Section 6.2(a).

     “Straddle Period” means, in relation to a Person, the taxable period of that Person that
includes the Closing Date.

     “Subsidiary” means, with respect to any Person (herein referred to as the “parent”), any
corporation, partnership, company, association, trust or other business entity (a) of which
securities or other ownership interests representing more than 50% of the equity or more than 50% of
the ordinary voting power or more than 50% of the general partnership or analogous interests are,
at the time such determination is being made, owned, Controlled or held by the parent and/or one or
more other Subsidiaries of the parent, or (b) which is, at the time such determination is made,
otherwise Controlled, by the parent and/or one or more other Subsidiaries of the parent;
provided that it shall be deemed that (i) as from the Closing Date, none of the Merial
Venture Companies shall be a Subsidiary of either Merck or RP; and (ii) none of the Existing Other
JVs or Qualified Future Other JVs shall be a Subsidiary of either Merck or RP.

     “Successor Entity” has the meaning set forth in the definition of Change of Control
above.

     “Supply Agreements” means, collectively, the Merck Supply Agreement and the RP Ag Supply
Agreement.

     “Tax” means any tax, including, without limitation, income (net or gross), corporations,
capital gains, gross receipts, franchise, estimated, alternative, minimum,

37

 

add-on minimum, sales, use, transfer, registration, value added, excise, natural resources,
severance, stamp, occupation, premium, windfall profit, customs, duties, real property, personal
property, capital stock, social security, unemployment, disability, payroll, license, employee or
other withholding, or other tax, of any kind whatsoever, and including any interest, penalties or
additions to tax, levied by any Taxing Authority.

     “Taxing Authority” means any governmental authority, including, but not limited to agencies of
the European Union, the United States federal government, the government of the French Republic,
the government of the United Kingdom, or the government of any other country, and any political
subdivision of any of the foregoing, having jurisdiction over the assessment, determination,
collection, or other imposition of Tax.

     “Tax Benefit” means any items of loss, deduction or credit or any other item to the extent
such item decreases Taxes paid or payable including any interest and penalty with respect
thereto or interest that would have been payable but for such item.

     “Tax Matter” means any Tax matter, including any audit, examination, assessment, notice of
deficiency or other adjustment or proposed adjustment, or administrative or judicial proceeding,
the settlement of any of the foregoing, or the filing of any amended return.

     “Third Party” means a person who or which is neither a Merial Venture Company nor a Merck
Company nor an RP Company.

     “Third Party Claim” has the meaning set forth in Section 14.7(a).

     “Transactions” means, collectively, all the transactions contemplated by this Agreement
and the Ancillary Agreements.

     “Transferred Subsidiaries” means, collectively, the RM Transferred Subsidiaries and the
Merck Transferred Subsidiaries.

38

 

     “U.S.” means the United States of America.

     “U.S. Animal Health Employees” has the meaning set forth in Section 7.1(f).

     “U.S. Person” means any company or other Person that is formed or domesticated under the laws
of any state of the United States of America.

39

 

ARTICLE III

MERIAL VENTURE COMPANIES

SECTION 3.1. Merial

     (a) Merial as Principal Entity. Merial shall be the parent company of the Merial
Venture. Any entity created by Merial or any Merial Venture Company in any country to conduct
Merial Venture Business operations shall be a Subsidiary of Merial.

     (b) Location of Offices. The principal office of Merial shall be in London, England.

SECTION 3.2. Reorganization of Subsidiaries Prior to Closing

     Prior to the Closing, the following actions shall be taken:

     (a) Merck shall cause each of the Merck Transferred Subsidiaries that is a U.S. Person to be
reorganized as a limited liability company which is not classified as an association taxable as a
corporation for U.S. federal income tax purposes.

     (b) RP shall cause RM to be reorganized as a SAS, which is not classified as an association
taxable as a corporation for U.S. federal income tax purposes. RP shall cause such reorganized
entity to be wholly owned by Merial, except for one share therein which will be owned by a
newly-formed single member Delaware limited liability company which is not classified as an
association taxable as a corporation for U.S. federal income tax purposes, which shall itself be
wholly owned by Merial.

     (c) RP shall cause the share ownership of all the Subsidiaries of Rhone Merieux, Inc. that are
not U.S. Persons to be transferred to Merial or to Subsidiaries of Merial that are not U.S.
Persons, it being understood that RP shall not be required to cause any such transfer which would
result in an aggregate (for all such transfers) adverse

40

 

tax consequence for the RP Group in excess of [*].

     (d) IM shall cause Merial to elect classification as a partnership for U.S.
federal income tax purposes.

41

 

ARTICLE IV

GOVERNANCE

     Merial is, as at the date hereof, an English private company limited by shares governed by the
Laws of England and Wales and shall, as of the Closing, be governed by the Association Documents.
As of the Closing, Merial will, pursuant to the Delaware Act, be domesticated in Delaware as a
Delaware limited liability company governed by the LLC Agreement and, to the extent applicable,
Delaware Laws. To the extent that the provisions of English Laws governing Merial and the
provisions of Delaware Laws governing Merial are not identical, the Directors and the Members shall
take such steps as are reasonably required to ensure that Merial complies with both such Laws.
Merial is, in addition, otherwise subject to the relevant provisions of this Agreement.

SECTION 4.1. Company Bodies of Merial

     The company bodies of Merial are:

	 	•	 	the members of Merial acting through a meeting of the Members or a unanimous
written resolution (the “Members’ Meeting”),
	 
	 	•	 	the Board of Directors, and
	 
	 	•	 	the Executive Officers.

SECTION 4.2. Members’ Meeting

     (a) Members’ Meeting as Ultimate Authority of Merial. The Members’ Meeting shall be
the ultimate authority of Merial. Certain fundamental decisions affecting Merial shall require the
approval of the Members’ Meeting.

     (b) Resolutions of the Members’ Meeting. The following actions shall require a
resolution of the Members’ Meeting:

42

 

     (i) the dissolution or winding up of, or any merger, joint venture or partnership
involving, or the acquisition or reorganization of, Merial;

     (ii) any arrangement for the acquisition of all or substantially all of the assets or
undertakings of Merial;

     (iii) any modification of the Association Documents or the LLC Agreement, including,
without limiting the generality of the foregoing, any increase or decrease of Merial’s authorized
share capital or the issuance by Merial of any securities or interests, or any options, warrants or
other rights to acquire such securities or interests;

     (iv) the undertaking of any significant business activities outside the scope of the
Merial Venture Business;

     (v) the approval of the annual financial statements (including income and cash flow
statements and balance sheet) of Merial;

     (vi) the payment or declaration of any dividend or distribution or the entering into of
any transaction by reference to, or which will have the effect of reducing, Merial’s Distributable
Profits, except as expressly contemplated by this Agreement, and in particular by Article VI ;

     (vii) any request for capital contributions by the Members;

     (viii) the appointment or removal of the auditor(s) of Merial;

     (ix) any matter put to the Members’ Meeting for its resolution by the Board of Directors
or either of the Members; and

     (x) all other matters required by applicable Laws to be decided or approved by the
Members.

43

 

     (c) Unanimous Vote in the Members’ Meeting. Decisions of the Members’ Meeting shall
require the agreement of both Members.

     (d) Selection of Representatives. Each of the Members shall designate, prior to or
at the commencement of the Closing Meeting, either (A) one representative who shall be authorized
to cast such Member’s vote at all meetings of the Members until another individual is designated to
cast such vote or (B) several representatives, each of whom shall be authorized to cast such
Member’s vote at the meetings which shall be specified in such representative’s designation, and,
for each such representative, until another individual is designated to cast such vote. Each such
designation may specify the terms of any substitution (as in the case of absence or otherwise). A
memorandum in the form set out in the Association Documents recording such designation shall be
made in writing and delivered to the other Member, and details of the relevant designation may be
read into the minutes of the meeting at the commencement of the meeting and the memorandum
thereafter so delivered. The vote of a Member’s designated representative or of the substitute
for such representative, if applicable (such designated representative or substitute being the
“Representative”), in the Members’ Meeting shall in all cases be deemed to be the decision of such
Member. Any appointment by or notification of either such Representative under this Article IV
shall in all cases be deemed to be the appointment by or notification of the respective Member.

     (e) Voting by the Members in the Members’ Meeting. Each of the Members shall at all
times exercise or cause to be exercised all of its powers and votes as a member of Merial such that
Merial shall comply with all obligations under and implement all provisions of this Agreement, the
LLC Agreement and the Association Documents, as validly amended from time to time.

     (f) Members’ Meetings. Non-voting representatives of either Member may attend any
Members’ Meetings in addition to the Representatives. A quorum shall exist in a Members’ Meeting
if Representatives of both Members are present. Decisions may also be taken by the Members’
Meeting by unanimous written resolution of both Members.

44

 

     (g) New Members’ Meeting in Case of Inability to reach a Decision. If, with
respect to a specific matter, the Members are unable to reach a decision in the Members’ Meeting,
then each Member has the right to request a new Members’ Meeting to discuss the same matter. Such
new Members’ Meeting shall occur within thirty (30) days after the date of the last Members’
Meeting.

     (h) Deadlock, Conciliation. If at such second Members’ Meeting, the Members are
still deadlocked with respect to said matter, within seven (7) days thereafter the matter shall be
referred for resolution pursuant to the terms of Section 18.1 to the RP Animal Health Executive and
the Merck Animal Health Executive.

     (i) Discussion of Agenda Prior to Members’ Meeting. At the request of either
Member, the points of the agenda shall be discussed between representatives of the Members prior to
any Members’ Meeting.

     (j) Calling for a Members’ Meeting. A Members’ Meeting may be called by the
Board of Directors or by any Member. Members’ Meetings shall take place at the registered office
of Merial unless another location is agreed upon by both Members.

     (k) Annual Members’ Meeting. Subject to the requirements of the Companies Act,
the annual Members’ Meeting shall be held within six (6) months after the end of each Fiscal Year.
It shall consider the approval of Merial’s annual financial statements, the allocation (in
accordance with the other provisions of this Agreement) of any Distributable Profits and the
appointment of Merial’s auditors, when required.

SECTION 4.3. Board of Directors

     (a) Powers of the Board of Directors. The fundamental policies and the
strategy of Merial shall be determined by its board of directors (the “Board of Directors”). The
Board of Directors shall have responsibility for approving the annual budget and Business Plan and
shall oversee their implementation by the Executive Chairman and the other Executive Officers.
Except for matters requiring the approval of

45

 

the Members’ Meeting and subject to the Members’ Meetings’ decisions, the Board of Directors shall
have the responsibility for making all significant decisions of Merial. In particular, Merial
shall not do, either directly or indirectly, any of the following with respect to the Merial
Venture without the prior approval of the Board of Directors:

     (i) take any action that affects the ownership or nature of the share capital of
RM or the nature of the share capital of Merial, it being understood that any change in the
ownership of the share capital of Merial shall be deemed for the purposes of this Section
4.3(a)(i) not to affect the ownership or nature of the share capital of RM or the nature of
the share capital of Merial (the Directors appointed by the RP Member being hereby reminded
by RP that they should, prior to participating in such approval or taking any other action
affecting the RP Member’s ownership interest in Merial, consult with tax counsel and may
wish to obtain confirmation from the French Direction Générale des Impôts of the effect of
such action on the agrément fiscal described in Section 11.2(b) and any potential for
substantial Taxes to be imposed on RP);

     (ii) except as previously approved in writing in the annual budget, invest in,
acquire or dispose of assets or businesses in any manner, or encumber assets in any manner,
or incur or assume any indebtedness, enter into long term contracts, or generally undertake
any other matter of extraordinary importance or particular strategic importance, in one
transaction or a series of related transactions, in each case in excess of [*];

     (iii) subject to Section 4.3(a)(1), acquire, purchase, subscribe for, dispose of or
transfer any shares, debentures, partnership interest or other interests in or securities of
(or any interest therein) any Person, in one transaction or a series of related
transactions, in each case in excess of [*];

     (iv) approve Merial’s annual financial statements prior to their
submission to the Members’ Meeting;

46

 

     (v) form, sell, dissolve, liquidate or terminate any Merial Venture Company or take
any company action in connection therewith;

     (vi) undertake or terminate any major research or development program;

     (vii) initiate or settle any significant litigation or provide any undertaking (except in
the ordinary course of business) to a Public Authority;

     (viii) appoint, remove or replace any of the Executive Officers;

     (ix) enter into any agreement providing for (A) the sale or licensing out of any
potentially significant Intellectual Property; or (B) the purchase or licensing in of any
Intellectual Property involving the payment or potential payment of more than [*];

     (x) change any of the accounting principles or practices to be applied in the preparation
of financial statements or change Merial’s accounting reference date;

     (xi) determine the remuneration and other terms and conditions of employment of any of the
Executive Officers of Merial, except as applicable to employees generally;

     (xii) enter into (except for the Ancillary Agreements to be entered into as provided in
this Agreement) or terminate or amend or waive any material term or condition under any contract or
transaction between any Merial Venture Company, on the one hand, and either an RP Company or a
Merck Company, on the other;

     (xiii) provide any loan or advance or credit (other than customary trade credit) to, or
incur any guarantee, surety, indemnity, Encumbrance or other obligation in favor of, any RP Company
or Merck Company;

47

 

     (xiv) make aggregate (across all Merial Venture Companies) charitable contributions
in any year in excess of [*];

     (xv) enter into, or terminate or amend or waive any material term or condition
under, any employment or other contract with any Executive Officer or with any other
employee of Merial whose annual emoluments are reasonably expected to exceed [*],
create or adopt new employee benefit or general bonus plans or materially amend existing
employee benefit or bonus plans, except as required to comply with the terms of this
Agreement, or make loans or severance payments to employees except in accordance with
policies previously approved by the Board of Directors or with the terms of this Agreement;

     (xvi) approve and implement, or disapprove, any corrective, preventive or remedial
plan in response to an Environmental Liability at any site where the total projected costs
of such plan (including all phases of such plan responding to the Environmental Liability)
at such site are expected to exceed [*];

     (xvii) the issuance by any Subsidiary of Merial of any equity securities or
interests, or any options, warrants or other rights to acquire such equity securities or
interests; and

     (xviii) any other matter required by applicable Laws to be decided upon or approved by
the Board of Directors.

     (b) Formation and Members of the Board of Directors. At the Closing, a Board of
Directors shall be formed for Merial which shall consist of six (6) members. Three (3) members
shall be appointed by the RP Member and three (3) members shall be appointed by the Merck Member,
each for a term of office of six (6) years (each, a “Director”, and together, the “Directors”).
The right of the RP Member and the Merck Member to appoint Directors shall include the right to
remove and to replace Directors they have each appointed.

48

 

     (c) Executive Officers not Directors. None of the Executive Officers shall be
Directors or shall have the right to vote at any meeting of the Board of Directors.

     (d) Executive Chairman and CEO to be Observers. Unless the Board of Directors
expressly decides otherwise with respect to a particular matter or meeting, the Executive Chairman
and, for so long as there is one, the CEO shall be observers of the Board of Directors, with the
right to be notified of, to attend and to be heard at every meeting of the Board of Directors.

     (e) Agenda for and Chairing of Meetings. The agenda for meetings of the Board of
Directors shall be prepared by the secretary of Merial and shall include all matters proposed by
either Member. Each meeting of the Board of Directors shall be chaired by one Director, who shall
be named in the agenda for the meeting. The Closing Meeting shall be chaired by a Director
nominated by IM. The following meeting of the Board of Directors shall be chaired by a Director
nominated by Merck SH and, thereafter, each meeting shall alternatively be chaired by a Director
appointed by the RP Member and a Director appointed by the Merck Member.

     (f) Quorum in Meetings of the Board of Directors, Unanimous Vote. A quorum shall exist
in a meeting of the Board of Directors if at least four (4) Directors, two (2) nominees of the RP
Member and two (2) nominees of the Merck Member, are present or represented. Resolutions of the
Board of Directors shall only be valid if passed unanimously by all the Directors present at a
meeting.

     (g) New Meeting in Case of Inability to Reach a Decision. If, with respect to a
specific matter, the Board of Directors is unable to reach a decision in a meeting of the Board of
Directors, then any Director has the right to request a new meeting to discuss the same matter.
Such new meeting of the Board of Directors shall occur within thirty (30) days after the date of
the last meeting.

     (h) Deadlock, Conciliation. If, at such second meeting of the Board of Directors,
unanimity cannot be reached and the Board of Directors is still deadlocked,

49

 

within seven (7) days after such meeting the matter shall be referred for resolution pursuant to
the terms of Section 18.1 to the RP Animal Health Executive and the Merck Animal Health Executive.

     (i) Meetings of the Board of Directors. The Board of Directors shall meet at least
three (3) times per calendar year and at such other times as may be requested by any Director.
Meetings shall be in person and take place at the registered office of Merial or in any other
manner by which all persons participating in the meeting may hear and speak to each other, unless
all of the Directors agree otherwise. Alternatively, decisions of the Board of Directors may be
taken by unanimous written resolution of all the then-incumbent Directors.

     (j) Minutes of Meetings of the Board of Directors. All meetings of the Board of
Directors shall be recorded in minutes reflecting the place and date of the meeting, the
participants therein, the items on the agenda, the material contents of discussions and the
resolutions adopted by the Board of Directors. The minutes shall be signed by the Director chairing
the meeting pursuant to Section 4.3(e) and by at least one Director nominated by the other Member,
and a copy of the minutes shall be delivered to each Director, to each Member, to the Executive
Chairman and, for so long as there is one, to the CEO.

     (k) Committees

     Subject to the general oversight and authority of the full Board of Directors, the following
committees of the Board of Directors shall be established and maintained:

     (i) an Audit Committee, which shall consist of four persons appointed by the Board of
Directors, two of whom shall be appointed by each of the Members and which shall be
responsible for (aa) reviewing the accounts and accounting policies of Merial, (bb) meeting
with Merial’s auditor(s) to review accounting issues, (cc) discussing potential
distributions, and (dd) for presenting the yearly financial statements of Merial to the
Board of Directors for its

50

 

consideration, and shall have such powers as the Board of Directors may delegate to it from
time to time;

     (ii) a Compensation Committee, which shall consist of four persons two of whom shall
be appointed by each of the Members, and which shall be responsible for reviewing the
executive and employee compensation policies of Merial and for proposing employee benefit
plans and arrangements to the Board of Directors for its consideration, and shall have such
powers as the Board of Directors may delegate to it from time to time;

     (iii) a Financing Committee, which shall consist of four persons two of whom shall be
appointed by each of the Members, and which shall be responsible for reviewing the
financing policies of Merial, including generally Merial’s capital and debt structure,
capital expenditures and other matters of a financial and tax nature to be discussed by the
Board of Directors, and for presenting resolutions relating to financing to the Board of
Directors for its consideration, and shall have such powers as the Board of Directors may
delegate to it from time to time; and

     (iv) an Executive Committee, of two persons, consisting of one Director appointed by
each of the Members, and which shall assist the Executive Chairman, the CEO, and the Board
of Directors in order to facilitate and expedite decision making by the Board of Directors,
and shall have such powers as the Board of Directors may delegate to it from time to time.

     The Board of Directors may delegate any of its powers to any other committee, temporary or
permanent, as it deems appropriate.

     (1) Limitations on Directors’ Duties. Merck agrees that it shall not (and shall cause
its Subsidiaries not to), in relation to any Directors appointed by the RP Member, and RP agrees
that it shall not (and shall cause its Subsidiaries not to), in relation to any Directors appointed
by the Merck Member, take any action against such Director for negligence, default, breach of duty
or breach of trust on the grounds that such negligence,

51

 

default, breach of duty or breach of trust arose by virtue of the Director acting in accordance
with the instructions of the Member appointing such Director. Merck, the Merck Member, RP and the
RP Member agree that, in the event of any Director acting in accordance with the instructions, or
in the interests of, the Member appointing such Director, then any resultant dispute shall be
considered to be a dispute between the Parties to be resolved exclusively in accordance with the
provisions of Article XVIII hereof.

SECTION 4.4. The Executive Chairman. CEO and other Executive Officers

     (a) Day-to-Day Management of the Merial Venture. Except for matters requiring the
approval of the Members’ Meeting or of the Board of Directors, and subject to the decisions of the
Members’ Meeting and of the Board of Directors, the Executive Chairman of Merial (the “Executive
Chairman”) shall have the responsibility and authority to manage and operate the day-to-day
business of Merial with the assistance of the other Executive Officers and in accordance with
Merial’s current annual budget and Business Plan.

     (b) Appointment of the Executive Chairman

     (i) The Executive Chairman’s term of office shall have a duration of two years.

     (ii) The Person designated as initial Executive Chairman (the “Initial Chairman”) in
Schedule 4.4 shall be nominated by the Merck Member and shall be appointed as Executive
Chairman of Merial as of the Closing Date. At the expiry of his term of office, the parties
intend that the Initial Chairman shall no longer be an officer or employee of the Merial
Venture and at that time may return to a position within Merck. At the expiry of the Initial
Chairman’s term of office, a new Executive Chairman shall be appointed by the RP Member,
subject to the consent of the Merck Member (which consent shall not be unreasonably
withheld). The RP Member shall communicate in writing its choice of Executive

52

 

Chairman to the Merck Member at the latest one (1) month prior to the end of the Initial
Chairman’s term of office.

     (iii) Subsequent Executive Chairmen shall be appointed by the Board of Directors,
which shall also have the right to remove and replace the Executive Chairman.

     (c) Responsibilities of the Executive Chairman. The Executive Chairman shall be the
head of the executive organization of the Merial Venture and (subject to Sections 4.2(b) and
4.3(a)) shall have the full authority to represent and bind Merial. The Initial Chairman appointed
pursuant to the first sentence of Section 4.4(b)(ii) shall, in particular, be responsible for
overseeing and managing the research and development and corporate staff functions and Poultry
Genetics Business activities of the Merial Venture. The Executive Chairman shall also be
responsible for strategic planning, including the preparation and presentation to the Board of
Directors of Merial’s annual budget and its rolling three (3) year business plan (the “Business
Plan”). The Business Plan shall set forth the goals, strategies and action plans of the Merial
Venture over the current Fiscal Year and the two succeeding Fiscal Years, and shall include
sub-plans for investment, research and development, manufacturing, marketing and personnel. The
Members may at any time alter the duration or scope of the Business Plan. The Executive Chairman
shall report to the Board of Directors.

     (d) Appointment of other Executive Officers. Merial shall have such other executive
officers in addition to the Executive Chairman (together with the Executive Chairman, each an
“Executive Officer” and, collectively, the “Executive Officers”) as shall be determined by the
Board of Directors after receiving the recommendation of the Executive Chairman (it being
understood that the Board of Directors may nominate Executive Officers other than those recommended
by the Executive Chairman). The list of initial Executive Officers is set forth in Schedule 4.4.
The Board of Directors shall have the power to appoint, remove and replace any of the Executive
Officers.

53

 

     (e) Appointment of the Chief Executive Officer (the “CEO”). The person designated as
CEO in Schedule 4.4 shall be nominated by the RP Member and shall be appointed as CEO of Merial for
a two year term of office as of the Closing Date. At the expiry of such term of office, unless the
Board of Directors expressly decides otherwise, the position of CEO shall be terminated, and all
the responsibilities of the CEO shall be combined with those of the Executive Chairman.

     (f) Responsibilities of the CEO. The CEO appointed pursuant to Section 4.4(e)
shall be responsible for overseeing and managing the sales, marketing and manufacturing
activities of the Merial Venture, and shall have other specific responsibilities and
authority as delegated to him from time to time by the Executive Chairman. The CEO shall
report to the Executive Chairman.

54

 

ARTICLE V

CONTRIBUTIONS TO THE MERIAL VENTURE

CERTAIN TAX MATTERS

SECTION 5.1. Contributions of Assets and Assumption of Liabilities

     (a) Merck Contribution. On the terms and subject to the conditions of this
Agreement (and subject specifically to the representations, warranties and covenants made by Merck
in this Agreement) and the Merck Transfer Agreement, and subject to subsections (i), (ii) and (iii)
below and to Sections 11.2(c) and 11.6, (x) Merck shall, on or prior to the Closing Date or as soon
thereafter as practicable as provided in Section 5.1(a)(ii), assign, transfer, convey and deliver
(by merger, sale or otherwise) to Merial or its Subsidiaries, or cause to be assigned, transferred,
conveyed and delivered (by merger, sale or otherwise) to Merial or its Subsidiaries, all of the
Merck Contributed Assets, and (y) Merial (or its relevant Subsidiary) shall, on the Closing Date,
assume and agree to pay, perform, fulfill and discharge when due all of the Merck Contributed
Liabilities.

     (i) U.S. Assets and Liabilities. Merck shall, on or prior to the Closing
Date, assign, transfer, convey and deliver to Merck Transitory LLC: (A) the entirety of the
assets and liabilities of Hubbard Farms, Inc., together with all of Hubbard Farms, Inc.’s
direct and indirect ownership interests in each of its Subsidiaries except as indicated in
Schedule 2-8 (such transaction to be effected in accordance with Section 1.3(a)(i)(B)), (B)
to the extent indicated in Schedules 10.12 and 10.13, all of the Product Registrations and
trademark registrations and trademark applications included in the Merck Contributed Assets
that are owned by Merck or a Subsidiary of Merck that is a U.S. Person, (C) all other Merck
Contributed Assets not covered by (A) and (B) above that are located in or registered in the
U.S., including real estate or personal property, or that are owned by Merck or a Subsidiary
of Merck that is a U.S. Person (other than the Retained Receivables and the Retained
Inventory, as defined in Section 5.1(a)(ii)(C)), (D) all of the contracts included in the
Merck Contributed Assets to which Merck or a Subsidiary of Merck that is a U.S. Person is a
party (the assets

55

 

listed in (A) through (D) together being the “Merck Contributed U.S. Assets”). Merck Transitory LLC
shall, on or prior to the Closing Date, assume and agree to pay, perform, fulfill and discharge
when due all of the Merck Contributed Liabilities reasonably attributable to the Merck Contributed
U.S. Assets contributed to Merck Transitory LLC or their ownership or operation. The Parties
understand that the contribution of the entirety of the assets and liabilities of Hubbard Farms,
Inc. to Merck Transitory LLC will result in Merial being engaged in both the Animal Health Business
and the Poultry Genetics Business. Merial shall create separate divisions within the Merial Venture
for each of these businesses and shall prepare stand-alone financial statements for each division.

     (ii) Non-U.S. Assets and Liabilities.

     (A) Purchase of Assets and Assumption of Liabilities.

     (1) Valuation. Prior to the Closing, the Principals will agree
on the aggregate fair market value of all the Merck Contributed Non-U.S. Assets
(other than the cash and cash equivalent items included in such assets) net of the
Merck Contributed Liabilities (other than the Merck Contributed Debt and the Merck
Accrued Tax Liabilities (as defined in Section 5.1(a)(ii)(B)) reasonably
attributable to such assets that will be purchased by Merial or any of its
Subsidiaries (such value, after netting, being the “Merck Non-U.S. Net Assets
Value”). For purposes of calculating the Merck Non-U.S. Net Assets Value, [*]

56

 

[*].

     (2) Purchasing Entity. Merial or the appropriate Merial Subsidiaries agreed
upon by the Principals (which generally shall be the Merial Subsidiaries located in the country in
which each such asset is to be used) shall purchase each Merck Contributed Non-U.S. Asset from the
Merck Subsidiary that owns such asset. Merial shall, and shall cause each of its Subsidiaries that
has purchased any Merck Contributed Non-U.S. Assets to, on the Closing Date, assume and agree to
pay, perform, fulfill and discharge when due all of the Merck Contributed Liabilities reasonably
attributable to

57

 

such purchased Merck Contributed Non-U.S. Assets or their ownership or operation.

     (3) Consideration for Purchase. The aggregate consideration for the Merck Non-U.S.
Assets shall be cash in an amount equal to the Merck Cash Contribution Amount as defined in and
contributed by Merck pursuant to Section 5.1(a)(ii)(B) and/or promissory notes issued to the
selling Merck Subsidiaries, in accordance with the provisions of this Section 5.1(a)(ii)(A)(3).
To the extent the actual aggregate purchase price paid for all the Merck Contributed Non-U.S.
Assets pursuant to clause (1) above exceeds the Merck Cash Contribution Amount (as defined in
Section 5.1(a)(ii)(B)), or to the extent the Principals otherwise agree, purchases of the Merck
Contributed Non-U.S. Assets by Merial and the Merial Subsidiaries may be made with promissory notes
issued to the selling Merck Subsidiaries.

     (4) Timing of Purchase. Each of the Parties shall (and shall procure that their
respective Subsidiaries shall) cooperate and use commercially reasonable efforts (x) to give effect
to, on the Closing Date, the purchase and sale of all the Merck Contributed Non-U.S. Assets and the
assumption of the Merck Contributed Liabilities reasonably attributable thereto in accordance with
this Section 5.1(a)(ii)(A), and (y) to the extent it is not possible (including by reason of not
having obtained required approvals from appropriate Public Authorities and/or having completed
workers’ council consultations or similar processes under applicable Laws) or reasonably
practicable to purchase and sell certain Merck Contributed Non-U.S. Assets or to assume the Merck
Contributed Liabilities reasonably attributable thereto effective as of the Closing Date, to give
effect to the purchase and sale of each such asset and the assumption of such Liabilities (the
“Delayed Purchase Assets”)

58

 

in accordance with this Section 5.l(a)(ii)(A) as soon as reasonably practicable following
the Closing.

     (5) Expenses of Purchase. Each of the purchase agreements giving
effect to the purchase of Merck Contributed Non-U.S. Assets (whether concurrently with or
after the Closing) shall provide that all of the costs and expenses associated with such
purchase (other than the specified consideration for such purchase), including the costs
and expenses of counsel and other advisors, and all registration, transfer or stamp duties
and other comparable duties and Taxes, but excluding any allocation for salaries, shall be
paid by the seller (Merck or a Merck Subsidiary, as the case may be), and that to the
extent any of such costs or expenses has been incurred by the purchaser or any of its
Affiliates (Merial or a Merial Subsidiary, as the case may be), the seller shall indemnify
the payor thereof for such costs or expenses.

     (B) Merck Cash Contribution Amount. Merck shall, on or prior to the Closing
Date, contribute cash to Merck Transitory LLC in an amount (the “Merck Cash Contribution Amount”)
equal to the amount, if any, by which the Merck Non-U.S. Net Assets Value exceeds the “Merck
Estimated Available Contributed Debt”, as defined below. The “Merck Estimated Available
Contributed Debt” shall be the amount equal to [*] (the “Merck Negotiated Debt”)
plus an estimate of the “Merck Closing Cash” (as defined below) less the sum of (w) an
estimate of the “Merck Accrued Tax Liabilities” (as defined below), (x) an estimate of the “Merck
Other Debt” (as defined below), (y) the value of the Retained Receivables (as defined in Section
5.1(a)(ii)(C)) and (z) the value of the Retained Inventory (as defined in Section 5.1(a)(ii)(C)).

     The “Merck Closing Cash” shall be equal to the cash and the fair market value of cash
equivalent items that are included in the Merck

59

 

Contributed Assets, but shall exclude the Merck Asset Sale Proceeds, as defined in Section 10.9(a).

     The “Merck Accrued Tax Liabilities” shall be the amount equal to the net (after netting the
payables and the receivables) accrued Liabilities for Taxes (excluding deferred Taxes) to the
extent they are Merck Contributed Liabilities at the Closing Date.

     The “Merck Other Debt” shall be the amount of Debt at the Closing assumed or otherwise payable
by Merck Transitory LLC, Merial or any Merial Subsidiary (without duplication) in favor of Merck
(or another Merck Company designated by Merck) or the Debt payable to a Third Party assumed from a
Merck Company or owed at the Closing by any Merck Transferred Subsidiary, other than the amount of
Debt consisting of the promissory notes (the “Purchase Promissory Notes”) issued by Merial or the
appropriate Merial Subsidiaries to purchase Merck Contributed Non-U.S. Assets, the Retained
Receivables and the Retained Inventory pursuant to Sections 5.1(a)(ii)(A)(3), 5.1(a)(ii)(C)(l) or
5.1(a)(ii)(C)(2), respectively.

     (C) Retained Receivables and Retained Inventory.

     (1) Retained Receivables. Merck may (in its sole discretion) elect to
retain (i.e., not contribute as part of the Merck Contributed U.S. Assets) certain of its
Receivables (the “Retained Receivables”) selected by it from among the Receivables that
are part of the Merck Contributed U.S. Assets, at face value. To the extent Merck
elects to retain Retained Receivables: Merck shall deliver to RP at the Closing a list of
the Retained Receivables, which list shall include a description in reasonable detail
including the face amount of each such Retained Receivable. Merck shall
use commercially reasonable efforts to collect all Retained
Receivables within ninety (90) days following the Closing Date. After such

60

 

ninety (90) day period, Merck shall furnish to Merial a list of all Retained Receivables that
remain uncollected, together with all information and supporting documentation which Merck has for
each such uncollected Retained Receivable; and Merial shall within five (5) Business Days of
receiving such list, information and documentation, purchase all such outstanding Retained
Receivables from Merck at the face amount thereof (calculated in U.S.$ at the closing midpoint
exchange rates quoted by the London edition of the Financial Times on the Closing Date). Such
purchase shall be made, at Merial’s option, with cash and/or with promissory notes issued to the
seller.

     (2) Retained Inventory. Merck may (in its sole discretion) elect to retain
(i.e., not contribute as part of the Merck Contributed U.S. Assets) certain of its finished goods
Inventory (the “Retained Inventory”) selected by it from among the finished goods Inventory of the
Merck Contributed U.S. Assets. To the extent Merck elects to retain any Retained Inventory, Merck
shall deliver to RP at the Closing a list of the Retained Inventory, which list shall include a
description in reasonable detail including a breakdown of the value of such Retained Inventory.
For purposes of calculation in this Section 5.1(a), the value attributed to the Retained Inventory
shall be calculated in accordance with the Merck Manufacturing Supply Price Formula. On the
Closing Date, Merial shall purchase the Retained Inventory from Merck with promissory notes at a
fair market value price that to the extent possible excludes any intercompany (between Merck
Companies) margin already included in the book value for such Inventories as recorded in the
accounts of the selling Merck Company, except for the markup on standard cost and the adjustment
provided for in the Merck Negotiated Supply Price. To the extent the Inventories cannot be
purchased at a fair market value price that excludes any such margin, the Parties shall

61

 

use commercially reasonable efforts and negotiate in good faith to find and give effect to
a solution (which will not include taking actions that would reduce Merck’s net income
below that which Merck would realize if such Inventories were sold at a price calculated
according to the Merck Negotiated Supply Price) that will eliminate the effect of the
purchase of such Retained Inventory at a price that includes such margin on the net income
of RP. To the extent the price at which the Merial Venture ultimately purchases the
Retained Inventory exceeds the Merck Negotiated Supply Price, such excess shall be
included in the calculation of the Supply Price Adjustment Special Dividend, pursuant to
Section 6.7.

     (D) Non-Contributed Subsidiaries. The Parties hereby agree that
none of Merck’s interests in Johnson & Johnson MSD Consumer
Pharmaceuticals (formerly Centra Healthcare (U.K.)) or Blue Jay CV
(Holland) shall be contributed to the Merial Venture. Merck shall defend,
indemnify and hold harmless the Merial Venture and (only to the extent RP
and its Subsidiaries suffer Damages separate and distinct from Damages
suffered by the Merial Venture) RP and its Subsidiaries from and against
any and all Damages incurred by the Merial Venture or RP and its
Subsidiaries arising out of, based upon or resulting from an action or claim
brought by a Third Party to the extent arising out of, based upon or
resulting from the past, present or future operations of Johnson & Johnson
MSD Consumer Pharmaceuticals (formerly Centra Healthcare (U.K.)) or
Blue Jay CV (Holland).

     (E) Delayed Purchase Assets. Pending the purchase and sale of
a Delayed Purchase Asset and the assumption of the Merck Contributed
Liabilities reasonably attributable thereto in accordance with Section
5.1(a)(ii)(A) (collectively, a “Delayed Transfer”):

62

 

     (1) Merck shall (or shall cause the relevant Merck Subsidiary to) hold all benefits
of such Delayed Purchase Assets to the extent related to the Merial Venture Business as
agent for the Merial Venture and promptly pay to Merial (or a Merial Subsidiary that is
the expected purchaser of such assets as designated by Merial) without any deduction,
set-off or counterclaim, any and all net sums (after netting any amounts contemplated by
clause (2) below to the extent not previously paid or reimbursed by the Merial Venture)
received by the Merck Company on account of the operation of such Assets; and

     (2) Merial shall (or shall cause the relevant Merial Subsidiary to) (at the Merial
Venture’s own cost and for its own account) pay, perform, fulfill and discharge when due
all of the Liabilities, costs, expenses and obligations suffered or incurred by Merck or
any of its Subsidiaries in respect of the ownership or operation of such Delayed Purchase
Asset from the Closing Date until the Delayed Transfer of such Delayed Purchase Asset;
provided, however, that Merck (or the relevant Merck Subsidiary) shall be
responsible for any Damages payable to a Third Party to the extent such Damages result
from Merck’s or any of its Subsidiaries’ negligence, recklessness or willful misconduct in
the operation of such Delayed Purchase Asset, which negligence, recklessness or willful
misconduct occurred prior to the Delayed Transfer of such Delayed Purchase Asset.

     No effect shall be given to clauses (i) or (ii) above if and to the extent that there is a
significant risk that such arrangements would not be in material compliance with applicable Laws if
effect were given thereto, in which case the principles set forth in clause (y) of Section
5.1(a)(ii)(A)(4) shall apply, and the Principals and Merial shall cooperate to seek an alternative
solution designed to provide the Merial Venture with the

63

 

     material benefits (or the substantial equivalent of the benefits of) such Assets and
Liabilities.

     (iii) British United Turkeys, Ltd (“BUT”) (A) Merck shall, subject to the
condition specified in (B) immediately below, assign, transfer, convey and deliver to Merck
Transitory LLC the entirety of the share capital of BUT; provided, however, that
(B) if, as a result of implementing the “BUT Steps”, as defined below, any Merck Company would or
would be reasonably likely to recognize taxable gain in excess of [*] with respect to the
BUT Steps under the terms of (aa) any amendment to Code § 355 and/or the Treasury Regulations
thereunder adopted on or after the date hereof and prior to the Closing, (bb) any proposal of any
such legislation or Treasury Regulations made since January 1, 1997, or (cc) any official notice or
pronouncement with respect thereto made since January 1, 1997, in the case of any of (aa), (bb) and
(cc), indicating that such amendment would have an effective date that would make it applicable to
the BUT Steps, the Parties agree that BUT will be transferred directly to Merial by Merck Sharp &
Dohme (Holdings) Limited in return for an issue of fixed-rate preference shares (the “Preference
Shares”) with a face amount of [*]. The Parties acknowledge that, in either case, BUT
shall not be treated as part of the Merck Contributed Non-U.S. Assets pursuant to clause (ii)
above. The Parties further agree that, if Merial issues such Preference Shares to Merck Sharp &
Dohme (Holdings) Limited, Merial will issue Preference Shares with a face amount of [*] to
IM in consideration for IM’s contribution to Merial hereunder of shares of RM with a fair market
value equal to the fair market value of the Preference Shares received. The Parties agree that,
after said issue, and all other Closing Date share transactions and events, each Principal shall
own, directly or indirectly, exactly the same general ownership interest and Preference Share
interest in Merial.

     For purposes of this Section 5.1(a)(iii), the “BUT Steps” shall mean all or any part of the
following: the distribution of the shares of BUT by its shareholder(s), followed by additional
distribution to shareholders, followed by a

64

 

contribution of the shares of BUT to Merck Transitory LLC, followed by the merger of Merck
Transitory LLC with and into Merial. Whether any Merck Company would or would be
reasonably likely to recognize taxable gain in excess of [*] with respect to the BUT
Steps shall be determined in the good faith judgment of Merck, after having provided to RP
all material and relevant information which is reasonably available to Merck.

     If Preference Shares are issued pursuant to clause 5.1(a)(iii)(B) above, the
Preference Shares shall remain outstanding in perpetuity (unless and until Merial is
liquidated). The Preference Shares shall be entitled to an annual dividend per share such
that the aggregate outstanding Preference Shares shall be entitled to an annual dividend
of: [*], which shall be paid out of Distributable Profits for each Fiscal Year
remaining after payment of the Net Special Dividend, as provided in Section 6.2, and which
dividend shall be cumulative (but shall be paid in any event after payment of the Net
Special Dividend, as provided in Section 6.2). The Preference Shares shall have the
liquidation rights specified in Section 6.11. The Preference Shares shall not be entitled
to any voting rights, except any voting rights which are required under applicable Laws.
The Preference Shares shall not be transferable, except in connection with a Transfer of a
Member’s entire Merial Venture Interest in accordance with Article XVII hereof. The
Association Documents shall be modified to the extent reasonably necessary or appropriate
to implement this Section 5.1(a)(iii).

     (b) RP Contribution. On the terms and subject to the conditions of this
Agreement (and subject specifically to the representations, warranties and covenants made by RP, IM
and RM in this Agreement) and the RP Transfer Agreement, and subject to subsections (i), (ii) and
(iii) below, IM shall, on or prior to the Closing Date, assign, transfer, convey and deliver to
Merial or cause to be assigned, transferred, conveyed and delivered to Merial, the entirety of the
share capital of RM, together with all of RM’s direct and indirect ownership interests in each of
its Subsidiaries as set forth in Schedule 2-11 hereto. As a consequence, and without limitation,
Subsidiaries of Merial

65

 

shall thereby be obligated to pay, perform, fulfill and discharge when due all of the RM
Contributed Liabilities.

     (i) Goubin. The Parties intend that Goubin shall be sold either (x)
by the Merial Venture, in which case Merial shall (and shall procure that the other Merial
Venture Companies shall) cooperate with RP and provide any information or assistance
reasonably requested by RP to find a purchaser for Goubin, or (y) by RP, should RP exercise
its call option described in (B) below.

     (A) Goubin Operations Pending Sale. RP hereby represents, as of
the date hereof and as of the Closing Date, to Merck, Merck SH and Merial that,
since December 31, 1996, Goubin has been operated in the ordinary course of business
(including capital expenditures made in accordance with approved programs)
consistent with past practice and there has not been any material change in the
assets or Liabilities of Goubin (other than the payment of dividends and such
approved programs of capital expenditures), including any material contribution of
assets by RM or ISA of any kind to Goubin, as compared with the balance sheet of
Goubin as of December 31, 1996 set forth in Schedule 5.1B-1. For purposes of this
Section 5.1(b)(i), a “material” contribution of assets means a contribution of
assets in excess of [*]. Merial covenants that, as of the Closing Date and
until the second anniversary of the Closing Date, or the sale of Goubin if earlier,
it shall not cause Goubin to take any action that is outside the ordinary course of
business consistent with past practice and shall not cause Goubin to incur any
additional Debt, except in the ordinary course of business, as compared with the
Debt of Goubin as of the Closing Date, provided that Merial may, upon RP’s request
and subject to the consent of Merck (which consent shall not be unreasonably
withheld), cause an action out of the ordinary course to be taken or a material
contribution of assets to be made if necessary to facilitate the sale of Goubin.
RP shall indemnify the Merial Venture for any costs and expenses incurred by the
Merial Venture in connection with, and shall defend,

66

 

indemnify and hold harmless the Merial Venture for any Damages incurred by the Merial Venture as a
result of, any such action and/or material contribution. RP shall also defend, indemnify and hold
harmless the Merial Venture for any and all Damages (but not for any capital accounting loss
recorded by the Merial Venture in selling Goubin in accordance with this Section 5.1(b)(i)) arising
out of the operation or condition of Goubin before the earlier of (x) the sale of Goubin and (y)
the second anniversary of the Closing Date (except for any such Damages payable to a Third Party
other than the purchaser (or its Affiliates) of Goubin, to the extent resulting from the
negligence, recklessness or willful misconduct of the Merial Venture, including that of the
management of Goubin).

     (B) Purchaser and Timing of Goubin Sale.

     (1) At any time on or prior to the second anniversary of the Closing Date, if a firm offer to
purchase Goubin is received from a Third Party (which may include the employees of Goubin) at a
price that is acceptable to RP and that is greater than or equal to the Goubin Book Value at the
Closing Date plus any amounts contributed by any other Merial Venture Company to Goubin pursuant to
Section 5.1(b)(i) that have not been reimbursed by RP, less the sum of [*] (translated
into FF at the closing midpoint exchange rate indicated in the London edition of the Financial
Times on the Closing Date) and all the dividends paid by Goubin to any other Merial Venture Company
between the Closing Date and the date when such offer is received, then the Merial Venture shall
sell Goubin to such purchaser.

     (2) At any time on or prior to the second anniversary of the Closing Date, RP shall have the
option to purchase Goubin from the Merial Venture for an amount equal to the Goubin Book Value at
the Closing Date plus any amounts contributed by any other Merial Venture Company to Goubin
pursuant to Section 5.1(b)(i) that have not been reimbursed by RP,

67

 

less the sum of [*] (translated into FF at the closing midpoint exchange rate indicated
in the London edition of the Financial Times on the Closing Date) and all the dividends paid by
Goubin to any other Merial Venture Company between the Closing and the exercise by RP of its call
option. If such purchase results in a capital loss to the Merial Venture, RP shall not sell
Goubin to a Third Party at a profit (to the RP Group) for a period of six months after the exercise
of such option. For the avoidance of doubt, the Parties understand that the ownership by RP and
the operation of the current business of Goubin in accordance with this Section 5.1(b)(i) is not
within the scope of the Animal Health Business or the Poultry Genetics Business and is therefore
not subject to the non-competition provisions set forth in Article XV.

     (3) On or within two Business Days after the second anniversary of the Closing Date, if
Goubin has not been sold to a Third Party or RP as provided in (1) or (2) above, then Merck will
have the option, which it may exercise in its own discretion (by notice to RP and Merial sent at
any time prior to the end of the second Business Day after the second anniversary of the Closing
Date, which notice may be conditioned upon the transactions in (1) or (2) above occurring or not
occurring) and will be binding on both Merial and RP, to require Merial (or the Merial Venture
Company that owns Goubin) to sell Goubin to RP for an amount equal to the Goubin Book Value at
Closing Date plus any amounts contributed by any other Merial Venture Company to Goubin pursuant to
Section 5.1(b)(i) that have not been reimbursed by RP, less the sum of [*] (translated
into FF at the closing midpoint exchange rate indicated in the London edition of the Financial
Times on the Closing Date) and all the dividends distributed by Goubin to any other Merial Venture
Company during the two year plus two Business Day period following the Closing Date. If Merck
does not exercise this put option, Goubin shall continue as an integral part of the Merial Venture
Business after two years and the

68

 

indemnification obligations of RP under this Section 5.1(b)(i) in connection with the sale of
Goubin shall terminate.

     (C) Goubin Sale for RP’s Account.

     (1) Special Dividend to RP. In the case of the sale of Goubin pursuant to (B) above,
Merial shall credit to the RP Member in respect of the year in which the sale of Goubin occurs a
Special Dividend equal to the cash (or the fair market cash equivalent of any non-cash proceeds)
received by the Merial Venture (whether from a Third Party purchaser or from RP) for the sale of
Goubin, less any costs, expenses or Damages (including Taxes, fees and registration fees) incurred
by the Merial Venture in connection with such sale.

     (2) Purchase Agreement, etc. The sale of Goubin shall be by means of the sale of its
entire capital stock, the sale of all its assets subject to all its Liabilities, or any
substantially similar transaction; provided, however, that if the Principals agree
to a partial sale of Goubin, they shall adjust the mechanism set forth in this Section 5.1(b)(i) as
they deem appropriate. Any sale of Goubin shall be without any recourse against the Merial Venture
except as to title matters and except as to any Damages payable to a Third Party other than the
purchaser (or its affiliates) of Goubin to the extent resulting from the negligence, recklessness
or willful misconduct of the Merial Venture, including of the management of Goubin. Subject to the
following sentence, all Damages, Liabilities and contingencies associated with a sale of Goubin
pursuant to this Section 5.1(b)(i) above suffered or incurred by Merck, Merial and their respective
Subsidiaries shall be for the account of RP. RP shall (and no Merial Venture Company shall), in
any contract for the sale of Goubin to a Third Party purchaser, undertake to indemnify the
purchaser thereof for all breaches of representations, warranties or covenants in such contract
related to Goubin and its sale; provided that RP shall have approved all of

69

 

such representations, warranties and covenants prior to the contract being concluded; and
further provided that Merial shall indemnify RP for any Damages owed to
such Third Party purchaser of Goubin to the extent arising from Damages payable to a Third
Party other than the purchaser (or its Affiliates) of Goubin to the extent resulting from
the negligence, recklessness or willful misconduct of the Merial Venture, including of the
management of Goubin. Except to the extent Merial has an obligation to indemnify RP
pursuant to the preceding sentence, RP shall defend, indemnify and hold harmless the Merial
Venture and (to the extent they suffer any Damages distinct from those suffered by the
Merial Venture) Merck and its Subsidiaries for all Damages suffered or incurred by the
Merial Venture or Merck and its Subsidiaries arising out of, based upon or resulting from
such sale.

     The “Goubin Book Value” at any date shall equal the book value of Goubin on such date in the
accounts of ISA, determined according to U.S. GAAP applied consistently with the principles used to
calculate Goubin’s book value in the December 31, 1996 balance sheet of ISA. RP represents and
warrants that the insurance claim made by Goubin with respect to damages in connection with a fire
at a hatchway in Plougenast ([*]) was finally resolved and paid to Goubin
prior to the date of this Agreement.

     (ii) Certain RM Liabilities and Receivables Excluded. Notwithstanding Sections
5.1(b) and (c), RM shall, prior to the Closing, (A) assign to RP (or another RP Company designated
by RP), and RP shall assume and pay, perform and discharge when due, the payable to Sanofi of RM,
which is described on Schedule 5.1B-2 (the “Sanofi Payable”), and (B) assign to RP (or another RP
Company designated by RP) the related financial receivable of RM due by RM’s unconsolidated
Subsidiary Rhône Mérieux Animal Health Company Ltd. (China) (“RM China”), which is described in
Schedule 5.1B-2 (the “RM China Financial Receivable”). In addition, as from the Closing Date, RP
(or another RP Company designated by RP) will be entitled to an amount equal to the difference
between

70

 

the Sanofi Payable and the RM China Financial Receivable as of the Closing Date ([*]), which amount will be paid by RM China to RP over time only from and to the extent of the
proceeds of specific assets that are part of the current assets held by RM China as of the Closing
Date (the “RP Chinese Assets”). The RP Chinese Assets shall consist of specific trade receivables,
Inventories and/or other current assets each as existing on the Closing Date in the books of RM
China. At the Closing, RM shall provide Merck with a list and description in reasonable detail
(including book value) of the RP Chinese Assets. The aggregate book value of the RP Chinese Assets
shall be equal to or less than the difference between the Sanofi Payable and the RM China Financial
Receivable. The Parties acknowledge that the RP Chinese Assets are specifically allocated to the
reimbursement of RP and that each time any of the RP Chinese Assets is sold for cash or collected
for cash by RM China, the net proceeds of such asset will be used promptly upon their being
received to reimburse RP to the extent provided in this Section 5.1(b)(ii). The Parties
understand that the only obligation of RM China is to sell or collect the RP Chinese Assets in the
ordinary course of business, without any extraordinary sale or litigation and without recourse to,
or any other obligation of, the Merial Venture. RP represents and agrees that, as indicated in
Schedule 5.1B-2, at December 31, 1996, the amount outstanding under the RM China Financial
Receivable is [*]. The Parties agree that such
RM China Financial Receivable is deemed to be Debt. The Parties further agree that in the event
the aggregate of the values of all the RP Chinese Assets as recorded in the books of RM China on
the Closing Date is less than the amount equal to the difference between (x) the Sanofi Payable and
(y) the RM China Financial Receivable, the amount (the “RP Chinese Assets Value Shortfall”) by
which the book value of all the RP Chinese Assets is less than such difference shall become a Debt
obligation payable by RM to RP and such amount shall be deemed to be Debt. The Parties agree that
the proceeds collected with respect to each RP Chinese Asset that is paid to RP pursuant to this
Section 5.1(b)(ii) shall not exceed the value of each such RP Chinese Asset as recorded in the
books of RM China on the Closing Date.

71

 

     (iii) Central Biologics Inc. RM represents that (x) Select Laboratories,
Inc., a Subsidiary of RM (“Select”), is currently in the process of acquiring Central
Biologics Inc. (“Central Biologics”) for a purchase price of [*] (this acquisition
being the “Central Biologics Acquisition”); and (y) as part of the Central Biologics
Acquisition, [*]. The Parties hereby agree that both the Central Biologics
Acquisition and the Central Biologics Consulting Agreement are entered into for the account
of Merial. As a result, the Parties further agree that (aa) any Debt assumed by RM, Select
or any other Subsidiary of RM to acquire Central Biologics, (bb) any cash or cash
equivalents, if any, used by Select or any other Subsidiary of RM to acquire Central
Biologics shall be added to the RM Closing Cash when determining the actual contributions of
the Parties in accordance with Sections 5.3 and 6.8, (cc) any cash or cash equivalents
included in Central Biologics upon completion of its acquisition by RM, Select, or any
Subsidiary of RM shall be excluded from the RM Closing Cash, and (dd) any Debt included in
Central Biologics upon completion of its acquisition by RM, Select or any other Subsidiary
of RM, shall not be included in the RP Outstanding Debt.

     (c) Contributed Assets Free of Debt. The Merck Contributed Assets, on the one hand,
and RM and its Subsidiaries, on the other hand, shall be contributed to the Merial Venture together
with the assumption of or the continued obligation for the Merck Contributed Liabilities and the RM
Contributed Liabilities, respectively. Except as set forth in Section 5.2 or as provided for in
Article VII, however, such respective contributions shall be free of (i) any related financial
indebtedness (“Debt”), including any Liability, contingent or otherwise, for borrowed money, any
obligations in respect of or evidenced by bonds, debentures, notes, letters of credit or similar
instruments and any obligations under finance lease obligations (as defined by U.S. GAAP).

     (d) Currency Exchange for Asset Contributions. The respective contributions of each
Group to the Merial Venture shall be calculated in U.S. dollars as of the Closing

72

 

Date. The value of any contribution not denominated in U.S. dollars shall be converted into U.S.
dollars at the closing midpoint exchange rate quoted by the London edition of the Financial Times
on the Closing Date, or as otherwise agreed upon. Subject to Section 5.2(c), all other necessary
currency conversions in respect of the value of the respective contributions (e.g., to English
pounds sterling or French francs) shall also be based on the closing mid-point exchange rates
quoted by the London edition of the Financial Times on the Closing Date, or as otherwise agreed
upon.

SECTION 5.2 Debt Contributions

     (a) Merck Debt Contribution. On the terms and subject to the conditions of this
Agreement, Merial shall (or Merial shall, in accordance with the terms of this Agreement, cause one
or more Subsidiaries of Merial to), on the Closing Date, assume on behalf of and/or in favor of
Merck or a Merck Subsidiary, and shall pay, perform and discharge when due, all Liabilities related
to the “Merck Contributed Debt”, as defined below. The “Merck Contributed Debt” shall consist of
(and its aggregate amount shall be calculated by adding the amounts of): (i) the Purchase
Promissory Notes, as defined in Section 5.1(a)(ii)(B), if any, (ii) the Merck Accrued Tax
Liabilities, as defined in Section 5.1(a)(ii)(B), and (iii) the Merck Other Debt, as defined in
Section 5.1(a)(ii)(B). The Purchase Promissory Notes shall be on substantially the same terms and
conditions as the Merck Interim Financing described in Section 5.2(d) (except that the Purchase
Promissory Notes shall not be subject to reborrowing to the extent repaid, i.e., not a revolving
credit).

     (b) RP Debt Contribution. On the terms and subject to the conditions of this
Agreement, RM and its Subsidiaries shall, on the Closing Date, have Liability (the “RP Contributed
Debt”) (i) for Debt consisting of (and its aggregate amount shall be calculated by adding the
amounts of) the “RM Intercompany Debt” (as defined below), the “RM Outstanding Debt” (as defined
below), the RM China Financial Receivable and the RP Chinese Assets Value Shortfall, if any, and
(ii) for the “RM Accrued Tax Liabilities” (as defined below).

73

 

     The “RM Intercompany Debt” shall be RM’s estimate as of the Closing Date of the aggregate
principal amount equal to: [*] (the “RP Negotiated Debt”) plus the estimated
amount of “RM Closing Cash” (as defined below) and minus the estimated sum of (A)
the “RM Outstanding Debt”, (B) the estimated net amount (after netting the payables and the
receivables) equal to the accrued Liabilities for Taxes (excluding deferred Taxes) of RM and for RM
Transferred Subsidiaries at the Closing Date (the “RM Accrued Tax Liabilities”), (C) the RM China
Financial Receivable as described in Section 5.1(b)(ii), and (D) without duplication of (C), the RP
Chinese Assets Value Shortfall (as defined in Section 5.1(b)(ii)). The RM Intercompany Debt shall
not be subject to any covenants and shall be on substantially the same terms and conditions as the
RP Interim Financing described in Section 5.2(d) (except that this Debt shall not be subject to
reborrowing to the extent repaid, i.e., not a revolving credit).

     The “RM Outstanding Debt” shall consist of (x) the sum of the aggregate principal amount
outstanding at Closing and any accrued unpaid interest or other amounts, calculated as of the
Closing Date, in respect of the Debt owed by RM or its Subsidiaries to Third Parties as reflected
on the December 31, 1996 balance sheet included in the RM Financials, and (y) without duplication
of any Debt included in (x) above, any other Debt owed by RM or its Subsidiaries at the Closing
Date less (without duplication) (aa) any Debt owed by Goubin on the Closing Date, (bb) any
Debt incurred by RM, Select or any other Subsidiary of RM to pay for the Central Biologics
Acquisition, and (cc) any Debt owed by Central Biologics on the Closing Date. RP shall obtain any
consents or waivers required under the terms of the RM Outstanding Debt to give effect to the
Transactions (so that the RM Outstanding Debt is not and does not become in default and does not
give the counterparty to any of the RM Outstanding Debt any rights of termination, amendment,
acceleration, suspension, revocation or cancellation) and RP shall pay any and all costs and
expenses, including any increased interest expenses, penalties or charges, necessary to obtain such
consents or waivers. Subject to the preceding sentence, the “RM Outstanding Debt” shall continue
on its stated terms and conditions after the Closing.

74

 

     The “RM Closing Cash” shall be equal to the cash and the fair market value of cash equivalent
items contributed by RM and its Subsidiaries to the Merial Venture, but shall exclude (aa) the RM
Asset Sale Proceeds, as defined in Section 8.9(a), (bb) the cash and cash equivalents items owned
by Goubin on the Closing Date, (cc) any cash and cash equivalent items owned by Central Biologics
upon completion of its acquisition by RM, Select or any other Subsidiary of RM, and (dd) any
proceeds from the Diagnostic Disposal.

     In the event Goubin is not sold pursuant to, and within the time periods specified in, Section
5.1(b)(i) and remains part of the Merial Venture, the Parties shall at such time negotiate in good
faith to find and give effect to a solution that will take account of the Debt of, and the cash and
cash equivalent items that were owned by, Goubin on the Closing Date.

     (c) Currency Exchange for Contributed Debt. The currency exchange rates used to
calculate the U.S. dollar value of any Merck Contributed Debt, Retained Receivables, Retained
Inventory or RP Contributed Debt not denominated in U.S. dollars shall be the closing midpoint
exchange rates quoted by the London edition of the Financial Times on the Closing Date, or as
otherwise agreed between the Parties.

     (d) Interim Financing. Both RP and Merck shall provide, or shall arrange with
outside financial institutions to provide, the Merial Venture with a revolving working capital
financing facility available when needed as from the Closing Date (the “RP Interim Financing” and
the “Merck Interim Financing”, respectively), with a maximum aggregate principal amount to be
outstanding from time to time of [*] for each such facility. Should Merial request
an increase of the maximum aggregate principal amount of the RP Interim Financing and the Merck
Interim Financing, RP and Merck agree to discuss in good faith the terms and conditions of any such
increase and whether any such increase will be provided. The Parties agree that the RP Interim
Financing shall not be included in, and shall be in addition to, the RP Contributed Debt and the
Merck Interim Financing shall not be included in, and shall be in addition to, the Merck
Contributed Debt. The RP Interim Financing and the Merck Interim Financing shall have

75

 

substantially equivalent terms and conditions, both be available through the earlier of December
15, 1997 and the date that is six (6) months after the Closing Date, at which earlier date all
amounts outstanding thereunder shall be due and payable, and bear interest at the [*] in which the advances that are part of the interim financing are made [*]. Merial shall use commercially reasonable efforts to establish its own financing as soon
as practicable after the Closing to be used, first, to repay the RP Contributed Debt and the Merck
Contributed Debt, second, to repay the RP Interim Financing and the Merck Interim Financing, with
the RP Interim Financing and the Merck Interim Financing being repaid simultaneously on the same
terms and conditions and, third, for other purpose of the Merial Venture Business. The Principals
shall meet before the Closing to determine further terms and conditions of the RP Interim Financing
and the Merck Interim Financing.

SECTION 5.3. Preparation and Audit of Closing Balance Sheets

     (a) Preparation of Closing Balance Sheets — General. As soon as possible after
the Closing Date, and in no event more than thirty (30) Days after the Closing Date, each of RM and
Merck shall prepare and deliver to each other a consolidated balance sheet (the “RM Closing Balance
Sheet” and the “Merck Closing Balance Sheet”, respectively, and, collectively, the “Closing Balance
Sheets”) for RM and the Merck Contributed Business, respectively. These balance sheets shall
include as special purpose line items (i) the RM Closing Cash and the Merck Closing Cash, (ii) the
RM Intercompany Debt, the RM Outstanding Debt, the RM China Financial Receivable, the RP Chinese
Assets Value Shortfall and the Merck Other Debt, and (iii) the RM Accrued Tax Liabilities and the
Merck Accrued Tax Liabilities. The RM Intercompany Debt, the RM Outstanding Debt, the RM China
Financial Receivable, the RP Chinese Assets Value Shortfall, the RM Accrued Tax Liabilities and the
RM Closing Cash shall be used to calculate the “RM Actual Contributed Net Debt Variance” and the
“Contributed Debt Adjustment Special Dividend”, both as defined in Section 6.8 below. The Merck
Accrued Tax Liabilities, the Merck Other Debt and the Merck Closing Cash shall be used to calculate
the “Merck Actual Contributed Net Debt Variance” and the “Contributed Debt Adjustment Special
Dividend”, both as defined in Section 6.8 below. Merck shall also provide RP with a list

76

 

of all Delayed Purchase Assets, which list shall include a description in reasonable detail of all
such Delayed Purchase Assets and an estimate of the fair market value of all the Delayed Purchase
Assets on an aggregate basis.

     (b) Audit of Closing Balance Sheets and Retroactive Closing Financial Statements.
As soon as possible after the preparation of the Closing Balance Sheets and the Retroactive Closing
Financial Statements, as defined in Section 6.3, Merck shall send the Merck Closing Balance Sheet
and the Merck Retroactive Closing Financial Statements to its accounting firm and to RM, and RM
shall send the RM Closing Balance Sheet and the RM Retroactive Closing Financial Statements to its
accounting firm and to Merck. Each of RM’s and Merck’s accounting firms shall promptly be provided
with any relevant financial data they may reasonably request. Each of RM’s and Merck’s accounting
firms shall have a maximum of sixty (60) days to conduct an audit of the Closing Balance Sheets and
the Retroactive Closing Financial Statements of their respective client, which audit shall include,
among other things, (x) an audit of the Debt and the cash and the cash equivalent items contributed
by each Party to the Merial Venture, (y) at the request and expense of RP, an analysis of whether
or not all the Merck Contributed Assets are fairly reflected in all material respects in the Merck
Closing Balance Sheet and, to the extent not included therein, have been specified by Merck to RP
as Delayed Purchase Assets, and (z) an audit of the Retroactive Closing adjustments to ensure such
adjustments have been calculated in accordance with the provisions set forth in Section 6.3 and in
Exhibit XIX.

     As soon as possible, and in no event more than sixty (60) days after being sent the Closing
Balance Sheets and the Retroactive Closing Financial Statements, each of RM’s and Merck’s
accounting firms shall make available to the other their working papers, reports and comments on
the Closing Balance Sheets and the Retroactive Closing Financial Statements. In the event there
are any disagreements, the Parties will then have twenty (20) Business Days to agree on the changes
to be made to the Closing Balance Sheets and/or the Retroactive Closing Financial Statements and
resolve any disputes arising between them. In the event there is any unresolved dispute at the end
of this twenty (20) Business Day period, the Parties will jointly submit such unresolved disputes

77

 

to the Board of Directors. The Board of Directors shall then have ten (10) Business Days to
resolve such disputes. In the event there are any unresolved disputes at the end of this further
ten (10) Business Day period, the Board of Directors shall have five (5) Business Days to engage a
“Big Six” accounting firm to resolve any such dispute, except that (i) if the Board of Directors
cannot reach agreement on the selection of such accounting firm, then such accounting firm shall be
selected and appointed by the ICE (which selection and appointment shall be final and binding on
the Board of Directors and on the Principals) and (ii) the firm so selected and appointed may not
be the primary accounting firm for Merck, RP, RM or Merial. Each of the Principals shall submit to
the selected accounting firm their detailed calculations and such firm shall promptly be provided
with any relevant financial data that it may request. The selected accounting firm shall act as
expert and shall have twenty (20) Business Days to resolve all the disputes, and such resolution
shall be final and binding on the Parties and the Board of Directors. The fees and reasonable
expenses of the selected accounting firm shall be split equally between Merck and RP.

SECTION 5.4. Alternative Tax Structuring and Tax Planning

     (a) Changes in Law. With respect to Merial or any other Merial Venture Company, if,
due to any change or proposed change in applicable Law (including, without limitation, actions of
any Public Authority) after the Closing, the continuation of the structure described in Section 1.3
and Article III entails (or, in the case of a proposed change, would, if enacted, entail)
materially adverse tax or other legal consequences to a Principal or its Affiliates, or a
significant risk thereof, at the request of such Principal the Parties shall use commercially
reasonable efforts to agree on an appropriate alternative structure that will be designed, to the
extent possible, to minimize such adverse consequences to the requesting Principal and its
Affiliates but have no less favorable economic, commercial and legal characteristics to the other
Principal and its Affiliates as the structure described elsewhere in this Agreement and the
Ancillary Agreements.

     (b) Restructurings to Minimize Taxes.

78

 

     (i) General. Each Party shall bear the tax consequences of its transfers to
the Merial Venture and (unless otherwise agreed in writing) the performance of its obligations
under this Agreement and any and all Ancillary Agreements to which it is a party or by which it is
bound. [*].

     (ii) Alternative Contribution of Merck Contributed Non-U.S. Assets. Without
limiting the generality of Section 5.4(b)(ii) and notwithstanding the provisions of Sections
1.3(a)(i)(B), 1.3(c), and 5.1, and subject to the conditions set forth in (t), (u), (v), (w), (x),
(y) and (z) below, Merck may elect to exclude from the Non-U. S. Merck Contributed Assets to be
sold to the Merial Venture and/or from the Merck Contributed Liabilities reasonably attributable
thereto assumed by the Merial Venture, certain of such assets and Liabilities [*], provided that (t) intangible assets included in the Merck Contributed Assets may
not be so excluded, (u) Merck identifies in reasonable detail in writing to RP on or prior to the
Closing Date such assets and/or liabilities; (v) an arrangement with respect to such assets and/or
liabilities is entered into among the Parties or their Affiliates and/or other adjustments are made
to the terms and conditions of the transactions contemplated by this

79

 

Agreement so that they have, in the aggregate, no less favorable economic, commercial and
legal characteristics to RP, the Merial Venture and their respective Affiliates as the
structure described elsewhere in this Agreement; (w) RP consents in writing to this
alternative prior to its implementation (which consent shall not be unreasonably withheld
or unreasonably delayed if, in RP’s reasonable opinion, all the other conditions specified
in this clause (ii) have been satisfied); (x) [*]; (y) Merck
shall be responsible for all out-of-pocket costs and fees reasonably incurred by RP or any
of its Subsidiaries in assessing the alternative structure proposed by Merck pursuant to
this clause (ii); and (z) no such alternative structure shall be proposed if such
alternative structure would result in such assets and/or Liabilities being transferred to
the Merial Venture after December 31, 1997.

     (iii) Except as provided elsewhere in this Agreement or in the Ancillary Agreements,
each Party and its Affiliates will, however, ultimately be responsible for its own Taxes.

SECTION 5.5. Certain U.S. Tax Matters

     (a) Designation of Tax Matters Partner. The Merck Member is hereby designated
as the “Tax Matters Partner” under Section 6231(a)(7) of the Code to manage the administrative Tax
proceedings conducted at the Merial Venture level by the IRS with respect to Merial Venture
matters. The Merck Member is specifically directed and authorized to take whatever steps the Merck
Member, in its sole discretion, deems necessary or desirable to assure the Merck Member’s
designation as the Tax Matters Partner, including, without limitation, filing any forms or
documents with the IRS and taking such other action as may from time to time be required under
Treasury Regulations. Expenses of administrative proceedings relating to the determination of
Merial Venture items at the Merial Venture level undertaken by the Merck Member in accordance with
this Section 5.5 will be deemed to be Merial Venture expenses.

80

 

     (b) Tax Elections. All Tax elections required or permitted to be made under the Code
and any applicable U.S. federal, state or local Tax law with respect to the Merial Venture (or any
of its Subsidiaries) shall be made by the Tax Matters Partner, subject to the express prior written
approval of the RP Member, which approval shall not be unreasonably withheld, and any decision with
respect to the treatment of Merial Venture transactions on the Merial Venture’s U.S. federal, state
or local Tax Returns shall be made by the Members jointly. The RP Member hereby approves the
election to classify Merial as a partnership for U.S. Tax purposes, as well as any other election
to classify any other Merial Venture Company (other than BUT) which is an eligible entity as either
a partnership or branch, as the case may be; provided that no such election shall result in
increased Tax Liabilities or exposure for RP; and further provided that no such election
shall require any restructuring of or other company action affecting any such Merial Venture
Company. The RP Member also hereby approves any action the Tax Matters Partner may deem necessary
in its sole discretion to give effect to any election approved pursuant to the preceding sentence.
RP will (or cause its Subsidiaries to) provide to the Tax Matters Partner and sign all documents
necessary to give effect to all elections to be made pursuant to this Section 5.5(b).

     (c) Allocations of Income, Gain or Loss

     (i) Net Income. For U.S. Tax purposes, net income with respect to any
taxable period shall be allocated as follows:

     (A) First, to the Members in proportion to the excess, if any, of (i) the
cumulative amount paid to each Member pursuant to Section 6.2 through the date the
Net Special Dividend is calculated after the closing of such period in respect of
such period, over (ii) the cumulative amount previously allocated to such Member in
respect of such period pursuant to this paragraph (A) until such excess has been
eliminated;

     (B) Second, to the holders of any Preference Shares (if issued pursuant to
Section 5.1(a)(iii)), proportionately, in an amount equal to the

81

 

amount, if any, of dividends paid thereon during such period (whether such dividends
represent payment of a current or accumulated dividend thereon); and

     (C) Third, 50% to each of the Members, as set forth in Section 6.1 hereof.

     (ii) Net Loss. For Tax purposes, net loss with respect to any taxable period
shall be allocated 50% to each of the Members, as set forth in Section 6.1 hereof.

     (iii) Tax Adjustments. In the event that the Merial Venture’s income, gains,
losses, deductions or credits are adjusted by any Taxing Authority by reason of any transaction
between one or more Members and/or the Merial Venture, including adjustments pursuant to Section
482 of the Code or similar provisions under state, local or foreign law (any such adjustment herein
being referred to as a “Tax Adjustment”), the allocation of any item of gross income, gain, loss,
deduction or credit resulting from such Tax Adjustment (either as the result of a primary or
correlative adjustment) and the treatment of any deemed transfers of value between or among the
Merial Venture and one or more Members (including deemed contributions to and deemed distributions
from the Merial Venture on account of such Tax Adjustment) shall be governed by this Agreement.
Allocations, including allocations of items of gross income and the treatment of deemed transfers
of value between or among the Merial Venture and the Members shall be made, to the extent possible,
in an appropriate manner by the Tax Matters Partner so as to avoid any Tax consequences from a Tax
Adjustment to a Member who is not affected by such Tax Adjustment. In the event that any Tax
Adjustment results in an increase in the Merial Venture’s gross income, such gross income shall be
allocated as an item of gross income under Code Section 702(a)(7) to the Member whose income is
adjusted in connection with such Tax Adjustment to the Merial Venture’s income and the Merial
Venture shall be treated as making a deemed transfer of value that is treated as a distribution to
such Member in the

82

 

same amount. In the event that any Tax Adjustment results in an increase in an item of
Merial Venture deduction or loss, such deduction or loss shall be allocated as an item of
deduction under Code Section 702(a)(7) to the Member whose income is adjusted in connection with such Tax Adjustment to the Merial
Venture’s income and such Member shall be treated as making in the same amount a deemed
transfer of value that is treated as a contribution to the Merial Venture. In the case of a
deemed transfer of value by the Merial Venture to a Member that is treated as a guaranteed
payment as a result of a Tax Adjustment that reduces an item of the Merial Venture’s loss or
deduction, the deduction attributable to such guaranteed payment shall be allocated in the
same manner the item of loss or deduction reduced by the Tax Adjustment was allocated.

     (d) Capital Accounts. A separate capital account shall be established and
maintained for each Member. Maintenance of capital accounts is intended for U.S. Tax reporting
purposes only and has no application to any other provision of this Agreement or the interpretation
thereof.

     (i) The initial balance of each capital account shall be zero.

     (ii) The capital account of each Member shall be increased by (x) any capital
contribution by such Member when such capital contribution is made and (y) the net
income allocated to such Member pursuant to Section 5.5(c)(i).

     (iii) The capital account of each Member shall be reduced by (x) the amount of any
distribution of cash or the fair market value of any property (net of any liability secured
by such property that the Member is considered to assume or take subject to under Section
752 of the Code) distributed to such Member when such distribution is made and (y) the net
loss allocated to such Member pursuant to Section 5.5(c)(ii).

     (iv) The capital account of each Member shall be adjusted to reflect any
adjustment to the value of the Merial Venture’s assets attributable to the

83

 

application of Sections 732, 734 or 743 to the extent required pursuant to Treas. Reg. §
1.704-1(b)(2)(iv)(m).

     (v) Except as otherwise provided in this Agreement, whenever it is necessary to
determine the capital account of any Member, the capital account of such Member shall be
determined after giving effect to the allocations of net profit, net loss and other items
realized prior or concurrent to such time (including, without limitation any net profits
and net losses attributable to adjustments to values with respect to any concurrent
distribution), and all contributions and distributions made prior or concurrent to the time
as of which such determination is to be made.

     (vi) No Principal or Member shall have any obligation to Merial or any Merial
Venture Company, the other Principal, the other Member or to any other Person, including,
without limitation, any creditors of the Merial Venture, to restore or otherwise make good
any negative balance in any Member’s capital account.

     (vii) Distributions in liquidation of the Merial Venture shall be made in
accordance with capital accounts; [*].

     (e) Certain Tax Benefits. For U.S. federal Tax purposes, the Principals, the
Members and Merial agree (and Merial agrees to cause the Merial Venture Companies) to treat the
prices charged to the Merial Venture for products purchased under the Merck Supply Agreement and
the RP Ag Supply Agreement as the Merial Venture’s “cost” therefor. In furtherance thereof, the
Principals, the Members and Merial agree (and Merial agrees to cause the Merial Venture Companies
to agree) that any benefits derived under Section 936 of the Code or any successor Code section
thereof by Merck Member or any Affiliate of Merck Member on the manufacture of any products sold to
the Merial

84

 

Venture pursuant to the Merck Supply Agreement shall be for the benefit of Merck Member and not for
the benefit of the Merial Venture, the RP Member nor any other member of the RP Group.

85

 

ARTICLE VI

PROFIT AND LOSS ALLOCATIONS; DIVIDENDS

SECTION 6.1. General Profit and Loss Principles

     As a general principle, the Parties have agreed that the profits and losses of the Merial
Venture shall be allocated to the Members in such a way that each Member will be entitled to 50.0%
of the profits and losses of the Merial Venture, subject to the specific adjustments set forth in
this Agreement and to such other adjustments as the Members’ Meeting may determine.

     For accounting purposes only and for no other purpose, the Members intend that, for each
accounting period, each Member’s share of Merial’s net income will include fifty percent (50%) of
Merial’s net income (after subtracting Net Special Dividends and dividends on Preference Shares)
plus any Net Special Dividends and dividends on Preference Shares made to that Member that may be
income or expense to such Member.

SECTION 6.2. Special Dividends

     (a) Special Dividends Generally. The Parties have agreed to certain financial
arrangements that shall be exceptions to the general principle set forth in Section 6.1 of a 50/50
allocation of profits as between the Members. Certain of these financial arrangements (set forth
in Sections 5.1(b)(i)(C)(i) [Goubin], 6.3 through 6.9, 7.1(b), (c) and (d), 7.1(f)(ii) and (vii),
7.2(c) and (e), 7.4, 7.5(a)(i), 7.5(b)(i), 7.5(c) and 14.19 [Tax Reserves Adjustment] of this
Agreement and in Sections 3.5 and 4.4 of the Merck Employee Leasing Agreement shall give rise to
special distributions or dividends (each, a “Special Dividend” and, together, the “Special
Dividends”) which shall be calculated and credited to one or the other of the Members in accordance
with the provisions of the relevant Sections. Each of the Special Dividends is creditable in
respect of one or more Fiscal Years. For each Fiscal Year in respect of which one or more Special
Dividends is to be credited, all the Special Dividends to be credited in respect of such year shall
be

86

 

calculated and netted together in accordance with Section 6.2(b) and the resulting “Net Special
Dividend” shall be paid in accordance with Section 6.2(c). A numerical example of the Net Special
Dividend is provided in Exhibit XVIII hereto.

     (b) Calculation of Net Special Dividend. Upon the earlier of (x) the approval
by the Board of Directors of Merial’s consolidated financial statements for any Fiscal Year, and (y)
the date that is one (1) month after the completion of the preparation of such financial statements
by the management of Merial (it being understood that preparation of such financial statements
shall be completed no later than the twentieth (20th) Business Day following the end of the Fiscal
Year), but no later than sixty (60) days after the end of such Fiscal Year, Merial shall, and if
Merial does not, each of the Principals may, promptly (based upon such financial statements and/or
any other reasonably necessary or available financial information, which shall be made available to
both Principals by Merial upon any request by either Principal), and in any case within twenty (20)
Business Days of such earlier date, (such deadline being the “Special Dividend Calculation Date”)
calculate each of the Special Dividends that is applicable in respect of such year. The “Net
Special Dividend” for a particular Fiscal Year shall be the single payment payable to either the RP
Member or the Merck Member that results from the netting of all such Special Dividends, which shall
be calculated by taking the difference between the sum of all the Special Dividends, if any,
creditable to one of the Members in respect of such year and the sum of all those, if any,
creditable to the other Member in respect of such year. The Net Special Dividend shall be
calculated in U.S. dollars, using, as necessary, the exchange rate of the last day of the Fiscal
Year, except as otherwise provided in this Agreement. The Net Special Dividend shall be payable
to the Member to which the greater dollar aggregate amount of Special Dividends in respect of such
year is payable. Notwithstanding Article XVIII, any disagreements between the Principals as to the
calculation of any of the Special Dividends or of the Net Special Dividend shall be resolved
exclusively pursuant to Section 6.2(d), but without modifying or limiting other rights or remedies
of the Parties under other provisions of this Agreement.

87

 

     (c) Payment of the Net Special Dividend. The Net Special Dividend in respect of
any Fiscal Year shall be paid by Merial out of Distributable Profits in the form of a preferential
dividend. No other dividends or distributions to the Members shall be paid or declared by Merial
until the entirety of any outstanding Net Special Dividend has been paid in full. If the Net
Special Dividend to be paid in respect of any year is greater than the Distributable Profits
available for distribution at the time dividends are to be paid in respect of such year, then the
Net Special Dividend shall be paid to the appropriate Member to the extent of the available
Distributable Profits (with the result that no other dividends shall be paid in respect of such
year), and the unpaid balance shall be increased by an amount equal to interest calculated at a
rate equal to the [*] accruing from April 15 of the year next
following the year in question until such time as it is paid in full. In the event a Principal
wishes to receive payment of the Net Special Dividend in a currency different from the U.S. Dollar,
such Principal shall so notify Merial in writing sixty (60) days in advance of the payment date of
the Net Special Dividend, and Merial shall convert the Net Special Dividend to the desired payment
currency on the actual date of payment (at the then spot exchange rate). In the event of a dispute
between the Principals as to the calculation of any Special Dividend or of the Net Special Dividend
in respect of any year, the Principals shall follow the procedure described in 6.2(d) and, when the
dispute is resolved, the Net Special Dividend will, together with the corresponding amount
calculated as interest mentioned above, to the extent of available Distributable Profits, be paid
through a partial Net Special Dividend payment. In the event any unpaid balance of a Net Special
Dividend payable with respect to any year remains at the time the Net Special Dividend to be paid
in respect of the following year is payable, such Net Special Dividend in respect of the following
year shall be equal to the amount resulting from netting (or adding, as appropriate) such unpaid
balance (and any accrued amount calculated as interest thereon) with the Net Special Dividend
calculated for such following year in accordance with Section 6.2(b). Any undisputed amount in the
calculation of the Net Special Dividend will be paid immediately, and any disputed amount shall be
subject to the Special Dividend Calculation Dispute Resolution described in Section 6.2(d) below.

88

 

     (d) Special Dividend Calculation Dispute Resolution. In the event there is any
dispute between the Principals as to the calculation of any Special Dividend or of the Net Special
Dividend in respect of any year, the Principals shall meet and negotiate in good faith to resolve
such dispute. If the dispute has not been resolved within thirty (30) days of the Special Dividend
Calculation Date, then either Principal may submit such dispute to arbitration as set forth below
in this Section 6.2(d). In connection with any such dispute, a “Big Six” accounting firm
acceptable to both the Principals shall be engaged to resolve the dispute, except that (i) if the
Principals cannot reach agreement on the selection of such accounting firm, then such accounting
firm shall be selected and appointed by the ICE (which selection and appointment shall be final and
binding on the Parties), and (ii) the firm so selected and appointed may not be the primary
accounting firm for Merck, Merial, RM or RP. Each of the Principals shall submit to the accounting
firm selected their detailed calculations and such firm shall promptly be provided with any
relevant financial data of the Merial Venture or of either of the Principals that it may request.
In making its determination, the accounting firm shall refer to the methods of calculation set
forth in this Article VI and to the numerical examples for calculating each of the Special
Dividends and the Net Special Dividend set forth in Exhibit XVIII. The accounting firm shall be
jointly requested to make its decision within thirty (30) days of having been selected. The
decision of the accounting firm selected by the Principals or the ICE shall be final and binding on
the Parties on any issue relating to the calculation of any Special Dividend or of the Net Special
Dividend. The fees and reasonable expenses of the accounting firm shall be borne by the losing
party; if the dispute is not resolved solely in favor of one party, then the parties shall share
such fees and reasonable expenses equally. Pending such decision of the accounting firm, Merial,
the Members and the Board of Directors shall continue to fulfill all their obligations under
applicable Laws and this Agreement, including attending required meetings. In the event the
Annual Member’s Meeting is held in accordance with Section 4.2(k) prior to such decision of the
accounting firm, the Members’ Meeting shall only declare dividends in respect of the relevant year
to the extent that the Distributable Profits remaining after the payment of such dividends would be
sufficient to pay the greater of the Net Special Dividends claimed by the Principals under this
Section 6.2(d), it being understood that in any such case the Net Special Dividend decided upon by
the accounting firm (together with an

89

 

amount calculated as interest thereon calculated in accordance with Section 6.2(c)) shall be
declared by the first Members’ Meeting following such decision and paid as a partial Net Special
Dividend.

SECTION 6.3. Retroactive Closing Mechanism

     (a) The Parties shall give effect to a closing adjustment mechanism (the “Retroactive Closing
Mechanism”) pursuant to this Section 6.3 with the intention of putting the Principals, to the
extent possible, in the same economic position they would have been in had the Closing occurred on
the Economic Effective Date (as defined below). For the avoidance of doubt, as between the
Parties, the actual commencement of the Merial Venture for accounting and Tax purposes shall be the
first day following the Closing Date. The Retroactive Closing Mechanism shall not be applied if a
change in Tax Laws occurring between the date hereof and the date of the Closing causes the
application of the Retroactive Closing Mechanism to have an adverse Tax consequence of [*] for either Principal. “Economic Effective Date” shall be April 1, 1997. “The
Retroactive Period” shall be the period between the Economic Effective Date and the Closing Date.

     (b) The Retroactive Closing Mechanism shall be implemented through a Retroactive Closing
Special Dividend, which shall be calculated based on the Retroactive Closing Financial Statements,
as defined in, and prepared in accordance with, the instructions set forth in Exhibit XIX.
Subject to the instructions set forth in Exhibit XIX, the Retroactive Closing Special Dividend
shall be credited, in calculating the Net Special Dividend in respect of Fiscal Year 1997, to the
Member whose pro forma cash generated (used), as calculated in accordance with the instructions set
forth in Exhibit XIX, is lower than its share in the pro forma cash generated (used) by the Merial
Venture during the Retroactive Period.

     (c) Pre-Closing Preparation of Financial Statements. Each of Merck and RM hereby represents
to the other as of the date hereof and as of the Closing Date that (i) each of the monthly actual
and pro forma consolidated income statements and

90

 

consolidated statements of cash flows that it has provided to the other in respect of the
operations of the Merck Contributed Business and of RM and its Subsidiaries, respectively, for the
first quarter of Fiscal Year 1997 and for each calendar month since and including April 1997, and
(ii) each of the quarterly actual and pro forma consolidated balance sheets that it has provided to
the other in respect of the Merck Contributed Business and of RM and its Subsidiaries,
respectively, since and including the consolidated balance sheets as of March 31, 1997, was
prepared, (x) with respect to the actual consolidated income statements and consolidated statements
of cash flows referred to above, consistently with the Merck Contributed Business Financials
attached as Exhibit XVI hereto in the case of Merck, and the RM Financials attached as Exhibit XVII
hereto in the case of RM, and (y) with respect to the pro forma consolidated income statements and
consolidated statements of cash flows referred to above, consistently with the instructions set
forth in Exhibit XIX; and each of Merck and RM hereby agrees to continue to provide such statements
to the other, prepared in a consistent manner, for each calendar month and as of the end of each
calendar quarter, as the case may be, until the Closing.

SECTION 6.4. Early Year Adjustment

     If the actual Net Reported Sales by the Merial Venture (or by RM and Merck and their
respective Subsidiaries during the Retroactive Period) of certain products specified below in any
of 1997, 1998 or 1999 are less than the assumed Baseline Net Reported Sales amounts for such
products set forth below, the Principals will give effect in each such year to an adjustment
mechanism (the “Early Year Adjustment Mechanism”) set forth in this Section 6.4. A numerical
example of the Early Year Adjustment Mechanism is provided in Exhibit XVIII hereto.

     (a) Early Year Adjustment Special Dividend. The Early Year Adjustment Mechanism
Entitlements of each Principal, if any, calculated pursuant to this Section 6.4 in respect of each
Fiscal Year 1997 through 1999 shall be offset against each other, with the difference between them
being the “Early Year Adjustment Special Dividend” for each such Fiscal Year. In calculating the
Net Special Dividend in respect of each such

91

 

Fiscal Year, the Early Year Adjustment Special Dividend shall be credited to the
Merck Member if the Merck Section 6.4 Entitlement (as defined below) is greater
or to the RP Member if the RP Section 6.4 Entitlement (as defined below) is
greater.

Baseline Net Reported Sales ($ millions)

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	1997	 	1998	 	1999
	RP Adjustment Products
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Merck Adjustment Products
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 

Gross Margin Rate (%)

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	1997	 	1998	 	1999
	RP Adjustment Products
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Merck Adjustment Products
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 

     (b) Merck Section 6.4 Entitlement. The amount, if any, by which (x)
the sum of actual Net Reported Sales of Biological Products and Fipronil Products
(together, “RP Adjustment Products”), for any of 1997, 1998 or 1999, are less than
(y) the respective Baseline Net Reported Sales for RP Adjustment Products for such
year, shall be the “RP Sales Shortfall Amount” for such year. Merck shall be
entitled in respect of any such year to a dollar amount (the “Merck Section 6.4
Entitlement”) equal to the product of (xx) the RP Sales Shortfall Amount, (yy) the
percentage equal to the Gross Margin Rate set forth above for RP Adjustment Products
for such year, and (zz) [*].

     (c) RP Section 6.4 Entitlement. The amount, if any, by which (x)
actual Net Reported Sales of Avermectin Products (“Merck Adjustment Products”), for
any of 1997, 1998 or 1999, are less than (y) the respective Baseline Net Reported
Sales for Merck Adjustment Products for such year, shall be called the “Merck Sales
Shortfall Amount” for such year. RP shall be entitled in respect of any such year to
a dollar amount (the “RP Section 6.4 Entitlement”) equal to the product of (xx) the
Merck Sales Shortfall Amount, (yy) the percentage equal to the Gross Margin Rate set
forth above for Merck

92

 

Adjustment Products for such year, and (zz) [*].

     (d) 1997 Partial Year. In calculating the Sales Shortfall Amounts, if any, in
respect of 1997, the relevant Baseline Net Reported Sales amounts for the full Fiscal Year shall be
reduced proportionately (i.e., multiplied by a fraction the numerator of which is the actual Net
Reported Sales amount during the period from the Economic Effective Date to the end of 1997 and the
denominator of which is actual Net Reported Sales amount for the full calendar year 1997) and
compared to actual Net Reported Sales during the period from the Economic Effective Date to the end
of 1997.

     (e) Foreign Currency Fluctuation. In order to eliminate the effects of certain
foreign currency fluctuations, the Net Reported Sales calculated with respect to all sales of RP
Adjustment Products or Merck Adjustment Products denominated in any of the currencies listed
hereafter shall be translated into U.S. dollars on the basis of the following exchange rates:
English pound sterling .63, French franc 5.00, German deutschemark 1.43, Italian lira 1624, Spanish
peseta 125, Japanese yen 93, and Australian dollar 1.35. If any of such sales of RP Adjustment
Products or Merck Adjustment Products in one of such countries are denominated in ecus or euros,
the Net Reported Sales in U.S. dollars with respect to such sales shall be determined by first
translating the amount in ecus or euros, as the case may be, into an amount denominated in the
national currency of such country (the English pound sterling, French franc, German deutschemark,
Italian lira or Spanish peseta, as the case may be) at the exchange rate in effect at the date of
such sale (or, if the national currency no longer exists at such time, the last such exchange rate
in effect prior to the elimination of the national currency), and then translating the resulting
national currency amount into U.S. dollars at the exchange rates set forth above.

     (f) Early Dissolution. The Early Year Adjustment Mechanism shall only be applied to
full calendar years (and to the partial 1997 year as contemplated in Section 6.4(d)). In the
event the Merial Venture is Dissolved prior to December 31, 1999, the Principals shall negotiate in
good faith at such time in order to adjust the payment(s)

93

 

made in connection with such Dissolution to account for the estimated present value of the
adjustments that would have been made pursuant to the Early Year Adjustment Mechanism set forth in
this Section 6.4 had such Dissolution not occurred. In the event such Dissolution occurs pursuant
to the purchase by one Principal of the Merial Venture interest of the other, the adjustment shall
be made to the purchase price. In the event such Dissolution occurs pursuant to the purchase by a
Third Party of all or substantially all of the Merial Venture, the adjustment shall be made to the
apportionment of the purchase price between the Principals (which apportionment would otherwise be
50/50, before accounting for any undistributed Special Dividends or other early Dissolution
adjustments).

     (g) Change of Early Year Adjustment Mechanism Premises. If, prior to the
Closing, the Principals or, after the Closing, Merial’s Board of Directors, approves a transaction
or the development and marketing of a product that can be reasonably viewed as changing the
premises upon which the Baseline Net Reported Sales amounts were agreed, then Merck and RP shall
negotiate in good faith to determine appropriate and equitable modifications to the Baseline Net
Reported Sales amounts and until both Principals agree on such modifications, the foregoing
provisions of this Section 6.4 shall continue to apply.

SECTION 6.5. Band Adjustment

     If the average annual actual Net Reported Sales of RP Adjustment Products or Merck Adjustment
Products by the Merial Venture during the four calendar-year period of 1998, 1999, 2000 and 2001 is
more than [*] the Baseline Net Reported Sales for such products set forth in this Section
6.5, the Parties will give effect to a band adjustment mechanism (the “Band Adjustment Mechanism”)
set forth in this Section 6.5. A numerical example of the Band Adjustment Mechanism is provided in
Exhibit XVIII hereto.

     (a) Band Adjustment Special Dividend. The Band Adjustment Mechanism
Entitlements of each Principal, if any, as calculated pursuant to this Section 6.5, shall be

94

 

offset against each other, with the difference between them being the “Band Adjustment
Special Dividend”. The Band Adjustment Special Dividend shall be credited to the RP Member
if the RP Section 6.5 Entitlement, as defined below, is greater than the Merck Section 6.5
Entitlement, as defined below, or to the Merck Member if the Merck Section 6.5 Entitlement
is greater than the RP Section 6.5 Entitlement, in calculating the Net Special Dividend in
respect of Fiscal Year 2001.

     Baseline Net Reported Sales ($ millions)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	1998	 	1999	 	2000	 	2001	 	Average
	RP Adjustment Products
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 
	Merck Adjustment Products
	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 	 	 	[*]	 

     (b) Merck Section 6.5 Entitlement. The amount, if any, by which (x) the
average of the actual annual Net Reported Sales for RP Adjustment Products, during the
period 1998-2001 inclusive, is less than (y) the average of the annual Baseline Net
Reported Sales for RP Adjustment Products, during such period, shall be the “Average RP
Sales Shortfall Amount”. If the Average RP Sales Shortfall Amount is greater than [*] (the “RP Threshold”), then Merck shall be entitled to an amount (the “Merck Section
6.5 Entitlement”) [*]. The RP Threshold was calculated [*].

     (c) RP Section 6.5 Entitlement. The amount, if any, by which (x) the average
of the actual annual Net Reported Sales for Merck Adjustment Products, during the period
1998-2001 inclusive, is less than (y) the average of the annual Baseline Net Reported Sales
for Merck Adjustment Products during such period, shall be the “Average Merck Sales
Shortfall Amount”. If the Average Merck Sales Shortfall Amount is greater than [*] (the “Merck Threshold”), then RP shall be entitled to an amount (the “RP Section
6.5 Entitlement”) [*]. The Merck Threshold was
calculated [*]

95

 

[*].

     (d) Foreign Currency Fluctuation. In order to eliminate effects of certain foreign
currency fluctuations, actual Net Reported Sales (with respect to sales made in certain currencies
other than U.S. dollars) shall be calculated using the same agreed upon exchange rates as for the
Early Year Adjustment Mechanism, as set forth in Section 6.4(e) above.

     (e) Early Dissolution. If the Merial Venture liquidates, sells or otherwise disposes
of all or substantially all of its assets or is Dissolved prior to January 1, 2002, then the Band
Adjustment Mechanism shall be applied as follows:

     (i) if the Dissolution Date is prior to January 1, 1999, the Band Adjustment
Mechanism shall not apply;

     (ii) in the case of a Dissolution Date on or after January 1, 1999, the Band
Adjustment Mechanism shall be applied as set forth in Section 6.5(a)-(d) above, except as
follows:

     The Average RP Sales Shortfall Amount and the Average Merck Sales Shortfall Amount
shall be calculated on an annualized basis, based on the number of full calendar quarters
from January 1, 1998 through the Dissolution Date, rather than on the average of the four
full calendar years of actual Net Reported Sales. The Baseline Net Reported Sales used for
the quarters comprising any partial year prior to the Dissolution Date shall equal the
product of the Baseline Net Reported Sales for such year and a fraction, the numerator of
which is the Net Reported Sales for the relevant products shown (or implicit) in the
Approved Budget (as defined below) for the full calendar quarters in such year prior to the
Dissolution Date, and the denominator of which is the Net Reported Sales for such Products
shown (or implicit) in the Approved Budget for the full year in which the Dissolution
occurs. “Approved Budget” means the latest business plan or budget

96

 

which covers the year in question that has been approved by Merial’s Board of Directors
(or, if no such plan or budget has been so approved, then the actual Net Reported Sales for
the relevant products during the corresponding periods in the preceding calendar year shall
be used in place of the Net Reported Sales shown in the Approved Budget for purposes of the
calculation described in the preceding sentence).

     (f) Change of Band Adjustment Mechanism Premises. If, prior to the Closing, the
Principals or, after the Closing, Merial’s Board of Directors, approve a transaction or the
development and marketing of a product that can be reasonably viewed as changing the premises upon
which the Baseline Net Reported Sales amounts were agreed, then Merck and RP shall negotiate in
good faith to determine appropriate and equitable modifications to the Baseline Net Reported Sales
amounts and until both Principals agree upon such modifications, the foregoing provisions of this
Section 6.5 shall continue to apply.

SECTION 6.6. Special Poultry Genetics Profit Allocation

     (a) Merial shall, in respect of each Fiscal Year from 1997 to 2001 inclusive, credit a Special
Dividend (the “PG Profit Special Dividend”) to the Merck Member equal to [*] of the “Adjusted
Poultry Genetics Profits” for such year. The “Adjusted Poultry Genetics Profits” for each such year
shall be calculated by taking the pre-tax profits before interest expenses of the Poultry Genetics
Business reflected in the stand alone pro forma financial statements referred to below in this
Section 6.6(a) for the relevant Fiscal Year, [*]. The Parties acknowledge (i) that the PG Profit Special Dividend shall be calculated
and credited regardless of the proportion of the Poultry Genetics Business’ profits that Merial
actually receives in the form of dividends in respect of such year, and (ii) that all dividends
actually received by Merial from its Poultry Genetics Business shall be allocated as between the
Members as otherwise provided in this Agreement. The Parties agree that the impact of any
acquisitions by Merial in the Poultry Genetics Business after

97

 

the Closing Date, which impact shall be determined by the management of Merial at the time of such
acquisitions, shall be excluded from the calculation of the PG Profit Special Dividend. In the
event of a divestiture by Merial or any other Merial Venture Company of a part (but less than all
or substantially all) of the Poultry Genetics Business contributed to the Merial Venture (other
than Goubin) between the Economic Effective Date and December 31, 2001, the Special Poultry
Genetics Profit Allocation in respect of the Fiscal Year during which such divestiture occurred
shall be increased by an amount equal to [*]. Merial shall prepare stand-alone pro forma financial statements reflecting
the operations of the entirety of its Poultry Genetics Business for each Fiscal Year from 1997
through 2001 inclusive, including profit and loss statements, prepared consistently with the
accounting principles and practices used to prepare the Merial financial statements (but excluding
any financial or interest charges actually incurred by the Poultry Genetics Business). In preparing
these financial statements, any expenses for overheads or corporate services shall be allocated on
a fair and equitable basis, based on the actual use of corporate resources. These financial
statements for the Fiscal Year 1997 shall reflect the operations of the Poultry Genetics Business
from the Closing Date to December 31, 1997. The PG Profit Special Dividend in respect of 1997 shall
be based on the profits of the Poultry Genetics Business during the period from the Closing Date to
December 31, 1997. A numerical example of the Poultry Genetics Special Dividend is provided in
Exhibit XVIII hereto.

     (b) Deemed Interest Expense. For the purposes of calculating the Adjusted Poultry
Genetics Profits, [*] of Debt shall be deemed to have been initially allocated to the
Poultry Genetics Business. The “Deemed Interest Expense” for each year from 1997 through 2001 shall
equal [*]

98

 

[*]. For the calculation of the 1997 Deemed Interest Expense, [*] shall be used.

     (c) PG Profit Special Dividend. Subject to Section 6.6(d), the PG Profit Special
Dividend calculated in respect of each Fiscal Year from 1997 to 2001 inclusive shall be credited to
the Merck Member in calculating the Net Special Dividend pursuant to Section 6.2 in respect of such
Fiscal Year.

     (d) Early Disposal or Dissolution. If the Merial Venture liquidates, sells or
otherwise disposes of all or substantially all of its Poultry Genetics Business or if the Merial
Venture is Dissolved prior to January 1, 2002, then the Principals shall negotiate in good faith at
such time, in order to adjust the payment(s) made in connection with such disposal or Dissolution
to account for the estimated present value of the remaining PG Profit Special Allocation (the “PG
Profit Allocation Present Value”). In the event the Principals are not able to agree within 30 days
of the closing of such disposal or Dissolution on the amount of the PG Profit Allocation Present
Value, it shall be determined in accordance with the procedures set forth in Section 17.2(g)(ii).
In the event of an early sale or other disposition by the Merial Venture of all or substantially
all of its Poultry Genetics Business, Merial shall, pursuant to Section 6.2, credit the PG Profit
Allocation Present Value to the Merck Member as a Special Dividend in respect of the calendar year
during which such sale was completed. In the event of a Dissolution of the Merial Venture pursuant
to the sale by one Principal of its Merial Venture Interest to the other, the purchase price shall
be increased (in the case of a sale to RP) or decreased (in the case of a sale to Merck), as
appropriate, by the PG Profit Allocation Present Value (on a dollar for dollar basis). In the event
of a Dissolution of the Merial Venture pursuant to the sale of all or substantially all of the
Merial Venture to a Third Party, the apportionment of the sales proceeds to the Merck Member (which
apportionment as between the Members would otherwise be 50/50, before accounting for any
undistributed Special Dividends or other adjustments provided for in this Article VI) shall be
increased on a dollar for dollar basis equal to the PG Profit Allocation Present Value.

99

 

SECTION 6.7. Supply Price Adjustments

     (a) Merck Supply Price Adjustment. In respect of each Fiscal Year, the RP Member shall
have an entitlement (the “RP Section 6.7 Entitlement”) equal to the product of (i) [*], and (ii) (x) the sum of all amounts accrued by the Merial Venture
to the Merck Group for such Fiscal Year for the supply of products (or bulk) pursuant to the Merck
Supply Agreement, and (without duplication) of all amounts paid by Merial or its Subsidiaries
during such Fiscal Year to purchase the Inventories included in the Merck Contributed Non-U.S.
Assets and the Retained Inventory, if any, less (y) the sum of (AA) all amounts that would
have been so accrued with respect to such Fiscal Year if calculated in accordance with the Merck
Manufacturing Supply Price Formula and (BB) the Avermectin Products Sales Adjustment for such
Fiscal Year calculated in accordance with Exhibit XXI [Avermectin Products Sales Adjustment], but
only if the amount (the “Delta”) equal to the amount determined pursuant to clause (x) above
less the amount determined pursuant to clause (y) above, is a positive amount. The sum of
the amounts specified in (AA) and (BB) shall be the “Merck Negotiated Supply Price”. If the Delta
is a negative number, then in respect of such Fiscal Year (whether or not the Merck Supply
Agreement is then in effect), the Merck Member shall have an entitlement (the “Merck Section 6.7(a)
Entitlement”) equal to the product of (i) [*], and (ii)
the absolute amount of the Delta. Merck hereby represents that the formula for calculating standard
direct cost in the Merck Supply Agreement is on the same basis as the formula used to calculate
standard direct cost in the Merck Base Case and the multiple of standard direct cost in the Merck
Base Case roughly approximates (on average over the five years following the Closing Date given the
product mix included in the Merck Base Case) the multiple of standard direct cost provided for in
the Merck Manufacturing Supply Price Formula.

     (b) RP Supply Price Adjustment. In respect of each Fiscal Year, the Merck Member shall
have an entitlement (the “Merck Section 6.7(b) Entitlement”) equal to the product of (i) [*], and (ii) (x) the sum of all amounts accrued by the Merial
Venture to the RP Group for such Fiscal Year for the

100

 

supply of products (or bulk) pursuant to the RP Ag Supply Agreement, less (y) the sum of all
amounts that would have been so accrued if calculated at Fully Allocated Cost (as defined in the
RP Ag Manufacturing Supply Price Formula). RP hereby represents that the purchase price for
Fipronil used in preparing the projections set forth in the RM Base Case was calculated using
Fully Allocated Cost (as defined in the RP Ag Manufacturing Supply Price Formula).

     (c) Supply Price Adjustment Special Dividend. The “Supply Price Adjustment Special
Dividend” shall be equal to the difference between the respective Entitlements of the Principals,
if any, in respect of each relevant Fiscal Year, as calculated pursuant to Sections 6.7(a) and (b)
above. The Supply Price Adjustment Special Dividend shall be credited to the RP Member if the RP
Section 6.7 Entitlement is greater than the Merck Section 6.7(a) Entitlement plus the Merck Section
6.7(b) Entitlement or to the Merck Member if the Merck Section 6.7(a) Entitlement plus the Merck
Section 6.7(b) Entitlement is greater than the RP Section 6.7 Entitlement, in calculating the Net
Special Dividend in respect of such year pursuant to Section 6.2. A numerical example of the
Supply Price Adjustment is provided in Exhibit XVIII hereto.

     (d) Alternative Upon Dissolution, Sale, Etc. In the event that, as a result of any
Dissolution, any transaction contemplated by Articles XVI or XVII or otherwise, this Section 6.7 is
no longer operative or no longer effectively gives effect to the economic principle that on a net
basis Merck is selling and the Merial Venture is purchasing Avermectin Products at the Merck
Manufacturing Supply Price Formula and Merck receives amounts calculated pursuant to the Avermectin
Products Sales Adjustment Exhibit, the Parties agree that, prior to the effectiveness of any such
event, alternative arrangements shall be entered into by and among the Parties and/or a purchaser
in order to provide the equivalent economic benefits to the Parties of the arrangements
contemplated by this Section 6.7 that, in the aggregate, have no less favorable economic, tax,
commercial and legal characteristics to each of the Parties.

SECTION 6.8 Contributed Debt Adjustment Special Dividend

101

 

     (a) From the Closing Balance Sheets, the Parties shall calculate the “RM Actual Contributed
Net Debt Variance”, as defined below, and the “Merck Actual Contributed Net Debt Variance”, as
defined below. The difference between the RM Actual Contributed Net Debt Variance and the Merck
Actual Contributed Net Debt Variance, calculated as set forth below, shall be the “Contributed Debt
Adjustment Special Dividend”. In calculating the Net Special Dividend in respect of the 1997
Fiscal Year pursuant to Section 6.2, the Contributed Debt Adjustment Special Dividend shall be
credited to the RP Member if the Merck Actual Contributed Net Debt Variance is greater than the RM
Actual Contributed Net Debt Variance, and to the Merck Member if the RM Actual Contributed Net Debt
Variance is greater than the Merck Actual Contributed Net Debt Variance. A numerical example of
the Contributed Debt Adjustment Special Dividend is provided in Exhibit XVIII hereto.

     (b) The “RM Actual Contributed Net Debt Variance” shall be equal to:

     the RM Intercompany Debt (as defined in Section 5.2(b)),

plus

     the RM Outstanding Debt (as defined in Section 5.2(b)),

plus

     the RM Accrued Tax Liabilities (as defined in Section 5.2(b)),

plus

     the RM China Financial Receivable (as defined in Section 5.1(b)(ii)),

plus

     the RP Chinese Assets Value Shortfall (as defined in Section 5.1(b)(ii)),

less

     the RM Closing Cash (as defined in Section 5.2(b)),

less

     [*]

     (c) The “Merck Actual Contributed Net Debt Variance” shall be equal to:

     the Merck Non-U.S. Net Assets Value (as defined in Section 5.1(a)(ii)(A)),

102

 

plus

     the Retained Receivables (as defined in Section 5.1(a)(ii)(C)),

plus

     the Retained Inventories (as defined in Section 5.1(a)(ii)(C)),

plus

     the Merck Accrued Tax Liabilities (as defined in Section 5.1(a)(ii)(B)),

plus

     the Merck Other Debt (as defined in Section 5.1(a)(ii)(B)),

less

     the Merck Cash Contribution Amount (as defined in Section 5.1(a)(ii)(B)),

less

     the Merck Closing Cash (as defined in Section 5.1(a)(ii)(B)),

less

     [*].

     (d) The Contributed Debt Adjustment Special Dividend shall equal the difference between
the RM Actual Contributed Net Debt Variance and the Merck Actual Contributed Net Debt Variance,
which difference shall be calculated taking into account any negative amounts (for example, if one
amount is -4 (negative four) and the other is 4, the difference between them shall be 8).

SECTION 6.9. Delayed Purchase Assets and Liabilities Special Dividend

     The Parties shall agree on the estimated aggregate fair market value of the Delayed Purchase
Assets, such estimated value being the “Estimated Delayed Purchase Assets Value”. For purposes of
this Section 6.9, the amount in U.S. dollars to be used in calculating any purchase price for
Delayed Purchase Assets denominated in a currency other than U.S. dollars shall be calculated using
the closing midpoint exchange rate set forth in the London edition of the Financial Times on the
date the payment is made.

     (a) Purchases of Delayed Purchase Assets during the 1997 Fiscal Year. As soon
as practicable after the end of the 1997 Fiscal Year, and in no event later than the

103

 

twentieth (20th) Business Day following the end of such Fiscal Year, Merial shall (i) determine
whether all the Delayed Purchase Assets have been purchased during the 1997 Fiscal Year, and (ii)
calculate the difference between (x) the Estimated Delayed Purchase Assets Value and (y) the
purchase price actually paid for all the Delayed Purchase Assets purchased during the 1997 Fiscal
Year (the “1997 Aggregate Purchase Price”), which difference shall be the “1997 Delayed Purchase
Assets Variance”.

(A) If the 1997 Aggregate Purchase Price is greater than the Estimated Delayed
Purchase Assets Value, the 1997 Delayed Purchase Assets Variance shall be credited
as a 1997 Delayed Purchase Assets Special Dividend to the RP Member, pursuant to
Section 6.2 and in respect of the 1997 Fiscal Year.

(B) If the purchase of all Delayed Purchase Assets is completed by December 31,
1997 and the Estimated Delayed Purchase Assets Value is greater than the 1997
Aggregate Purchase Price, the 1997 Delayed Purchase Assets Variance shall be
credited as a 1997 Delayed Purchase Assets Special Dividend to the Merck Member
pursuant to Section 6.2 and in respect of the 1997 Fiscal Year.

(C) If the purchase of all Delayed Purchase Assets is not completed by December 31,
1997 and the 1997 Aggregate Purchase Price is lower than the Estimated Delayed
Purchase Assets Value, no Delayed Purchase Assets Special Dividend shall be
credited with respect to the 1997 Fiscal Year.

     (b) Purchases during 1998. As soon as practicable after the end of the 1998
Fiscal Year, and in no event later than the twentieth (20th) Business Day following the end of such
Fiscal Year, Merial shall (i) determine whether all the remaining Delayed Purchase Assets have been
purchased during the 1998 Fiscal Year, and (ii) calculate the difference between (x) the Estimated
Delayed Purchase Assets Value and (y) the purchase price actually paid for all the Delayed Purchase
Assets purchased during the 1997 and the

104

 

1998 Fiscal Years (the “Global Purchase Price”), which difference shall be the “Global Delayed
Purchase Assets Variance”.

(A) If the purchase of all Delayed Purchase Assets is completed by December 31,
1998 and the Global Purchase Price is greater than the Estimated Delayed Purchase
Assets Value, a Delayed Purchase Assets Special Dividend equal to the difference
between the Global Delayed Purchase Assets Variance and the 1997 Delayed Purchase
Assets Special Dividend credited to the RP Member and specified in Section
6.9(a)(A) shall be credited to the RP Member, pursuant to Section 6.2 and in
respect of the 1998 Fiscal Year. If the purchase of all Delayed Purchase Assets is
completed by December 31, 1998 and the Global Purchase Price is lower than the
Estimated Delayed Purchase Assets Value, a Delayed Purchase Assets Special Dividend
equal to the difference between the Global Delayed Purchase Assets Variance and the
1997 Delayed Purchase Assets Special Dividend credited to the Merck Member and
specified in Section 6.9(a)(B) shall be credited to the Merck Member, pursuant to
Section 6.2 and in respect of the 1998 Fiscal Year.

(B) If the purchase of all Delayed Purchase Assets is not completed by December 31,
1998, the Parties shall meet no later then the twentieth (20th) Business Day of the
1999 Fiscal Year to determine the consequences, financial and otherwise, of such a
failure, and such consequences shall be taken into account to determine the 1998
Delayed Purchase Assets Special Dividend.

SECTION 6.10. Early Dissolution and the Merck Research Payment

     No RM Funding Commitment payments (as defined in the Merck Research Agreement) shall be made
by RM SAS after the Dissolution of the Merial Venture; provided, however, that if
the Merial Venture is Dissolved before December 31, 2003, the payment(s) made in connection with
such Dissolution to the Merck Member shall be

105

 

increased (or to the RP Member shall be decreased) by an amount equal to the present value of
future RM Funding Commitment payments (the “Research Payment Present Value”), which shall be deemed
to be [*] for a Dissolution during the calendar year 1997, and [*]. In the event of a Dissolution of the Merial Venture pursuant to the sale by one
Principal of its Merial Venture Interest to the other, the purchase price shall be increased or
decreased, as appropriate, by the Research Payment Present Value (on a dollar for dollar basis).
In the event of a Dissolution of the Merial Venture pursuant to the sale of all or substantially
all of the Merial Venture to a Third Party, the apportionment of the sales proceeds to the Merck
Member (which apportionment as between the Members would otherwise be 50/50, before accounting for
any undistributed Special Dividends or other adjustments provided for in this Article VI) shall be
increased on a dollar for dollar basis equal to the Research Payment Present Value.

SECTION 6.11. Distribution Upon Liquidation

     In any liquidation of the Merial Venture, the assets of the Merial Venture shall, subject to
applicable Laws, be distributed in accordance with the following priorities:

(i) First, to the creditors of the Merial Venture (including to any RP
Companies or Merck Companies to whom any Debt or accounts payable may be owed by
the Merial Venture) in accordance with applicable Laws and any judgments or
orders of competent Public Authorities;

(ii) second, to the extent of any assets remaining, if there is any unpaid
Net Special Dividend balance outstanding in respect of any prior Fiscal Year, an
amount equivalent to such balance to the Member to whom such unpaid Net Special
Dividend balance is due (together with any interest accrued thereon);

106

 

(iii) third, to the extent of any assets remaining, each of the adjustments contemplated by
Section 6.4(f) [Early Year Adjustment], 6.5(e) [Band Adjustment], 6.6(d) [Poultry Genetics] and
6.10 [Research Payments] shall be added or netted, as appropriate, and the resulting net adjustment
amount paid to the Member entitled thereto; and

(iv) fourth, any remaining assets shall be distributed as between the Members and/or their
Affiliates that hold the Preference Shares, if any, in the following order of priority: first, to
the Members in an amount equal to the amount of any Net Special Dividend that would be calculated
for the Member for the Fiscal Year in which the Dissolution of Merial occurs, treating such Fiscal
Year as ending on the date of such Dissolution (to the extent not duplicative of (iii) above);
second, in respect of any accumulated but unpaid dividends on the Preference Shares, to the holders
thereof; third, in a return to the holders of the Preference Shares of capital equal to the nominal
value of such shares, to the holders thereof; and fourth, equally as between the Members in respect
of their general ownership interest in Merial.

107

 

ARTICLE VII

EMPLOYEES AND EMPLOYEE BENEFIT MATTERS

SECTION 7.1. Animal Health Division — U.S.

     (a) Leasing of Merck Employees. The Merck Group employees employed in the Animal
Health Business in the U.S. as of the Closing Date listed on a schedule to be provided by Merck on
the Closing Date, which list shall include not only employees then actively employed but also those
then on leave of absence, short-term disability, long-term disability and workers compensation (the
“Merck Leased Employees”), shall be leased to Merial, or to a Merial Venture Company designated by
Merial, as of the Closing Date pursuant to the terms set forth in the Merck Employee Leasing
Agreement. Each Merck Leased Employee who is employed by Merck as of December 31, 1997 including
not only employees then actively employed but also those then on leave of absence, short-term
disability, long-term disability and workers compensation shall be offered employment with Merial,
or a Merial Venture Company designated by Merial, as of January 1, 1998 at a rate of base salary
determined by Merial and shall be eligible to participate in all employee benefit plans established
and/or maintained by Merial or such Merial Venture Company, as the case may be. Notwithstanding
the foregoing sentence, each Merck Leased Employee who has commenced, or is eligible to commence,
benefits under the Merck & Co., Inc. Long-Term Disability Plan for Non-Union Employees (the “Merck
LTD Plan”) prior to January 1, 1998 (a “Merck LTD Employee”) shall continue to receive medical,
dental, life insurance and long-term disability benefits under the terms and conditions of the
applicable Merck benefit plans, as each may be amended from time-to-time, and such continuation of
benefits shall be at Merck’s sole cost and expense; provided, however, that the
costs of benefits provided to a Merck Leased Employee who returns to work during the term of the
Leasing Agreement or, thereafter, returns to work with the Merial Venture, shall be borne by
Merial. Merck shall reimburse Merial (or the appropriate Merial Venture Company) for the cost of
providing long-term disability benefits to each Merck Leased Employee who has commenced or is
eligible to commence benefits under the Merck & Co., Inc. Short-Term Disability Plan for Non-Union

108

 

Employees prior to the Closing Date and becomes eligible to receive, on or after January 1, 1998,
benefits under the Merial long-term disability plan as a result of such pre-Closing disability,
provided such disability is continuous in accordance with the terms of the Merial long-term
disability plan. Those Merck Leased Employees (including the Merck LTD Employees) who accept
employment with Merial, or a Merial Venture Company designated by Merial, shall be referred to as
the “Merial Merck Employees.”

     (b) Grandfathered Merck Retirement Benefits. All Merial Merck Employees shall
be 100% vested in the Retirement Plan for Salaried Employees of Merck & Co., Inc. (the “Qualified
Plan”) and in the Merck & Co., Inc. Supplemental Retirement Plan, as each such plan may be amended
from time to time, (together with the Qualified Plan, the “Merck Retirement Plans”) as of December
31, 1997. Each Merial Merck Employee, the sum of whose age plus years of credited service (within
the meaning of the Qualified Plan) as of December 31, 1997 equals at least 60 (collectively, the
“Grandfathered Merck Employees”) shall receive credit for his or her years of service with the
Merial Venture for purposes of determining eligibility to receive a subsidized early retirement
benefit with respect to his or her benefit accrued through December 31, 1997 under the Merck
Retirement Plans. Unless required by law, benefits under the Merck Retirement Plans shall not
commence until the Grandfathered Merck Employee terminates employment with the Merial Venture. The
compensation that each Merial Merck Employee receives from the Merial Venture during the period
from January 1, 1998 to December 31, 2007 will for purposes of determining his or her final average
pay under the Merck Retirement Plans be treated as if it were compensation received from Merck. An
accounting or actuarial firm mutually agreed upon by Merck and RP shall determine the present value
of the benefits to be provided to Merial Merck Employees pursuant to this Section 7.1(b) that are
in excess of the benefits they would otherwise be entitled to receive under the Merck Retirement
Plans in the absence of this Section 7.1(b) (such excess amount shall be defined as the “Retirement
Cost”). The Retirement Cost shall be determined as of December 31, 1997 using the December 31, 1997
demographics of Merial Merck Employees and shall be based upon the actuarial assumptions used by
Merck for purposes of determining pension expense pursuant to Financial Accounting Standards
(“FAS”) 87 for the Merck Retirement Plans for 1998. Merial shall credit to the Merck Member in

109

 

respect of the Fiscal Year in which the Retirement Cost is calculated a Special Dividend equal to
the Retirement Cost (as increased by an amount calculated as interest at [*] from December 31, 1997 through the earlier of (x) the date on which the Net Special
Dividend in respect of such Fiscal Year is paid in full, and (y) April 15 of the Fiscal Year
immediately following the Fiscal Year in respect of which the Special Dividend is to be paid).

     (c) Grandfathered Retiree Medical and Dental Benefits. Each Grandfathered Merck
Employee whose employment with the Merial Venture terminates and who, at the time of such
termination, (i) is at least 55 years old with at least 10 years of credited service (as defined
under the Qualified Plan and including service with the Merial Venture) or (ii) if hired by Merck
prior to January 1, 1989 is at least 65 years old or meets the requirements of the foregoing clause
(i), shall be eligible to receive retiree medical benefits under the terms applicable to retirees
under the Merck & Co., Inc. Medical Plan for Nonunion Employees as it may be amended from time to
time (the “Merck Medical Plan”) and shall be eligible to receive retiree dental benefits under the
terms applicable to retirees under the Merck & Co., Inc. Dental Plan for Nonunion Employees as it
may be amended from time to time (the “Merck Dental Plan”). An accounting or actuarial firm
mutually agreed upon by Merck and RP shall determine the present value of the accumulated post
retirement benefit obligation existing for eligible Grandfathered Merck Employees (other than those
employees who, as of December 31, 1997 (i) are at least 55 years old with at least 10 years of
credited service (as defined under the Qualified Plan), or (ii) if hired by Merck prior to January
1, 1989 are at least 65 years old or meet the requirements of the immediately foregoing clause (i))
pursuant to this Section 7.1(c) (the “Health Cost”). The Health Cost shall be determined as of
December 31, 1997 using the December 31, 1997 demographics of eligible Grandfathered Merck
Employees and shall be based upon the actuarial assumptions used by Merck for calculating the
expense for the Merck Medical Plan and the Merck Dental Plan pursuant to FAS 106 for 1998. Merial
shall credit to the Merck Member in respect of the Fiscal Year in which the Health Cost is
calculated a Special Dividend equal to the Health Cost (as increased by an amount calculated as
interest at [*] from December 31, 1997 through the earlier of (x)
the date on which the Net

110

 

Special Dividend in respect of the 1998 Fiscal Year is paid in full, and (y) April 15 of the Fiscal
Year immediately following the Fiscal Year in respect of which the Special Dividend is to be paid).

     (d) Merck Stock Options. In addition to any stock option grants made prior to
the date of this Agreement under any Merck incentive stock plan (all such plans collectively, the
“Merck Stock Option Plans”), Merck may make an additional grant under the current Merck Stock
Option Plan to be priced as of the Closing Date to selected employees as determined by Merck who
shall become Merck Leased Employees. Merck will provide the shares of Merck common stock obtained
upon exercise of any stock option grants which have been made by Merck under the Merck Stock Option
Plans to any Merial Merck Employee which are outstanding as of the Closing Date. Promptly after
any such exercise, Merck may invoice on an employee by employee basis and, if so invoiced, Merial
(or the appropriate Merial Venture Company) will pay to Merck (within fifteen (15) days after
receipt of such invoice), the amount (the “Spread”) equal to the product of (A) the excess of (i)
the per share market price of shares of Merck common stock purchased on the exercise of the option,
over (ii) the per share exercise price of the stock option (adjusted for stock splits, stock
dividends, reclassification and similar events between the date the stock option was granted and
the exercise date, as considered appropriate by Merck), times (B) the number of shares issued upon
such exercise. Merial shall credit to the RP Member in respect of any Fiscal Year in which it pays
a Spread to Merck, a Special Dividend equal to the aggregate of (x) all Spreads paid in such Fiscal
Year by Merial to Merck plus (y) any incidental costs associated with the payment of such Spreads
and paid by the Merial Venture (i.e., any employer taxes paid). The Special Dividend (as described
in the foregoing sentence) that may be credited to the RP Member in any particular Fiscal Year
shall be increased by an amount calculated as interest at a rate equal to [*] accruing from December 31 of such Fiscal Year through the earlier of (x) the date on
which the Net Special Dividend in respect of such Fiscal Year is paid in full, and (y) April 15 of
the Fiscal Year immediately following the Fiscal Year in respect of which the Special Dividend is
to be paid.

111

 

     (e) RM Plans. Following the Closing and until December 31, 1997, Merial shall, or
shall cause RM or its Subsidiaries to continue to, maintain the employee benefit plans that were in
effect for the employees of RM or its Subsidiaries employed in the Animal Health Business in the
U.S. (“RM U.S. Employees”) immediately prior to the Closing, other than any stock option plans (the
“RM Plans”). Prior to January 1, 1998, such RM Plans shall only be amended (i) as required by law,
(ii) to maintain the tax qualified status of any such plan or (iii) as determined by the Board of
Directors; provided, however, that the RM/Select 401 (k) Plan (the “RM 401 (k) Plan”) shall be
amended as of July 1, 1997 to provide an employer matching contribution of [*] each $1.00
deferred by a participant under the plan up to [*] of compensation.

     (f) Merial Plans. Effective January 1, 1998, Merial shall, or shall cause the
appropriate Merial Venture Company to, amend the RM Plans or otherwise establish such employee
benefit plans in accordance with the terms set forth herein (other than a severance plan which
shall be established as of the Closing Date) in which Merial Merck Employees and RM U.S. Employees
(collectively the “U.S. Animal Health Employees”) shall participate as Merial shall deem
appropriate subject to the terms and conditions set forth herein. It is the intention that such
plans shall be initially designed so that the expected aggregate cost for the plans shall not, on
an annualized basis, exceed the total combined aggregate benefit plan costs of RM and its
Subsidiaries and Merck for such employees on an annualized basis prior to the Closing Date.

     (i) Cash Balance Plan. Effective as of January 1, 1998, Merial shall, or
shall cause the appropriate Merial Venture Company to, establish one or more cash balance
retirement plans (tax-qualified or non-tax qualified) (the “Cash Balance Plan”) in which the
U.S. Animal Health Employees shall be eligible to participate upon satisfying the applicable
age and service requirements established for such plan. All U.S. Animal Health Employees
shall be credited for their prior service with the Merial Venture, Merck or RM (or their
respective Subsidiaries) for vesting and eligibility purposes with respect to the Cash
Balance Plan. The Cash Balance Plan and the Amended RM 401(k) Plan (as hereinafter defined)
shall

112

 

be initially designed to collectively provide retirement benefits at the median of the Watson Wyatt
sample of 731 companies as provided to the parties by Watson Wyatt prior to the date hereof. It is
the intention that the annual costs of employer contributions to such plans for 1998 shall not
exceed the total combined aggregate costs for the U.S. Animal Health Employees under the RM 401 (k)
Plan, Merck 401 (k) Plan and the Merck Retirement Plan on an annualized basis prior to the Closing
Date.

     (ii) 401(k) Plan. The profit sharing contribution provided for under the RM 401(k)
Plan for the 1997 plan year shall be made by Merial (or the appropriate Merial Venture Company) and
shall not exceed [*] of the compensation of participants in the plan, which contribution amount
shall be split between RP and Merial on a pro-rata basis, with RP bearing the contribution amount
(pursuant to the Special Dividend described in the following sentence) for the portion of the plan
year up to and including the Closing Date (the “RM Profit Sharing Cost”) and Merial the portion of
the plan year after the Closing Date. Merial shall credit to the Merck Member in respect of the
1998 Fiscal Year a Special Dividend equal to the RM Profit Sharing Cost [*], as increased by an amount calculated as interest at
[*] from the date on which the profit sharing contribution with
respect to the 1997 plan year is made by Merial through the earlier of (x) the date on which the
Net Special Dividend in respect of the 1998 Fiscal Year is paid in full, and (y) April 15, 1999.
Effective January 1, 1998, the RM 401(k) Plan shall be amended to provide (A) an employer matching
contribution of [*] for each $1.00 deferred by a participant under the plan up to [*]
of compensation (or such other level of contribution as the Board of Directors shall decide), (B)
investment options permitting participants to invest in Merck and RP stock (provided that the plan
purchases such stock in open market transactions and not directly from Merck or RP), and (C) that
the profit sharing portion of the plan is terminated (as so amended, the “Amended RM 401(k) Plan”).
Effective January 1, 1998, all Merial Merck Employees who were participants in the Merck 401 (k)
Plan shall cease to be participants in such plan

113

 

and shall become participants in the Amended RM 401(k) Plan and the Amended RM 401(k) Plan shall
credit for eligibility and vesting purposes all service by a Merial Merck Employee for which such
service was recognized under the Merck 401(k) Plan prior to January 1, 1998. As soon as practicable
after January 1, 1998, Merck shall cause the trustee of the Merck 401(k) Plan to transfer to the
trustee of the Amended RM 401(k) Plan assets equal to the account balances as of the valuation date
immediately preceding the date of transfer of the Merial Merck Employees who were participants in
the Merck 401(k) Plan; provided, however, that no such transfer shall occur until
Merial demonstrates to the reasonable satisfaction of Merck and Merck demonstrates to the
reasonable satisfaction of Merial that, at the time of the transfer, the Amended RM 401(k) Plan and
the Merck 401(k) Plan, respectively, satisfy the requirements for qualification under Section
401(a) of the Code. The transfer referred to in the preceding sentence may be made in shares of
Merck stock (to the extent the transferred account balances are invested in the Merck Unitized
Common Stock Fund under the Merck 401(k) Plan), promissory notes or other documents evidencing
participant loans (to the extent the transferred account balances consist of participant loans) and
cash. Upon the transfer of assets contemplated in this Section 7.1(f)(ii), the Merck 401(k) Plan
shall be relieved of, and the Amended RM 401(k) Plan shall assume, all liability with respect to
the payment of the transferred account balances.

     (iii) Medical Plan. Effective January 1, 1998, the RM Nonunion Medical Benefits Plan
(“RM Medical Plan”) shall be amended (A) to the extent necessary, to provide that Merial Merck
Employees are eligible to participate in the plan, (B) where feasible, to provide for managed care
in locations where Merck provides managed care to its employees immediately prior to January 1,
1998, and (C) to provide that the percentage of the cost of coverage under the plan borne by each
participant shall not be more than [*]. Merial shall cause the RM Medical Plan to waive any preexisting condition
exclusions or restrictions to the extent necessary to provide immediate coverage under the plan for
Merial Merck Employees.

114

 

     (iv) Dental Plan. Effective January 1, 1998, the RM/Select Laboratories, Inc. Dental
Plan (the “RM Dental Plan”) shall be amended to provide that (A) Merial Merck Employees are
eligible to participate in the plan, and (B) to provide that the percentage of the cost of coverage
under the plan borne by each participant shall not be more than [*]. Merial shall cause the RM Dental Plan to waive
any preexisting condition exclusions or restrictions to the extent necessary to provide immediate
coverage under the plan for Merial Merck Employees.

     (v) Other Plans. Effective as of January 1, 1998, Merial shall, or shall cause the
appropriate Merial Venture Company to, establish a health care reimbursement account, dependent
care reimbursement account, group life insurance, accidental death and dismemberment insurance, a
Section 125 plan, and long-term and short-term disability plans that shall cover all U.S. Animal
Health Employees the terms of which shall be determined by the Board of Directors, and such other
plans as are determined by the Board of Directors.

     (vi) Severance Policies.

     (A) Effective as of the Closing Date, Merial shall, or shall cause the appropriate
Merial Venture Company to, establish a severance policy (the “Regular Severance Policy”)
covering the RM U.S. Employees (and, effective as of January 1, 1998, all of the U.S.
Animal Health Employees) that provides, in exchange for an executed release, a severance
benefit of [*] of salary (salary to be defined as base salary excluding overtime,
premiums and other extraordinary payments) for each full year (for any partial year,
prorated based on full calendar months) of service with the Merial Venture, RM and/or Merck
(or their respective Subsidiaries) under circumstances and on terms and conditions as
determined by the Board of Directors. For RM U.S. Employees, for the period from the
Closing Date through December 31, 1997, such Regular Severance Policy shall include

115

 

outplacement services and an additional [*] of salary for each full year of service (for any
partial year, prorated based on full calendar months) plus [*] of salary in lieu of
notice. Benefits payable under the Regular Severance Policy are in lieu of any other severance
arrangements or benefits provided to employees by RM or its Subsidiaries or the Merial Venture.

     (B) Effective prior to the Closing Date, RM shall establish a special severance policy (the
“Special Severance Policy”) covering the employees listed by RM on Schedules 7.1 F-1 and 7.1 F-2
(collectively, the “Eligible Employees”) that provides, in exchange for an executed release by the
Eligible Employees and an agreement as to certain other terms and conditions, a severance benefit
in the event of a termination of employment described in the following sentence of (i) for the
Eligible Employees listed on Schedule 7.1 F-1, [*] of salary [*] of salary for
each full year of service (partial years will not be counted) subject to a maximum of [*]
of salary and for the Eligible Employees listed on Schedule 7.1 F-2, [*] of salary plus
[*] of salary for each full year of service (partial years will not be counted) subject to a
maximum of [*] of salary, (ii) an amount equal to the applicable premium cost to an
Eligible Employee of [*] of continuation of coverage under the RM Medical Plan and the RM
Dental Plan (the “Premium Payment”) plus an additional amount equal to the estimated tax liability
incurred by an Eligible Employee with respect to the Premium Payment (as set forth in the letter
agreement with such Eligible Employee), and (iii) outplacement services. An Eligible Employee (x)
whose employment with RM or the Merial Venture is terminated prior to December 31, 1997, (1) by RM
or the Merial Venture for reasons other than for misconduct or other cause, or (2) by the Eligible
Employee upon reasonable written notice to RM or the Merial Venture if the position offered to the
Eligible Employee by RM or the Merial Venture is not substantially comparable in base salary and
job responsibilities as the

116

 

position held by the Eligible Employee immediately prior to such offer or (y) who is notified prior
to December 31, 1997 that his employment with the Merial Venture will be terminated as of a
specified date occurring after December 31, 1997 and who remains employed through the specified
date, in either case, shall be entitled to the severance benefits described in clauses (i) or (ii),
as applicable, of the first sentence of this paragraph (B). Eligible Employees whose employment is
terminated prior to December 31, 1997 for reasons other than misconduct or other cause will also be
entitled to outplacement services. Benefits payable under the Special Severance Policy are in lieu
of any other severance arrangements or benefits provided to employees by either RM and it
Subsidiaries or the Merial Venture, including the Regular Severance Policy. An Eligible Employee
who is informed prior to December 31, 1997 that his or her employment with the Merial Venture will
be terminated as of a specified date occurring after December 31, 1997 who does not remain employed
through such date will not be entitled to receive, and will not receive, any severance benefits
under the Special Severance Policy or under any other plan, policy or program of RM and its
Subsidiaries or the Merial Venture including the Regular Severance Policy. The Special Severance
Policy will expire on December 31, 1997 and as of January 1, 1998 the Eligible Employees will
participate in the Regular Severance Policy; except those Eligible Employees who are informed prior
to December 31, 1997 that their employment with the Merial Venture will be terminated on a date
after December 31, 1997, in which case, the Special Severance Policy shall continue to apply to
each such Eligible Employee until such specified date. Merial shall (or shall cause the appropriate
Merial Venture Company to) bear the costs of the Special Severance Policy.

     (C) From the Closing Date through December 31, 1997, Merck Leased Employees shall participate
in a severance plan (the “Merck Leased Employees Severance Plan”) to be established by Merck the
terms of which are described in the Merck Employee Leasing Agreement. Effective as of

117

 

the Closing Date, Merck shall establish a special severance policy, covering those Merck
Leased Employees determined by the Board of Directors on terms (including the reimbursement
of Merck by Merial for payments made under such policy) described in the Merck Employee
Leasing Agreement.

     (vii) Bonus Programs. Merial shall establish annual sales and annual incentive
programs effective as of January 1, 1998 on terms and conditions established by the Board of
Directors in which employees of the Merial Venture shall be eligible to participate. RM and Merck
shall continue their respective sales and incentive plans for 1997 for the RM US Employees and the
Merck Leased Employees, respectively; provided, however, that, to the extent
feasible, Merial shall establish the goals for the sales plans for the RM U.S. Employees and the
Merck Leased Employees for the period beginning on the Closing Date and ending on December 31,
1997. Merck shall pay bonuses under the applicable Merck sales and incentive plans to the Merck
Leased Employees. Merial shall reimburse Merck for the cost of the payment of such bonuses on a pro
rata basis in accordance with the terms of the Merck Employee Leasing Agreement.

     Merial shall (or shall cause the appropriate Merial Venture Company to) pay that portion of
the bonuses earned by the RM U.S. Employees under the RM annual sales and incentive plan[s] with
respect to the 1997 bonus period up to and including the Closing Date to the RM U.S. Employees as
soon as practicable after the Closing Date. RP shall bear the obligation for the bonuses paid under
the foregoing sentence pursuant to the Special Dividend described in the following sentence. Merial
shall credit to the Merck Member for the 1997 Fiscal Year a Special Dividend equal to the amount of
such bonuses paid by Merial under the RM annual sales and incentive plan[s] multiplied by [*], as increased by an amount calculated as interest at
[*] from the Closing Date through the earlier of (x) the date on
which the Net Special Dividend in respect of the 1997 Fiscal Year is paid in full, and (y) April
15, 1998. The appropriate Merial Venture Company shall

118

 

pay that portion of the bonuses earned by the RM U.S. Employees under such annual sales and
incentive plan[s] with respect to the 1997 bonus period following the Closing Date to the
RM U.S. Employees in accordance with the terms and conditions of such plans and shall bear
the costs of such payments.

     (viii) Service Credit. Without limiting any of the foregoing provisions of
this Section 7.1, Merial shall, or shall cause the appropriate Merial Venture Company to,
recognize for U.S. Animal Health Employees all service with Merck and RM and their
respective affiliates and predecessors prior to such employees becoming employees of the
Merial Venture for all purposes under the plans of the Merial Venture, other than pension
benefit accrual, for which such service was recognized by Merck or RM or their respective
Subsidiaries and Merial shall, or shall cause the appropriate Merial Venture Company, to
waive for U.S. Animal Health Employees any pre-existing condition exclusions or
restrictions and, for other than the Merck LTD Employees, any actively-at-work requirements
imposed by any of the Merial plans.

     (ix) Change in Transfer Date. January 1, 1998 is assumed to be the date on
which Merck Leased Employees shall become Merial Merck Employees. If January 1, 1998 is not
the transfer date, Merck and RP shall agree on the appropriate transfer date and
appropriate adjustments to be made to the terms and costs provided for in this Article VII.

     (g) Transfer of Certain Rhône Mérieux, Inc. Employees. As of the Closing Date, Rhône
Mérieux, Inc. shall cause the employment of those RM U.S. Employees who are employed by Rhône
Mérieux, Inc. as of such date as sales and distribution employees (the “S&D Employees”) to be
transferred to Merial (or to a Merial Venture Company designated by Merial). Effective as of the
Closing Date, Merial (or the appropriate Merial Venture Company) shall become a participating
employer in the RM Plans in which the S&D Employees participated prior to the Closing Date and the
S&D Employees shall remain participants in such plans to the extent and under the terms in which
they participated in such plans prior to the Closing Date.

119

 

SECTION 7.2. Animal Health Division — Outside U.S.

     (a) Leasing or Transfer of Merck Group Employees Outside of the U.S. Except as
otherwise agreed by Merck and RM prior to the Closing, after the Closing, employees of the Merck
Group employed in the Animal Health Business outside of the U.S. may be leased to Merial, or to a
Merial Venture Company designated by Merial, to the extent permitted by local law and as agreed to
by Merck and RM on or prior to the Closing, and transferred to Merial, or to a Merial Venture
Company designated by Merial as soon as practicable after the Closing. The terms of any leasing
agreement for each applicable country shall be substantially similar to the terms of the Merck
Employee Leasing Agreement, with the percentage of payroll for benefits for the leased employees
charged to Merial (or the appropriate Merial Venture Company) to be not less than the actual charge
for benefits to the Animal Health Division of the Merck Group for such employees in effect
immediately prior to the Closing Date. Where leasing is not permitted or where Merck and RM have
not agreed on or prior to the Closing that leasing is appropriate, employees of the Merck Group
employed in the Animal Health Business outside the U.S. shall be transferred to Merial, or to a
Merial Venture Company designated by Merial, as of the Closing Date and shall participate in plans
of the Merial Venture (or such other plans as Merial shall deem appropriate) as of the Closing
Date.

     (b) Compensation and Benefit Plans. The compensation and benefit programs of the
Merial Venture for employees of the Animal Health Business outside of the U.S. shall be reviewed on
a country by country basis and such revisions, if any, as may be necessary to ensure that such
programs are competitive in the applicable marketplace shall be made by Merck and RM prior to the
Closing Date and by the Board of Directors after the Closing Date. Any transition arrangements,
including but not limited to those regarding grandfathered pension and retiree health arrangements
(and cost-sharing among the parties hereto with respect to such arrangements), credit for prior
service, waiver of any pre-existing condition exclusions or restrictions, severance arrangements
and cost sharing, shall be determined on a country-by-country basis by Merck and RM prior to the
Closing Date and by the Board of Directors after the Closing Date.

120

 

     (c) Costs of Transaction. Notwithstanding anything to the contrary in this Article
VII, in the event that Merck or its Subsidiaries or RM or its Subsidiaries incurs liability or
obligation as a result of the consummation of the transactions contemplated in this Agreement, to,
or with respect to their respective employees outside of the U.S. whose employment is being
transferred or assumed by the Merial Venture, Merial shall (i) credit to the Merck Member in
respect of the Fiscal Year in which such liability or obligation is paid by the Merck Group, a
Special Dividend equal to the cost multiplied by [*]
Merck or its Subsidiaries incurs with respect to such liability or obligation (as increased by an
amount calculated as interest at [*] from the date such liability
or obligation is paid by the Merck Group through the earlier of (x) the date on which the Net
Special Dividend in respect of such Fiscal Year is paid in full, and (y) April 15 of the calendar
year immediately following the Fiscal Year in respect of which the Special Dividend is to be paid)
and (ii) honor the obligation of RM or its Subsidiaries.

     (d) Assumption of Employment Contracts. Notwithstanding anything to the contrary
contained in this Article VII, to the extent required by law, the appropriate Merial Venture
Company will assume the existing employment contracts and obligations arising out of the employment
relationship of those employees of the Merck Group employed in the Animal Health Business outside
the U.S. whose employment is transferred to a Merial Venture Company in connection with the
consummation of the transactions contemplated under this Agreement, unless and until otherwise
negotiated by Merial with the consent of such employees.

     (e) Merck Stock Options. In addition to any stock option grants made prior to the
date of this Agreement under the Merck Stock Option Plans, Merck may make an additional grant under
the current Merck Stock Option Plan to be priced as of the Closing Date to selected employees of
the Merck Group employed in the Animal Health Business outside of the U.S., as determined by Merck,
who become employees of the Merial Venture as of the Closing Date. Merck will provide shares of
Merck common stock obtained upon exercise of any stock option grants which have been made by Merck
under the Merck Option Plans to any such employees which are outstanding as of the Closing

121

 

Date. Promptly after such exercise, Merck may invoice on an employee by employee basis and, if so
invoiced, Merial (or the appropriate Merial Venture Company) will pay to Merck (within fifteen (15)
days after receipt of such invoice), the Spread with respect to such exercise. Merial shall credit
to the RP Member in respect of any Fiscal Year in which it pays a Spread to Merck, a Special
Dividend equal to the aggregate of (x) all Spreads paid in such Fiscal Year by Merial to Merck plus
(y) any incidental costs associated with the payment of such Spreads and paid by the Merial Venture
(i.e, any employer taxes paid). Any Special Dividend (as described in the foregoing sentence) that
may be credited to the RP Member in respect of any Fiscal Year shall be increased by an amount
calculated as interest at a rate equal to [*] accruing from December
31 of such Fiscal Year through the earlier of (x) the date on which the Net Special Dividend in
respect of that Fiscal Year is paid in full, and (y) April 15 of the Fiscal Year immediately
following the Fiscal Year in respect of which the Special Dividend is to be paid.

SECTION 7.3 Animal Health Division — Worldwide

     As of January 1, 1998, Merial shall establish a long-term incentive plan in which key
management employees of the Merial Venture employed in the Animal Health Business both inside and
outside of the U.S. and deemed appropriate by Merial shall participate. The plan shall be a
[*].

SECTION 7.4. Poultry Genetics Division

     (a) Compensation and Benefit Plans. Following the Closing and until a date
agreed upon by Merck and RM before the Closing or by the Board of Directors after the Closing (but,
to the extent feasible, not less than one year following the Closing Date), Merial shall, or shall
cause the Transferred Subsidiaries engaged in the Poultry Genetics Business (the “Poultry Genetics
Subsidiaries”), to continue to, maintain the employee benefit plans (or substantially equivalent
employee benefit plans) other than stock based plans that were in effect for the employees of the
respective Poultry Genetics Subsidiaries immediately prior to the Closing. Merial (or the Poultry
Genetics Subsidiary maintaining

122

 

such plan) shall bear the costs of all such employee benefit plans other than Pre-Closing Benefit
Liabilities. For individuals who are employees of the Poultry Genetics Subsidiaries immediately
prior to Closing, Merial shall, or shall cause the Poultry Genetics Subsidiaries to, (i) recognize
all service with Merck, RM and the Poultry Genetics Subsidiaries and their respective affiliates
and predecessors for all purposes under the Merial Venture plans established after the Closing for
employees of the Poultry Genetics Subsidiaries, other than pension benefit accrual, for which such
service was recognized for such individuals by Merck, RM or the Poultry Genetics Subsidiaries and
(ii) waive any pre-existing condition exclusions or restrictions and actively at work requirements
imposed by any such Merial Venture plans.

     (b) Merck Stock Options. In addition to any stock option grants made prior to
the date of this Agreement under the Merck Stock Option Plans, Merck may make an additional grant
under the current Merck Stock Option Plan, to be priced as of the Closing Date, to selected
employees of the Merck Transferred Subsidiaries as determined by Merck. Merck will provide the
shares of Merck common stock obtained upon exercise of any stock option grants which have been made
by Merck under the Merck Stock Option Plans to any employee of the Merck Transferred Subsidiaries
which are outstanding as of the Closing Date. Promptly after any such exercise, Merck may invoice
on an employee by employee basis and, if so invoiced, Merial will pay to Merck (within fifteen (15)
days after receipt of such invoice), the Spread with respect to such exercise. Merial shall credit
to the RP Member in respect of any Fiscal Year in which it pays a Spread to Merck, a Special
Dividend equal to the aggregate of (x) all Spreads paid in such Fiscal Year by Merial to Merck plus
(y) any incidental costs associated with the payment of such Spreads and paid by the Merial Venture
(i.e., any employer taxes paid). Any Special Dividend (as described in the foregoing sentence) to
be credited to the RP Member in respect of any Fiscal Year shall be increased by an amount
calculated as interest at a rate equal to [*] accruing from
December 31 of such Fiscal Year through the earlier of (x) the date the Net Special Dividend in
respect of such year is paid in full, and (y) April 15 of the Fiscal Year immediately following the
Fiscal Year in respect of which the Special Dividend is to be paid.

123

 

SECTION 7.5. Employee and Employee Benefit Plan Related Indemnities or Special Dividends

     (a) RP Indemnities and Merck Special Dividends.

     (i) Merial shall credit to the Merck Member in respect of the Fiscal Year in
which the RM Plans’ Liabilities/Assets Calculation (as defined below) is calculated, a
Special Dividend equal to the amount, if any, by which the aggregate of the Pre-Closing
Benefit Liabilities with respect to the RM Transferred Benefit Plans exceed the aggregate
fair market value of the assets of the RM Transferred Benefit Plans as of the Closing Date
which assets shall include insurance proceeds actually recovered by the Merial Venture that
cover any such liabilities (the “RM Plans’ Liabilities/Assets Calculation”). Any such
amount to be credited as a Special Dividend pursuant to the foregoing sentence shall be
increased by an amount calculated as interest at [*] from
the Closing Date through the earlier of (x) the date the Net Special Dividend in respect of
such year is paid in full, and (y) April 15 of the Fiscal Year immediately following the
Fiscal Year in respect of which the Special Dividend is to be paid. The calculation of
liabilities for RM Transferred Benefit Plans shall not include any liability for which RP is
obligated to reimburse the Merial Venture, or that is otherwise specifically retained by RP,
pursuant to Section 7.1. The RM Plans’ Liabilities/Assets Calculation shall be calculated as
soon as reasonably practicable after the Closing Date. Merial shall credit to the RP Member
in respect of the Fiscal Year in which the RM Plans’ Liabilities/Assets Calculation is
calculated, a Special Dividend equal to the amount, if any, by which the aggregate fair
market value of the assets of the RM Transferred Benefit Plans as of the Closing Date exceed
Pre-Closing Benefits Liabilities under the RM Plans’ Liabilities/Assets Calculation (as
increased by an amount calculated as interest at [*] from
the Closing Date through the earlier of (x) the date the Net Special Dividend in respect of
such year is paid in full, and (y) April 15 of the Fiscal Year immediately following the
Fiscal Year in respect of which the Special Dividend is to be paid).

124

 

     (ii) RP shall indemnify the Merial Venture against, and agrees to hold it harmless from, any
Damages (including lawsuits and Third Party claims, whether or not meritorious) incurred or
suffered by the Merial Venture following the Closing resulting from, arising out of, or relating to
any violation of law, ruling or regulation occurring or existing prior to the Closing with respect
to any RM Transferred Benefit Plan; provided, however, that this indemnity shall
not apply to (A) any claim for benefits under an RM Transferred Benefit Plan the liabilities for
which were accounted for in the RM Plans’ Liabilities/Assets Calculation, or (B) RM Pre-Closing
Taxes.

     (iii) RP shall indemnify the Merial Venture against, and agrees to hold it harmless from,
Damages (including lawsuits and Third Party claims, whether or not meritorious) incurred or
suffered by the Merial Venture following the Closing resulting from, arising out of, or relating to
any Benefit Plan established, sponsored or maintained by RP, any of its Subsidiaries or any RP
ERISA Affiliate (other than the RM Transferred Benefit Plans) whether arising out of any event or
state of facts occurring or existing prior to, on, or after the Closing Date; provided,
however, that this indemnity shall not apply to any RM Pre-Closing Taxes; provided,
further, however, that in the event that a Merial Venture Company becomes a
participating employer in an RM Benefit Plan (other than an RM Transferred Benefit Plan) this
indemnity will not apply to Damages incurred or sustained by the Merial Venture Company as a result
of its action or failure to act in accordance with the terms and conditions of its agreement with
any member of the RP Group to be such a participating employer.

     (b) Merck Indemnities and RP Special Dividends.

     (i) Merial shall credit to the RP Member in respect of the Fiscal Year in which the Merck
Plans’ Liabilities/Assets Calculation (as defined below) is calculated, a Special Dividend equal to
the amount, if any, by which the aggregate of the Pre-Closing Benefit Liabilities with respect to
the Merck Transferred Benefit Plans exceed the aggregate fair market value of the assets of the
Merck

125

 

Transferred Benefit Plans as of the Closing Date, which assets shall include insurance proceeds
actually recovered by the Merial Venture that cover any such liabilities (the “Merck Plans’
Liabilities/Assets Calculation”). Any amount to be credited as a Special Dividend pursuant to the
foregoing sentence shall be increased by an amount calculated as interest at [*] from the Closing Date through the earlier of (x) the date the Net Special Dividend
in respect of such year is paid in full, and (y) April 15 of the Fiscal Year immediately following
the Fiscal Year in respect of which the Special Dividend is to be paid. The calculation of
liabilities for Merck Transferred Benefit Plans shall not include any liability for which Merck is
obligated to reimburse the Merial Venture, or that is otherwise specifically retained by Merck,
pursuant to Section 7.1. The Merck Plans’ Liabilities/Assets Calculation shall be calculated as
soon as reasonably practicable after the Closing Date. Merial shall credit to the Merck Member in
respect of the Fiscal Year in which the Merck Plans’ Liabilities/Assets Calculation is calculated,
a Special Dividend equal to the amount, if any, by which the aggregate fair market value of the
assets of the Merck Transferred Benefit Plans exceed Pre-Closing Benefits Liabilities under the
Merck Plans’ Liabilities/Assets Calculation (as increased by an amount calculated as interest at
[*] from the Closing Date through the earlier of (x) the date the
Net Special Dividend in respect of such year is paid in full, and (y) April 15 of the Fiscal Year
immediately following the Fiscal Year in respect of which the Special Dividend is to be paid).

     (ii) Merck shall indemnify the Merial Venture against, and agrees to hold it harmless from,
Damages (including lawsuits and Third Party claims, whether or not meritorious) incurred or
suffered by the Merial Venture following the Closing resulting from, arising out of, or relating to
any violation of law, ruling or regulation occurring or existing prior to the Closing with respect
to any Merck Transferred Benefit Plan; provided, however, that this indemnity shall
not apply to (A) any claim for benefits under a Merck Transferred Benefit Plan the liabilities for
which were accounted for in the Merck Plans’ Liabilities/Assets Calculation, or (B) Merck
Pre-Closing Taxes.

126

 

     (iii) Merck shall indemnify the Merial Venture against, and agrees to hold it harmless
from, Damages (including lawsuits and Third Party claims, whether or not meritorious)
incurred or suffered by the Merial Venture following the Closing resulting from, arising
out of, or relating to any Benefit Plan established, sponsored or maintained by Merck, any
of its Subsidiaries or any Merck ERISA Affiliate (other than the Merck Transferred Benefit
Plans and the Merck Stock Option Plans) whether arising out of any event or state of facts
occurring or existing prior to, on, or after the Closing Date; provided,
however, that this indemnity shall not apply to any Merck Pre-Closing Taxes;
provided, further, however, that in the event that a Merial Venture
Company becomes a participating employer in a Merck Benefit Plan (other than a Merck
Transferred Benefit Plan) this indemnity will not apply to Damages incurred or sustained by
the Merial Venture Company as a result of its action or failure to act in accordance with
the terms and conditions of its agreement with any member of the Merck Group to be such a
participating employer.

     (c) FAS
106 Reduction Merck Special Dividend. If the FAS 106 liability on an
accumulated post-retirement benefit obligation basis with respect to post retirement benefits for
participants in the plans of Hubbard Farms Inc. or its successor which provide post-retirement
benefits (other than pension benefits), as those plans are in effect on the Closing Date, is
reduced after the Closing Date as a result of amendments made to such plans effective on or before
January 1, 1999, then the Merck Member shall be credited with a special dividend (a “Reduction
Special Dividend”) equal to the amount of such reduction. A Reduction Special Dividend shall be
determined as of the effective date of the benefit reduction (the “Reduction Date”) using the
Reduction Date demographics of eligible participants under the applicable plans and based upon the
actuarial assumptions used by Merck for calculating the expense for the applicable plans pursuant
to FAS 106 on an accumulated post-retirement benefit obligation basis for 1997. Merial shall credit
to the Merck Member in respect of the Fiscal Year in which the Reduction Special Dividend is
calculated, a Special Dividend equal to the Reduction Special Dividend (as increased by an amount
calculated as interest at [*] from the Reduction Date through the
earlier of (x) the date the Net Special Dividend in respect of

127

 

such year is paid in full, and (y) April 15 of the Fiscal Year immediately following the Fiscal
Year in respect of which the Special Dividend is to be paid.).

     (d) Procedures Governing Indemnities. The procedures set forth in Section 14.7 shall
govern the indemnities set forth in Sections 7.5(a)(ii) and (iii) and 7.5(b)(ii) and (iii). The
provisions set forth in Sections 7.5(a)(i), 7.5(b)(i) and 7.5(c) shall not be governed by the
procedures set forth in Section 14.7 but according to the provisions set forth in such Sections.

     (e) Certain Indemnities Subject to Basket. The indemnities and other provisions set
forth in Sections 7.5(a)(ii) and 7.5(b)(ii) shall be subject to the limitations set forth in
Section 14.6. The indemnities set forth in Sections 7.5(a)(i) and (iii), 7.5(b)(i) and (iii) and
7.5(c) shall not be subject to the limitations set forth in Section 14.6.

128

 

ARTICLE VIII

REPRESENTATIONS AND WARRANTIES OF IM AND RM

     IM and RM hereby represent and warrant, as of the date hereof and as of the Closing Date, to
Merck and Merck SH and to Merial as follows:

SECTION 8.1. Organization; Powers

     IM and RM and each of RM’s Subsidiaries (a) is a corporation or company duly organized and
validly existing and (to the extent applicable) in good standing under the laws of its jurisdiction
of organization, (b) has all requisite corporate or similar power and authority to own or lease and
operate its property and assets and to carry on its business as now conducted, (c) is qualified or
licensed to do business and is in good standing in every jurisdiction where such qualification or
licensing is required, except where the failure so to qualify would not result in a Material
Adverse Change or Effect, and (d) has the corporate or similar power and authority to execute,
deliver and to perform its obligations under (as applicable) this Agreement and any and all
Ancillary Agreements to which it is a party or by which it is bound.

SECTION 8.2. Authorization; No Breach

     The execution and delivery by each of IM and RM (as applicable) of each of this Agreement and
any and all Ancillary Agreements to which it is a party or by which it is bound, and the
consummation of the Transactions, (a) have been duly authorized by all necessary action and do not
require the consent or approval of its shareholders or partners, except such consents or approvals
as have been obtained, and (b) do not (i) violate or conflict with (A) any Law or regulation
applicable to it or any of its assets or properties, or (B) its statuts, or (ii) violate, conflict
with, result in a breach of or constitute (alone or with notice or lapse of time or both) a default
under, require any consent under, or give to any Third Party any rights of termination, amendment,
acceleration, suspension, revocation or cancellation of or result in any Encumbrance on

129

 

any of the assets of IM, RM or its Subsidiaries pursuant to, any provisions of any agreements
(including any notes, contracts, leases, licenses or other instruments or arrangements) by which it
or any RM Subsidiary is bound, except, in the case of this clause (ii), for such violations,
conflicts, breaches, defaults, required consents, rights or Encumbrances, (x) that would not in the
aggregate cause a Material Adverse Change or Effect or (y) that are listed in Schedule 8.20-2.

SECTION 8.3. Enforceability

     This Agreement has been duly executed and delivered by each of IM and RM and constitutes, and
each Ancillary Agreement when executed and delivered by each of IM and/or RM (as applicable)
constitutes or will constitute, its legal, valid and binding obligation, enforceable against it in
accordance with its terms, subject, however, to any limitations with respect to enforcement which
may be imposed in connection with (i) bankruptcy, insolvency, reorganization, moratorium or other
laws affecting the enforcement of creditors’ rights generally, and (ii) general principles of
equity (regardless of whether considered and applied in a proceeding at law or in equity).

SECTION 8.4. Governmental Approvals

     All permits, consents and approvals of, registrations with, notices to, and other actions by,
all Public Authorities that are required by IM or RM or any RM Subsidiary in connection with the
Transactions (collectively the “RM Approvals”) have been made or obtained and are in full force and
effect, except that, as of the date hereof (but not as of the Closing), the following RM Approvals
have not been made or obtained: (i) the approval of the merger control authorities of the European
Union, (ii) the agrément fiscal described in Section 11.2(b), (iii) the required approvals of
Public Authorities listed in Schedule 8.4, and (iv) such other items which the failure to obtain,
individually or in the aggregate, would not have a Material Adverse Change or Effect. None of IM or
RM or any RM Subsidiary has taken or omitted to take any action which permits, or after notice or
lapse of time or both would permit, any modification or termination of any of the RM Approvals.

130

 

SECTION 8.5. Historical Financial Data

     True and complete copies of RM’s audited consolidated financial statements, i.e., the balance
sheet and income statement as of and for the year ended December 31, 1996 (together, the “RM
Financials”) are provided as Exhibit XVII. The RM Financials were derived from the books and
records of RM and its Subsidiaries, and such RM Financials were prepared in accordance with U.S.
GAAP consistently applied and consistent with the accounting principles of the RP Group as
described in note 1 to the Consolidated Financial Statements included in the RP 1996 Annual Report
filed on Form 20-F, and present fairly RM’s and its Subsidiaries’ consolidated assets and
Liabilities, income and expenses and cash flows as of the dates and for the periods indicated.

SECTION 8.6. No Undisclosed Liabilities

     (a) Liabilities at December 31, 1996. As at December 31, 1996, RM and its Subsidiaries
had no Liabilities of any nature, whether accrued, contingent or otherwise (including Liabilities
as guarantor or otherwise with respect to obligations of others, Liabilities for taxes due or then
accrued or to become due or Liabilities that have been incurred but not yet reported), that were
not adequately reflected or reserved against on the December 31, 1996 balance sheet of the RM
Financials and which individually exceeded [*] or which in the aggregate exceeded [*].

     (b) RM Contributed Liabilities. Except for any such Liabilities that would not
in the aggregate exceed [*], and except for the Debt incurred in connection with the Central
Biologics Acquisition, all the Liabilities of RM and its Subsidiaries that are being contributed to
the Merial Venture as a result of the Transactions either (i) are reflected on the December 31,
1996 balance sheet of the RM Financials, as described in Section 8.5, (ii) arose in the ordinary
course of business since December 31, 1996, or (iii) are or will be disclosed in Schedule 14.2A-2
in accordance with Section 14.2(a).

131

 

SECTION 8.7. Receivables

     Except to the extent, if any, indicated on the December 31, 1996 balance sheet of the RM
Financials, all Receivables reflected thereon arose from the sale of Inventory or services in the
ordinary course of business consistent with past practice and constitute only valid, undisputed
claims of RM or its Subsidiaries not subject to valid claims of set-off or other defenses or
counterclaims other than normal cash discounts accrued in the ordinary course of business
consistent with past practice. All Receivables reflected on the December 31, 1996 balance sheet
of the RM Financials or arising since the date thereof (subject to the reserves for bad debts, if
any, reflected on the December 31, 1996 balance sheet of the RM Financials) are good, and have been
collected or are or will be collectible, without resort to extraordinary collection activity, in
the ordinary course of business and, in any case, by the later of (x) the date that is twelve (12)
months from the Closing Date, or (y) if a Receivable is not by its terms due within such 12 month
period, the date that is three months after its due date.

SECTION 8.8. Inventories

     Subject to amounts reserved therefor on the December 31, 1996 balance sheet of the RM
Financials, the values at which all Inventories are carried on the December 31, 1996 balance sheet
of the RM Financials reflect the historical inventory valuation policy of RM and its Subsidiaries
of stating such Inventories at the lower of cost (determined on the first-in, first-out method) or
market value. Except as set forth in Schedule 8.8-1, RM and its Subsidiaries have good and
marketable title to the Inventories free and clear of all liens or other Encumbrances. Except as
set forth in Schedule 8.8-2 or reserved against in the RM Financials, the Inventories do not
consist of, in any material amount, items that are obsolete, damaged or slow-moving or of any items
held on consignment. Neither RM nor any of its Subsidiaries is under any obligation or Liability
with respect to accepting returns of items of Inventory or merchandise in the possession of its
customers other than in the ordinary course of business consistent with past practice. No
clearance or extraordinary sale of the Inventories has been conducted since December 31, 1996.
Since December 31, 1996, neither RM nor any of its Subsidiaries has acquired or

132

 

committed to acquire or manufacture Inventory for sale which is not of a quality and quantity
usable in the ordinary course of business within a reasonable period of time and consistent with
past practice, nor has RM or any of its Subsidiaries changed the price of any Inventory except for
(i) reductions to reflect any reduction in the cost thereof to RM or its Subsidiaries, (ii)
reductions and increases responsive to normal competitive conditions and consistent with past sales
practices, or (iii) increases to reflect any increase in the cost thereof to RM or its
Subsidiaries. Other than as reflected on the December 31, 1996 balance sheet of the RM
Financials, the Inventories of RM and its Subsidiaries are in good and merchantable condition in
all material respects, are suitable and usable for the purposes for which they are intended and are
in a condition such that they can be sold in the ordinary course of business consistent with past
practice.

SECTION 8.9. Absence of Certain Developments

     Except for the actions taken by IM, RM or RM’s Subsidiaries in connection with the creation of
the Merial Venture as contemplated by this Agreement and the applicable Ancillary Agreements or as
disclosed in Schedule 8.9, since December 31, 1996, RM and its Subsidiaries have operated in the
ordinary course of business consistent with past practice, and there has not been:

     (a) any sale, assignment, transfer or other disposition to any Third Party of, or
imposition of any liens or other Encumbrance on, any properties, assets, Inventories or obsolete
items of RM or any of its Subsidiaries, without any and all proceeds [*] for all such sales, assignments, transfers or other dispositions (other than sales of
Inventory in the ordinary course of business consistent with past practice) remaining within RM and
its Subsidiaries. IM and RM covenant and agree that all such proceeds [*] (plus all the proceeds from the Diagnostic Disposal, which the Parties hereby agree
is not subject to the [*] exclusion referred to above) shall through the Closing Date be
segregated and held in a separate bank account owned by RM or an RM Subsidiary (these proceeds [*] being referred to as the “RM Assets Sale Proceeds”) and
thereby contributed to the Merial Venture on the Closing Date;

133

 

     (b) any damage, destruction or casualty loss to any assets or properties of RM or any of its
Subsidiaries, whether or not covered by insurance, which, individually or in the aggregate, has a
Material Adverse Change or Effect;

     (c) any material change in any accounting principle used by RM or any of its Subsidiaries;

     (d) other than in the ordinary course of business, any transaction, commitment or agreement
entered into by RM or any of its Subsidiaries, or any relinquishment by RM or any of its
Subsidiaries of any rights under any agreement or otherwise, having a value or involving aggregate
payments [*];

     (e) any grant of any rights or licenses or entry into any licensing or
distributorship or agency arrangements by RM or any of its Subsidiaries which,
individually or in the aggregate, has a Material Adverse Change or Effect;

     (f) any loss of employees or any changes in any of RM’s or any of its Subsidiaries’ employee
benefit plans (other than those required by applicable law) which, individually or in the
aggregate, has a Material Adverse Change or Effect;

     (g) other than in the ordinary course of business, any disclosure of any secret or
confidential Intellectual Property (except by way of issuance of a patent or pursuant to this
Agreement or the Ancillary Agreements) or any lapse or abandonment of Intellectual Property (or any
registration or grant thereof or any application relating thereto) to which, or under which, RM or
its Subsidiaries has any right, title, interest or license;

     (h) expenditures or failure to make expenditures on capital investment projects by RM or
any of its Subsidiaries that were not substantially consistent with the investment plans in
existence as of December 31, 1996 relating to such projects as disclosed in writing to Merck prior
to the date of this Agreement;

134

 

     (i) any transaction, commitment or agreement entered into between RP or any of its
Subsidiaries (other than RM and its Subsidiaries), on the one hand, and RM or any of its
Subsidiaries, on the other hand; or

     (j) any authorization, approval, agreement or other binding commitment to do any of the
foregoing.

SECTION 8.10. Title to Properties; Possession Under Leases

     (a) RM and its Subsidiaries own and have good title to all of their assets and properties
reflected as owned on the December 31, 1996 balance sheet included in the RM Financials, free and
clear of any material Encumbrances, except for (i) any Encumbrances specifically disclosed in the
RM Financials or set forth in Schedule 8.10A, (ii) assets and properties disposed of, or subject to
purchase or sales orders, in the ordinary course of business since December 31, 1996, (iii)
Encumbrances securing the rights of materialmen, carriers, landlords and like persons, all of which
are not yet due and payable, and (iv) liens for taxes not yet delinquent.

     (b) (i) RM and each of its Subsidiaries has complied with all its material obligations under
all material leases to which it is a party as lessee of property, (ii) all such leases are in full
force and effect, (iii) RM or the relevant Subsidiary enjoys peaceful and undisturbed possession
under each such lease, (iv) to the knowledge of RM, the other parties to such leases have complied
with all their material obligations thereunder, and (v) there are no material unresolved disputes
under any of such leasehold interests.

     (c) (i) All material real property, and all material buildings, improvements and fixtures
thereon have been maintained in accordance with the standard practices and procedures of RM and its
Subsidiaries and are in all material respects in good condition and have no material structural
defects, (ii) such material real property, buildings, improvements and fixtures and the use thereof
conform in all material respects to all applicable building, zoning, land use and like requirements
and all material certificates and permits for the lawful use and occupancy thereof and the
machinery and equipment

135

 

thereon have been issued, and (iii) no current use of any of such property is dependent in any
material respect on a non-conforming use or permit or violates any Law, regulation or decision of
any Public Authority.

     (d) Set forth in Schedule 8.10D is a true and complete list as of the date of this
Agreement of all real property owned by RM or any of its Subsidiaries or in respect of which RM or
any of such Subsidiaries is lessee.

          Subject only to Section 11.6(b) (and to consents that may be required under RM contributed
contracts other than those required to be listed in Schedule 8.20-1), and except as set forth in
Schedule 8.10C, following the consummation of the Transactions, the Merial Venture will own, with
good valid and marketable title, or lease, under valid and subsisting leases, or otherwise acquire
the assets of RM and its Subsidiaries, free and clear of any Encumbrances except as referred to
above in clauses (i) through (iv) of Section 8.10(a), and without incurring any penalty or other
adverse consequence, including without limitation, any increase in rentals, royalties, or license
or other fees imposed as a result of, or arising from, the consummation of the Transactions.

SECTION 8.11. Intellectual Property

     (a) To the knowledge of RM, RM and its Subsidiaries own, or are licensed to use, or
otherwise have the right to use all Patents, trademarks, service marks, trade names, logos,
franchises, and copyrights, and all applications for any of the foregoing, and all technology,
inventions, trade secrets, Know-How, computer software and processes used in the conduct of their
respective businesses as now conducted, including for the manufacture and sale of all RM Existing
Products; and none of such rights shall be adversely affected by the execution, delivery or
performance of this Agreement or any Ancillary Agreement. Except as indicated in Schedule 8.11, RM
is not aware of any reason that would prevent any pending applications to register material
trademarks, or any pending material patent applications, from being granted.

136

 

     (b) Set forth in Schedule 8.11 are true and complete lists of all Patents and registered
trademarks and trademark applications which are owned by RM or any of its Subsidiaries or which RM
or any such Subsidiaries are licensed to use or otherwise have the right to use (collectively, the
“RM Proprietary Rights”). To the extent indicated in Schedule 8.11, all owned RM Proprietary
Rights have been registered in, filed in or issued by the appropriate Public Authorities in each
relevant jurisdiction, and in each case such proprietary rights are currently in effect and all
maintenance fees and renewals thereof have been duly made with respect thereto.

     (c) Except as set forth in Schedule 8.11, RM is not aware (i) that any of its activities or
those of any of its Subsidiaries as currently conducted infringe upon the proprietary rights of
others, nor has RM or any of its Subsidiaries received any notice or claim from any Third Party of
such infringement by RM or any of its Subsidiaries, or (ii) of any infringement by any Third Party
on, or any competing claim of right to use or own any of, the RM Proprietary Rights. RM and its
Subsidiaries have the right to use, free and clear of claims or rights of others, all customer
lists and computer software used in the conduct of their respective businesses.

SECTION 8.12. Product Registrations

     Set forth in Schedule 8.12 are true and complete lists of the Animal Health Products and
Poultry Genetics Products of RM and its Subsidiaries for which Product Registrations have been
applied for, are valid and in full force and effect or are in the process of being timely renewed,
indicating for each product the jurisdiction of each such Product Registration, application or
renewal, and whether such application has been applied for, is valid, or is in the process of being
renewed. Such product registrations permit RM to market the products covered thereby in the
jurisdiction indicated thereby, and RM is aware of nothing that would interfere with RM’s right to
market such products in the jurisdiction indicated. Each such Product Registration shall become
the property of the Merial Venture upon (and shall not be adversely affected by) the contribution
of RM and its Subsidiaries to Merial.

137

 

SECTION 8.13. Product Warranty and Product Recalls; Labels

     (a) Other than as indicated in Schedule 8.13, since January 1, 1993, there have been no
“recalls” or “seizures” or “market withdrawals” (as such terms, or words of similar import, are
used in the regulations promulgated under the U.S. Food, Drug and Cosmetic Act or similar food and
drug laws promulgated by any Public Authority in any other jurisdiction) with respect to any RM
Existing Product. The Label of each RM Existing Product sold by RM or any of its Subsidiaries in
any country accurately reflects the conditions for safe and effective use of such Existing Product
in accordance with the laws and regulations of such country and each such Product is sold under an
appropriate Label.

     (b) Other than as indicated in Schedule 8.13, since January 1, 1993 neither RM nor any of its
Subsidiaries has received any adverse experience reports indicating any material safety or efficacy
problems that would materially change the general risk/benefit assessment upon which such Existing
Product is prescribed for its approved indications and no material change in any Label of any RM
Existing Product has been required by any Public Authority or otherwise been implemented as a
result of any such report.

SECTION 8.14. Absence of Third Party Joint Ventures

     Except as set forth in Schedule 8.14, neither RM nor any of its Subsidiaries has an ownership
interest in any joint venture (whether or not organized as a legal entity) or other company or
business (except RM and its Subsidiaries) which conducts Merial Venture Business activities and the
ownership of or profits from which are shared with Third Parties.

SECTION 8.15. Litigation; Compliance with Laws

     (a) Except as set forth in Schedule 8.15A, and except for such actions, suits or
proceedings with amounts or potential amounts individually in issue of less than $100,000, there
are no actions, suits or proceedings at law or in equity or by or before

138

 

any Public Authority pending or, to the knowledge of RM, threatened against it or any of its
Subsidiaries or in respect of this Agreement or any of the Ancillary Agreements. Schedule 8.15A
sets forth a complete and correct list of all such actions, suits or proceedings that are active or
have been active since January 1, 1993 (or with respect to actual or potential Environmental
Liabilities, January 1, 1991), and includes for completed matters a general description of the
results thereof (including the amount of any monetary judgments and the principal terms of any
other relief assessed in connection therewith).

     (b) Except for any non-compliance which would not, individually or in the aggregate, result in
a Material Adverse Change or Effect, RM and its Subsidiaries at all times since January 1, 1993
have been and are currently in compliance with (i) all Laws, Permits, published standards that have
the force and effect of Laws, and Environmental Laws, and (ii) all judgments, orders, writs,
injunctions, decrees or rulings of Public Authorities applicable to them.

     (c) In each case other than such Permits the absence of which would not, individually or in
the aggregate, result in a Material Adverse Change or Effect, RM and its Subsidiaries have all
licenses, permits, franchises, orders or approvals of any Public Authority, including under
Environmental Laws, necessary to the conduct of their respective businesses (collectively,
“Permits”); such Permits are in full force and effect; and no proceeding is pending or, to the best
knowledge of RM, threatened, to revoke or limit any such Permit. Schedule 8.15C identifies all
Permits that are non-transferable or that will require the consent of any Public Authority in order
to give effect to the Transactions.

SECTION 8.16. Tax Returns

     RM and each of its Subsidiaries have filed or caused to be filed in a timely manner all Tax
Returns required to have been filed by them (or have obtained or timely applied for an extension
with respect to any such filing) and have paid or caused to be paid, or made adequate provision for
the payment of, all Taxes shown to be due and

139

 

payable on such returns or on any assessments received by them, except Taxes that are being
contested by them in good faith and except where the failure to file such returns or pay Taxes
would not in the aggregate (i) cause a Material Adverse Change or Effect, or (ii) result in the
imposition of an Encumbrance on any of their assets. Neither RM nor any of its Subsidiaries is
party to or bound by (a) any agreement providing for the allocation or sharing of Taxes with any
Third Party which agreement will be in effect after the Closing, or (b) any agreement (other than
elections prescribed by generally applicable Tax Laws and regulations) with any Taxing Authority
which may restrict the Merial Venture’s tax planning, other than the CFM Agreement.

SECTION 8.17. Environmental Matters

     Except for the matters disclosed in Schedule 8.17, neither RM nor any of its Subsidiaries has
since January 1, 1991 received written notice of, or other written communication concerning, any
failure to comply with any applicable Environmental Laws, or written notice or other written
communication that RM or any of its Subsidiaries is or may be a potentially responsible party or
otherwise liable in connection with any site allegedly containing Hazardous Materials. None of
RM’s or its Subsidiaries’ facilities have in the past, or do at the present time, use, generate,
treat, store, dispose of, process, handle or manage any Hazardous Materials or other materials in
violation of any applicable Environmental Law, and there has been no release or migration of any
Hazardous Materials at, on, under, about, within, from or onto any such properties, where such
violation, release, or migration will or is reasonably likely to result, individually or in the
aggregate, in a Material Adverse Change or Effect. Except as will not individually or in the
aggregate result in a Material Adverse Change or Effect, there are no past or present conditions,
circumstances, facts, events, practices, incidents, actions or omissions existing or occurring at
any location (including any off-site location) that will or is reasonably likely to (i) cause RM or
any of its Subsidiaries or, subsequent to the Closing, any Merial Venture Company in respect of RM
or any of its Subsidiaries, to incur any Environmental Liability, (ii) form the basis for any
claim, action, suit, proceeding, hearing, investigation or inquiry against RM or any of its
Subsidiaries or, subsequent to the Closing, any Merial Venture Company in respect of RM or any of
its

140

 

Subsidiaries, under any Environmental Law, or (iii) interfere with or prevent continued
compliance by RM or any of its Subsidiaries or, subsequent to the Closing, any Merial Venture
Company in respect of RM or any of its Subsidiaries, with any Environmental Law.

SECTION 8.18. Labor Relations; Employees: Employee Benefit Plans

     (a) Schedule. Schedule 8.18A-1 contains a true and complete list of each material RM
Benefit Plan. Within six (6) weeks after the date of this Agreement, RM will complete Schedule
8.18A-I by providing to Merck a list of all RM Employee Agreements. Except as set forth in
Schedule 8.18A-2, neither RM, any of its Subsidiaries nor any RM ERISA Affiliate has any plan or
commitment, whether legally binding or not, to establish any new RM Benefit Plan, to enter into any
RM Employee Agreement or to materially modify or to terminate any RM Benefit Plan or RM Employee
Agreement (except to the extent required by law or to conform any such RM Benefit Plan or RM
Employee Agreement to the requirements of any applicable law, or as required by this Agreement),
nor has any intention to do any of the foregoing been communicated to RM Employees.

     (b) Documents. RM has provided, or has caused to be provided, or will cause to be
provided prior to the Closing to Merck (i) current, accurate and complete copies of all documents
embodying or relating to each RM Transferred Benefit Plan and each RM Employee Agreement, including
all amendments thereto, written interpretations thereof and trust or funding agreements with
respect thereto; (ii) the two (2) most recent annual actuarial valuations, if any, prepared for
each RM Transferred Benefit Plan; and (iii) the two (2) most recent annual reports (Series 5500 and
all schedules thereto), if any, required under ERISA in connection with each RM Transferred Benefit
Plan or related trust.

     (c) Multi-Employer Plans. Except with respect to employees who are not RM Employees,
neither RM nor any of the RM Transferred Subsidiaries contribute to or are

141

 

required to contribute to, or have incurred any withdrawal liability (within the meaning of Section
4201 of ERISA) to, any “multi-employer plan” within the meaning of Section 3(37) of ERISA.

     (d) No Post-Employment Obligations. Except as expressly set forth on
Schedule 8.18D, neither RM, any of its Subsidiaries nor any RM ERISA Affiliate
(i) maintains or contributes to any RM Transferred Benefit Plan which provides, or has any
Liability to provide, life insurance, medical, severance or other employee welfare benefits to any
RM Employee upon his retirement or termination of employment, except as may be required by Section
4980B of the Code; or (ii) has ever represented, promised or contracted (whether in oral or written
form) to any RM Employee (either individually or to RM Employees as a group) that such RM
Employee(s) would be provided with life insurance, medical, severance or other employee welfare
benefits upon their retirement or termination of employment, except to the extent required by
Section 4980B of the Code.

     (e) Effect of Transaction. Except as set forth on Schedule 8.18E, the
execution of, and performance of the transactions contemplated in, this Agreement will
not (either alone or upon the occurrence of any additional or subsequent events)
(i) constitute an event under any RM Transferred Benefit Plan, RM Employee Agreement, or related
trust or loan that will or may result in any payment (whether of severance pay or otherwise),
acceleration, forgiveness of indebtedness, vesting, distribution, increase in benefits or
obligation to fund benefits with respect to any RM Employee, or (ii) result in the triggering or
imposition of any restrictions or limitations on the right of the Merial Venture Companies to amend
or terminate any RM Transferred Benefit Plan. No payment or benefit which will or may be made by
RM or any of its Subsidiaries with respect to the transactions contemplated herein will be
characterized as an “excess parachute payment,” within the meaning of Section 280G(b)(l) of the
Code.

     (f) Collective Bargaining Agreement (“CBA”). Except as set forth on
Schedule 8.18F, no RM Employee is employed pursuant to a CBA or a works council
agreement to which a member of the RP Group is a party that any Merial Venture
Company will be bound by after the Closing or will otherwise be obligated to honor or

142

 

assume in connection with this Agreement or the transactions contemplated by this Agreement, other
than those agreements that the Merial Venture is obligated to assume under applicable law.

     (g) Pension Plan Funding. Except as set forth on Schedule 8.18G-1, the present
value of all accrued benefits of each RM Transferred Pension Plan, determined on the basis of the
actuarial assumptions used by the plan’s actuary for purposes of calculating minimum funding
contributions for the most recently completed plan year, do not as of the date hereof and will not
as of the Closing Date exceed the fair market value of the assets (which for this purpose shall not
include any accrued but unpaid contributions) of such Transferred Benefit Plan. Except as set
forth on Schedule 8.18G-2, the present value of all accrued benefits of each RM Transferred Foreign
Pension Plan, determined using the actuarial assumptions employed by the actuary of the plan, do
not as of the date hereof and will not as of the Closing Date exceed the fair market value of the
assets (which for this purpose shall not include any accrued but unpaid contributions) of such RM
Transferred Foreign Pension Plan or, in the case of an unfunded RM Transferred Foreign Pension
Plan, the reserves provided for in the RM Financials.

     (h) Labor Relations. Except as set forth in Schedule 8.18H-1, RM and its
Subsidiaries generally enjoy good employer-employee relations with the RM Employees. Approximately
4,900 full-time equivalent employees are employed by RM and the RM Transferred Subsidiaries and
will be transferred to the Merial Venture together with RM and such Subsidiaries. Schedule 8.18H-2
contains the names of all current employees of the RP Group, other than RM and each RM Transferred
Subsidiary, which RM expects will transfer to the Merial Venture after the Closing. Subject to
their receiving compensation and benefit offers from the Merial Venture comparable to their current
compensation and benefit packages, RM has no reason to believe that substantially all of the
employees listed in Schedule 8.18H-2 will not accept employment offers with the Merial Venture.

     (i) Employment Matters. None of RM or any of its Subsidiaries is delinquent in
payments to any of the RM Employees for any wages, salaries, commissions, bonuses

143

 

or other direct compensation for any services performed by them to the date hereof or to the
Closing Date (as applicable) or amounts required to be reimbursed to such employees. With respect
to the RM Employees, each of RM and its Subsidiaries has (i) complied in all material respects with
applicable laws, rules and regulations relating to the employment of the RM Employees, including
those-relating to wages, hours, collective bargaining, and the payment and withholding of taxes,
and (ii) withheld and paid to the appropriate Public Authority, or are holding for payment not yet
due to such Public Authority, all amounts required by law, rule, regulation or agreement to be
withheld from the wages or salaries of the RM Employees. Since January 1, 1993, there has been no
material adverse change in the relationship of RM and its Subsidiaries with the respective RM
Employees (including any threatened union organization or renegotiation of any union or other
collective bargaining contract) nor any material strike or labor disturbance by such employees, and
none of RM or its Subsidiaries is aware of any indication that such a change, strike or labor
disturbance is likely.

SECTION 8.19. Insurance

     Schedule 8.19-1 contains a complete and accurate list of all insurance policies in force under
which premiums in excess of [*] per year are payable and that provide coverage in favor of RM
and its Subsidiaries, or relating to real property, whether leased or owned by RM or its
Subsidiaries, specifying for each such policy the insurer, amount of coverage and type of insurance
under each. Each such policy is in full force and effect and all premiums are currently paid or
accruals provided for and no notice of cancellation or termination has been received with respect
to any such policy. Such policies are sufficient for compliance with all requirements of Law.
Schedule 8.19-2 sets forth a complete list of all claims in excess of [*] made or filed by RM
or any of its Subsidiaries with their insurers since January 1, 1993 and any such claims incurred
but not yet so made or filed of which RM is aware.

144

 

SECTION 8.20. Contracts and Licenses

     Schedule 8.20-1 lists all contracts or agreements by RM or its Subsidiaries having a value or
involving payments in excess of [*] per year or otherwise material to RM or its Subsidiaries.
Other than as indicated in Schedule 8.20-2, none of such contracts or agreements require the
consent of any Third Party to be assigned or transferred to the Merial Venture as contemplated by
this Agreement or the Ancillary Agreements. Schedule 8.20-3 lists all of such agreements that may
restrict in any way, such as through non-compete or exclusivity clauses, the ability of the Merial
Venture to undertake Merial Venture Business activities and lists all other agreements that include
such a restriction, the compliance with by the Merial Venture on or after the Closing would have a
material adverse effect on the ability of the Merial Venture to combine the Contributed Merial
Venture Businesses or to conduct the activities contemplated herein.

SECTION 8.21. Share Capital of RM and RM’s Subsidiaries

     Schedule 8.21 (as updated in accordance with Section 3.2 hereof, as applicable) contains a
true and complete description of the authorized and outstanding capitalization (including the
record owners) of RM and of each of RM’s Subsidiaries. The indicated shares of capital stock or
other ownership interests of RM and of each of RM’s Subsidiaries represent all of the respective
issued and outstanding shares of capital stock or other ownership interests of each such company.
Except as set forth in Schedule 8.21, (a) the record and beneficial ownership of RM and each such
RM Subsidiary is free and clear of any lien or other Encumbrance; (b) all of the issued and
outstanding shares of capital stock or other ownership interests of RM and each of RM’s
Subsidiaries have been duly authorized and validly issued and are fully paid and nonassessable; (c)
none of RM, any RM Subsidiary or any direct or indirect parent company thereof is bound by, has
granted, issued or made or agreed to grant, issue or make any security interests, warrants,
options, subscription rights or any other commitments of any character relating to the issued or
unissued shares of capital stock or other ownership interests of RM or any of RM’s Subsidiaries
(other than this Agreement and the Ancillary Agreements), nor is there any agreement providing for
(i) any restriction on the transfer of any of the issued

145

 

and outstanding shares of capital stock or other ownership interests (other than with respect to
directors’ qualifying and nominee shares which are as set forth in Schedule 8.21) of any of RM or
any of RM’s Subsidiaries, (ii) the amendment of the charter or statuts (or comparable
organizational documents) of any of RM or any of RM’s Subsidiaries so as to increase the amount of
authorized capital stock or other ownership interests of such entity, or (iii) obligating any of
such persons to grant, offer, or enter into any of the foregoing; (d) none of RM or any of RM’s
Subsidiaries is a party to any voting trust or other agreement or understanding with respect to the
voting of the capital stock or other ownership interests of RM or any of RM’s Subsidiaries; and (e)
the record owner of any such shares or other ownership interests possesses good and marketable
title to such shares or other ownership interests.

SECTION 8.22. Merial

     Merial has not entered into any transactions or undertaken any obligations, except for any
transactions or obligations necessary to give effect to the Transactions as contemplated by this
Agreement and the Ancillary Agreements.

SECTION 8.23. Survival of Representations and Warranties

     IM and RM acknowledge that their representations and warranties are an inducement to Merck and
Merck SH and to Merial to enter into this Agreement and the Ancillary Agreements. The
representations and warranties contained in this Article VIII shall survive (and not be affected in
any respect by) any investigation by or on behalf of any Party and the Closing. Notice of any
claim in respect of the representations and warranties in Section 8.1 [Organization; Powers], 8.2
[Authorization; No Breach], 8.3 [Enforceability], and 8.10(a) [Title] and 8.11(b) [Intellectual
Property — existing Proprietary Rights], may be given at any time (subject to any statute of
limitations under applicable law); notice of any claim in respect of the representations and
warranties in Sections 8.4 [Governmental Approvals], 8.11 (a) and (c) [Intellectual Property —
other], 8.12 [Product Registrations], 8.16 [Tax Returns] and 8.17 [Environmental Matters] must be
given before the fifth anniversary of the Closing Date; notice of claim in respect of all

146

 

other representations and warranties in Article VIII must be given before the second anniversary of
the Closing Date; it being understood that in the event notice of any claim for indemnification
under Section 14.1 shall have been given (as contemplated by Section 14.7) within the applicable
survival period, the representations and warranties that are the subject of such indemnification
claim shall survive until such time as such claim is finally resolved.

147

 

ARTICLE IX

REPRESENTATIONS AND WARRANTIES OF RP

     RP hereby represents and warrants, as of the date hereof and as of the Closing Date, to Merck
and Merck SH and to Merial as follows:

SECTION 9.1. Organization; Powers

     (a) RP (i) is a société anonyme duly organized and validly existing under the laws of
France, and (ii) has the corporate or similar power and authority to execute, deliver and to
perform its obligations under (as applicable) this Agreement and any and all Ancillary Agreements
to which it is a party or by which it is bound.

SECTION 9.2. Authorization; No Breach

     The execution and delivery by RP of each of this Agreement and any and all Ancillary
Agreements to which it is a party or by which it is bound, and the consummation of the
Transactions, (a) have been duly authorized by all necessary corporate action and do not and will
not require the consent or approval of its shareholders or partners, except such consents or
approvals as have been obtained, and (b) do not (i) violate or conflict with (A) any law or
regulation applicable to it or to any of the assets or properties of RM or RM’s Subsidiaries, or
(B) its statuts, or (ii) violate, conflict with, result in a breach of or constitute (alone or with
notice or lapse of time or both) a default under, require any consent under, or give to any Third
Party any rights of termination, amendment, acceleration, suspension, revocation or cancellation of
or result in any Encumbrance on any of the assets of RM or RM’s Subsidiaries pursuant to, any
provisions of any agreements (including any notes, contracts, leases, licenses or other instruments
or arrangements) by which it is bound, except, in the case of this clause (ii), for such
violations, conflicts, breaches, defaults, required consents, rights or Encumbrances that would not
in the aggregate cause a Material Adverse Change or Effect.

148

 

SECTION 9.3. Enforceability

     This Agreement has been duly executed and delivered by RP and constitutes, and each Ancillary
Agreement when executed and delivered by RP (as applicable) constitutes or will constitute, its
legal, valid and binding obligation, enforceable against it in accordance with its terms, subject,
however, to any limitations with respect to enforcement which may be imposed in connection with (i)
bankruptcy, insolvency, reorganization, moratorium or other laws affecting the enforcement of
creditors’ rights generally, and (ii) general principles of equity (regardless of whether
considered and applied in a proceeding at law or in equity).

SECTION 9.4. Entirety of RP Animal Health Business Activities

     Except for the Animal Health Business activities to be conducted by certain other RP Companies
pursuant to the Ancillary Agreements and except for activities of RP Companies (other than RM and
its Subsidiaries) that are listed on Schedule 9.4, the entirety of the Merial Venture Business
activities of the RP Group is conducted by RM and its Subsidiaries.

SECTION 9.5 Absence of Third Party Joint Ventures

     Except as set forth in Schedule 9.5, neither RP nor any of its Subsidiaries has an ownership
interest in any joint venture (whether or not organized as a legal entity) or other company or
business (except RP and its Subsidiaries) which conducts Merial Venture Business activities and the
ownership of or profits from which are shared with Third Parties.

SECTION 9.6 Governmental Approvals

     All permits, consents and approvals of, registrations with, notices to, and other actions by,
all Public Authorities that are required by RP or any RP Subsidiary in connection with the
Transactions (collectively the “RP Approvals”) have been made or

149

 

obtained and are in full force and effect, except that, as of the date hereof (but not as of the
Closing), the following RP Approvals have not been made or obtained: (i) the approval of the merger
control authorities of the European Union, (ii) the agrément fiscal described in Section 11.2(b),
(iii) the required approvals of Public Authorities listed in Schedule 9.6, and (iv) such other
items which the failure to obtain, individually or in the aggregate, would not have a Material
Adverse Change or Effect. None of RP or any RP Subsidiary has taken or omitted to take any action
which permits, or after notice or lapse of time or both would permit, any modification or
termination of any of the RP Approvals.

SECTION 9.7. Intragroup Agreements

     Other than as listed on Schedules 9.7-1 and 9.7-2, there are no agreements between RM or any
of its Subsidiaries, on the one hand, and any other RP Companies, on the other hand, that will
survive the Closing. Schedule 9.7-1 lists all such written agreements (the “RP InterCo
Contracts”) that will survive the Closing, and Schedule 9.7-2 lists all such existing customary
arrangements (the “RP InterCo Customary Agreements”) not evidenced by a written agreement. RP and
RM hereby agree that the corporate management agreements between any RP Company (other than RM and
its Subsidiaries), on the one hand, and RM or its Subsidiaries, on the other hand, pursuant to
which any RP Company (other than RM and its Subsidiaries) provides corporate management services to
RM or its Subsidiaries in consideration for the payment of a management fee, shall terminate on or
prior to the Closing Date, and the Merial Venture shall have no liability with respect thereto.
Since January 1, 1995, there have not been any transactions, commitments or agreements, other than
on terms and conditions that are no less favorable to RM and its Subsidiaries than those that could
have been obtained by a non-Affiliate at arm’s length, entered into by or in effect between RM or
any of its Subsidiaries, on the one hand, and any other RP Company (other than RM and its
Subsidiaries), on the other hand.

150

 

SECTION 9.8. Share Capital of IM and RM

     Schedule 9.8 (as updated in accordance with Section 3.2 hereof, as applicable) contains a true
and complete description of the authorized and outstanding capitalization (including the record
owners) of IM and RM. The indicated shares of capital stock or other ownership interests of each of
IM and RM represent all of the respective issued and outstanding shares of capital stock or other
ownership interests of each such company. Except as set forth in Schedule 9.8, (a) the record and
beneficial ownership of each of IM and RM is free and clear of any lien or other Encumbrance; (b)
all of the issued and outstanding shares of capital stock or other ownership interests of each of
IM and RM have been duly authorized and validly issued and are fully paid and nonassessable; (c)
none of IM, RM or any direct or indirect parent company thereof is bound by, has granted, issued or
made or agreed to grant, issue or make any security interests, warrants, options, subscription
rights or any other commitments of any character relating to the issued or unissued shares of
capital stock or other ownership interests of IM or RM (other than this Agreement and the Ancillary
Agreements), nor is there any agreement providing for (i) any restriction on the transfer of any of
the issued and outstanding shares of capital stock or other ownership interests (other than with
respect to directors’ qualifying and nominee shares which are as set forth in Schedule 9.8) of
either of IM or RM; (ii) the amendment of the charter or statuts (or comparable organizational
documents) of either of IM or RM so as to increase the amount of authorized capital stock or other
ownership interests of such entity, or (iii) obligating any of such persons to grant, offer, or
enter into any of the foregoing; (d) none of RP, IM or RM is a party to any voting trust or other
agreement or understanding with respect to the voting of the capital stock or other ownership
interests of IM or RM; and (e) the record owner of any such shares or other ownership interests
possesses good and marketable title to such shares or other ownership interests.

SECTION 9.9. Other Agreements

     Except as set forth in Schedule 9.9 and except for any agreements, arrangements or commitments
between RM and its Subsidiaries or between such Subsidiaries, there are

151

 

no agreements, arrangements or commitments of any character (contingent or otherwise) relating to
any Acquisition Transaction pursuant to which any person is or may be entitled to receive from RM
or any of its Subsidiaries any payment based on their revenues, earnings or similar items (or any
portion thereof) or on the occurrence or value of the Acquisition Transactions (or similar
circumstances), or calculated in accordance therewith. For the purposes of this Section 9.9,
“Acquisition Transaction” shall mean any merger, purchase of substantial assets, purchase of shares
of capital stock or similar transactions involving RM or any Subsidiary.

SECTION 9.10. Labor Relations; Employees; Employee Benefit Plans

     (a) No payment or benefit which will or may be made by RP or any of its Subsidiaries to RM
Employees with respect to the transactions contemplated herein will be characterized as an “excess
parachute payment”, within the meaning of Section 280G(b)(l) of the Code.

     (b) The RP Group generally enjoys good employer-employee relations with the RM Employees.

     (c) No member of the RP Group is delinquent in payments to any of the RM Employees for any
wages, salaries, commissions, bonuses or other direct compensation for any services performed by
them to the date hereof or to the Closing Date (as applicable) or amounts required to be reimbursed
to such employees. With respect to the RM Employees, each member of the RP Group has (i) complied
in all material respects with applicable laws, rules and regulations relating to the employment of
the RM Employees, including those relating to wages, hours, collective bargaining, and the payment
and withholding of taxes, and (ii) withheld and paid to the appropriate Public Authority, or are
holding for payment not yet due to such Public Authority, all amounts required by law, rule,
regulation or agreement to be withheld from the wages or salaries of the RM Employees. Since
January 1, 1993, there has been no material adverse change in the relationship of the RP Group with
the respective RM Employees (including any threatened union organization or renegotiation of any
union or other collective bargaining

152

 

contract) nor any material strike or labor disturbance by such employees, and no member of the RP
Group is aware of any indication that such a change, strike or labor disturbance is likely.

SECTION 9.11. Survival of Representations and Warranties

     RP acknowledges that its representations and warranties are an inducement to Merck and Merck
SH and to Merial to enter into this Agreement and the Ancillary Agreements. The representations and
warranties contained in this Article IX shall survive (and not be affected in any respect by) any
investigation by or on behalf of any Party and the Closing. Notice of any claim in respect of the
representations and warranties in Sections 9.1 [Organization; Powers], 9.2 [Authorization; No
Breach], 9.3 [Enforceability], 9.6 [Government Approvals] and 9.8 [Share Capital] may be given at
any time (subject to any statute of limitations under applicable law); notice of any claim in
respect of all other representations and warranties in Article IX must be given before the second
anniversary of the Closing Date; it being understood that in the event notice of any claim for
indemnification under Section 14.1 shall have been given (as contemplated by Section 14.7) within
the applicable survival period, the representations and warranties that are the subject of such
indemnification claim shall survive until such time as such claim is finally resolved.

153

 

ARTICLE X

REPRESENTATIONS AND WARRANTIES OF MERCK AND MERCK SH

     Merck and Merck SH hereby represent and warrant, as of the date hereof and as of the Closing
Date, to RP, IM and RM and to Merial as follows:

SECTION 10.1. Organization; Powers

     Each of Merck, Merck SH, each Merck Transferred Subsidiary and each other Merck Subsidiary
engaged in Merial Venture Business activities (a) is a corporation or company duly organized and
validly existing and is (to the extent applicable) in good standing under the laws of its
jurisdiction of organization, (b) has all requisite corporate or similar power and authority to own
or lease and operate its property and assets used in the Merck JV Business and to carry on such
business as now conducted, (c) is qualified or licensed to do business and in good standing in
every jurisdiction where such qualification or licensing is required, except where the failure so
to qualify would not result in a Material Adverse Change or Effect, and (d) has the corporate or
similar power and authority to execute, deliver and to perform its obligations under (as
applicable) this Agreement and any and all Ancillary Agreements to which it is a party or by which
it is bound.

SECTION 10.2. Authorization; No Breach

     The execution and delivery by each of Merck and Merck SH (as applicable) of each of this
Agreement and any and all Ancillary Agreements to which it is a party or by which it is bound, and
the consummation of the Transactions, (a) have been duly authorized by all necessary corporate
action and do not require the consent or approval of its shareholders or partners, except such
consents or approvals as have been obtained, and (b) do not (i) violate or conflict with (A) any
Law or regulation applicable to it or any of its assets or properties, including any of the Merck
Contributed Assets, or (B) its certificate or articles of incorporation or by-laws, or (ii)
violate, conflict with, result in a breach of or constitute (alone or with notice or lapse of time
or both) a default under,

154

 

require any consent under, or give to any Third Party any rights of termination, amendment,
acceleration, suspension, revocation or cancellation of or result in any Encumbrance on any of the
Merck Contributed Assets pursuant to, any provisions of any agreements (including any notes,
contracts, leases, licenses or other instruments or arrangements) by which it or any other Merck
Company is bound, except, in the case of this clause (ii), for such violations, conflicts,
breaches, defaults, required consents, rights or Encumbrances (x) that would not in the aggregate
cause a Material Adverse Change or Effect, or (y) that are indicated as such in Schedule 10.2.

SECTION 10.3. Enforceability

     This Agreement has been duly executed and delivered by each of Merck and Merck SH and
constitutes, and each Ancillary Agreement when executed and delivered by each of Merck and/or Merck
SH (as applicable) constitutes or will constitute, its legal, valid and binding obligation,
enforceable against it in accordance with its terms, subject, however, to any limitations with
respect to enforcement which may be imposed in connection with (i) bankruptcy, insolvency,
reorganization, moratorium or other laws affecting the enforcement of creditors’ rights generally,
and (ii) general principles of equity (regardless of whether considered and applied in a proceeding
at law or in equity).

SECTION 10.4. Governmental Approvals

     All permits, consents and approvals of, registrations with, notices to, and other actions by,
all Public Authorities that are required by Merck or Merck SH or any Merck Subsidiary in connection
with the Transactions (collectively the “Merck Approvals”) have been made or obtained and are in
full force and effect, except that, as of the date hereof (but not as of the Closing), the
following Merck Approvals have not been made or obtained: (i) the approval of the merger control
authorities of the European Union, (ii) registrations with and consents of the appropriate Public
Authorities in each relevant country to transfer Product Registrations in respect of each Merck
Existing Product and Pipeline Product (as applicable), (iii) the tax ruling described in Section
11.2(b), (iv) the required approvals of Public Authorities listed in Schedule 10.4, and (v) such
other items

155

 

which the failure to obtain, individually or in the aggregate, would not have a Material Adverse
Change or Effect. None of Merck, Merck SH or any Merck Subsidiary has taken or omitted to take any
action which permits, or after notice or lapse of time or both would permit, any modification or
termination of any of the Merck Approvals.

SECTION 10.5. Historical Financial Data

     True and complete copies of the consolidated financial statements, i.e., the balance sheet and
income statement, for the Merck Contributed Business as of and for the year ended December 31, 1996
(together, the “Merck Contributed Business Financials”) are provided as Exhibit XVI. Except as
indicated on any such financial statements, the Merck Contributed Business Financials (i) were
derived from the books and records of Merck and its Subsidiaries, (ii) were prepared in accordance
with United States GAAP consistently applied, and (iii) present fairly the assets and Liabilities,
income and expenses of the Merck Contributed Business, as of the dates and for the periods
indicated.

SECTION 10.6. No Undisclosed Liabilities

     (a) Liabilities at December 31, 1996. As at December 31, 1996, the Merck Contributed
Business had no Liabilities of any nature, whether accrued, contingent or otherwise (including,
without limitation, Liabilities as guarantor or otherwise with respect to obligations of other
Liabilities for taxes due or then accrued or to become due or Liabilities that have been incurred
but not yet reported that would be transferred to or assumed by the Merial Venture), that were not
adequately reflected or reserved against on the December 31, 1996 balance sheet of the Merck
Contributed Business Financials and which [*].

     (b) Merck Contributed Liabilities. Except for any such Liabilities that would not [*], all Merck Contributed Liabilities either (i) are reflected in the
Merck Contributed Business Financials, as defined in Section 10.5, (ii)

156

 

arose in the ordinary course of business since December 31, 1996, or (iii) are or will be disclosed
in Schedule 14.2A-1 in accordance with Section 14.2(a).

SECTION 10.7. Receivables

     Except to the extent, if any, indicated on the December 31, 1996 balance sheet of the Merck
Contributed Business Financials, all Receivables reflected thereon, including Retained Receivables,
if any, arose from the sale of Inventory or services in the ordinary course of business consistent
with past practice and constitute only valid, undisputed claims of Merck or its Subsidiaries not
subject to valid claims of set-off or other defenses or counterclaims other than normal cash
discounts accrued in the ordinary course of business consistent with past practice. All
Receivables, including Retained Receivables, if any, reflected on the December 31, 1996 balance
sheet of the Merck Merial Venture Business Financials or arising since the date thereof (subject to
the reserve for bad debts, if any, reflected on the December 31, 1996 balance sheet of the Merck
Merial Venture Business Financials), are good and have been collected or are or will be
collectible, without resort to extraordinary collection activity, in the ordinary course of
business and, in any case, by the later of (x) the date that is twelve (12) months from the Closing
Date, or (y) if a Receivable is not by its terms due within such 12 month period, the date that is
three months after its due date.

SECTION 10.8. Inventories

     Subject to amounts reserved therefor on the December 31, 1996 balance sheet of the Merck
Contributed Business Financials, the values at which all Inventories are carried on the December
31, 1996 balance sheet of the Merck Contributed Business Financials, including Retained Inventory,
if any, reflect the valuation of such Inventories at the lower of cost or market value, where cost
is the supply price calculated pursuant to the Merck Manufacturing Supply Price Formula. Except as
set forth in Schedule 10.8-1, Merck and its Subsidiaries have good and marketable title to the
Inventories, including Retained Inventory, if any, free and clear of all liens or other
Encumbrances. Except as set forth in Schedule 10.8-2 or reserved against in the Merck Financials,
the Inventories, including

157

 

Retained Inventory, if any, do not consist of, in any material amount, items that are obsolete,
damaged or slow-moving or of any items held on consignment. Neither Merck nor any of its
Subsidiaries is under any obligation or Liability with respect to accepting returns of items of
Inventory or merchandise in the possession of its customers, including Retained Inventory, if any,
other than in the ordinary course of business consistent with past practice. No clearance or
extraordinary sale of the Inventories has been conducted since December 31, 1996. Neither Merck
nor any of its Subsidiaries has acquired or committed to acquire or manufacture Inventory,
including Retained Inventory, if any, for sale by the Merck Contributed Business which is not of a
quality and quantity usable in the ordinary course of business within a reasonable period of time
and consistent with past practice, nor has Merck or any of its Subsidiaries changed the price of
any Inventory, including Retained Inventory, if any, except for (i) reductions to reflect any
reduction in the cost thereof to Merck or its Subsidiaries, (ii) reductions and increases
responsive to normal competitive conditions and consistent with past sales practices, or (iii)
increases to reflect any increase in the cost thereof to Merck or its Subsidiaries. Other than as
reflected on the December 31, 1996 balance sheet of the Merck Contributed Business Financials, the
Inventories, including Retained Inventory, if any, of Merck and its Subsidiaries are in good and
merchantable condition in all material respects, are suitable and usable for the purposes for which
they are intended and are in a condition such that they can be sold in the ordinary course of
business consistent with past practice.

SECTION 10.9. Absence of Certain Developments

     Except for the actions taken by Merck, Merck SH or any Merck Subsidiaries pursuant to this
Agreement and the applicable Ancillary Agreements or as disclosed in Schedule 10.9, since December
31, 1996, the Merck Contributed Business has been operated in the ordinary course of business
consistent with past practice, and there has not been:

     (a) any sale, assignment, transfer or other disposition to any Third Party
of, or imposition of any lien or other Encumbrance on, any Merck

158

 

Contributed Assets or any of the properties, assets, Inventories or obsolete items of the Merck
Transferred Subsidiaries, without any and all proceeds [*] for
all such sales, assignments, transfers or other dispositions (other than sales of Inventory in the
ordinary course of business consistent with past practice) being contributed to the Merial Venture.
Merck covenants and agrees that all such proceeds [*] shall
through the Closing Date be segregated and held in a separate bank account owned by Merck or a
Merck Subsidiary (these proceeds [*] being referred to as the
“Merck Assets Sale Proceeds”) and thereby contributed to the Merial Venture on the Closing Date;

     (b) any damage, destruction or casualty loss to any Merck Contributed Assets or to any of
the assets or properties of the Merck Transferred Subsidiaries, whether or not covered by
insurance, which, individually or in the aggregate, has a Material Adverse Change or Effect;

     (c) any material change in any accounting principle relevant to the Merck Contributed
Business used by Merck or any of its Subsidiaries;

     (d) other than in the ordinary course of business, any transaction, commitment or agreement
relating to the Merck JV Business entered into by Merck or any of its Subsidiaries, or any
relinquishment by Merck or any of its Subsidiaries of any rights relating to the Merck JV Business
under any agreement or otherwise, having a value or involving aggregate payments [*];

     (e) any grant of any rights or licenses or entry into any licensing or distributorship or
agency arrangements by Merck or any of its Subsidiaries with respect to the Merck JV Business
which, individually or in the aggregate, has a Material Adverse Change or Effect;

159

 

     (f) any loss of employees or any changes in any of Merck’s or any of its Subsidiaries’
employee benefit plans (other than those required by applicable law) which, individually or
in the aggregate, has a Material Adverse Change or Effect;

     (g) other than in the ordinary course of business, any disclosure of any secret or
confidential Intellectual Property (except by way of issuance of a patent or pursuant to
this Agreement or the Ancillary Agreements) or any lapse or abandonment of Intellectual
Property (or any registration or grant thereof or any application relating thereto) related
to the Merck JV Business to which, or under which, Merck or any Subsidiary has any right,
title, interest or license;

     (h) expenditures or failure to make expenditures on capital investment projects
by any Merck Transferred Subsidiaries or in respect of any Merck Contributed Assets that
were not substantially consistent with the investment plans in existence as of December 31,
1996 relating to such projects as disclosed in writing to RP prior to the date of this
Agreement;

     (i) any transaction, commitment or any agreement involving the Merck JV Business
entered into between two or more Merck Companies; or

     (j) any authorization, approval, agreement or other binding
commitment to do any of the foregoing.

SECTION 10.10. Merck Contributed Assets

     (a) The assets to be contributed to the Merial Venture by Merck or its Subsidiaries (the
“Merck Contributed Assets”) pursuant to Section 5.1(a) and to the Merck Transfer Agreement (which
include all the assets of the Merck Transferred Subsidiaries and, in accordance with Section
5.1(a), the Merck Contributed Liabilities) include all assets, properties and rights used to
conduct the entirety of the Merck JV Business activities (other than those assets, properties and
rights (i) that are not primarily

160

 

used for Merial Venture Business activities, (ii) used to conduct those activities that will be
conducted by certain Merck Companies pursuant to the Ancillary Agreements, (iii) used to conduct
those activities conducted by certain Merck Companies that are listed on Schedule 10.10-1A, (iv)
those Patents, Patent applications, registered trademarks and trademark applications that will be
licensed to the Merial Venture by Merck or its Subsidiaries pursuant to the Ancillary Agreements,
(v) to the extent determined by Merck in its sole discretion, cash and cash equivalents, (vi) those
set forth in Schedule 2-7, and (vii) those agreements listed on Schedule 10.10-1B, which Merck
hereby represents do not relate to the use of any product in the Animal Health Business or the
Poultry Genetics Business), in all material respects as reflected on the December 31, 1996 balance
sheet of the Merck Contributed Business Financials (subject to acquisitions, sales or other
dispositions permitted pursuant to Section 12.1(a)). Within six (6) weeks of the signature of
this Agreement, Merck will provide to RP and to RM as Schedule 10.10-2 a list of all fixed assets
(including U.S. and non-U.S. assets) used to conduct the entirety of the Merck JV Business
activities other than those excepted pursuant to clauses (i) — (vi) above.

     (b) For the avoidance of doubt, the Parties acknowledge that Merck Contributed Assets do not
include the name, trademark and/or service mark “Merck”, “Merck Sharp & Dohme”, and “MSD”, or any
name or mark containing such names and marks, the copyright in and to the work “The Merck
Veterinary Manual”, and the Annual Authorizations Service Repertory License Agreement between
Copyright Clearance Center, Inc. and Merck & Co., Inc. dated December 31, 1995.

     (c) No person has any rights to use, possess or acquire or has any Encumbrance on any Merck
Contributed Assets, except for (i) the rights of the Merial Venture Companies pursuant to this
Agreement and the Ancillary Agreements, (ii) any rights retained by, or licensed to, any Merck
Companies in accordance with this Agreement and the Ancillary Agreements, and (iii) any prior
rights granted to Third Parties set forth in Schedule 2-7. Subject only to Sections 11.2(c) and
11.6(a) (and to consents that may be required under contracts that are Merck Contributed Assets,
other than those listed in Schedule 10.22B), and except for such Merck Contributed Assets that

161

 

are set forth in Schedule 2-7, following the consummation of the Transactions and the execution of
the instruments of transfer contemplated by this Agreement and the Ancillary Agreements, the Merial
Venture will own, with good, valid and marketable title, or lease, under valid and subsisting
leases, or otherwise acquire the interests of Merck and its Subsidiaries in the Merck Contributed
Assets, free and clear of any Encumbrances except for such Encumbrances as are described in clauses
(i) through (iv) of Section 10.11(a), and without incurring any penalty or other adverse
consequence, including any increase in rentals, royalties, or license or other fees imposed as a
result of, or arising from, the consummation of the Transactions.

SECTION 10.11. Title to Properties; Possession Under Leases

     (a) Merck and its Subsidiaries own and have good title to all of the Merck Contributed Assets
and to all of the assets and properties reflected as owned by Merck Transferred Subsidiaries on the
December 31, 1996 balance sheet included in the Merck Contributed Business Financials, in each case
free and clear of any material lien, claim or other Encumbrance, except for (i) the liens, claims
or other Encumbrances reflected in the Merck Merial Venture Business Financials, (ii) assets and
properties disposed of, or subject to purchase or sales orders, in the ordinary course of business
since December 31, 1996, (iii) liens or other Encumbrances securing the rights of materialmen,
carriers, landlords and like persons, all of which are not yet due and payable, and (iv) liens for
taxes not yet delinquent.

     (b) (i) Merck and each of its Subsidiaries has complied with all its material obligations
under all material leases to which it is a party as lessee and that are part of the Merck
Contributed Assets, (ii) all such leases are in full force and effect, (iii) Merck or the relevant
Subsidiary enjoys peaceful and undisturbed possession under each such lease, (iv) to the knowledge
of Merck, the other parties to such leases have complied with all their material obligations
thereunder, and (v) there are no material unresolved disputes under any of such leasehold
interests.

162

 

     (c) (i) All material real property, and all material buildings, improvements and fixtures
thereon that are part of the Merck Contributed Assets have been maintained in accordance with the
standard practices and procedures of Merck and its Subsidiaries and are in all material respects in
good condition and have no material structural defects, (ii) such material real property,
buildings, improvements and fixtures and the use thereof conform in all material respects to all
applicable building, zoning, land use and like requirements and all material certificates and
permits for the lawful use and occupancy thereof and the machinery and equipment thereon have been
issued, and (iii) no current use of any of such property is dependent in any material respect on a
non-conforming use or permit or violates any Law, regulation or decision of any Public Authority.

     (d) Set forth in Schedule 10.11D is a true and complete list as of the date of signature of
this Agreement of all real property whether owned or leased (as tenant) included in the Merck
Contributed Assets.

SECTION 10.12. Intellectual Property

     (a) To the knowledge of Merck, Merck and its Subsidiaries (i) own, or are licensed to
use, or otherwise have the right to use all Patents, trademarks, service marks, trade names, logos,
franchises, and copyrights, and all applications for any of the foregoing, and all technology,
inventions, trade secrets, Know-How, computer software and processes used in the conduct of the
Merck JV Business as now conducted, including for the manufacture and sale of all Merck Existing
Products, and (ii) except as set forth in Schedule 10.12, have the right to transfer or license to
the Merial Venture all of such rights to be transferred or licensed thereto under this Agreement
and the Ancillary Agreements; and none of such rights shall be adversely affected by the execution,
delivery or performance of this Agreement or any Ancillary Agreement. Except as indicated in
Schedule 10.12, Merck is not aware of any reason that would prevent any pending applications to
register material trademarks, or any pending material patent applications, from being granted.

163

 

     (b) Set forth in Schedule 10.12 are true and complete lists of all Patents and registered
trademarks and trademark applications in respect of Animal Health Products or Poultry Genetics
Products which are owned by Merck or any of its Subsidiaries or which Merck or any such
Subsidiaries are licensed to use or otherwise have the right to use in respect of Animal Health
Products or Poultry Genetics Products (other than those items referred to in Section 10.10(b)
(collectively, the “Merck Proprietary Rights”). To the extent indicated in Schedule 10.12, all
owned Merck Proprietary Rights have been registered in, filed in or issued by the appropriate Public
Authorities in each relevant jurisdiction, and in each case such proprietary rights are currently
in effect and all maintenance fees and renewals thereof have been duly made with respect thereto.

     (c) Except as set forth in Schedule 10.12, Merck is not aware (i) that any of the activities
of the Merck JV Business as currently conducted infringe upon the proprietary rights of others, nor
has Merck or any of its Subsidiaries received any notice or claim from any Third Party of such
infringement by the activities of the Merck JV Business, or (ii) of any infringement by any Third
Party on, or any competing claim of right to use or own any of, the Merck Proprietary Rights in the
field of the Merial Venture Business. Merck and its Subsidiaries have the right to use, free and
clear of claims or rights of others, all customer lists and computer software used in the conduct
of the Merck JV Business.

SECTION 10.13. Product Registrations

     Set forth in Schedule 10.13 are true and complete lists of all Product Registrations that have
been applied for, are valid and in full force and effect or are in the process of being timely
renewed in respect of any Animal Health Products and Poultry Genetics Products of Merck and its
Subsidiaries (collectively, the “Merck Product Registrations”), indicating for each product the
jurisdiction of each such Product Registration, application or renewal, and whether such
application has been applied for, is valid, or is in the process of being renewed. Such product
registrations permit Merck to market the products covered thereby in the jurisdiction indicated
thereby, and Merck is aware of nothing that would interfere with Merck’s right to market such
products in the jurisdiction

164

 

indicated. No such Product Registration shall be adversely affected by its contribution to the
Merial Venture in accordance with the terms of this Agreement (and in particular Section 11.2(c)),
the Transfer Agreement and the Ancillary Agreements.

SECTION 10.14. Product Warranty and Product Recalls: Labels

     (a) Since January 1, 1993, there have been no “recalls” or “seizures” or “market withdrawals”
(as such terms, or words of similar import, are used in the regulations promulgated under the U.S.
Food, Drug and Cosmetic Act or similar food and drug laws promulgated by any Public Authority in
any other jurisdiction) with respect to any Merck Existing Product. The Label of each Existing
Product of Merck sold by Merck or any of its Subsidiaries in any country accurately reflects the
conditions for safe and effective use of such Existing Product in accordance with the laws and
regulations of such country and each such Product is sold under an appropriate Label.

     (b) Other than as indicated on Schedule 10.14, since January 1, 1993, neither Merck nor any of
its Subsidiaries has received any adverse experience reports indicating any material safety or
efficacy problems that would materially change the general risk/benefit assessment upon which such
Existing Product is prescribed for its approved indications, and no material change in any Label of
any Merck Existing Product has been required by any Public Authority or otherwise been implemented
as a result of any such report.

SECTION 10.15. Absence of Third Party Joint Ventures

     Except as set forth in Schedule 10.15, neither Merck nor any of its Subsidiaries has an
ownership interest in any joint venture (whether or not organized as a legal entity) or other
company or business (except Merck and its Subsidiaries) which conducts Merial Venture Business
activities and the ownership of or profits from which are shared with Third Parties.

165

 

SECTION 10.16. Litigation; Compliance with Laws

     (a) Except as set forth in Schedule 10.16, and except for such actions, suits or proceedings
with amounts or potential amounts individually in issue of less than [*], there are no
actions, suits or proceedings at law or in equity or by or before any Public Authority relating to
or arising from the Merck JV Business or any properties or assets part of the Merck Contributed
Assets, or in respect of this Agreement or any of the Ancillary Agreements, and which is pending
or, to the knowledge of Merck, threatened against it or any of its Subsidiaries. Schedule 10.16
sets forth a complete and correct list of all such actions, suits or proceedings that are active or
have been active since January 1, 1993 (or, with respect to actual or potential Environmental
Liabilities, January 1, 1991), and includes for completed matters a general description of the
results thereof (including the amount of any monetary judgments and the principal terms of any
other relief assessed in connection therewith).

     (b) Except for any non-compliance which would not, individually or in the aggregate, result in
a Material Adverse Change or Effect, Merck and its Subsidiaries at all times since January 1, 1993
have been and are currently in compliance with (i) all Laws, Permits, published standards that have
the force and effect of Laws, and Environmental Laws, applicable to the Merck JV Business, and (ii)
all judgments, orders, writs, injunctions, decrees or rulings of Public Authorities applicable to
the Merck JV Business.

     (c) In each case other than such Permits the absence of which would not, individually or in
the aggregate, result in a Material Adverse Change or Effect, Merck and its Subsidiaries have all
licenses, permits, franchises, orders or approvals of any Public Authority, including under
Environmental Laws, necessary to the conduct of the Merck JV Business (collectively, “Permits”);
such Permits are in full force and effect; and no proceeding is pending or, to the best knowledge
of Merck, threatened, to revoke or limit any such Permit. Schedule 10.16 identifies all Permits
that are nontransferable or that will require the consent of any Public Authority in order to give
effect to the Transactions.

166

 

SECTION 10.17. Tax Returns

     Each of Merck SH and each Merck Transferred Subsidiary has filed or caused to be filed in a
timely manner all Tax Returns required to have been filed by it (or have obtained or timely applied
for an extension with respect to any such filing) and has paid or caused to be paid, or made
adequate provision for the payment of, all Taxes shown to be due and payable on such returns or on
any assessments received by it, except Taxes that are being contested by it in good faith and
except where the failure to file such returns or pay Taxes would not in the aggregate (i) cause a
Material Adverse Change or Effect, or (ii) result in the imposition of a lien on any of the Merck
Contributed Assets. None of the Merck Transferred Subsidiaries is party to or bound by (a) any
agreement providing for the allocation or sharing of Taxes with any Third Party which agreement
will be in effect after the Closing, or (b) any agreement (other than elections prescribed by
generally applicable Tax Laws or regulations) with any Taxing Authority which may restrict the
Merial Venture’s tax planning.

SECTION 10.18. Environmental Matters

     With respect to the Merck JV Business, except for the matters disclosed in Schedule 10.18,
neither Merck nor any of its Subsidiaries has since January 1, 1991 received written notice of, or
other written communication concerning, any failure to comply with any applicable Environmental
Laws, or written notice or other written communication that Merck or any of its Subsidiaries is or
may be a potentially responsible party or otherwise liable in connection with any site allegedly
containing Hazardous Materials. None of Merck’s or its Subsidiaries’ facilities used in the Merck
JV Business have in the past, or do at the present time, use, generate, treat, store, dispose of,
process, handle or manage any Hazardous Materials or other materials in violation of any applicable
Environmental Law, and there has been no release or migration of any Hazardous Materials at, on,
under, about, within, from or onto any such properties, where such violation, release, or migration
will or is reasonably likely to result, individually or in the aggregate, in a Material Adverse
Change or Effect. Except as will not result in a Material Adverse Change or Effect, there are no
past or present

167

 

conditions, circumstances, facts, events, practices, incidents, actions or omissions existing or
occurring at any location (including any off-site location) that will or is reasonably likely to
(i) cause Merck or any of its Subsidiaries or, subsequent to the Closing, any Merial Venture
Company, to incur any Environmental Liability in respect of the Merck JV Business, (ii) form the
basis for any claim, action, suit, proceeding, hearing, investigation or inquiry against Merck or
any of its Subsidiaries or, subsequent to the Closing, any Merial Venture Company, under any
Environmental Law in respect of the Merck JV Business, or (iii) interfere with or prevent continued
compliance by Merck or any of its Subsidiaries or, subsequent to the Closing, any Merial Venture
Company, with any Environmental Law in respect of the Merck JV Business.

SECTION 10.19. Labor Relations; Employees; Employee Benefit Matters

     (a) Schedule. With respect to the employees who are expected to be employed by a
Merial Venture Company as of the Closing Date, Schedule 10.19A-1 contains a true and complete list
of each material Merck Benefit Plan. Within six (6) weeks after the date of this Agreement, Merck
will complete Schedule 10.19A-1 by providing to RM a list of all Merck Employee Agreements.
Except as set forth in Schedule 10.19A-2 and with respect to the employees who are expected to be
employed by a Merial Venture Company as of the Closing Date, neither Merck, any of its Subsidiaries
nor any Merck ERISA Affiliate has any plan or commitment, whether legally binding or not, to
establish any new Merck Benefit Plan, to enter into any Merck Employee Agreement or to materially
modify or to terminate any Merck Benefit Plan or Merck Employee Agreement (except to the extent
required by law or to conform any such Merck Benefit Plan or Merck Employee Agreement to the
requirements of any applicable law, or as required by this Agreement), nor has any intention to do
any of the foregoing been communicated to Merck Employees.

     (b) Documents. Merck has provided, or has caused to be provided, or will cause to be
provided prior to the Closing to RM (i) current, accurate and complete copies of all documents
embodying or relating to each Merck Transferred Benefit Plan and each

168

 

Merck Employee Agreement, including all amendments thereto, written interpretations thereof and
trust or funding agreements with respect thereto; (ii) the two (2) most recent annual actuarial
valuations, if any, prepared for each Merck Transferred Benefit Plan; and (iii) the two (2) most
recent annual reports (Series 5500 and all schedules thereto), if any, required under ERISA in
connection with each Merck Transferred Benefit Plan or related trust.

     (c) Multi-Employer Plans. Except with respect to employees who are not Merck
Employees, neither Merck nor any of the Merck Transferred Subsidiaries contribute to or are
required to contribute to, or have incurred any withdrawal liability (within the meaning of Section
4201 of ERISA) to, any “multi-employer plan” within the meaning of Section 3(37) of ERISA.

     (d) No Post-Employment Obligations. Except as expressly set forth on Schedule 10.19D,
neither Merck, any of its Subsidiaries nor any Merck ERISA Affiliate (i) maintains or contributes
to any Merck Transferred Benefit Plan which provides, or has any Liability to provide, life
insurance, medical, severance or other employee welfare benefits to any Merck Employee upon his
retirement or termination of employment, except as may be required by Section 4980B of the Code; or
(ii) has ever represented, promised or contracted (whether in oral or written form) to any Merck
Employee (either individually or to Merck Employees as a group) that such Merck Employee(s) would
be provided with life insurance, medical, severance or other employee welfare benefits upon their
retirement or termination of employment, except to the extent required by
Section 4980B of the Code.

     (e) Effect of Transaction. Except as set forth on Schedule 10.19E, the execution of,
and performance of the transactions contemplated in, this Agreement will not (either alone or upon
the occurrence of any additional or subsequent events)
(i) constitute an event under any Merck Transferred Benefit Plan, Merck Employee Agreement, or
related trust or loan that will or may result in any payment (whether of severance pay or
otherwise), acceleration, forgiveness of indebtedness, vesting, distribution, increase in benefits
or obligation to fund benefits with respect to any Merck

169

 

Employee, or (ii) result in the triggering or imposition of any restrictions or limitations on the
right of the Merial Venture Companies to amend or terminate any Merck Transferred Benefit Plan. No
payment or benefit which will or may be made by Merck or any of its Subsidiaries to any Merck
Employee with respect to the transactions contemplated herein will be characterized as an “excess
parachute payment,” within the meaning of Section 280G(b)(l) of the Code.

     (f) Collective Bargaining Agreement (“CBA”). Except as set forth on Schedule 10.19F,
no Merck Employee is employed pursuant to a CBA or a works council agreement to which a member of
the Merck Group is a party that any Merial Venture Company will be bound by after the Closing or
will otherwise be obligated to honor or assume in connection with this Agreement or the
transactions contemplated by this Agreement, other than those agreements that the Merial Venture is
obligated to assume under applicable law.

     (g) Pension Plan Funding. Except as set forth on Schedule 10.19G-1, the present value
of all accrued benefits of each Merck Transferred Pension Plan, determined on the basis of the
actuarial assumptions used by the plan’s actuary for purposes of calculating minimum funding
contributions for the most recently completed plan year, do not as of the date hereof and will not
as of the Closing Date exceed the fair market value of the assets (which for this purpose shall not
include any accrued but unpaid contributions) of such Transferred Benefit Plan. Except as set forth
on Schedule 10.19G-2, the present value of all accrued benefits of each Merck Transferred Foreign
Pension Plan, determined using the actuarial assumptions employed by the actuary of the plan, do
not as of the date hereof and will not as of the Closing Date exceed the fair market value of the
assets (which for this purpose shall not include any accrued but unpaid contributions) of such
Merck Transferred Foreign Pension Plan or, in the case of an unfunded Merck Transferred Foreign
Pension Plan, the reserves provided for in the December 31, 1996 balance sheet of the Merck
Contributed Business Financials.

     (h) Labor Relations. Except as set forth in Schedule 10.19H-1, the Merck Group
generally enjoys good employer-employee relations with the Merck Employees.

170

 

Approximately 723 full-time equivalent employees are employed by the Merck Transferred Subsidiaries
and will be transferred to the Merial Venture together with such Subsidiaries. Schedule 10.19H-2
contains the names of all current employees of the Merck Group, other than the Merck Transferred
Subsidiaries, which Merck expects will transfer to the Merial Venture after the Closing. Subject to
their receiving compensation and benefit offers from the Merial Venture comparable to their current
compensation and benefit packages, Merck has no reason to believe that substantially all of the
employees listed in Schedule 10.19H-2 will not accept employment offers with the Merial Venture.

     (i) Employment Matters. No member of the Merck Group is delinquent in payments to any
of the Merck Employees for any wages, salaries, commissions, bonuses or other direct compensation
for any services performed by them to the date hereof or to the Closing Date (as applicable) or
amounts required to be reimbursed to such employees. With respect to the Merck Employees, each
member of the Merck Group has (i) complied in all material respects with applicable laws, rules and
regulations relating to the employment of the Merck Employees, including those relating to wages,
hours, collective bargaining, and the payment and withholding of taxes, and (ii) withheld and paid
to the appropriate Public Authority, or are holding for payment not yet due to such Public
Authority, all amounts required by law, rule, regulation or agreement to be withheld from the wages
or salaries of the Merck Employees. Since January 1, 1993, there has been no material adverse
change in the relationship of the Merck Group with the respective Merck Employees (including any
threatened union organization or renegotiation of any union or other collective bargaining
contract) nor any material strike or labor disturbance by such employees, and no member of the
Merck Group is aware of any indication that such a change, strike or labor disturbance is likely.

SECTION 10.20. Insurance

     Merck believes it maintains adequate insurance coverage (both with respect to levels of
coverage and deductibles, and including self-insurance), consistent with prudent practices,
including for general and product liability and business interruption, in respect of its Merck JV
Business assets and operations. Each of the policies comprising such coverage is in full force and
effect and all premiums are currently paid or accruals

171

 

provided for and no notice of cancellation or termination has been received with respect to any
such policy. Such policies are sufficient for compliance with all requirements of Law. Schedule
10.20 sets forth a complete list of all claims [*] made or filed by Merck or any
of its Subsidiaries with their insurers since January 1, 1993 with respect to the Merck JV Business
and any such claims incurred but not yet so made or filed of which Merck is aware.

SECTION 10.21. Share Capital of Merck Transferred Subsidiaries

     Schedule 10.21 (as updated in accordance with Section 3.2 hereof, as applicable) contains a
true and complete description of the authorized and outstanding capitalization (including the
record owners) of each of the Merck Transferred Subsidiaries. The indicated shares of capital stock
or other ownership interests of each of the Merck Transferred Subsidiaries represent all of the
respective issued and outstanding shares of capital stock or other ownership interests of each such
company. Except as set forth in Schedule 10.21, (a) the record and beneficial ownership of each
Merck Transferred Subsidiary is free and clear of any lien or other Encumbrance; (b) all of the
issued and outstanding shares of capital stock or other ownership interests of the Merck
Transferred Subsidiaries have been duly authorized and validly issued and are fully paid and
nonassessable; (c) none of the Merck Transferred Subsidiaries or any direct or indirect parent
company thereof is bound by, has granted, issued or made or agreed to grant, issue or make any
security interests, warrants, options, subscription rights or any other commitments of any
character relating to the issued or unissued shares of capital stock or other ownership interests
of the Merck Transferred Subsidiaries (other than this Agreement and the Ancillary Agreements), nor
is there any agreement providing for (i) any restriction on the transfer of any of the issued and
outstanding shares of capital stock or other ownership interests (other than with respect to
directors’ qualifying and nominee shares as set forth in Schedule 10.21) of any of the Merck
Transferred Subsidiaries, (ii) the amendment of the certificate or articles of incorporation or
by-laws (or comparable organizational documents) of any of the Merck Transferred Subsidiaries so as
to increase the amount of authorized capital stock or other ownership interests of such entity, or
(iii) obligating any of such persons to grant, offer, or enter into any of the foregoing; (d) none

172

 

of the direct or indirect parent companies of any of the Merck Transferred Subsidiaries is a party
to any voting trust or other agreement or understanding with respect to the voting of the capital
stock or other ownership interests of the Merck Transferred Subsidiaries; and (e) the record owner
of any such shares or other ownership interests possesses good and marketable title to such shares
or other ownership interests.

SECTION 10.22. Contracts and Licenses

     (a) Other than the agreements listed in Schedule 10.22A, there are no agreements between
any Merck Companies other than the Merck Transferred Subsidiaries, on the one hand, and any
Merck Transferred Subsidiaries, on the other hand, that will survive the Closing.

     (b) Schedule 10.22B lists all contracts or agreements having a value or involving payments [*] or otherwise material to the Merck Contributed Business between one or
more Merck Companies, on the one hand, and one or more Third Parties, on the other hand, to be
assigned or transferred to the Merial Venture pursuant to this Agreement or the Ancillary
Agreements. Other than as indicated in Schedule 10.22B, none of such contracts or agreements
require the consent of any Third Party to be assigned or transferred, as the case may be, to the
Merial Venture as contemplated by this Agreement or the Ancillary Agreements.

     (c) Schedule 10.22C lists all of the agreements listed in Schedule 10.22B that may restrict in
any way, such as through non-compete or exclusivity clauses, the ability of the Merial Venture to
undertake Merial Venture Business activities and lists all other agreements to be assigned or
transferred to the Merial Venture that include such a restriction, the compliance with by the
Merial Venture on or after the Closing would have a material adverse effect on the ability of the
Merial Venture to combine the Contributed Merial Venture Businesses or to conduct the activities
contemplated herein.

SECTION 10.23. Other Agreements

173

 

     Except as set forth in Schedule 10.23 and except for any agreements, arrangements or
commitments between Merck and its Subsidiaries or between such Subsidiaries, there are no
agreements, arrangements or commitments of any character (contingent or otherwise) relating to any
Acquisition Transaction pursuant to which any person is or may be entitled to receive from the
Merck Transferred Subsidiaries or any of their Subsidiaries any payment based on their revenues,
earnings or similar items (or any portion thereof) or on the occurrence or value of the Acquisition
Transactions (or similar circumstances), or calculated in accordance therewith. For the purposes of
this Section 10.23, “Acquisition Transaction” shall mean any merger, purchase of substantial
assets, purchase of shares of capital stock or similar transactions involving the Merck Transferred
Subsidiaries or any Subsidiary thereof.

SECTION 10.24. Survival of Representations and Warranties

     Merck and Merck SH acknowledge that their representations and warranties are an inducement to
RP, IM and RM and to Merial to enter into this Agreement and the Ancillary Agreements. The
representations and warranties contained in this Article X shall survive (and not be affected in
any respect by) any investigation by or on behalf of any Party and the Closing. Notice of any claim
in respect of the representations and warranties in Sections 10.1 [Organization; Powers], 10.2
[Authorization; No Breach],
10.3 [Enforceability], 10.11(a) [Title], 10.12(b) [Intellectual Property — existing Proprietary
Rights] and 10.21 [Share Capital] may be given at any time (subject to any statute of limitations
under applicable law); the representations and warranties in Sections
10.4 [Governmental Approvals], 10.12 (a) and (c) [Intellectual Property — other], 10.13 [Product
Registrations], 10.17 [Tax Returns] and 10.18 [Environmental Matters] must be given before the
fifth anniversary of the Closing Date; notice of claim in respect of all other representations and
warranties in Article X must be given before the second anniversary of the Closing Date; it being
understood that in the event notice of any claim for indemnification under Section 14.1 hereof
shall have been given (as contemplated by Section 14.7) within the applicable survival period, the
representations and warranties that are the subject of such indemnification claim shall survive
until such time as such claim is finally resolved.

174

 

ARTICLE XI

COVENANTS OF THE RP GROUP AND THE MERCK GROUP

SECTION 11.1. Legal Existence

     Each of the Principals shall do or cause to be done all things necessary to preserve, renew
and keep in full force and effect its legal existence, for so long as such Principal is a party to
this Agreement or any Ancillary Agreement; provided that nothing in this Section 11.1 shall prevent
either Principal from taking any action permitted by Articles XVI or XVII. .

SECTION 11.2. Public Authority Approvals

     Each of Merck and Merck SH, on the one hand, and RP, RM and IM, on the other hand, shall use
commercially reasonable efforts to promptly obtain or make all permits, consents and approvals of,
registrations with and notices to all Public Authorities that may be or become necessary for its
execution and delivery of, and the performance of its obligations under, this Agreement and the
Ancillary Agreements, and will cooperate fully with any company in the other Group in promptly
seeking to obtain or make all such permits, consents, approvals, registrations and notices,
including, without limitation:

     (a) Each Principal agrees to make appropriate filings pursuant to Council Regulation No.
4064/89 of the European Union with respect to the Transactions within seven (7) days of the date
hereof, and to supply as promptly as practicable to the appropriate Public Authorities any
additional information and documentary material that may be requested in connection with such
filings or with their filings made in the United States pursuant to the HSR Act.

     (b) RP and, if necessary, its Subsidiaries, shall use commercially reasonable efforts to
obtain an agrément fiscal from the French Ministère du Budget to the effect that the contribution
by IM to Merial of the share capital of RM shall be treated as an apport partiel d’actif under
article 210B of the Code Général des Impôts, and Merck and, if

175

 

necessary, its Subsidiaries, shall use commercially reasonable efforts to obtain from the I.R.S. a
tax ruling to the effect that Section 1491 and the Treasury Regulations thereunder do not apply to
Merck or its Affiliates with respect to the transactions contemplated by this Agreement and that
neither Merck nor its Affiliates will be required to recognize gain with respect to such
transactions for U.S. Federal income tax purposes.

     (c) Merck shall, and shall cause each of its relevant Subsidiaries to use commercially
reasonable efforts to: (i) transfer to Merck Transitory LLC prior to the Closing all the Merck
Product Registrations that are part of the Merck Contributed U.S. Assets, and (ii) transfer as many
as practicable of the Merck Product Registrations that are part of the Merck Contributed Non-U.S.
Assets to the appropriate Merial Subsidiary in the country of each such Product Registration at the
Closing. Merck shall reimburse the Merial Venture for any and all costs and expenses (excluding
any allocation of salaries of employees of the Merial Venture), including all fees of regulatory
counsel and registration, filing, stamp duty or other comparable duties incurred by it in effecting
such transfers at the Closing. All of the Merck Product Registrations that are not transferred at
the Closing shall be Delayed Purchase Assets and shall be transferred to the appropriate Merial
Subsidiary in the country of each such Product Registration in accordance with Section 5.1(a)(ii).
Merck hereby irrevocably authorizes Merial or the appropriate Merial Subsidiaries to sell the
Merial Venture Products under Merck Product Registrations pending perfection of the transfer of
Registrations or obtaining of new Registrations. In the event any Merck Product Registration
cannot be transferred to the Merial Venture as set forth above or has not been so transferred
before the first anniversary of the Closing Date, Merck shall, and shall cause each relevant Merck
Subsidiary to, fully cooperate with the Merial Venture in obtaining a new Product Registration.
Merck shall indemnify the Merial Venture Companies for all costs and expenses reasonably incurred
by them (excluding any allocation of salaries of employees of the Merial Venture), including fees
and expenses of counsel and registration, filing, stamp duty, transfer or other comparable duties,
in obtaining such new Product Registrations.

176

 

     (d) RTPA. Promptly after the date of this Agreement, each of RP and
Merck shall confirm to the other whether it, or any of its subsidiaries who are parties to any of
the Ancillary Agreements, carry on business in the United Kingdom in the production or supply of
goods or the supply or services for the purposes of the Restrictive Trade Practices Act 1976 as
amended (the “RTPA”) For the purposes of this clause, “subsidiaries” shall be construed in
accordance with Section 736 of the Companies Act. If either RP or Merck determines that there are
any provisions of this Agreement (or of an arrangement of which it forms part) by virtue of which
particulars of this Agreement (or of an arrangement of which it forms part), at the date of this
Agreement, are required to be furnished to the Director General of Fair Trading under the
Restrictive Trade Practices Acts 1976 and 1977, RP and Merck shall ensure that those particulars
and any other required information are furnished as soon as possible and in any event within the
time specified by those Acts.

SECTION 11.3. No Limitation on Other Activities of Principals

     Other than as expressly provided in this Agreement or any of the Ancillary Agreements, each
Principal (and its Subsidiaries) shall be free to pursue its (and such Subsidiaries’) respective
businesses other than the Merial Venture Business in any manner chosen by it (and such
Subsidiaries) and shall have no obligation to limit in any way its activities with respect to new
products or to offer other business opportunities to the Merial Venture or to disclose any
information concerning its (or such Subsidiaries’) other businesses to the other Principal (or any
Subsidiary thereof). Nothing in this Section 11.3 shall be interpreted as excusing any Party from
compliance with Sections 15.1 [Non-Competition], 19.3 [Confidentiality] and 19.13 [Publicity].

SECTION 11.4. Fiscal Year; Annual Audits; Selection of Auditors

     The fiscal year (the “Fiscal Year”) of Merial (and all other Merial Venture Companies, except
as provided by the Board of Directors) shall begin on January 1 (or, in the case of the first
Fiscal Year, the Closing Date) and end on December 31 of each calendar year. Following the close
of each Fiscal Year, consolidated financial statements

177

 

shall be prepared by Merial and audited by an independent accounting firm selected by the Members’
Meeting; provided that the consolidated financial statements for the Fiscal Years ending December
31, 1997 and 1998 shall be audited jointly by Arthur Andersen and Coopers and Lybrand.

SECTION 11.5. Books and Records of the Merial Venture

     (a) Accounts of Merial Venture. Merial shall keep full and proper ledgers and
other books of account, including all books of account required by the Companies Act, and the
following financial reports or information shall be provided to each Member (and, upon request, to
each Principal):

     (i) within a reasonable period of time after the expiration of each quarter of
Merial’s Fiscal Year as the Principals shall request, the unaudited consolidated balance
sheet and the related statements of income and cash flows of Merial and its Subsidiaries,
prepared in accordance with U.S. GAAP and any other accounting standards as may be required
by applicable Laws, as of the end of, and for, such quarter and the Fiscal Year-to-date;

     (ii) as required by the Principals and no more than 20 days following the end of
each calendar month, a monthly operating summary of the Merial Venture’s activities in a
form to be agreed upon by the Principals; the Principals and the Merial Venture will each
provide (to the extent reasonably available to such Person) in a timely manner all
information necessary to determine the Principals’ respective entitlements associated with
the Merial Venture;

     (iii) within such period of time after the end of each Fiscal Year of Merial as the
Principals shall request, the audited consolidated balance sheet and the related statements
of income and cash flows of Merial and its Subsidiaries, prepared in accordance with U.S.
GAAP and any other GAAP as may be required by applicable Laws or reasonably required by
either of the Principals, as well as all necessary tax reporting information required by
each of the Members and

178

 

Principals for preparation of their national, state and local income tax returns,
including each Member’s share of income, gain, loss, deductions and credits for
such Fiscal Year, including, in the case of RP, the financial information required
by the CFM Agreement; and

     (iv) within a reasonable period of time, such other financial information with
respect to Merial or any of its Subsidiaries as any Member or Principal shall reasonably
request to permit such Member or Principal to prepare its respective financial statements.

In addition to such financial reports and information listed in clauses (i) through (iv) above, the
financial statements of Merial shall be prepared in accordance with the requirements of the
Companies Act and each Merial Venture Company shall prepare its financial statements in accordance
with the accounting standards imposed by the Laws applicable to it.

     Merial and, as appropriate, its independent auditors, shall certify that the financial
information provided in clauses (i) – (iii) above (A) has been prepared in accordance with the
books of account and other financial records of the Merial Venture, (B) presents fairly the
financial condition and results of operations of the Merial Venture as of the date thereof or for
the periods covered thereby, (C) has been prepared in accordance with U.S. GAAP (or another GAAP,
as the case may be), and (D) includes all adjustments that are necessary for a fair presentation of
the financial condition of the Merial Venture as of the dates thereof or for the periods covered
thereby.

     (b) Examination of Merial Venture’s Records, Facilities, etc. Subject to Section
11.5(c), Merial shall, upon reasonable notice, and shall cause each of its Subsidiaries, employees
and agents to: (i) afford the officers, employees and authorized agents, certified auditors or
counsel of the Principals reasonable access, during normal business hours, to the offices,
properties, other facilities, books and records of the Merial Venture (which access shall include
the right to conduct Phase I environmental assessments and, for a period of two years after the
date of this Agreement, to the extent

179

 

the findings of any such Phase I environmental assessments give rise to a reasonable concern (from
the standpoint of a reasonably prudent business person) that contamination or other circumstances
that may cause the incurrence of an Environmental Liability exist,
shall also include the right of
sampling and analysis of air, surface or subsurface soil, groundwater, surface water, building
materials and/or wastes; provided that such sampling and analysis is conducted in a
commercially reasonably manner designed to minimize interference with ongoing operations and is no
more expansive than is reasonably necessary to ascertain whether Damages will be incurred) and to
appropriate officers, employees, agents and counsel of the Merial Venture, and (ii) furnish to the
officers, employees and authorized agents, certified auditors or counsel of the Principals such
additional financial and operating data and other information regarding the operations, assets,
properties and goodwill of the Merial Venture as either Principal may from time to time reasonably
request. Prior to the time when a Merial Venture Business or asset to be transferred to the Merial
Venture is so transferred, the Principal in control of such Merial Venture Business or asset shall
provide the other Principal with the same access to and information regarding such Merial Venture
Business or asset as is described in the preceding sentence. Except as provided in Article XIV,
each Principal shall bear all expenses incurred by it in any such examination made by it pursuant
to this Section 11.5.

     (c) Confidentiality Exception. Each Principal acknowledges the right of the
other Principal and its Subsidiaries to keep confidential certain commercial, product, technical
and scientific information provided by such other Principal or its Subsidiaries to the Merial
Venture, including information provided pursuant to the Research Agreements or obtained pursuant to
agreements with Third Parties containing confidentiality provisions. Accordingly, each Principal
agrees that it shall not exercise its right of inspection with respect to, and shall direct the
Directors nominated by it not to inspect, such information pursuant to this Agreement or otherwise
without obtaining the prior written consent of the other Principal and, if such consent is given,
it shall follow such procedures as are determined by the other Principal in its sole discretion in
order to prevent the disclosure of such information (it being acknowledged that a Principal may
prohibit entirely the disclosure of such information by the Merial Venture to the other

180

 

Principal and, in such case, the Merial Venture will not disclose such information and will take
all reasonable steps necessary to prevent such disclosure).

     (d) Merial Venture Records Following Dissolution. Notwithstanding anything
contained in this Agreement to the contrary (except for and subject to Section 11.5(c)), in the
event of the Dissolution of the Merial Venture, the accounting and product records of the Merial
Venture shall be preserved and shall be made freely available to both Principals for consultation
or copying until five years after such Dissolution or such earlier time as both Principals agree
that such records may be destroyed or need no longer be made available.

SECTION 11.6. Obtaining Third Party Consents

     (a) Merck Agreements. Merck shall use commercially reasonable efforts to
procure that, on the Closing Date or, if not practicable, as soon as possible thereafter, the
benefit to the extent related to the Merial Venture Business of all agreements listed in Schedule
10.22B (the “Merck Agreements”) shall have been transferred to the Merial Venture. The following
principles shall apply to each Merck Agreement in respect of which any consent, approval or waiver
by any Third Party (a “Consent”) is still required to be obtained as of the Closing Date in order
for Merck to fully transfer or assign such Merck Agreement to the Merial Venture:

     (i) Merck shall inform Merial and RP of that fact and shall use
commercially reasonable efforts to obtain such Consent promptly;

     (ii) pending such Consent being obtained, Merck shall hold all benefits of such
Merck Agreement to the extent related to the Merial Venture Business as agent for the Merial
Venture and account promptly to the Merial Venture, without any deduction, set-off or
counterclaim, for any and all sums received by Merck pursuant to such Merck Agreement, and
shall not agree to any material variation of, or modification to, termination of, or waiver
of any right under or in relation

181

 

to such Merck Agreement without the prior consent of Merial (which shall not be
unreasonably withheld or delayed);

     (iii) pending such Consent being obtained, the Merial Venture shall (at the Merial
Venture’s own cost and for its own account) perform all of Merck’s obligations in respect
of such Merck Agreement; and

     (iv) in the case of any such Merck Agreements relating to intellectual property
rights, Merial, Merck, RP and the relevant Third Party (as appropriate) shall (where
necessary) have discussions with a view to establishing by mutual agreement those Merck
Agreements where a sub-license is to be granted and/or those where a separate license is to
be granted to the Merial Venture and/or those which are to be novated or otherwise assigned
(subject, where appropriate, to existing licenses) to the Merial Venture, and Merck shall,
pending such sub-license, license, novation or other assignment, continue to the extent
reasonably requested by Merial to carry on all activities for which the intellectual
property rights covered by such Merck Agreement are necessary;

provided that, any Merck Agreement in respect of which a Consent is required but not obtained shall
not be deemed transferred or assigned and no effect shall be given to clauses (ii) or (iii) above
if there is a significant risk that the relevant Merck Agreement would be treated as repudiated by
a Third Party co-contractant or that Merck would be held to be in breach of its obligations
thereunder if effect were given thereto. If any necessary Consent has not been obtained on or
before the first anniversary of the Closing Date, the Principals and Merial shall cooperate to seek
an alternative solution designed to provide the Merial Venture with the material benefits of (or
the substantial equivalent of the benefits of) such Agreement, and until such an alternative
solution is agreed upon, the foregoing provisions of this Section 11.6(a) shall continue to apply.

     (b) RM Agreements. RM shall use commercially reasonable efforts to obtain, prior to
the Closing, all consents, approvals or waivers necessary under any agreement to which RM or a
Subsidiary thereof is a party and without which there is a significant risk

182

 

that such agreement would be treated as repudiated by a Third Party co-contractant. In the event
RM or its Subsidiaries are unable to obtain any such consent, approval or waiver prior to or
concurrently with the Closing, RM shall inform Merial and Merck of that fact and the Principals and
Merial shall cooperate to seek an alternative solution designed to provide the Merial Venture with
the benefit thereof, and until such an alternative solution is agreed upon, the foregoing
provisions of this Section 11.6(b) shall continue to apply.

     (c) Restrictive Agreements. Each Party shall use commercially reasonable
efforts to procure that, on or prior to the Closing Date or, if not practicable, as soon as
possible thereafter, each of the “Restrictive Agreements”, as defined below, shall be either (i)
terminated, or (ii) amended so as to permit the Merial Venture to manufacture, sell or distribute
all of the Merial Venture Products as contemplated by this Agreement without being in breach of any
such Restrictive Agreement. The Merial Venture shall operate after the Closing on the basis that
all of the Restrictive Agreements have been so terminated or modified on or prior to the Closing
Date. The relevant Principal (RP for any Restrictive Agreement to which an RP Company or RM or any
of its Subsidiaries is a party, and Merck for any Restrictive Agreement contributed by Merck to
which a Merck Company is a party) shall bear all the costs related to or resulting from, and
indemnify the Merial Venture for any and all Damages incurred or suffered by the Merial Venture in
connection with the matters set forth in the two preceding sentences. For purposes of this Section
11.6(c), a “Restrictive Agreement” is any agreement to which an RP Company or a Merck Company
(including those agreements to be contributed by Merck to the Merial Venture) or RM or its
Subsidiaries is a party, and which contains restrictions which, if not terminated or amended, will
be breached by Merial or any of its Subsidiaries in undertaking the Merial Venture Business
activities contemplated to be undertaken by the Merial Venture as of the Closing pursuant to this
Agreement. Notwithstanding the immediately preceding sentence, the Parties agree that the Stock
Purchase Agreement among RM, ISA, Rhône Mérieux Diagnostics S.A.S. and Synbiotics Corporation which
has been disclosed to Merck prior to the date hereof is not, and shall not be considered or treated
as, a Restrictive Agreement.

183

 

SECTION 11.7. Trademarks

     (a) On or before the Closing, Merck shall provide to RP and Merial a listing
of the registered trademarks and trademark applications shown on Schedule 10.12
indicating which:

     (i) have uses outside of the field of the Animal Health Business or the Poultry
Genetics Business (“Multiple Use Trademark”),

     (ii) will be held by Merck Transitory LLC and thereby contributed to Merial
(“Merck Contributed Trademarks”), or

     (iii) will be assigned by Merck or its Subsidiaries to the Merial Venture (other
than as contemplated in (ii) above) (“Merck Assigned Trademarks”).

     (b) Merck shall, in accordance with the terms and conditions of this Agreement, use
commercially reasonable efforts to assign or cause to be assigned to Merial (or to a Merial
Subsidiary agreed upon by the Principals) concurrently with the Closing all the Merck Assigned
Trademarks. Merck shall be responsible for any and all costs and expenses (excluding any
allocation of salaries of employees of the Merial Venture) related to the assignment to the Merial
Venture of the Merck Assigned Trademarks, including all intellectual property counsel fees and
expenses and registration, filing, stamp duty or other comparable duties, and shall indemnify the
Merial Venture for any such costs and expenses incurred by it.

     (c) With respect to the Merck Assigned Trademarks, if any, that are not assigned to the Merial
Venture concurrently with the Closing and to the Multiple Use Trademark, Merck shall grant or cause
to be granted to the Merial Venture effective as of the Closing a royalty-free, exclusive in the
field of the Animal Health Business, license to use such trademarks until they are assigned to the
Merial Venture. Unless Merial, Merck and RP agree otherwise, (x) each Multiple Use Trademark shall
be assigned to the Merial Venture upon (and subject to) its no longer being a Multiple Use
Trademark, and (y) the

184

 

parties shall use commercially reasonable efforts to cause to be assigned to the Merial Venture as
soon as possible after the Closing all Merck Assigned Trademarks, if any, not assigned to the
Merial Venture at the Closing.

     (d) Merck shall promptly inform Merial of any notification or claim it may receive in
respect of the Merck Assigned Trademarks which have not yet been assigned to the Merial Venture
and, upon the request and at the expense of Merial, take any and all actions reasonably necessary
to renew, maintain, prosecute and defend any of such trademarks which have not yet been assigned to
the Merial Venture.

SECTION 11.8. Information and Assistance of Principals Made Available

     Each Principal shall:

     (a) to the extent any such records are not transferred to the Merial Venture, preserve
for a period ending on the third (3rd) anniversary of the Closing Date any and all
accounting, product, marketing or legal records in respect of such Principal’s Merial
Venture Business activities prior to the formation of the Merial Venture (provided
that each Principal shall in all cases preserve all records not transferred to the Merial
Venture to the extent required to be preserved by the Laws of all jurisdictions applicable
to any asset contributed to the Merial Venture), and (subject to Section 11.5(c)) shall
either provide access to such records to appropriate employees or agents of the Merial
Venture or furnish the Merial Venture with any specific information from such records as may
be reasonably requested by the Merial Venture and shall use its best efforts to cooperate
fully with the Merial Venture in the case of any investigation or audit carried out by any
Public Authority; and

     (b) until December 31, 1998, provide any services for the Merial Venture or furnish to
the Merial Venture access to any infrastructure (including to computer systems and software)
as may be necessary for the Merial Venture to continue to conduct the Merial Venture
Business activities contributed by such

185

 

Principal in a manner substantially consistent with such Principal’s (or its Subsidiaries’)
provision of services or access to infrastructure or services prior to the establishment of
the Merial Venture, in each case on terms and conditions no less favorable to the Merial
Venture than those that could have been obtained by a non-Affiliate at arm’s length and
subject to any significant concerns relating to confidentiality (which concerns the Merial
Venture and such Principal shall cooperate in good faith to address without excluding the
Merial Venture’s access to the relevant services or infrastructure). The Parties
acknowledge that, with respect to RP, some of such services shall be provided pursuant to
the RP Intragroup Agreements described in Section 11.12. Merial shall, and shall cause
the Merial Venture Companies to, use commercially reasonable efforts to develop and put in
place its own infrastructure and access to services independent from the Principals as soon
as possible after the Closing.

SECTION 11.9. Compliance with Laws

     Merial shall (and shall cause the other Merial Venture Companies to) comply in all material
respects with all Laws (x) applicable to the Merial Venture and its properties or activities, or
(y) where the failure to so comply could result in either Principal or any of its Affiliates being
liable or otherwise responsible for any non-compliance with or violation of any Laws by virtue of
its Merial Venture Interest. In addition, Merial shall (and shall cause the other Merial Venture
Companies to) establish policies and procedures which shall be designed to ensure that neither
Principal nor any of its Affiliates would, due to any activities of the Merial Venture, become
liable or otherwise responsible for any non-compliance with or any violation of Laws or directive
of any Public Authority in respect of which such Party could be held liable or otherwise
responsible by virtue of its Merial Venture Interest. In addition, Merial shall (and shall cause
the other Merial Venture Companies to) comply fully with any such policies or procedures.

SECTION 11.10. Merial Venture Product Safety

186

 

     The Parties acknowledge that, since each Principal is engaged in, among other things, the
discovery and development, manufacturing, marketing and sale of pharmaceutical and biological
products, the safety of Merial Venture Products may be an appropriate concern of either Principal.
Accordingly, either Principal may, following consultation between the RP Animal Health Executive
and the Merck Animal Health Executive, request Merial to cease (and to cause the other Merial
Venture Companies to cease) the marketing and sale of any Merial Venture Product, the use of which
the Principal in good faith believes poses a risk to human, animal or environmental safety. Upon
receiving such request, Merial shall (and shall cause the other Merial Venture Companies to)
promptly cease the manufacture, marketing and sale of the Merial Venture Product.

SECTION 11.11. Environmental Meetings

     The Parties intend to meet before the Closing to discuss the elements of environmental and
safety process management programs to be established by the Merial Venture.

SECTION 11.12. Intragroup Agreements

     (a) General. RP and IM represent that all of the RP InterCo Contracts and RP
InterCo Customary Arrangements (each as defined in Section 9.7 and together, the “RP Intragroup
Agreements”) are on terms and conditions that are no less favorable to the Merial Venture than
those that could have been obtained by a non-affiliate at arm’s length and that none of these are
Restrictive Agreements (as defined in Section 11.6(c)). Merck represents that all of the
agreements (i) listed on Schedule 10.22A that will survive the Closing, and (ii) that will be
contributed to the Merial Venture and to which a Merck Company will be a party after the Closing
(all such agreements described in (i) or (ii) being the “Merck Intragroup Agreements” and, together
with the RP Intragroup Agreements, the “Intragroup Agreements”), are on terms and conditions that
are no less favorable to the Merial Venture than those that could have been obtained by a
non-affiliate at arm’s length and that none of these are Restrictive Agreements (as defined in

187

 

Section 11.6(c)). Each of the RP Intragroup Agreements and each of the Merck Intragroup
Agreements shall continue to be governed by its stated terms and conditions after the Closing
except to the extent inconsistent with the terms and conditions of this Section 11.12, in which
case the terms and conditions of this Section 11.12 shall control and govern. The Parties
acknowledge and agree that the Ancillary Agreements (and the contracts, agreements or arrangements
referred to in the PMSV Research Agreement) are not, and are not intended to be treated pursuant to
this Section 11.12 as, Intragroup Agreements.

     (b) Each of RP and Merck agrees (and shall cause their respective Subsidiaries that are
parties to Intragroup Agreements to agree) not to terminate the RP Intragroup Agreements and the
Merck Intragroup Agreements, respectively, before December 31, 1998. With respect to each
Intragroup Agreement, Merial, RP and Merck shall (and shall cause their respective Subsidiaries
that are parties to Intragroup Agreements to) negotiate in good faith from the Closing Date until
December 31, 1998 to either (i) renew such Intragroup Agreement under the same terms and conditions
as those in effect on the Closing Date, (ii) amend the terms and conditions of such Intragroup
Agreement, or (iii) terminate such Intragroup Agreement. If the parties to any Intragroup
Agreement have not reached agreement by December 31, 1998, such Intragroup Agreement will terminate
automatically as of such date.

     (c) Service Agreements. RP agrees that all of the RP Intragroup Agreements that are
service agreements (which shall be part of the services to be provided to Merial in accordance with
Section 11.8(b)) will be terminable after the Closing by Merial or the Subsidiary of Merial that is
a party to any such agreement on one month’s (or such shorter period as may be provided by the
terms thereof) advance notice of termination and without any cost to the Merial Venture (other than
to pay for goods or services ordered thereunder prior to such termination). Merck agrees that all
of the Merck Intragroup Agreements that are service agreements will be terminable after the Closing
by Merial or the Subsidiary of Merial that is a party to any such agreement on one month’s (or such
shorter period as may be provided by the terms thereof) advance notice of termination and

188

 

without any cost to the Merial Venture (other than to pay for goods or services ordered thereunder
prior to such termination).

     (d) Intragroup Toll Manufacturing Agreements and Distribution/Agency Agreements. RP agrees that all of the RP Intragroup Agreements that are toll
manufacturing agreements or distribution or agency agreements will be terminable after the Closing
by Merial or the Subsidiary of Merial that is a party to any such agreement on six months’ (or such
shorter period as may be provided by the terms thereof) advance notice of termination and without
any cost to the Merial Venture (other than to pay for goods or services ordered thereunder prior to
such termination). Merck agrees that all of the Merck Intragroup Agreements that are toll
manufacturing agreements or distribution or agency agreements will be terminable after the Closing
by Merial or the Subsidiary of Merial that is a party to any such agreement on six months’ (or such
shorter period as may be provided by the terms thereof) advance notice of termination and without
any cost to the Merial Venture (other than to pay for goods or services ordered thereunder prior to
such termination).

SECTION 11.13. EPA Fipronil Risk Assessment

     Until the Closing Date or the date such document is issued, RP shall (or shall cause the
relevant RP Company to) diligently seek and monitor the issuance or reissuance by the U.S.
Environmental Protection Agency (the “EPA”) of a document assessing the risk of the use of Fipronil
in the Animal Health Business, and shall promptly inform Merck of any and all (and provide copies
of any written) information or communications received from the EPA with respect to Fipronil. If
the EPA has not issued or reissued a document assessing the risk of the use of Fipronil in the
Animal Health Business before June 15, 1997, then RP shall (or shall cause the relevant RP Company
to) arrange a meeting with the EPA (which is attended also by a Merck representative) to discuss
these matters prior to the Closing. RP and RM shall use all commercially reasonable efforts to
counteract or oppose any withdrawal or limitations to the conditional approval granted by the EPA
to RM to use Fipronil in the Animal Health Business.

189

 

SECTION 11.14. Rhone Merieux, Inc. Restructuring

     The Parties agree that the following steps shall be undertaken after the Closing Date and
before December 31, 1997 with respect to Rhone Merieux, Inc. (“RMI”):

          (a) RP shall (or shall cause the relevant RP Company to) license Fipronil for the U.S.
market to Merial (in accordance with the RP Ag License Agreement);

          (b) Merial and RMI shall enter into a manufacturing agreement for Fipronil spray,
pursuant to which RMI shall manufacture on a cost-plus basis;

          (c) Merial and RMI shall enter into a research and development agreement for all non-vaccine
research and development, pursuant to which RMI shall provide research and development services on
a cost-plus basis;

          (d) RMI will transfer or license its U.S. product registrations to Merial;

          (e) all new equipment and other property purchases for the U.S. market shall be made by
Merial;

          (f) to the extent possible under applicable collective bargaining agreements and applicable
Laws, by December 31, 1997, or as soon as practicable thereafter, RMI’s sales force shall be
terminated but shall receive employment offers from Merial;

          (g) vaccine patents and research and development activities shall be transferred by RMI to a
new partnership, with Merial contributing cash as the other partner. RMI shall receive a
preferred return equal to the product of (i) [*] as
published monthly by the IRS, calculated assuming annual compounding, as in effect on the date of
such transfer to the new partnership by RMI (such rate being the “[*]”), and (ii) the fair
market value of its

190

 

contribution, and then RMI and Merial shall share the residual return pari passu until RMI has
obtained an internal rate of return on the fair market value of its contribution equal to [*]. Merial shall receive [*] of the residual return, i.e., the economic value
remaining after RMI’s internal rate of return has reached [*].

SECTION 11.15. Fundamental Public Authority Approvals

     The appropriate Merck Companies and RP Companies shall use all commercially reasonable efforts
to obtain the approvals of Public Authorities necessary for the Merck Group and the RP Group to
consummate the Transactions as set forth in Schedule 11.15. However, to the extent such approvals
have not been obtained on or prior to the Closing Date, the Parties shall find and give effect to a
solution that will provide the Merial Venture and the Principals with the same economic benefits as
if they had been obtained.

SECTION 11.16. Duration of Certain Ancillary Agreements

     RP hereby agrees with Merck that RP shall, (i) for so long as RPA is a Subsidiary of RP, cause
RPA (and RP and Merck shall take all actions within their legal ability to cause Merial) to renew
for the longest period enforceable under applicable Laws the RPA Research Agreement, the RPA
License Agreement and the RPA Supply Agreement no later than two (2) years prior to the end of the
term of each such respective agreement or of any renewal thereof, and (ii) should RP ever agree to
sell or otherwise dispose of some or all of its interest in RPA or should RPA effect a transaction
(collectively, a “Deconsolidation Event”) which Deconsolidation Event would result in RPA no longer
being a Subsidiary of RP, to renew, prior to giving effect to any such Deconsolidation Event, the
RPA Research Agreement, the RPA License Agreement and the RPA Supply Agreement, in each case for
the longest period enforceable under applicable Laws. RP hereby agrees with Merck that RP shall,
(i) for so long as PMSV is a Subsidiary of RP, cause PMSV (and RP and Merck shall take all actions
within their legal ability to cause Merial) to renew for the longest period enforceable under
applicable Laws the PMSV Research Agreement no later than two (2) years prior to the end of the
term of such

191

 

agreement or of any renewal thereof, and (ii) should there be a Deconsolidation Event with respect
to PMSV which Deconsolidation Event would result in PMSV no longer being a Subsidiary of RP, to
renew, prior to giving effect to any such Deconsolidation Event, the PMSV Research Agreement for
the longest period enforceable under applicable Laws.

     RP shall, for so long as RPA and PMSV remain Subsidiaries of RP, indemnify and hold harmless
the Merial Venture and (only to the extent Merck or any of its Subsidiaries suffer Damages separate
and distinct from Damages suffered by the Merial Venture) Merck and its Subsidiaries from and
against any Damages arising out of, based upon or resulting from, the termination or alleged
termination of any of the RPA Ancillary Agreements referred to in this Section 11.16 or the PMSV
Research Agreement by, through or on behalf of RP, RPA or PMSV or any of their respective
Affiliates (or any termination by a court or other tribunal arising in any dispute or controversy
between Merial, on the one hand, and any of the foregoing Persons, on the other hand, provided that
Merial has not alleged to such court or other tribunal in such dispute or controversy that the
duration of such Ancillary Agreement is invalid or non-enforceable under French law), as the case
may be, as a result of the invalidity or the alleged invalidity or non-enforceability or alleged
non-enforceability under French law of the duration of such Ancillary Agreements as provided for
therein or in this Section 11.16.

     This Section 11.16 relates to the term of the Ancillary Agreements referred to in this Section
11.16 and extensions of the term thereof and does not, and is not intended to, change (x) the time
periods as set forth in (i) the non-competition provisions of Section 15.1 of this Agreement or
(ii) the non-competition or obligation of first offer provisions of any of such Ancillary
Agreements applicable to RP or to any of its Subsidiaries, or (y) the rights of the parties to the
Ancillary Agreements referred to in this Section 11.16 to terminate early or modify any such
Ancillary Agreements in accordance with the provisions of such Ancillary Agreements.

SECTION 11.17. Ancillary Agreements

192

 

     To the extent any Ancillary Agreement contemplates any actions or discussions by the Merck Animal
Health Executive and/or the RP Animal Health Executive (or similar officers or representatives),
Merck and RP each agrees to cause such individuals to take such actions or engage in such
discussions consistently with the terms of such Ancillary Agreement (whether or not Merck or RP,
as the case may be, or any of their respective Subsidiaries, is a party to such Ancillary
Agreement

SECTION 11.18. Further Action

     Each of the Parties hereto shall use commercially reasonable efforts to take, or cause to be
taken, all appropriate action, do or cause to be done all things necessary, proper or advisable
under applicable Laws, and execute and deliver such documents and other papers, as may be required
to carry out the provisions of this Agreement and the Ancillary Agreements.

193

 

ARTICLE XII

CLOSING

SECTION 12.1. Conduct Prior to Closing

     (a) General. Prior to the Closing, each of RM and Merck hereby agrees that it
shall not, and shall not cause or permit any Transferred Subsidiary or, in the case of Merck, any
Merck Subsidiary engaged in Merial Venture Business activities, to take any action that will result
in any violation of any covenant or cause any representation or warranty contained herein including
in Sections 8.9 and 10.9, to become untrue as of the Closing Date. Without limitation of the
foregoing, each of RM and Merck hereby agrees that (except as otherwise expressly contemplated by
this Agreement or the applicable Ancillary Agreements, set forth in Schedule 8.9 or 10.9, as
applicable, or specifically agreed to by the other in writing), from and after the date hereof and
prior to the Closing:

     (i) Ordinary Course. It shall (A) carry on, or cause to be carried on,
its and its Subsidiaries’ Merial Venture Business activities in the ordinary course of
business in substantially the same manner as heretofore conducted, (B) operate, or cause to
be operated, all of its and its Subsidiaries’ assets material to its or their Merial Venture
Business activities in the ordinary course of business in substantially the same manner as
heretofore operated, (C) do, or cause to be done, all things necessary to obtain, preserve,
renew, extend and keep in full force and effect the rights, licenses, permits, franchises,
authorizations and Proprietary Rights material to its and its Subsidiaries’ Merial Venture
Business activities, (D) maintain and preserve, or cause to be maintained and preserved, all
property material to the conduct of its and its Subsidiaries’ Merial Venture Business
activities, (E) keep, or cause to be kept, such property in good repair, working order and
condition, and from time to time make, or cause to be made, all needful and proper repairs,
renewals, additions, improvements and replacements thereto necessary in order that its and
its Subsidiaries’ Merial Venture Business activities may be properly conducted at all times,
(F) maintain, or cause to be maintained,

194

 

insurance with reputable insurance companies on all of its and its Subsidiaries’ assets material
to its or their Merial Venture Business activities to the extent and in the manner consistent with
past practice and will bear the risk of any loss to all of such assets through the Closing, and
(G) use all reasonable efforts to preserve intact its present business organization, keep
available the services of its present officers and employees and preserve its relationships with
customers, suppliers and others having business dealings with it with respect to the Merial
Venture Business; all of the foregoing, to the end that the goodwill and other assets of its and
its Subsidiaries’ Merial Venture Business shall be unimpaired in any material respect at the
Closing. Without limiting the generality of the foregoing, RP and Merck shall cause each of
their respective Transferred Subsidiaries to comply with this subparagraph (i) with respect to the
portion of the Merial Venture Businesses of the RP Group and the Merck Group, respectively,
conducted by, and the portion of the assets material to the conduct of such Merial Venture
Businesses owned, used or held by, such Transferred Subsidiary.

     (ii) Notice of Changes. Without limiting the effect of Section 12.6, it shall
promptly advise the other Principal orally and in writing of (A) any information that indicates
that any of its or its Subsidiaries’ representations or warranties contained in this Agreement was
not true and correct as of the date hereof or will not be true and correct as of the Closing Date,
(B) the occurrence of any event which will result, or has a reasonable prospect of resulting, in
the failure to satisfy a condition specified in Section 12.6, (C) any notice or other communication
from any Public Authority or Third Party alleging that the consent of such Public Authority or
Third Party is or may be required in connection with the Transactions, other than any such required
consents already indicated in Schedules 8.20-1 or 10.22B, and (D) any other change or event having,
or which, insofar as can reasonably be foreseen, would have, a Material Adverse Change or Effect.

     (iii) Contracts. Without the consent of the other Principal, it shall not and
shall not permit any of its Subsidiaries to, enter into, amend, alter, modify or

195

 

terminate (other than in accordance with its terms) any
agreement which is or would be required to be reported in
Schedule 8.20-1 or 10.22B, as applicable, other than (x)
with respect to any agreement with a Third Party, in the
ordinary course of business consistent with past practice of
RM and its Subsidiaries or the Merck Contributed Business,
or (y) the Ancillary Agreements.

     (b) Business of Merial. RP and IM agree that, prior to the Closing, Merial shall not
enter into any transactions or business or have any operations, assets or Liabilities except those
necessary to give effect to the Transactions as contemplated by this Agreement and the Ancillary
Agreements.

     (c) Satisfaction of Closing Conditions. Each Party shall use its reasonable best
efforts to satisfy all conditions to the Closing on or prior to the date scheduled for the Closing
(to the extent contemplated by this Agreement to be satisfied by such Party or its Affiliates) and
to facilitate, consummate and give effect to the Transactions, including by preparing, executing,
delivering and filing, or causing to be executed, delivered and filed, such schedules assignments,
deeds, bills of sale, consents and other instruments, and taking such other actions, as shall be
reasonably necessary or desirable for such purpose.

SECTION 12.2. Pre-Closing Actions

     (a) RP Pre-Closing Actions. Prior to the Closing, RP shall, at its cost and expense,
(i) have caused all the obligations remboursables en actions and any warrants associated therewith
(together, “ORAs” or convertible bonds) issued by RM to be repurchased and cancelled, and (ii)
cause the entirety of the share capital of Rhodia Merieux Veterinaria Ltda (Brazil) that is owned
by Rhodia S.A. to be repurchased by RM or a Subsidiary of RM with the effect that Rhodia Merieux
Veterinaria Ltda (Brazil) shall be a (direct or indirect) wholly-owned Subsidiary of RM on the
Closing Date.

     (b) Merck Pre-Closing Actions. On or before the Closing, Merck shall ensure that the
agreement between Merck Foreign Sales Corp. and Hubbard Farms Inc. shall terminate.

196

 

SECTION 12.3. Closing

     Unless otherwise agreed to in writing by the Principals, and subject to each Principal’s
respective right not to consummate the Transactions until the conditions set forth in Section 12.6
have been satisfied, the closing of the Transactions, including the Closing, shall take place on
the last day of the month in which the last of the approvals of Public Authorities that are
conditions to Closing is obtained. The day on which the Closing takes place is referred to herein
as the “Closing Date”.

SECTION 12.4. Execution and Delivery of Ancillary Agreements

     At the Closing, the Ancillary Agreements listed in Section 1.3(b) shall (if not done
previously) be executed and delivered in substantially the form of each such Ancillary Agreement
attached hereto as an exhibit, by or on behalf of the applicable parties thereto (and, if any such
applicable party is a Subsidiary of a Principal, then such Principal shall cause such Subsidiary to
so execute and deliver).

SECTION 12.5. Merial Closing Meetings

     On the Closing Date, (i) the members of Merial at such time shall hold a meeting at which they
shall, in addition to the actions contemplated by Section 1.3(a)(i), appoint the members of
Merial’s Board of Directors, and (ii) the Board of Directors shall hold a meeting at which they
shall, among other things, appoint Coopers & Lybrand and Arthur Andersen as joint auditors to audit
the consolidated financial statements of Merial for the Fiscal Years ending December 31, 1997 and
December 31, 1998, approve the debt contributions, appoint the Executive Chairman, the Chief
Executive Officer and the Executive Officers and take any and all such other actions as may be
necessary to commence the operations of the Merial Venture. Such meetings of the Members and Board
of Directors shall together be the “Closing Meetings”.

197

 

SECTION 12.6. Conditions to Closing

     (a) The obligations of the RP Group and of the Merck Group to consummate
the Transactions shall be subject to the satisfaction of each of the following conditions on
or before the Closing Date:

     (i) the applicable waiting period under the HSR Act shall have expired or been
terminated and the appropriate permissions or clearances shall have been obtained from the
European Commission under the EU Merger Regulation;

     (ii) no action, suit or proceeding shall be pending before any court or any
Public Authority and no investigation of any Public Authority shall have been commenced
(and be pending) seeking to restrain, enjoin, invalidate or delay (or questioning the
validity or legality of) the Transactions, or seeking material damages in connection
therewith, which either Principal, in good faith and with the advice of counsel, believes
will result in a Material Adverse Change or Effect with respect to such Principal or the
Merial Venture; provided, however, that the Parties hereto shall use all
commercially reasonable efforts to end any such action, suit, proceeding or investigation;
and

     (iii) no Public Authority shall have enacted, issued, promulgated, enforced, or
entered any statute, rule, regulation, injunction or other order (whether temporary,
preliminary or permanent) which is in effect and has the effect of making the Transactions
illegal or otherwise restraining or prohibiting the consummation of the Transactions in any
material respect; provided, however, that the Parties hereto shall use all
commercially reasonable efforts to comply with or have vacated any such statute, rule,
regulation, injunction or other order.

     (b) The obligation of the RP Group to consummate the Transactions shall be
subject to the satisfaction of each of the following conditions, or waiver thereof by RP,
on or before the Closing Date:

198

 

     (i) the representations and warranties of the Merck Group set forth in Article X shall
be true and correct when made and as of the Closing Date, unless the effect of such representations
and warranties not being true and correct when made or as of the Closing Date, as the case may be,
does not adversely impact the value of, or does not otherwise have an adverse effect on, the Merial
Venture of [*];

     (ii) each of the Merck Companies shall have complied in all material respects with all of
their material obligations set forth herein and in the Ancillary Agreements to be performed by them
between the date hereof and the Closing Date;

     (iii) RP shall have received a certificate signed by an executive officer of Merck
certifying the matters set forth in clauses (i) and (ii);

     (iv) the agrément fiscal described in Section 11.2(b) shall have been obtained;

     (v) no information shall have been communicated by the EPA which indicates that the EPA
is likely to withdraw, or impose significant limitations on, the conditional approval granted to RM
to use Fipronil in the Animal Health Business; and

     (vi) no fact, event, condition or contingency shall have occurred after the date hereof,
which results in a Material Adverse Change or Effect (other than changes or effects arising from or
related to (x) economic, industry or competitive conditions or (y) this Agreement or the
Transactions and/or (z) changes in or effects on results of operations or financial condition
arising from any of the foregoing described in (x) or (y)) that adversely impacts the value of, or
otherwise has an adverse effect on, the Merck Contributed Business of [*];
provided, however, that the Parties hereto shall use all commercially reasonable
efforts to counteract the effect of any such fact, event, condition or contingency.

199

 

     (c) The obligation of the Merck Group to consummate the Transactions shall be subject to
the satisfaction of each of the following conditions, or waiver thereof by Merck, on or before the
Closing Date:

     (i) the representations and warranties of IM and RM set forth in Article VIII
and of RP set forth in Article IX shall be true and correct when made and as of the Closing
Date, unless the effect of such representations and warranties not being true and correct
when made or as of the Closing Date, as the case may be, does not adversely impact the value
of, or does not otherwise have an adverse effect on, the Merial Venture of [*];

     (ii) each of the RP Companies shall have complied in all material respects with
all of their material obligations set forth herein and in the Ancillary Agreements to be
performed by them between the date hereof and the Closing Date;

     (iii) Merck shall have received a certificate signed by an executive officer of
each of IM and RP certifying the matters set forth in clauses (i) and (ii) as they apply to
IM and RM or to RP, respectively;

     (iv) the tax ruling from the I.R.S. described in Section 11.2(b) shall have
been obtained;

     (v) no information shall have been communicated by the EPA which indicates that
the EPA is likely to withdraw, or impose significant limitations on, the conditional
approval granted to RM to use Fipronil in the Animal Health Business and, if required
pursuant to Section 11.13 [EPA Fipronil Risk Assessment], the meeting with the EPA
contemplated by the last sentence of Section 11.13 shall have occurred; and

     (vi) no fact, event, condition or contingency shall have occurred after the date
hereof, which results in a Material Adverse Change or Effect (other than

200

 

changes or effects arising from or related to (x) economic, industry or competitive conditions or
(y) this Agreement or the Transactions and/or (z) changes in or effects on results of operations or
financial condition arising from any of the foregoing described in (x) or (y)) that adversely
impacts the value of, or otherwise has an adverse effect on, RM and its Subsidiaries taken together
of [*]; provided, however, that the Parties hereto shall use all
commercially reasonable efforts to counteract the effect of any such fact, event, condition or
contingency.

201

 

ARTICLE XIII

GUARANTEES OF PERFORMANCE

SECTION 13.1. Guaranty by RP

          RP hereby unconditionally and irrevocably guarantees to each of Merck (and any Subsidiary of
Merck which is a party to this Agreement or any Ancillary Agreement) and the Merial Venture
Companies the performance of, and compliance with, the agreements, covenants and obligations
contained in this Agreement or any Ancillary Agreement: (i) of IM (and of any Subsidiary of RP that
succeeds IM as Member), (ii) with respect to any covenants or obligations relating to the period
prior to the Closing, of RM and its Subsidiaries, and (iii) so long it is a wholly-owned (other
than directors’ qualifying and nominee shares) Subsidiary of RP, each of RP Ag and PMSV.

SECTION 13.2. Guaranty by Merck

     Merck hereby unconditionally and irrevocably guarantees to each of RP (and any Subsidiary of
RP which is a party to this Agreement or any Ancillary Agreement) and the Merial Venture Companies
the performance of, and compliance with, the agreements, covenants and obligations contained in
this Agreement or any Ancillary Agreement (i) of Merck SH (and of any Subsidiary of Merck that
succeeds Merck SH as Member), and (ii) so long as it is a wholly-owned (other that directors’
qualifying and nominee shares) Subsidiary of Merck, of each Subsidiary of Merck.

SECTION 13.3. Guaranty by Merial

     Merial hereby unconditionally and irrevocably guarantees to each Principal (and to any
Subsidiary of such Principal which is a party to this Agreement or any Ancillary Agreement) the
performance of, and compliance with, the agreements, covenants and obligations contained in any of
the Ancillary Agreements or the Transfer Agreements of any of the Subsidiaries of Merial (including
RM) that is a party to any such Ancillary Agreement or the Transfer Agreements.

202

 

SECTION 13.4. Procedures

     (a) Definitions. The term “Guarantor” shall mean (i) Merck, with respect to any
Subsidiary of Merck referred to in Section 13.2, (ii) RP, with respect to any Subsidiary of RP
referred to in Section 13.1, or (iii) Merial, with respect to any Subsidiary of Merial referred to
in Section 13.3. The term “Beneficiary” shall mean (i) in the case of Section 13.1, the Merial
Venture Companies, Merck and any Subsidiary of Merck referred to in Section 13.1, and (ii) in the
case of Section 13.2, the Merial Venture Companies and RP, and any Subsidiary of RP referred to in
Section 13.2, and (iii) in the case of Section 13.3, each of the Principals and any Subsidiary of
such Principal referred to in Section 13.3. The term “Guaranteed Obligations” shall mean, as to
any Guarantor, all the obligations, or performances, observances or payments, now or hereafter
owing, due, required, contracted or payable under or out of this Agreement or any Ancillary
Agreement guaranteed by such Guarantor pursuant to this Article XIII.

     (b) Direct Action Against a Guarantor. In the event that any Subsidiary of a
Guarantor shall default in the payment of or fail to perform or observe any of the Guaranteed
Obligations when and as the same shall become due, any Beneficiary may proceed directly against the
Guarantor under this Article XIII, subject to the dispute resolution and arbitration procedures set
forth in the Ancillary Agreements and Article XVIII.

     (c) Notice; Claims, Etc. Each Guarantor hereby waives any and all notice of
the creation, renewal, amendment, extension or accrual of any of the Guaranteed
Obligations. Nothing contained herein shall affect (i) the right of a Guarantor to assert
any claim it may have against any Beneficiary in a separate action or proceeding, or (ii)
any defense (other than the bankruptcy or other insolvency of the Guarantor or its
Subsidiary which is a Member), set-off or counterclaim the Guarantor or any Subsidiary
of the Guarantor may have against any Beneficiary, its successors or assigns.
Notwithstanding the foregoing, in the event that the Liability of any Person in respect of
Guaranteed Obligations shall have been determined pursuant to the dispute resolution and
arbitration procedures set forth in Article XVIII hereof, the Guarantor of such Person’s

203

 

obligations shall not be entitled under any circumstances to invoke such procedures with regard to
the same subject matter that was arbitrated in such procedures.

     (d) Remedies Not Exclusive. No remedy conferred by this Article XIII is
intended to be exclusive of any other available remedy or remedies, and each and every such remedy
shall, subject to Section 14.6 and Article XVIII, be cumulative and shall be in addition to every
other remedy given under this Agreement or any Ancillary Agreement, now or hereafter existing at
law or in equity or by statute.

SECTION 13.5. Identity of Company Entitled to Receive Payment

     (a) Where RP is liable under Section 13.1 to make a payment for a Guaranteed Obligation to any
Subsidiary of Merck described in Section 13.1, the amount so payable shall be claimed by Merck as
trustee for the benefit of the relevant Merck Subsidiary and the amount shall be paid to Merck on
trust for the Subsidiary. The payment to Merck shall be deemed by all Parties to this Agreement
to be full and good discharge of the Guarantee obligation of RP to the extent of such payment.

     (b) Where Merck is liable under Section 13.2 to make a payment for a Guaranteed Obligation to
any Subsidiary of RP described in Section 13.2, the amount so payable shall be claimed by RP as
trustee for the benefit of the relevant RP Subsidiary and the amount shall be paid to RP on trust
for the Subsidiary. The payment to RP shall be deemed by all Parties to this Agreement to be full
and good discharge of the Guarantee obligation of Merck to the extent of such payment.

     (c) Where RP or Merck is liable under Section 13.1 or 13.2, respectively, to make a payment
for a Guaranteed Obligation to any Subsidiary of Merial, the amount so payable shall be claimed by
Merial as trustee for the relevant Merial Subsidiary and the amount shall be paid to Merial on
trust for the Subsidiary. The payment to Merial shall be deemed by all Parties to this Agreement
to be full and good discharge of the Guarantee obligation of RP or Merck, as the case may be, to
the extent of such payment.

204

 

     (d) Where Merial is liable under Section 13.3 to make a payment for a Guaranteed
Obligation to any Subsidiary of RP or of Merck described in Section 13.3, the amount so payable
shall be claimed by RP or Merck, as the case may be, as trustee for the benefit of its relevant
Subsidiary and the amount shall be paid to RP or Merck, as the case may be, on trust for the
Subsidiary. The payment to RP or Merck, as the case may be, shall be deemed by all Parties to this
Agreement to be full and good discharge of the Guarantee obligation of Merial to the extent of such
payment.

205

 

ARTICLE XIV

INDEMNITIES

SECTION 14.1. General Indemnity

     (a) Merck shall defend, indemnify and hold harmless the Merial Venture Companies and (only to
the extent RP or any of its Subsidiaries suffer Damages separate and distinct from Damages suffered
by the Merial Venture) RP and its Subsidiaries from and against any and all Damages (whether or not
incurred in connection with a Third Party Claim) arising out of, based upon or resulting from (i)
any inaccuracy as of the date hereof or the Closing Date of any representation, or breach of any
warranty, of Merck or any of its Subsidiaries contained in Article X of this Agreement or in any of
the schedules referred to therein, other than representations or warranties with respect to Taxes,
or (ii) any failure by Merck or the Merck Member to comply with any of its covenants or agreements
in this Agreement.

     (b) RP shall defend, indemnify and hold harmless the Merial Venture Companies and (only to the
extent Merck or any of its Subsidiaries suffer Damages separate and distinct from Damages suffered
by the Merial Venture) Merck and its Subsidiaries from and against any and all Damages (whether or
not incurred in connection with a Third Party Claim) arising out of, based upon or resulting from
(i) any inaccuracy as of the date hereof or the Closing Date of any representation, or breach of
any warranty, of RP or any of its Subsidiaries contained in Article VIII or IX, as applicable, or
in any of the schedules referred to therein, other than representations or warranties with respect
to Taxes, or (ii) any failure by RP or the RP Member or, in the case of any covenants or
obligations relating to the period up to the Closing, by RM, to comply with any of its covenants or
agreements in this Agreement.

     (c) Merial shall (and shall cause the other Merial Venture Companies to) defend, indemnify and
hold harmless both Principals and their respective Subsidiaries from and against any and all
Damages arising out of, based upon or resulting from any

206

 

 

failure by any Merial Venture Company to comply with any of its covenants or agreements
in this Agreement.

     (d) The representations and warranties in this Agreement shall survive in accordance
with Sections 8.23, 9.11 and 10.24. The right to indemnity under this Section 14.1 shall survive
such expiration for the longest period permitted by applicable law if the Indemnified Party shall
have notified the Indemnifying Party in writing of the claim for which indemnity is sought before
the expiration of the applicable representation or warranty.

SECTION 14.2. Indemnities Relating to Contributed Operations and Assets

     (a) Indemnification by the Principals. Each Principal shall (subject to Section
5.1(a)(ii)(E)(2)) defend, indemnify and hold harmless each Merial Venture Company and (only to the
extent a Principal or any of its Subsidiaries suffer Damages separate and distinct from Damages
suffered by the Merial Venture) the other Principal and its Subsidiaries from and against any and
all Damages arising out of, based upon or resulting from (x) an action or claim brought by a Third
Party, or (y) an Environmental Liability, in either case to the extent arising out of, based upon
or resulting from any act, omission, fact, circumstance, event or condition which occurred or
existed prior to the Closing Date in connection with (i) the conduct of such Principal’s Merial
Venture Business operations (or those of any of its Subsidiaries), or (ii) (A) in the case of RP,
the Intellectual Property, assets and properties of RM and its Subsidiaries, and (B) in the case of
Merck, the Merck Contributed Assets or the Intellectual Property, assets and properties of the
Merck Transferred Subsidiaries.

     Notwithstanding the foregoing in this Section 14.2(a), no Principal shall be liable for any
Damages pursuant to this Section 14.2(a):

     (xx) to the extent (not to exceed [*] for all such
Damages, [*]) that such Damages are specifically reflected in Schedule
14.2A-1 in the case of Merck or 14.2A-2 in the case of RM. Schedule

207

 

 

14.2A-1 or 14.2A-2, as the case may be, shall list all reserves included in the December 31, 1996
balance sheets of the Merck Contributed Business Financials or the RM Financials, respectively, and
subsequently recorded until the execution of this Agreement, excluding (A) deferred tax reserves,
(B) pension and benefit plan reserves and (C) reserves for current assets (including reserves for
receivables or inventory). To the extent specific reserves, subject to the exceptions described
above, are recorded on either Merck’s or RM’s Closing Date Balance Sheet but not listed on Schedule
14.2A-1 or 14.2A-2, as the case may be, these unscheduled reserves (not to exceed [*] for each Principal) shall be included with those reserves listed on Schedule 14.2A-1 or
14.2A-2, as the case may be, for the purpose of determining if the [*] has been
exceeded (but without increasing such aggregate [*]). The first time any Party brings
an indemnification claim against another Party pursuant to any of Sections 7.5(a)(ii), 7.5(b)(ii),
14.1(a)(i), 14.1(b)(i) or 14.2, the amount, if any, by which the “Excess Damages” (as defined
below) is greater than the “Excess Reserves” (as defined below) shall be counted (on a
dollar-for-dollar basis) toward determining if the Threshold Amount (as defined in Section 14.6(a))
has been reached, and, if and to the extent the Threshold Amount has been reached, shall be
indemnifiable pursuant to said Sections. The “Excess Damages” shall equal the aggregate of the
amounts, calculated on a matter by matter basis, by which the Damages that would have been
indemnifiable pursuant to this Section 14.2(a) (but for this clause (xx)), exceed the respective
amounts for such matters specifically reflected in Schedule 14.2A-1 or 14.2A-2 or the Closing Date
Balance Sheets (subject to the [*] limitation above). The “Excess Reserves” shall equal
the aggregate of the amounts, calculated on a matter by matter basis, by which the respective
amounts for such matters specifically reserved in Schedule 14.2A-1 or 14.2A-2 or the Closing Date
Balance Sheets (subject to the [*] limitation above), exceed the Damages actually incurred
or suffered in connection with any matters reserved for therein that are finally determined or
settled. If, after taking into account the difference between the Excess Damages and the Excess
Reserves as described above, the Threshold Amount has not been reached, the same calculations shall
be made again the next time an indemnification claim is brought;

208

 

 

     (yy) incurred solely due to a change of applicable Laws after the Closing Date; or

     (zz) to the extent such Damages result from the failure of the Indemnified Party or its
Affiliates to take reasonable steps to mitigate such Damages.

     The Indemnifying Party shall, in addition to any indemnification obligation it may have under
this Section 14.2(a) in respect of any Damages, reimburse the Merial Venture for all costs and
expenses it incurs in mitigating such Damages.

     Notice of any claim for indemnification under this Section 14.2(a) relating to (i) any
Environmental Liability (including any off-site Liability other than resulting from migration from
any real property directly or indirectly contributed by either Principal to the Merial Venture)
must be given before the tenth (10th) anniversary of the Closing Date, except that notice of any
claim for Damages relating to or arising from soil or groundwater contamination at or migrating
from any real property directly or indirectly contributed by either Principal to the Merial Venture
must be given before the seventh (7th) anniversary of the Closing Date; and (ii) Damages arising
out of, based upon, or resulting from the design, manufacture, development, testing, use, sale,
disposal, transport or otherwise with respect to a product (including Animal Health Products or
Poultry Genetics Products) must be given before the tenth (10th) anniversary of the Closing Date if
the Damage was suffered as a result of the death or injury of a human being and otherwise must be
given before the fifth (5th) anniversary of the Closing Date. Notice of any other claim for
indemnification under this Section 14.2(a) must be given before the fifth (5th) anniversary of the
Closing Date. In the event notice of any claim for indemnification hereunder shall have been given
(within the meaning of Section 14.7) within the time limitations specified above, the potential
right to indemnification pursuant to such claim shall survive until such time as such claim is
finally resolved.

     (b) Indemnification by Merial. To the extent either of the Principals or their
respective Subsidiaries suffer Damages separate and distinct from Damages suffered by the Merial
Venture, Merial shall (except as specified in the proviso to clause (2) of

209

 

 

Section 5.1(a)(ii)(E)) defend, indemnify and hold harmless the Principals and their respective
Subsidiaries from and against any and all Damages to the extent arising out of, based upon or
resulting from any act, omission, fact, circumstance, event or condition which first occurs or
exists after the Closing Date in connection with (i) the conduct of the Merial Venture’s
operations, or (ii) the Intellectual Property, assets and properties of the Merial Venture.

     Notwithstanding the foregoing in this Section 14.2(b), Merial shall not be liable to a
Principal or its Subsidiaries for any Damages pursuant to this Section 14.2(b):

     (x) to the extent that such Damages arise due to or result from (A) any breach by such
Principal or any of its Subsidiaries of any of their respective representations,
warranties, covenants or other agreements in this Agreement or (B) any action or omission
on the part of such Principal or any of its Subsidiaries for which (and to the extent) such
Principal or Subsidiary is obliged to indemnify the Merial Venture pursuant to an Ancillary
Agreement to which such Principal or Subsidiary is a party (in the case of either (A) or
(B), as applicable, an “RP Breach” or a “Merck Breach,” as the case may be), or

     (y) to the extent such Damages result from the failure of the Indemnified Party or its
Affiliates to take all reasonable steps to mitigate such Damages.

     Merial shall, in addition to any indemnification obligation it may have under this Section
14.2(b) in respect of any Damages, reimburse the relevant Indemnified Party for all costs or
expenses it incurs in mitigating such Damages.

     (c) Provisions Not Applicable to Taxes and Employee Benefit Plans True-ups. The
provisions of this Section 14.2 shall not apply to any Damages relating to employee benefit plans
or to Taxes, which are indemnified or the subject of a specified dividend under Article VII and
Sections 14.11, 14.12 and 14.18, respectively.

210

 

 

SECTION 14.3. Indemnities Relating to Ancillary Agreements

     The respective indemnification rights and obligations of the Parties to the Ancillary
Agreements shall be as set forth in the Ancillary Agreements.

SECTION 14.4   Identity of Company to be Indemnified; Extension of Indemnification of Officers, Directors, Employees, Agents, Representatives, Successors and Permitted Assigns

     (a) Where either of Merck or RP is liable under any provision of this Agreement to make a
payment by way of indemnification for any Tax or other Damage suffered by any Subsidiary of Merial
or the Merial Venture, the amount so payable shall be claimed by Merial as trustee for the relevant
Merial Subsidiary which has suffered the Tax or Damage and the amount shall be paid to Merial on
trust for the Subsidiary. The payment to Merial shall be deemed by all Parties to this Agreement
to be full and good discharge to such indemnification obligation to the extent of such payment.

     (b) Where either of Merck or Merial is liable under any provision of this Agreement to make a
payment by way of indemnification for any Tax or other Damage suffered by any Subsidiary of RP, the
amount so payable shall be claimed by RP as trustee for the relevant RP Subsidiary which has
suffered the Tax or Damage and the amount shall be paid to RP on trust for the Subsidiary. The
payment to RP shall be deemed by all Parties to this Agreement to be full and good discharge to
such indemnification obligation to the extent of such payment.

     (c) Where either of RP or Merial is liable under any provision of this Agreement to make a
payment by way of indemnification for any Tax or other Damage suffered by any Subsidiary of Merck,
the amount so payable shall be claimed by Merck as trustee for the relevant Merck Subsidiary which
has suffered the Tax or Damage and the amount shall be paid to Merck on trust for the Subsidiary.
The payment to Merck shall be deemed by all Parties to this Agreement to be full and good discharge
to such indemnification obligation to the extent of such payment.

211

 

 

     (d) The obligation to indemnify any Person for any Damages under Sections 14.1 through
14.3 shall include the obligation to indemnify that Person for any Damages suffered or incurred by
that Person’s officers, directors, employees, agents, representatives, successors and permitted
assignees in relation to that indemnity. For the avoidance of doubt, this Section does not confer
on any Person’s officers, directors, employees, agents or representatives any cause of action under
this Agreement, nor shall any Person be liable to account to its or any other Person’s officers,
directors, employees, agents or representatives for any such Damages.

SECTION 14.5. Tax Gross-Up

     If any Taxing Authority subjects any sum paid under any indemnification provision in this
Agreement to any Taxes, then the Party making the indemnification payment shall also pay (subject
to Section 14.6(d)) such additional amount as shall be required to ensure that the total amount
paid, less the Tax chargeable on such amount (or that would be so chargeable but for the use or
setoff of any tax relief), is equal to the amount that would otherwise be payable under the
relevant indemnification provision.

SECTION 14.6. Limitations of Indemnification

     The obligations of the Parties under this Article XIV shall be subject to the following
limitations:

     (a) An Indemnifying Party shall have no obligation pursuant to Sections 7.5(a)(ii),
7.5(b)(ii), 14.1(a)(i), 14.1(b)(i) or 14.2(a) unless the aggregate amount of Damages (suffered by
all Merial Venture Companies and other Indemnified Parties taken collectively, but without
duplication) in respect of all claims for indemnification that would otherwise be indemnifiable by
such Indemnifying Party and its Affiliates under said Sections shall exceed [*] (the “Threshold Amount”) and then only to the extent such aggregate
amount of Damages exceeds the Threshold Amount. With respect to any Taxes indemnifiable pursuant
to Sections 14.11 and 14.12, such indemnifiable Taxes shall not be subject to the [*]
Threshold

212

 

 

Amount but shall be subject to a separate Threshold Amount of [*] and
any Damages indemnifiable pursuant to Sections 14.11 and 14.12 shall not be taken into account in
determining whether the general [*] Threshold Amount has been reached. For the purposes
of this Section 14.6(a), in computing the aggregate amount of claims, the amount of each claim
shall be deemed to be an amount (i) net of any net Tax Benefit actually realized by the Indemnified
Party, and (ii) net of any net insurance proceeds and any indemnity, contribution or other similar
payment actually recovered by the Indemnified Party from any Third Party with respect thereto.

     (b) Payments by an Indemnifying Party pursuant to this Article XIV of any particular Damages
shall be limited to the amount of any Damages that remains after deducting therefrom (i) any net
Tax Benefit actually realized by the Indemnified Party, and (ii) any net insurance proceeds and any
indemnity, contribution or other similar payment actually recovered by the Indemnified Party from
any Third Party with respect thereto. If a payment is made by the Indemnifying Party in accordance
with this Article XIV, and if in a subsequent taxable year a net Tax Benefit is realized by the
Indemnified Party or any such payment is recovered from any Third Party (that was not previously
taken into account to reduce an amount otherwise payable by the Indemnifying Party under this
Article XIV), the Indemnified Party shall pay to the Indemnifying Party at the time of such
realization or recovery the amount of such net Tax Benefit (to the extent that the Tax Benefit
would have resulted in a reduction in the amount paid by the Indemnifying Party under Section 14.6
if the Tax Benefit had been obtained in the year of such payment) or of such payment actually
recovered from such Third Party, as the case may be. A Tax Benefit will be considered to be
realized for purposes of this Section 14.6 and Section 14.15(f) at the time that it is reflected on
a Tax return of the Indemnified Party or any consolidated tax group to which such Indemnified Party
belongs in the form of a refund, credit or reduction of Taxes otherwise due and payable.

     (c) Notwithstanding anything to the contrary contained in this Agreement, no Party shall have
any Liability under any provision of this Agreement for any consequential loss damages or for
punitive or penalty damages except (i) with respect to consequential loss damages, to the extent
(A) the value of a Principal’s interest in the

213

 

 

Merial Venture (consistent with the values contemplated by the Principals on the date of this
Agreement) is diminished as a result of an inaccuracy of a representation or a breach of a
warranty, covenant or agreement for which the other Principal has or would have indemnification
obligations pursuant to Section 14.1 or as a result of a claim based on an Environmental Liability
for which the other Principal has or would have indemnification obligations pursuant to Section
14.2 and (B) the Principal claiming indemnification for such consequential loss damages has not
been and will not be compensated by application of Section 6.4 [Early Year Adjustment] or Section
6.5 [Band Adjustment], and (ii) with respect to either punitive or penalty damages or consequential
loss damages, to the extent such damages result from a final decision or settlement of an Action or
claim of a Third Party against the Indemnified Party. Each Party shall take all reasonable steps
to mitigate its Damages upon and after becoming aware of any event which could reasonably be
expected to give rise to any Damages indemnifiable under this Agreement.

     (d) Anything to the contrary herein notwithstanding, no Indemnified Party shall be
entitled to recover an aggregate amount under the indemnities or under the guarantees set forth in
this Agreement with respect to any particular matter that results in duplicative compensation for
the same Damages.

SECTION 14.7. Indemnification Procedures

     All claims for indemnification under this Agreement (other than claims made pursuant to
Sections 14.11, 14.12 and 14.18 with respect to Taxes, procedures with respect to which are
provided therein and in Section 14.17) shall be asserted and resolved as follows:

     (a) A Principal or a Subsidiary thereof or a Merial Venture Company claiming
indemnification under this Agreement (the “Indemnified Party”) shall promptly notify in writing the
Person from whom indemnification is sought (the “Indemnifying Party”) of any Third Party claim or
claims (“Third Party Claim”) asserted or threatened against the Indemnified Party which could give
rise to a right of indemnification under this Agreement; provided, however, that
the failure to give such notice shall not relieve the

214

 

 

Indemnifying Party of its indemnity obligation hereunder except to the extent that such failure
substantially prejudices its rights hereunder, and provided further that in the
event that (i) any member of the RP Group is the Indemnifying Party, the Merck Companies and Merial
Venture Companies shall be deemed to satisfy such notice obligation by giving such notice to RP,
and (ii) any member of the Merck Group is the Indemnifying Party, the RP Companies and Merial
Venture Companies shall be deemed to satisfy such notice obligation by giving such notice to Merck.
The Indemnifying Party shall have the right to defend, at its sole cost and expense, such Third
Party Claim by all appropriate proceedings, which proceedings shall be prosecuted diligently by the
Indemnifying Party to a final conclusion or compromised or settled at the discretion of the
Indemnifying Party; provided, however, that the Indemnifying Party may not enter
into any such compromise or settlement which involves equitable relief against the Indemnified
Party unless the Indemnified Party consents thereto, which consent shall not be unreasonably
withheld; and provided further that the Indemnifying Party may not enter into any such
compromise or settlement that does not include as an unconditional term thereof, the giving by each
claimant or plaintiff to each Indemnified Party of a release from all Liability in respect of such
claim. If requested by the Indemnifying Party, the Indemnified Party agrees, at the sole cost and
expense of the Indemnifying Party (excluding costs and expenses not owed to Third Parties by the
Indemnified Party), to cooperate with the Indemnifying Party and its counsel in contesting any
Third Party Claim which the Indemnifying Party elects to contest, including the making of any
related counterclaim against the person asserting the Third Party Claim or any cross-complaint
against any person. The Indemnified Party may participate in, but not control, any defense or
settlement of any Third Party Claim controlled by the Indemnifying Party pursuant to this Section
14.7 and shall bear its own costs and expenses with respect to such participation;
provided, however, that the Indemnifying Party shall bear such costs and expenses
if counsel for the Indemnifying Party shall have reasonably determined that such counsel may not
properly represent both the Indemnified and Indemnifying Parties.

     If the Indemnifying Party fails to notify the Indemnified Party within twenty (20) days after
receipt of notice in accordance with the first sentence of this Section 14.7(a) that the
Indemnifying Party elects to defend the Indemnified Party pursuant to this

215

 

Section 14.7(a), or if the Indemnifying Party elects to defend the Indemnified Party pursuant to
this Section but fails to prosecute or settle the Third Party Claim diligently and promptly, then
the Indemnified Party shall have the right to defend, at the sole cost and expense of the
Indemnifying Party, the Third Party Claim by all appropriate proceedings, which proceedings shall
be promptly and vigorously prosecuted by the Indemnified Party to a final conclusion or settled;
provided, however, that in no event shall an Indemnifying Party be required to
indemnify an Indemnified Party for any amount paid or payable by such Indemnified Party in the
settlement of any such Third Party Claim agreed to without the consent of the Indemnifying Party
(which shall not be unreasonably withheld or delayed, it being understood that a timely
notification disputing an Indemnity Notice under Section 14.7(b) shall constitute a reasonable
basis for withholding consent).

     (b) In the event any Indemnified Party has a claim for indemnification by any
Indemnifying Party hereunder which does not involve a Third Party Claim, or knowledge of facts
which could reasonably be expected to give rise to such a claim, the Indemnified Party shall
transmit to the Indemnifying Party a written notice (an “Indemnity Notice”) describing in
reasonable detail the nature of the claim, an estimate, if reasonably possible, of the amount of
Damages attributable to such claim and the basis of the Indemnified Party’s claim for
indemnification under this Agreement, provided that the failure to give such notice shall not
relieve the Indemnifying Party of its indemnity obligations hereunder except to the extent that
such failure substantially prejudices its right hereunder. Any notice by an Indemnified Party of
an asserted or threatened Third Party Claim given pursuant to Section 14.7(a) shall also constitute
an Indemnity Notice for the purposes of this Section 14.7(b) and of Section 18.1. If the
Indemnifying Party does not notify the Indemnified Party within sixty (60) days from its receipt of
the Indemnity Notice that the Indemnifying Party disputes such claim, the claim specified by the
Indemnified Party in the Indemnity Notice shall be deemed a Liability of the Indemnifying Party
hereunder. If the Indemnifying Party has timely disputed such claim, as provided above, such
dispute shall be resolved in accordance with Article XVIII of this Agreement.

216

 

     (c) Notwithstanding any other provisions contained in this Agreement, each of the Parties
hereby irrevocably consents to the right and ability of either Principal to (i) bring a claim on
behalf of any Merial Venture Company against the other Principal or any of its Subsidiaries, or
(ii) represent Merial in defending against any claim brought by the other Principal or any of its
Subsidiaries against Merial, it being understood that, should either Principal bring a claim on
behalf of a Merial Venture Company, any amounts recovered by the Principal shall be for the account
of the Merial Venture Company.

     (d) The Parties expressly acknowledge and agree that any and all disputes between the
Parties with respect to claims for indemnification under this Article XIV shall, whether or
not the procedures for such claims are otherwise governed by this Section 14.7, be resolved
in accordance with the provisions of Article XVIII.

SECTION 14.8. [Intentionally Deleted]

SECTION 14.9. Receipt of Information, Etc.

     The obligations of the Principals and Merial under this Article XIV shall not in any way be
affected by any investigation by or on behalf of any of the Principals, Merial or any of their
respective Subsidiaries or by any information which any of the foregoing may have obtained with
respect thereto, in each case whether prior or subsequent to the Closing Date.

SECTION 14.10. Subrogation

     In the event that either of the Principals or Merial shall be an Indemnifying Party pursuant
to this Agreement with respect to a Third Party Claim, it shall, upon payment in full of its
indemnification obligation hereunder arising with respect to such Third Party Claim, be subrogated
to all rights of the Indemnified Party as against the Third Party with respect to the claims to
which such indemnification relates.

217

 

SECTION 14.11. Tax Indemnity by RP

     (a) Subject to sections 14.11(b) and 14.17(a), RP shall be liable for, and shall
indemnify and hold harmless the Merial Venture Companies from and against:

     (i) (A) any and all Income Taxes of the RM Transferred Subsidiaries to the extent
such Income Taxes are paid or become payable on or after the Closing but represent
liabilities in respect of the Pre-Closing Tax Period, (B) any and all Income Taxes of the RM
Transferred Subsidiaries for a Straddle Period apportioned to RP pursuant to Section 14.13,
and (C) any Other Taxes of the RM Transferred Subsidiaries with respect to any of (1) a
Pre-Closing Tax Period, (2) a Straddle Period, limited (X) in the case of sales, transfer,
excise, withholding, value added, gross receipts and any other taxes levied on transfers or
transactions, to Tax Liabilities accruing with respect to transfers or transactions
occurring on or before the time of Closing, and (Y) in the case of any Other Taxes not
otherwise enumerated, to Tax Liabilities attributable, on a days-elapsed basis, to the
portion of such Straddle Period ending on the Closing Date, or (3) in the case of Other
Taxes which are not reported on a periodic basis, any such Other Taxes attributable to
transactions occurring prior to the Closing.

     (ii) any and all Taxes assessed or imposed by any Taxing Authority against
the RM Transferred Subsidiaries (including the assets of any such Subsidiaries) and
properly attributable to any RP Company that is not an RM Transferred Subsidiary.

     (iii) any and all property Taxes of or assessed against the RM Transferred
Subsidiaries (including the assets of any such Subsidiaries) and properly attributable (on a
days-elapsed basis) to periods prior to the Closing. To the extent such property Taxes have
been paid by RP prior to the Closing Date with respect to the current fiscal period, RP’s
Liability with respect thereto shall be reduced by such amount; provided,
however, that if such payment of property Taxes exceeds the property Tax Liability
RP is responsible for pursuant to this

218

 

Section 14.11 with respect to the current fiscal period, RP’s Liability with respect
thereto shall be reduced by such amount, and Merial shall pay RP the amount of such excess
promptly upon receipt of a Tax refund, credit, or reduction of the amount of such Taxes
otherwise paid or required to be paid by the Merial Venture.

     The Taxes described in clauses (i), (ii) and (iii) above shall each be an “RM Pre-Closing
Tax”, and shall together be the “RM Pre-Closing Taxes”. For the avoidance of doubt, RM
Pre-Closing Taxes shall not include any deferred Taxes, except to the extent payments are actually
required to be made by a Merial Venture Company for RM deferred Taxes arising prior to the Closing.

     (b) RP’s indemnification obligation in favor of the Merial Venture under this Section
14.11 shall apply to the RM Pre-Closing Taxes paid or payable on or after the Closing, to the
extent such Taxes exceed the RM Accrued Current Tax Liabilities. Each indemnity required under
this Section 14.11 shall be made by RP to Merial (in accordance with Section 14.4) prior to or on
the later of ten (10) days after Merial’s request therefor and five (5) days prior to the date on
which the related Tax is due. Upon receiving Merial’s request for any such indemnification, RP
shall have the right, at its cost and expense, to challenge the assessment or imposition of the Tax
before the appropriate Taxing Authority or Public Authority, and in such case Merial shall, and
shall procure that the Merial Venture Companies shall cooperate with any reasonable request by RP
for assistance or information necessary to such challenge, including as may be necessary to permit
RP to bring the challenge in the appropriate Merial Venture Company’s name.

SECTION 14.12. Tax Indemnity by Merck

     (a) Subject to Sections 14.12(b) and 14.17(a), Merck shall be liable for, and shall
indemnify and hold harmless the Merial Venture Companies from and against:

219

 

     (i) (A) any and all Income Taxes of the Merck Transferred Subsidiaries or any and all
Income Taxes imposed on or with respect to, or otherwise related to, the Merck Contributed Assets,
in each case to the extent such Income Taxes are paid or become payable on or after the Closing but
represent liabilities in respect of the Pre-Closing Tax Period, (B) any and all Income Taxes of the
Merck Transferred Subsidiaries or any and all Income Taxes imposed on or with respect to, or
otherwise related to, the Merck Contributed Assets, for a Straddle Period apportioned to Merck
pursuant to Section 14.13, and (C) any Other Taxes of the Merck Transferred Subsidiaries or any and
all Other Taxes imposed on or with respect to, or otherwise related to, the Merck Contributed
Assets, with respect to any of (1) a Pre-Closing Tax Period, (2) a Straddle Period, limited (X) in
the case of sales, transfer, excise, withholding, value added, gross receipts and any other taxes
levied on transfers or transactions, to Tax Liabilities accruing with respect to transfers or
transactions occurring on or before the time of Closing (or, with respect to assets transferred
after the Closing, on or before the time of transfer), and (Y) in the case of any Other Taxes not
otherwise enumerated, to Tax Liabilities attributable, on a days-elapsed basis, to the portion of
such Straddle Period ending on the Closing Date, or (3) in the case of Other Taxes which are not
reported on a periodic basis, any such Other Taxes attributable to transactions occurring prior to
the Closing.

     (ii) any and all Taxes assessed or imposed by any Taxing Authority against the
Merck Transferred Subsidiaries or Merck Contributed Assets and properly attributable to any
Merck Company that is not a Merck Transferred Subsidiary.

     (iii) any and all property Taxes assessed against the Merck Transferred Subsidiaries or
assessed against any other Merial Venture Companies in respect of Merck Contributed Assets and
properly attributable (on a days-elapsed basis) to periods prior to the Closing. To the extent
such property Taxes have been paid by Merck prior to the Closing Date with respect to the current
fiscal period, Merck’s Liability with respect thereto shall be reduced by such amount;
provided, however,

220

 

that if such payment of property Taxes exceeds the property Tax Liability Merck is
responsible for pursuant to this Section 14.12 with respect to the current fiscal period,
Merck’s Liability with respect thereto shall be reduced by such amount, and Merial shall
pay Merck the amount of such excess promptly upon receipt of a Tax refund, credit, or
reduction of the amount of such Taxes otherwise paid or required to be paid by the Merial
Venture.

     The Taxes described in clauses (i), (ii) and (iii) above shall each be a “Merck Pre-Closing
Tax”, and shall together be the “Merck Pre-Closing Taxes”. For the avoidance of doubt, Merck
Pre-Closing Taxes shall not include any deferred Taxes, except to the extent payments are actually
required to be made by a Merial Venture Company for Merck deferred Taxes arising prior to the
Closing.

     (b) Merck’s indemnification obligation in favor of the Merial Venture under this Section 14.12
shall apply to the Merck Pre-Closing Taxes paid or payable on or after the Closing, to the extent
such Taxes exceed the Merck Accrued Current Tax Liabilities. Each indemnity required under this
Section 14.12 shall be made by Merck to Merial (in accordance with Section 14.4) prior to or on the
later of ten (10) days after Merial’s request therefor and five (5) days prior to the date on which
the related Tax is due. Upon receiving Merial’s request for any such indemnification, Merck shall
have the right, at its cost and expense, to challenge the assessment or imposition of the Tax
before the appropriate Taxing Authority or Public Authority, and in such case Merial shall, and
shall procure that the Merial Venture Companies shall cooperate with any reasonable request by
Merck for assistance or information necessary to such challenge, including as may be necessary to
permit Merck to bring the challenge in the appropriate Merial Venture Company’s name.

SECTION 14.13. Allocation of Certain Income Taxes

     Any Income Taxes of the Merial Venture attributable to a Straddle Period shall be apportioned
between (a) RP and Merck, on the one hand, based on the actual operations and transactions of or
involving (i) the RM Transferred Subsidiaries or the assets of any

221

 

such Subsidiaries and (ii) the Merck Transferred Subsidiaries or the Merck Contributed Assets,
respectively, during the portion of such period ending on the Closing Date, and (b) the respective
Merial Venture Companies, on the other hand, based on each of such company’s actual operations and
transactions during the portion of such period beginning on the day following the Closing Date;
provided, however, that to the extent estimated Income Taxes have been paid prior
to the Closing Date with respect to a Straddle Period by either RP or Merck, their respective
Liability with respect thereto shall be reduced by that amount.

SECTION 14.14. Filing Responsibility

     (a) RP shall timely prepare and file, or cause to be timely prepared and filed, all Returns of
the RM Transferred Subsidiaries (i) for all Pre-Closing Tax Periods or (ii) required to be filed on
or prior to the Closing Date, taking into account extensions of the time to file, and timely pay,
or cause to be paid, when due, all Taxes relating to such Returns. Such Returns shall be prepared
or completed in a manner consistent with prior practice of such Transferred Subsidiaries concerning
their respective income, properties or operations (including elections and accounting methods and
conventions), except as determined in RP’s good faith reasonable judgment as otherwise required by
law or regulation, or otherwise agreed to by Merck prior to the filing thereof. Prior to the filing
of any Return described in this Section 14.14(a) that was not filed before the Closing Date, RP
shall provide, or cause to be provided, to Merck a substantially final draft of such Return at
least fifteen (15) Business Days prior to the due date for filing such Return, and Merck shall have
the right to review such Return prior to the filing of such Return. Merck shall notify RP at least
eight (8) Business Days prior to such due date for filing of any reasonable objections Merck may
have to any items set forth in such draft Return which (i) are inconsistent with prior practice,
(ii) would have a Material Adverse Effect or (iii) are contrary to law or regulation, and Merck and
RP agree to consult and resolve in good faith any such objection and to mutually consent to the
filing of such Return.

222

 

     (b) Merck shall timely prepare and file, or cause to be timely prepared and filed, all Returns
of the Merck Transferred Subsidiaries (i) for all Pre-Closing Tax Periods or (ii) required to be
filed on or prior to the Closing Date, taking into account extensions of the time to file, and
timely pay, or cause to be paid, when due, all Taxes relating to such Returns. Such Returns shall
be prepared or completed in a manner consistent with prior practice of such Transferred
Subsidiaries concerning their respective income, properties or operations (including elections and
accounting methods and conventions), except as determined in Merck’s good faith reasonable judgment
as otherwise required by law or regulation, or otherwise agreed to by RP prior to the filing
thereof. Prior to the filing of any Return described in this Section 14.14(b) that was not filed
before the Closing Date, Merck shall provide, or cause to be provided, to RP a substantially final
draft of such Return at least fifteen (15) Business Days prior to the due date for filing such
Return, and RP shall have the right to review such Return prior to the filing of such Return. RP
shall notify Merck at least eight (8) Business Days prior to such due date for filing of any
reasonable objections RP may have to any items set forth in such draft Return which (i) are
inconsistent with prior practice, (ii) would have a Material Adverse Effect or (iii) are contrary
to law or regulation, and RP and Merck agree to consult and resolve in good faith any such
objection and to mutually consent to the filing of such Return.

     (c) Merial shall prepare and file, or cause to be prepared and filed, subject to RP’s and
Merck’s review and approval (which approval shall not be unreasonably withheld), all Returns for a
Straddle Period relating to each of the Transferred Subsidiaries not otherwise required to be filed
by RP or Merck pursuant to Section 14.14(a) or (b).

SECTION 14.15. Refunds and Carrybacks

     (a) RP (or any other RP Company designated by RP) shall be entitled to any refunds of Income
Taxes paid by or on behalf of the RM Transferred Subsidiaries (including refunds paid by means of a
credit against other or future Tax Liabilities) arising with respect to Pre-Closing Tax Periods.

223

 

     (b) Merck (or any other Merck Company designated by Merck) shall be entitled to any refunds of
Income Taxes paid by or on behalf of the Merck Transferred Subsidiaries (including refunds paid by
means of a credit against other or future Tax Liabilities) arising with respect to Pre-Closing Tax
Periods.

     (c) Refunds of Income Taxes received by the Merial Venture, RP or Merck or their respective
Subsidiaries (including refunds paid by means of a credit against other or future Tax Liabilities)
arising with respect to Straddle Periods shall be allocated to whichever of RP or Merck (or their
respective Subsidiaries) or the Merial Venture Companies initially bore the items to which such
refund is attributable.

     (d) Merial shall promptly forward, or cause to be forwarded, to RP, or reimburse, or cause to
be reimbursed to, RP, any refunds due RP (pursuant to the terms of this Section 14.15) after
receipt thereof. Merial shall promptly forward, or cause to be forwarded, to Merck, or reimburse,
or cause to be reimbursed to, Merck, any refunds due Merck (pursuant to the terms of this Section
14.15) after receipt thereof. In the case of a refund received in the form of a credit against
other or future Tax Liabilities, reimbursement in respect of such refund shall be due in each case
on the due date for payment of the Taxes against which such refund has been credited.

     (e) Merial agrees that the RM Transferred Subsidiaries and the Merck Transferred Subsidiaries
shall not carry back any item of loss, deduction or credit which arises in any taxable period
ending after the Closing Date (“Subsequent Loss”) into any taxable period beginning before the
Closing Date, except as required by law. If an RM Transferred Subsidiary or a Merck Transferred
Subsidiary carries back any Subsequent Loss into any taxable period beginning before the Closing
Date in compliance with the immediately preceding sentence, the Merial Venture shall be entitled to
any Tax Benefit or refund of Taxes actually realized as a result thereof.

     (f) If, as a result of the Merial Venture’s participation in the CFM Agreement, the Merial
Venture actually realizes a Tax Benefit and the RP Group is actually deprived of a Tax Benefit or
its Tax costs increase as a result of the Merial Venture realizing such

224

 

Tax Benefit, Merial shall take such action as may be necessary (including the payment of any
monetary amount resulting from the realization of such Tax Benefit) to provide such Tax Benefit to
RP (or a Subsidiary of RP designated by RP) but only to the extent the RP Group is actually
deprived of a Tax Benefit or its Tax costs increase as a result of the Merial Venture realizing
such Tax Benefit.

SECTION 14.16. Tax Cooperation

     After the Closing, (a) RP and Merck shall make available to the Merial Venture and (b) the
Merial Venture shall make available to RP and Merck, in each case as reasonably requested, and to
any appropriate Taxing Authority, all information, records and documents relating to Tax
Liabilities or potential Tax Liabilities of the RM Transferred Subsidiaries and the Merck
Transferred Subsidiaries, as relevant, for any Tax period and shall preserve all such information,
records and documents until the expiration of any applicable statute of limitations or extension
thereof. The Merial Venture shall prepare and provide to RP or Merck, as the case may be, such Tax
information packages as such parties shall reasonably request for their respective use in preparing
any Return that relates to the RM Transferred Subsidiaries or the Merck Transferred Subsidiaries,
as the case may be. Such Tax information packages shall be completed by the Merial Venture and
provided to RP or Merck, as the case may be, within 60 days after RP’s or Merck’s request therefor.

SECTION 14.17. Time Limits for Tax Indemnity; Tax Audits

     (a) In the case of Taxes indemnifiable pursuant to Sections 14.11 or 14.12, the indemnifying
Party shall not be obligated to provide indemnity for any claim with respect to any Tax first
asserted by or on behalf of an indemnified Party after the fifteenth (15th) anniversary of the
Closing Date, unless the indemnifying Party received notice of the existence of a claim with
respect to such Tax prior to the 15th anniversary of the Closing Date, in which case the obligation
to provide indemnity with respect to the Tax shall survive forever, subject to applicable statutes
of limitations. For purposes of the preceding sentence, (i) a “claim” means any (x) legally
enforceable deficiency or (y)

225

 

deficiency asserted or assessed, orally or in writing, by any Taxing Authority, whether or not
legally enforceable, and (ii) “notice” means any (x) written notice from a Taxing Authority or the
Merial Venture or (y) oral advice from a Taxing Authority or the Merial Venture received by any
employee, agent or representative of the RP Group or the Merck Group, as the case may be, whose
duties relate to Taxes which may be indemnifiable hereunder.

     (b) Merial shall promptly notify RP or Merck, as the case may be, in writing upon receipt by
any Merial Venture Company of notice of any pending or threatened Tax Matter which may affect the
Tax Liabilities for which RP or Merck, as the case may be, would be liable under Sections 14.11 and
14.12 hereunder, respectively; provided, however, that the failure to give such
notice shall not relieve the indemnifying Party of its indemnification obligation hereunder except
to the extent that such failure substantially prejudices its rights hereunder. RP or Merck, as the
case may be, shall have the sole right to represent its own interests and any relevant Transferred
Subsidiary’s interests in any Tax Matter involving a Tax Liability or potential Tax Liability for
which RP or Merck, as the case may be, would be solely liable under Sections 14.11 and 14.12
hereunder, respectively, and to employ counsel of its choice at its expense. Merial agrees that it
will (and will cause its Subsidiaries to) cooperate fully with RP or Merck, as the case may be, and
their respective counsel, in the defense or compromise of any such Tax Matter. All other Tax
Matters shall be controlled by Merial; provided, however, that RP and Merck shall
have the right to participate at their own expense in any Tax Matter which relates to a Straddle
Period and involves a Tax Liability or potential Tax Liability for which RP or Merck, as the case
may be, would be liable under Sections 14.11 and 14.12 hereunder, respectively, and no such Tax
Matter shall be settled without the consent of RP or Merck, as the case may be, which consent shall
not be unreasonably withheld.

SECTION 14.18. Tax Sharing

     Other than the CFM Agreement (which shall continue in effect after the Closing Date but
without any obligation on the part of any Merial Venture Company to make any

226

 

compensatory payments thereunder, other than any payments pursuant to Section 14.15(f)), any and
all existing Tax sharing, allocation, compensation or like agreements or arrangements, whether or
not written, that include the Transferred Subsidiaries, including, without limitation, any
arrangement by which the Transferred Subsidiaries make compensating payments to any member of any
affiliated, consolidated, combined, unitary or other similar Tax group for the use of certain Tax
attributes, shall be terminated as of the Closing Date (pursuant to a writing executed on or before
the Closing Date by all parties concerned) and shall have no further force or effect. With
respect to the CFM Agreement, RP shall be liable for and shall indemnify and hold harmless the
Merck Group and the Merial Venture from and against any and all Taxes assessed against any member
of the Merck Group or any Merial Venture Company which would not have been payable but for the
participation of Merial or any Merial Venture Company in the CFM Agreement (and any other Damages
suffered as a result of the assessment of any such Taxes). Any and all powers of attorney
relating to Tax Matters concerning the Transferred Subsidiaries (other than such matters relating
solely to a Pre-Closing Tax Period but only to the extent RP or Merck, as the case may be, is
liable therefor under Sections 14.11 and 14.12 hereunder, respectively) shall be terminated as to
the Transferred Subsidiaries on or prior to the Closing Date and shall have no further force or
effect.

SECTION 14.19. Tax Reserves Adjustments

     (a) Merck Tax Reserves Adjustment. The Merck Member shall have an entitlement
(the “Merck Section 14.19 Entitlement”) equal to the amount, if any, by which the Merck Accrued
Current Tax Liabilities exceed the aggregate of all Merck Pre-Closing Taxes actually paid by the
Merial Venture on or prior to the date on which the Net Special Dividend in respect of the year
1998 is calculated. If the Merial Venture expects to have to pay any such Taxes after such date,
the Merck Pre-Closing Taxes used for the purposes of calculating the Merck Section 14.19
Entitlement shall be increased by the amount the Merial Venture would accrue for the payment of
such Taxes based on its accounting principles and practices consistently applied.

227

 

     (b) RP Tax Reserves Adjustment. The RP Member shall have an entitlement (the “RP
Section 14.19 Entitlement”) equal to the amount, if any, by which the RM Accrued Current Tax
Liabilities exceed the aggregate of all RM Pre-Closing Taxes actually paid by the Merial Venture on
or prior to the date on which the Net Special Dividend in respect of the year 1998 is calculated.
If the Merial Venture expects to have to pay any such Taxes after such date, the RM Pre-Closing
Taxes used for the purposes of calculating the RP Section 14.19 Entitlement shall be increased by
the amount the Merial Venture would accrue for the payment of such Taxes based on its accounting
principles and practices consistently applied.

     (c) Tax Reserves Adjustment Special Dividend. The “Tax Reserves Adjustment Special
Dividend” shall be equal to the difference between the respective Section 14.19 Entitlements of the
Principals, if any, as calculated pursuant to Sections 14.19(a) and (b) above. The Tax Reserves
Adjustment Special Dividend shall be credited to the RP Member if the RP Section 14.19 Entitlement
is greater than the Merck Section 14.19 Entitlement, or credited to the Merck Member if the Merck
Section 14.19 Entitlement is greater than the RP Section 14.19 Entitlement, in calculating the Net
Special Dividend in respect of the 1998 Fiscal Year pursuant to Section 6.2.

228

 

ARTICLE XV

NON-COMPETITION

SECTION 15.1. Merial Venture Business

[*]  [Note: Approximately two and one-half pages of text are omitted.]

229

 

SECTION 15.2. Non-Solicitation of Merial Venture Employees

     During the Non-Solicitation Period (as hereinafter defined), each Principal will not without
the express written consent of Merial (and will cause its Subsidiaries not to), directly or
indirectly, solicit any employee of the Merial Venture Companies: (x) to leave such employ or (y)
to accept any other position or employment, or assist any Third Party in hiring such employee;
provided, however, that (A) an employee of the Merial Venture Companies who is
terminated by all such Merial Venture Companies shall be eligible thereafter to be offered
employment by either Principal or any of its Subsidiaries; and (B) an employee of the Merial
Venture who will no longer be employed by the Merial Venture (or any successor) due to the
Dissolution of the Merial Venture shall be eligible to be offered employment by either Principal or
any of its Subsidiaries at any time following the Dissolution Date. The Parties acknowledge and
agree that, during the Non-Solicitation Period, neither Principal nor any Subsidiary thereof shall
offer employment to an employee of the Merial Venture Companies (or a former employee of a Merial
Venture Company who resigned after the Closing Date) without the prior written consent of the other
Principal (which shall not be unreasonably withheld or delayed). For purposes of this Section
15.2, the “Non-Solicitation Period” with respect to a Principal

230

 

shall mean the period beginning on the Closing Date and ending on the date that is [*] after
the Closing Date.

SECTION 15.3. Modification of Non-Competition Provisions

     Each Principal acknowledges and agrees (and agrees not to dispute) that each of the
restrictions set forth in Sections 15.1 and 15.2 constitutes an entirely separate and independent
restriction and that the duration, extent and application of each restriction are no greater than
is reasonable and necessary for the protection of the respective interests of the Principals but
that, if any such restriction shall be adjudged by any Public Authority of competent jurisdiction
to be void or unenforceable but would be valid if part of the wording thereof were to be deleted
and/or the period thereof were to be reduced and/or the geographic and/or subject matter scope
thereof were to be reduced, the said restriction shall apply within the jurisdiction of that Public
Authority with such modifications as are necessary to make it valid and effective.

SECTION 15.4. Arrangements with Banyu

     Merck
and RP agree that (i) Merck shall be entitled to all the benefits and
detriments of that certain letter dated October 18, 1996 between
Banyu and Merck and any other agreements, arrangements or
understandings between Merck and Banyu (and their respective
Affiliates) (collectively, the “Banyu Arrangements”), and
(ii) Merck shall treat any molecules or compounds for which Merck
(or its Subsidiaries) exercises an option and thereby obtains rights
pursuant to the Banyu Arrangements with utility within the Field of
the Animal Health or Poultry Genetics Businesses as if they were
invented within Merck (outside of Animal Basic Research) under (and
as defined in) the Merck Research Agreement and subject to the terms
and conditions of the Merck Research Agreement.

231

 

ARTICLE XVI

TERMINATION

SECTION 16.1. Termination Prior to Closing

     (a) Either Principal may cause the termination of this Agreement prior to the
Closing by giving written notice of termination to the other Principal in case of the
occurrence of any of the following events:

     (i) the Closing shall not have occurred on or prior to December 31, 1997 for any
reason whatsoever, other than such Principal’s (or one of its Subsidiaries’) breach of or
failure to perform or comply with any agreement or provision hereof to be performed or
complied with by such Principal or such Subsidiary on or prior to the Closing Date;

     (ii) any Event of Insolvency affecting the Member of the other Group or any
person of which such Member is a direct or indirect Subsidiary;

     (iii) a refusal to authorize the proposed Merial Venture by the European
Commission or by any other competent Public Authority, which refusal would result in a
failure to satisfy a condition to the obligation of the Principal wishing to cause the
termination of this Agreement to consummate the Transactions pursuant to Section 12.6; or

     (iv) a court of competent jurisdiction in the United States, France or the United
Kingdom shall have decreed, issued or entered an injunction or other order which has the
effect of making the Transactions illegal or otherwise restraining or prohibiting the
consummation of the Transactions in any material respect and such injunction or other
order is or becomes final and non-appealable.

     (b) This Agreement may be terminated at any time prior to Closing upon the
mutual agreement of the Principals to do so.

232

 

SECTION 16.2. Duration

     Subject to any termination pursuant to this Article XVI, the duration of the Merial Venture
shall be perpetual.

SECTION 16.3. Termination Following Event of Insolvency, Material Breach or Change of Control

     (a) This Agreement may be terminated and the Merial Venture Dissolved according to
the provisions of this Section 16.3 upon the occurrence of any of the following events:

     (i) Any Event of Insolvency affecting a Member or any person of which a Member
is a direct or indirect Subsidiary. In any such event, the Principal of such Member’s
Group shall immediately notify the other Principal in writing of the occurrence of such
Event of Insolvency. Whether or not such other Principal has received such notification,
the other Principal shall, as of the occurrence of such Event of Insolvency, have the
rights of a Calling Principal governed by the terms of Section 16.3(b) below).

     (ii) The election by the non-breaching Principal (the “Non-Breaching Principal”),
to terminate this Agreement and Dissolve the Merial Venture, following the occurrence of a
“Breach Termination Event”, as defined in the next sentence. A “Breach Termination Event”
shall be deemed to have occurred if (A) the other Principal or any Subsidiary thereof (the
Group of such other Principal or Subsidiary being the “Breaching Group”) breaches or fails
to comply with any of its material covenants, agreements and obligations (including
representations and warranties) under this Agreement or any Ancillary Agreement in any
material respect, (B) such breach has a Material Adverse Effect on the Merial Venture and
materially frustrates the ability of the Merial Venture to conduct the Merial Venture
Business, and (C) subject to Section 18.4, such breach continues unremedied for a period of
sixty (60) days after receipt by the Principal

233

 

of the Breaching Group of notice thereof from the Non-Breaching Principal specifying such
breach or, in the event such breach does not concern the payment of monies and is of a
nature that it cannot, with due diligence and in good faith, be cured
within said sixty (60) day period, the Breaching Group fails to commence and pursue with due diligence and good
faith, to the extent reasonably possible, the cure of such breach
within the sixty (60) day period following its receipt of notice of such breach. Unless the Principal of the
Breaching Group acknowledges in writing that a Breach Termination Event has occurred, any
such alleged breach and the nature and effect thereof shall first be subject to the dispute
resolution and arbitration procedures set forth in Article XVIII. Should the Arbitrators
determine, pursuant to an arbitration proceeding conducted in accordance with Article XVIII,
that (x) a Breach Termination Event has occurred, and (y) the Breaching Group does not pay
and perform the award rendered by the Arbitrators within sixty (60) days of the date of its
receipt of the award (or if such award does not concern solely the payment of monies and is
of a nature that cannot, with due diligence and in good faith, be performed within said
sixty (60) day period, the Breaching Group fails to commence and pursue with due diligence
and good faith, to the extent reasonably possible, the performance of such award within the
sixty (60) day period following its receipt of the award), then the Non-Breaching Principal
shall, subject to Section 16.4(a)(ii) below, have the rights of a Calling Principal governed
by the terms of Section 16.3(b) below.

     (iii) A Change of Control, a Merck Restructuring Event or an RP Restructuring
Event, if such event satisfies the relevant conditions set forth in Section 17.4.
The Principal not subject to such Change of Control or to such Restructuring Event, as
the case may be, shall have the rights of a Calling Principal governed by the terms of
Section 16.3(b) below.

     (b) Call or Sale Right. If either Principal shall have rights pursuant to
Sections 16.3(a)(i), 16.3(a)(ii) or 16.3(a)(iii) above, then the Principal with such rights (the
“Calling Principal”) shall have the option (i) to purchase the Merial Venture Interest of the other
Principal (the “Callable Principal”), (ii) to require that the Merial Venture be

234

 

sold in its entirety to the highest bidder, or (iii) not to exercise either of options (i) or (ii).
The Calling Principal shall notify the Callable Principal of its decision within the later of (x)
[*] after the Calling Principal’s learning of the Event of Insolvency, Change of
Control, or Restructuring Event on which the exercise of the option is based or [*]
after an award of the Arbitrators pursuant to Section 16.3(a)(ii), as the case may be, and (y)
[*] after its receipt of the determination of the Merial Venture Value pursuant to
Section 16.3(c) below.

     In the event the Calling Principal exercises its call right option pursuant to Section
16.3(b)(i), the Calling Principal shall purchase the Callable Principal’s Merial Venture Interest
at a price equal to fifty percent (50%) (subject to adjustment as contemplated by Sections 6.4(f)
[Early Year Adjustment], 6.5(e) [Band Adjustment], 6.6(d) [Poultry Genetics] or 6.10 [Research
Payment]) of the Merial Venture Value determined according to the procedures set forth in Section
16.3(c). Any exercise of such call right shall be governed by the provisions of Section 16.5. In
the event the Calling Principal decides to exercise its sale right option pursuant to Section
16.3(b)(ii), the Calling Principal shall so notify the Callable Principal, and such sale shall be
governed by the provisions of Section 16.4(b).

     (c) Merial Venture Value. The “Merial Venture Value” shall mean the value of the
Merial Venture as a going concern, giving due consideration to all circumstances relevant to such
value, determined by a panel of three Investment Banks. In the event the Calling Principal wishes
to proceed with the determination of the Merial Venture Value, the Calling Principal shall notify
the Callable Principal in writing and each Principal shall, within
fifteen (15) days of such
notification, select an Investment Bank. Such two Investment Banks together shall select a third
Investment Bank. If the two Investment Banks have not selected a third Investment Bank within
fifteen (15) days of the later of the dates on which they were selected, such third Investment Bank
shall be selected and appointed by the ICE. The Principals shall procure that each of the two
Investment Banks is provided with all relevant information reasonably available. Each of the two
Investment Banks shall, within thirty (30) days of the selection of the third Investment Bank,
present their respective valuations of the Merial Venture to such third Investment

235

 

Bank which shall, within thirty (30) days after the later of the dates on which such two valuations
were presented, select one of such valuations as the Merial Venture Value. The valuation selected
by the third Investment bank shall be final and binding on all the Parties. The fees and expenses
of the Investment Banks shall be divided equally between the Principals.

SECTION 16.4. Termination Following Mutual Consent or Mutual Breach

     (a) This Agreement may be terminated and the Merial Venture Dissolved according to the
provisions of this Section 16.4 upon the occurrence of any of the following events:

     (i) The mutual consent of the Parties. In any such event, the Principals shall meet to
confirm or shall exchange a joint written acknowledgement confirming their mutual desire to
Dissolve the Merial Venture, which Dissolution shall be governed by the terms of Section
16.4(b).

     (ii) Following the termination of the dispute resolution and arbitration procedures
set forth in Article XVIII, the Arbitrators determine that the Merck Group and the RP Group
have each satisfied the provisions of Section 16.3(a)(ii) to be qualified as both a
Non-Breaching Principal and a Breaching Group. If the Arbitrators make such determination,
the Dissolution of the Merial Venture shall be governed by the procedures set forth in
Section 16.4(b).

     (iii) The Calling Principal opts pursuant to the terms of Section 16.3(b) to require
the sale of the Merial Venture pursuant to the terms of Section 16.4(b).

     (b) Sale of Merial Venture. If the Merial Venture is to be Dissolved pursuant to
Section 16.4(a)(i), 16.4 (a)(ii) or 16.4(a)(iii) above, then the Merial Venture shall be sold in
its entirety to the highest bidder as an independent going concern. The Principals shall, within
[*] after (i) the date they have confirmed their mutual intent to Dissolve the Merial
Venture, or (ii) the date [*] after the date of the award of

236

 

the Arbitrators that is the basis for such Dissolution or from the date of the decision of the
Calling Principal to exercise the option set forth in clause (ii) of Section 16.3(b), as the case
may be, together select an Investment Bank to represent them in such sale. In the event the
Principals cannot agree on an Investment Bank within such [*] period, the Investment Bank
shall be selected and appointed by the ICE. The fees and expenses of the Investment Bank shall be
divided equally between the Principals. Following consultations with both Principals, the
Investment Bank shall determine the conditions of the sale, including the date by which prospective
purchasers must have made their bids. Such conditions shall be consistent with the other terms of
this Agreement and the Ancillary Agreements continuing in effect after such sale. Either or both
Principals may concurrently bid to buy the Merial Venture Interest of the other Principal on the
conditions determined by the Investment Bank, and any such bid to buy the Merial Venture Interest
of the other Principal shall be multiplied by two (subject to adjustment as contemplated by
Sections 6.4(f) [Early Year Adjustment], 6.5(e) [Band Adjustment], 6.6(d) [Poultry Genetics] or
6.10 [Research Payment]) in comparing it with the bids of Third Parties to buy the entire Merial
Venture to determine the highest bidder. The net proceeds from any sale of the Merial Venture to a
Third Party shall be split 50% (fifty percent) to each of the Principals, subject to adjustment as
contemplated by Sections 6.4(f) [Early Year Adjustment], 6.5(e) [Band Adjustment], 6.6(d) [Poultry
Genetics] or 6.10 [Research Payment].

SECTION 16.5. Sale of Merial Venture Interest to the Other Principal

     In the event either Principal (the “Selling Principal”) sells or causes the sale of its Merial
Venture Interest to the other Principal (the “Non-Selling Principal”) pursuant to the provisions of
Section 16.3, Section 16.4 or Section 17.2, the Non-Selling Principal shall pay the purchase price
as determined by the Section applicable to such sale (subject to adjustment as contemplated by
Sections 6.4(f) [Early Year Adjustment], 6.5(e) [Band Adjustment], 6.6(d) [Poultry Genetics] or
6.10 [Research Payment]) upon the closing of such sale pursuant to the definitive sale agreement.
The purchase price will (subject to Section 17.2(f) in the case of a sale pursuant to Section 17.2)
be payable in cash. The Non-Selling Principal may assign to Merial (or any wholly-owned Subsidiary
of Merial)

237

 

its right to purchase the Merial Venture Interest of the Selling Principal (but such assignment
shall not release or reduce the Non-Selling Principal’s obligations to pay the purchase price for
such Merial Venture Interest or otherwise consummate such purchase under this Agreement or any
other obligations under the definitive sale agreement applicable to such purchase).

     The names of each and every Merial Venture Company will be changed to remove any reference, if
any, to the Selling Principal therefrom and filings will be made with appropriate Public
Authorities to effect such changes.

     The definitive sale agreement to be concluded by the Principals in the event one of them sells
its Merial Venture Interest to the other shall include: (i) representations and warranties similar
to those set forth in Sections 10.1 [Organization, Powers], 10.2 [Authorization], and 10.3
[Enforceability], and to the effect that the Merial Venture Interest is delivered free of
Encumbrances and adverse claims; (ii) conditions to closing including: (x) conditions similar to
the conditions set forth in Sections 12.6(b)(i)-(iii) [representations and warranties of Selling
Principal substantially true as of date of closing and material compliance with covenants in sale
agreements through closing — certified by officer’s certificate], (y) a condition that no
injunction or other court or regulatory order blocking the sale shall be in effect as of the
closing, and (z) a condition that all required governmental and regulatory consents that are
material shall have been obtained; provided, however, that if the Principals
disagree as to whether any material governmental or regulatory consents are required to consummate
the sale, the Non-Selling Principal shall obtain an opinion of independent counsel (reasonably
acceptable to the Selling Principal) to the effect that such consent is required; and
provided further that if no such opinion is obtained, such condition shall not be
included in such agreement; and (iii) a provision allowing the Selling Principal (in addition to
exercising any other applicable legal remedies) to terminate the agreement if (in the absence of
fault on the part of the Selling Principal or any of its Subsidiaries) the closing thereunder shall
not occur (x) within [*] after the determination of the Merial Venture Value if the
condition set forth in clause (ii) (z) above is not included in the sale agreement, or (y) within
[*] after the determination of the Merial Venture Value if such

238

 

condition is included in the sale agreement, subject to an extension of no more than [*], if a filing has been duly submitted under the HSR Act or an application has been
duly submitted to the Commission of the European Union with respect to the purchase of such Merial
Venture Interest and such extension is required to permit completion of the relevant approval
process pursuant to such filing or submission.

SECTION 16.6. Consequences of Termination

     (a) The termination of this Agreement in accordance with to the provisions of Sections 16.3,
16.4, 16.5 and/or 17.2(c)(i) or (ii) shall be effective as of the date the sale of the Merial
Venture or of the Merial Venture Interest of one of the Principals, as the case may be, is
consummated in full compliance with the provisions of the applicable Section, which shall also be
the dissolution date of the Merial Venture (the “Dissolution Date”).

     (b) In the event the Merial Venture is sold to a Thirty Party pursuant to Sections 16.3, 16.4
and/or 17.2(c)(i), the Principals shall include in the relevant agreements, and shall not waive, a
condition to such sale requiring that such Third Party purchaser and any parent company thereof, as
appropriate, enter into a written guaranty in favor of each Group guaranteeing the performance by
the Merial Venture Companies of their respective obligations to each Group under any Ancillary and
Future Agreements in effect on the date of such sale. The Parties shall cause all Ancillary
Agreements and Future Agreement in effect on the date of such sale to remain in full force and
effect until terminated in accordance with their terms, except that (i) the non-competition
provision and all provisions relating to any further research under the Research Agreements shall
terminate, as more specifically set forth in each Research Agreement, but all other provisions of
the Research Agreements, including those relating to confidentiality, licenses granted in or out
prior to such date and royalties payable, shall remain in effect, except as otherwise provided
therein; and (ii) each Future Agreement may expressly provide that certain or all of its provisions
shall terminate in the event of a sale of the Merial Venture to a Third Party.

239

 

     (c) In the event the Merial Venture Interest of one Principal is sold to the other Principal
pursuant to Sections 16.3, 16.4, 16.5 and/or 17.2(c)(ii), the Parties shall cause all Ancillary
Agreements and Future Agreements in effect on the date of such sale to remain in full force and
effect until terminated in accordance with their terms, except that: (i) if Merck is the Selling
Principal, all provisions relating to further research under the Merck Research Agreement shall
terminate effective on the Dissolution Date, as more specifically set forth therein, and the
non-competition provision thereunder shall terminate [*] following the Dissolution
Date; (ii) if RP is the selling Principal, all provisions relating to further research under the RP
Ag Research Agreement, the RPR Research Agreement and the PMSV Research Agreement shall terminate
effective on the Dissolution Date, as more specifically set forth in each such agreement, and the
respective non-competition provisions under such agreements shall terminate [*]
following the Dissolution Date; provided that, in the case of either (i) or (ii),
all other provisions in the relevant agreement(s), including those relating to confidentiality,
licenses granted in or out prior to such date and royalties payable, shall remain in effect after
such sale, except as otherwise provided therein; and (iii) each Future Agreement may expressly
provide that certain or all of its provisions shall terminate in the event of a sale of the Merial
Venture Interest of one Principal to the other Principal.

     (d) The termination of this Agreement as specified herein shall not serve to eliminate any
Liability arising out of circumstances or conduct prior to the actual date of termination hereof
and any Party hereto may, following such termination, pursue such remedies as may be available with
respect to such Liabilities. The termination of this Agreement shall not affect any rights or
obligations of any Party under this Agreement which are intended by the Parties to survive such
termination. Without limiting the generality of the foregoing, the following provisions of this
Agreement shall survive the termination hereof for the longest period permitted by applicable law:
Article II; Section 11.16; Section 11.17; this Section 16.6; Article XIII; Article XIV and the
other indemnities in this Agreement, including indemnities in Section 5.1(a)(ii)(D) or (E),
5.1(b)(i) or (ii), Article VII or Article XI; Article XV (for the duration specified therein);
Article XVIII; and Article XIX (in the case of Section 19.3, [*]
termination of this Agreement).

240

 

ARTICLE XVII

TRANSFER OF INTERESTS; CHANGE OF CONTROL

SECTION 17.1. Limitations on Transfer

     (a) General. Except in compliance with this Article XVII, neither IM nor Merck SH may
sell, assign, pledge, encumber, hypothecate or otherwise transfer in any manner (including through
any contractual grant of its economic or voting rights) all or any part of its Merial Venture
Interest (each a “Transfer”) except with the written consent of the other Member, which it shall be
in the sole discretion of such other Member to grant or withhold. Upon any Transfer, the transferee
of any Merial Venture Interest shall be admitted as a Member to the extent of the Merial Venture
Interest that such transferee has acquired, and for all purposes of this Agreement shall be deemed
to have the capacity of a Member. Any such permitted Transfer shall not cause the dissolution of
any of the Merial Venture Companies.

     (b) Transfer to an Affiliate. Either Member may transfer all (but not less than all)
of its Merial Venture Interest to any of its Affiliates; provided, however, that,
in the case of the Merck Group, Merck owns, directly or indirectly, at least fifty-one percent
(51%) of both the outstanding capital stock and the voting power of such Affiliate, and, in the
case of the RP Group, RP owns, directly or indirectly, at least fifty-one percent (51%) of both the
outstanding capital stock and the voting power of such Affiliate, and, provided further
that in each case such transfer would not (and would not be reasonably expected to) have or result
in a Material Adverse Change or Effect on the Merial Venture Companies. It shall be a condition to
any Transfer of a Merial Venture Interest that: (i) the Affiliate to which such Transfer is made
shall have executed a deed of adherence in the form of Exhibit XIII under which it agrees to assume
and be bound by all of the obligations of the transferor under this Agreement and (ii) any
amendments to this Agreement reasonably requested by the non-transferring Member in connection with
such Transfer shall be made; provided, however, that no such Transfer shall release
the transferor from its obligations hereunder except to the extent such obligations are performed
by such Affiliate. This Section 17.1(b) shall not prevent either Member from

241

 

appointing any of its Affiliates (other than the Merial Venture Companies) to act as its agent in
connection with the performance of such Member’s obligations pursuant to this Agreement.

SECTION 17.2. Transfer to a Non-Affiliate

     (a) General. At any time subsequent to the date (the “Permitted Transfer Date”) of the
earlier of (i) receipt by the Members of the audited financial statements of the Merial Venture for
the Fiscal Year ended December 31, 2001, or (ii) ninety (90) days after the last day of such Fiscal
Year, either Principal shall have the right, at its sole discretion, to Transfer all (but not less
than all) of its Merial Venture Interest pursuant to the procedures set forth in this Section 17.2.
During the period from delivery of the applicable Offer Notice to the sale of such Merial Venture
Interest as provided below, Merial will operate, or cause the operation of, the Merial Venture only
in the ordinary course of business according to the latest annual budget and Business Plan.

     (b) Offer Notice. In the event that one Principal (the “Transferring Principal”) has
negotiated a bona fide offer (the “Offer”) from any Third Party (the “Bona Fide Purchaser”) to
purchase all (but not less than all) of such Selling Principal’s Merial Venture Interest after the
Permitted Transfer Date, such Selling Principal shall promptly deliver a written notice (the “Offer
Notice”) of the Offer to the other Principal (the “Non-Transferring Principal”), indicating the
name of the Bona Fide Purchaser, the identities of the persons or entities that Control the Bona
Fide Purchaser, to the extent known, if the Bona Fide Purchaser does not have equity securities
which are then publicly traded, the Offer price, including the amount and kind of consideration
proposed to be paid with respect to such Transfer (the “Offer Price”) and describing in reasonable
detail all other material terms and conditions relating to the Offer.

     (c) Rights of Non-Transferring Principal. Following its receipt of an Offer Notice,
the Non-Transferring Principal shall have the following rights:

242

 

     (i) Should the Non-Transferring Principal also wish to sell its Merial Venture
Interest, the Transferring Principal shall not transfer its Merial Venture Interest to the
Bona Fide Purchaser unless the Bona Fide Purchaser also purchases all (but not less than
all) of the Non-Transferring Principal’s Merial Venture Interest at the same Offer Price
and on substantially the same terms and conditions as those specified in the Offer Notice.
The net proceeds from any such sale to such Bona Fide Purchaser shall be split 50% (fifty
percent) to each of the Principals, subject to adjustment as contemplated by Sections
6.4(f) [Early Year Adjustment], 6.5(e) [Band Adjustment], 6.6(d) [Poultry Genetics] or 6.10
[Research Payment].

     (ii) Alternatively, at the election of the Non-Transferring Principal, the
Transferring Principal shall transfer all (but not less than all) of its Merial Venture
Interest to the Non-Transferring Principal at a price equal to the Offer Price (subject to
adjustment as contemplated by Sections 6.4(f) [Early Year Adjustment], 6.5(e) [Band
Adjustment], 6.6(d) [Poultry Genetics] or 6.10 [Research Payment]) and on substantially the
same terms and conditions as those specified in the Offer Notice (but subject to subsection
(f) below relating to any non-cash consideration). Any such Transfer shall be subject to
the provisions of Sections 16.5 and 16.6.

     In order to exercise either of its rights described in (i) or (ii) above, the Non-Transferring
Principal must notify the Transferring Principal in writing of its election (a “Notice of
Election”) to exercise such rights within [*] of having received the Offer Notice. For
the purposes of this Section 17.2(c), the “Transferring Period” shall be defined as the period
ending [*] after the end of the [*] period referred to in the immediately
preceding sentence or such longer period (up to [*] in the aggregate) as is required by the
necessity of obtaining any material approval or consent from a Public Authority before proceeding
with such Transfer, to the extent that (and only for the additional period during which) such
approval or consent has not been obtained for any reason other than the failure by the Transferring
Principal or its Subsidiaries or by the Bona Fide Purchaser to diligently attempt to obtain such
consent or approval. If the Non-Transferring Principal does not elect to exercise either of its
rights

243

 

by delivery of a Notice of Election within such [*] period, (x) the Transferring
Principal may Transfer its Merial Venture Interest within the Transferring Period to the Bona Fide
Purchaser for the Offer Price and on substantially the terms and conditions set forth in the Offer
Notice, and the Non-Transferring Principal (and every Subsidiary of the Non-Transferring Principal
which is a Party) shall be deemed to have irrevocably consented, for purposes of Section 17.1, to
the Transfer of the Transferring Principal’s Merial Venture Interest to the Bona Fide Purchaser,
and (y) the Non-Transferring Principal will cooperate with any reasonable proposal by the
Transferring Principal to restructure the Merial Venture so as to reduce the transfer taxes
otherwise payable by the Bona Fide Purchaser (or, if applicable, by the Transferring Principal or
any of its Subsidiaries) in connection with such Transfer, provided such restructuring will not
have any materially adverse tax, legal or other business consequences to the Non-Transferring
Principal, its Subsidiaries or the Merial Venture (and any monetary cost of such restructuring is
borne by the Transferring Principal).

     In the event the Transfer to the Bona Fide Purchaser pursuant to the Offer as set forth in the
Offer Notice is not concluded within the Selling Period for any reason other than a material lack
of cooperation on behalf of the Non-Selling Principal or its Subsidiaries, the Selling Principal
may not Transfer its Merial Venture Interests except by submitting another Offer Notice and
complying with the provisions set forth in this Section 17.2.

     (d) Consequence of Sale to a Bona Fide Purchaser. The Transferring Principal
shall not effect a Transfer of its Merial Venture Interest to a Bona Fide Purchaser unless (x) such
Bona Fide Purchaser shall execute a deed of adherence in the form of Exhibit XIII under which it
agrees to assume and be bound by all the obligations of the Transferring Principal and its
Subsidiaries pursuant to this Agreement (but not the Ancillary or Future Agreements); and (y) any
parent company (or companies) of the Bona Fide Purchaser will enter into a written guaranty
reasonably satisfactory to the Non-Transferring Principal guaranteeing the performance of all
provisions of this Agreement that are applicable to the Transferring Principal or, at the election
of the Non-Transferring Principal, will become a party (or parties) to this Agreement.

244

 

Notwithstanding the Transfer by the Transferring Principal of its Merial Venture Interest, all of
the Ancillary Agreements and Future Agreements then in effect shall remain in full force and
effect, subject to the exceptions set forth in Section 16.6(c)(i) — (iii).

     (e) Timing of Transfer to Bona Fide Purchaser. If the Non-Transferring Principal
elects to exercise its right pursuant to clause (i) of Section 17.2(c) above, (i) the Transferring
Principal shall promptly seek to cause the Bona Fide Purchaser to purchase both its and the
Non-Transferring Principal’s entire Merial Venture Interest, and (ii) the Transferring Principal
may transfer its Merial Venture Interest only if the Bona Fide Purchaser purchases its and the
Non-Transferring Principal’s entire Merial Venture Interests for the Offer Price (as adjusted to
reflect the Transfer of the entire Merial Venture) and on substantially the terms and conditions
specified in the Offer Notice, within [*] of the Notice of Election or such longer
period up to [*] as is required by the necessity of obtaining any material approval or consent
from a Public Authority before proceeding with such Transfer, to the extent that (and only for the
additional period during which) such approval or consent has not been obtained for any reason other
than the failure by the Transferring Principal or its Subsidiaries the Non-Transferring Principal
or its Subsidiaries or by the Bona Fide Purchaser to diligently in attempt to obtain such consent
or approval.

     (f) Non-Cash Consideration. In the event the Offer Price specified in the Offer
Notice includes any property or other consideration other than cash (including notes or other
evidences or indebtedness) (collectively, “Non-Cash Consideration”), such Offer Price shall be
deemed to be the sum of the amount of any cash included in the Offer Price plus the fair market
value of such other property and other consideration. The fair market value of such property and
other consideration (the “Property Value”) shall be determined in good faith by the Transferring
Principal and set forth in the Offer Notice. If, within fourteen (14) days after receipt of the
Offer Notice, the Non-Transferring Principal questions such determination, then (i) the Property
Value shall be determined in accordance with the provisions for establishing Fair Market Value (as
defined in Section 17.2(g)) and (ii) the [*] period referred to in Section 17.2(c)
shall not commence until the determination of the Property Value. Any consideration to be paid

245

 

by the Non-Transferring Principal to the Transferring Principal pursuant to an election to exercise
its right pursuant to clause (ii) of Section 17.2(c) shall be, at the option of the
Non-Transferring Principal (x) in cash in an amount equal to the sum of the amount of cash and the
Property Value (as determined above) included in the Offer Price, or (y) the Offer Price, including
the cash and the Non-Cash Consideration components thereof.

     (g) For purposes of this Section 17.2, the “Fair Market Value” of property shall mean
the dollar value of such property determined (i) by mutual agreement of the Principals, or (ii) if
the Principals cannot so agree within fifteen (15) days after the Non-Transferring Principal first
questions in writing the Transferring Principal’s proposed determination of the Fair Market Value
of such property, by an Investment Bank selected by the Principals by mutual consent. If the
Principals have not agreed on their selection of an Investment Bank within fifteen (15) days after
the end of the fifteen (15) day period referred to in clause (i), the Investment Bank shall be
selected and appointed by the ICE. The Parties agree that (x) any determination by the Investment
Bank shall be final and binding on all the Parties, (y) the Investment Bank shall act as expert and
not as arbitrator, and (z) the Principals shall procure that the Investment Bank is provided with
all relevant information reasonably available. The fees and expenses of the Investment Bank shall
be divided equally between the Principals.

SECTION 17.3. Ownership of a Member

     For so long as Merck SH or any other Subsidiary of Merck, in the case of Merck, or IM or any
other Subsidiary of RP, in the case of RP, shall be a Member, Merck and RP each agrees that it
shall not take, and shall not permit any of its Subsidiaries to take, any action which would result
in Merck or RP (as the case may be) owning less than fifty-one percent (51%) of both the
outstanding capital stock and voting power of such Member (after giving effect to all equity
interests owned by Third Parties in any Person in the chain of ownership of Merck SH or IM,
respectively).

246

 

SECTION 17.4. Change of Control; RP Restructuring Event or Merck Restructuring Event

     (a) In the event of a Change of Control of either Principal or of an RP Restructuring Event or
a Merck Restructuring Event, the affected Principal shall deliver a written notice to the other
Principal within thirty (30) days of the closing of the Change of Control or the Restructuring
Event, as the case may be, stating that the transaction has occurred and describing such
transaction in reasonable detail.

     (b) In the event a Change of Control either (i) subject to the following sentence, results in
the Principal that is subject to such Change of Control being at any time thereafter an Affiliate
of one or more companies (such Principal and its Affiliates together, the “Affiliated Animal Health
Companies”) which together have annual sales of Animal Health Products in excess of [*],
or (ii) would result in a Material Adverse Change or Effect with respect to the Merial Venture,
then the Principal that is not subject to the Change of Control (the “Other Principal”) shall have
the rights of a Calling Principal governed by the terms of Section 16.3(b). With respect to
clause (i) of the preceding sentence, the Other Principal’s rights as a Calling Principal shall
only be exercisable after a period of either (A) one year from the date of the Change of Control,
if the sales of Animal Health Products by the Affiliated Animal Health Companies exceeded [*] during the last four full consecutive calendar quarters preceding the Change of Control and
could reasonably be expected to again exceed such amount during the calendar year in which the
Change of Control takes place, or (B) one year from the last day of the calendar year in which the
Change of Control occurs, if the sales of Animal Health Products by the Affiliated Animal Health
Companies first exceed [*] in any subsequent calendar year, provided that the Other
Principal shall have no rights as a Calling Principal pursuant to Section 17.4(b)(i) if, at any
time prior to the expiry of the relevant one year period described in clauses (A) or (B), the
Affiliated Animal Health Companies divest some or all of their Animal Health Business activities
such that they could no longer be reasonably expected to have annual sales of Animal Health
Products in excess of [*].

247

 

     (c) In the event of an RP Restructuring Event, Merck shall have the rights of a Calling
Principal governed by the terms of Section 16.3(b) if the RP Restructuring Event (i) would result
in a material adverse effect on the practical or legal ability of the Subsidiary or Subsidiaries of
RP that were the subject of the RP Restructuring Event to perform the activities contemplated by,
or fulfill the obligations under, the Ancillary Agreements to which they are parties, or (ii) would
result in a Material Adverse Change or Effect with respect to the Merial Venture.

     (d) In the event of a Merck Restructuring Event, RP shall have the rights of a Calling
Principal governed by the terms of Section 16.3(b) if the Merck Restructuring Event (i) would
result in a material adverse effect on the practical or legal ability of Merck to perform the
activities contemplated by, or fulfill its obligations under, the affected Ancillary Agreement, or
(ii) would result in a Material Adverse Change or Effect with respect to the Merial Venture.

248

 

ARTICLE XVIII

DISPUTE RESOLUTION AND ARBITRATION

SECTION 18.1. Good Faith Settlement

     Each of the Parties agrees to negotiate in good faith as provided in this Section 18.1 to
resolve amicably any dispute which arises respecting or in connection with this Agreement or any
Ancillary Agreement. Any Party may serve a written notice (a “Dispute Notice”) at any time upon
Merial and the other Parties stating that such a dispute has arisen and containing a brief
statement describing the nature of the dispute. A timely notification by an Indemnifying Party
disputing an Indemnity Claim under Section 14.7(b) shall be deemed to be a Dispute Notice under
this Article XVIII. Other than with respect to any matter referred to in Sections 5.3(b), 6.2(d),
7.1(b), 7.1(c), 16.3(c), 16.4(b) or 17.2(g) of this Agreement, which shall be resolved in
accordance with the procedures set forth therein, or any other matter for which another dispute
resolution procedure is expressly set forth in any Ancillary Agreement, Merial shall submit the
matter described in any Dispute Notice for resolution to the RP Animal Health Executive and the
Merck Animal Health Executive immediately upon receiving any such Dispute Notice.

     Upon receiving any such Dispute Notice, or upon receiving notice of a deadlock pursuant to
Section 4.2(h) or Section 4.3(h), as the case may be, RP and Merck, respectively, shall cause the
RP Animal Health Executive and the Merck Animal Health Executive, respectively, to negotiate in
good faith to resolve any such dispute or deadlock amicably. Throughout the pendency of any such
dispute or deadlock, the Parties shall cause the Merial Venture to continue to conduct its business
activities in accordance with the Business Plan of the Merial Venture then in effect, if any. The
RP Animal Health Executive and the Merck Animal Health Executive, may, if they so desire, consult
outside experts for assistance in arriving at a resolution. The resolution of any matter that is
accepted by both the RP Animal Health Executive and the Merck Animal Health Executive in accordance
with this Section 18.1 shall be binding on the Parties for all purposes. If the RP Animal Health
Executive and the Merck Animal Health Executive

249

 

are unable to resolve any Arbitrable Matter (as defined in Section 18.2) within thirty (30) days of
its having been referred to them in accordance with this Section 18.1, the provisions of Section
18.2 shall apply with respect to such Arbitrable Matter.

SECTION 18.2. Arbitration

     (a) Arbitrable Matters. Any dispute, controversy or claim (including, without
limitation, disputes, controversies or claims sounding in tort) between a Merck Company and an RP
Company (or between any Merck Company or RP Company, on the one hand, and any Merial Venture
Company, on the other hand) respecting or in connection with, without limitation, the validity,
interpretation, termination or performance of this Agreement, or any Ancillary Agreement, which
dispute, controversy or claim has not been resolved pursuant to the procedures set forth in Section
18.1, shall be an “Arbitrable Matter”; provided, however, that (A) any deadlock
within the Members’ Meeting or the Board of Directors with respect to any matter submitted to such
body for its consideration relating to the business activities or strategy of the Merial Venture,
(B) any other failure to agree between the Members or their respective Representatives on matters
of business judgment, or (C) any matter referred to in Sections 5.5 [Certain US Tax Matters],
6.2(d) [Special Dividend Calculation Dispute Resolution], 16.3(c) [Merial Venture Value], 16.4(b)
[Sale of Merial Venture], or 17.2(g) [Fair Market Value of Property] of this Agreement, which shall
be resolved in accordance with the procedures set forth therein, or (D) any other matter for which
another dispute resolution procedure is expressly set forth in any Ancillary Agreement, shall not
be an “Arbitrable Matter”. Any matter which is not an Arbitrable Matter shall not be referred to
arbitration under this Article XVIII and no Party shall, or permit any of its Subsidiaries to,
resort to any means whatsoever, including litigation, arbitration, dissolution by a judicial forum
or by operation of law, appointment of a trustee, receiver, custodian or similar person, or to any
other form of proceeding, other than the procedures provided for in Section 18.1, to seek any
resolution or settlement of any matter which is not an Arbitrable Matter.

     No Party shall, or permit any of its Subsidiaries to, make recourse to arbitration under this
Agreement until the procedure set out in Section 18.1 has been followed. If

250

 

the RP Animal Health Executive and the Merck Animal Health Executive shall fail to resolve any
Arbitrable Matter within thirty (30) days of the referral to them of such Arbitrable Matter in
accordance with Section 18.1, either Principal may commence an arbitration proceeding in respect of
such Arbitrable Matter by delivering an arbitration request (an “Arbitration Request”) in
accordance with this Section 18.2 to the ICC with a copy thereof to the other Principal. The
Principal delivering such Arbitration Request is herein referred to as the “Claimant” and the
Principal receiving the Arbitration Request, as the “Respondent.”

     (b) Parties in Interest Bound. In any arbitration pursuant to this Article XVIII,
RP, on the one hand, and Merck, on the other hand, shall be deemed to constitute the two parties in
interest and each Principal may (i) assert claims on its behalf or on behalf of any of its
Subsidiaries against the other Principal or against Merial or against any of their respective
Subsidiaries that have obligations under this Agreement or an Ancillary Agreement, or (ii) bring
claims on behalf of any Merial Venture Company against the other Principal or any such Subsidiary.
Each of the Parties hereby irrevocably consents to the ability of either Principal to (i) bring a
claim on behalf of any of its Subsidiaries or any Merial Venture Company against the other
Principal or a Subsidiary thereof that has obligations under this Agreement or an Ancillary
Agreement, as the case may be, or (ii) represent Merial or any Merial Venture Company in defending
against any claim brought by the other Principal or a Subsidiary thereof against such Merial
Venture Company. All the Parties hereby irrevocably consent to be bound by the award of the
Arbitrators (as defined below) pursuant to any such claim. In connection with any proceeding to
compel arbitration related hereto, any arbitration pursuant to this Article XVIII, any proceeding
seeking interim relief related hereto, and any proceeding in connection with the recognition and
enforcement of any award related hereto, no Party shall make, and each Party hereby expressly and
irrevocably waives, any defense or claim based on assertions of sovereign immunity or similar
grounds.

     (c) Arbitration Proceedings. All Arbitrable Matters not resolved pursuant to
Section 18.1 shall be finally resolved by three (or, if there are more than two parties in
interest, more than three) arbitrators (the “Arbitrators”) in accordance with the Rules of

251

 

Conciliation and Arbitration of the ICC (the “ICC Rules”). If there are two parties in interest,
the third Arbitrator, who will act as chairman of the arbitral tribunal, shall be nominated jointly
by the two Arbitrators nominated by the parties (one by each). If the two Arbitrators nominated
by the parties cannot agree on the nomination of the third Arbitrator within fifteen (15) Business
Days of the date the identity of the second to be nominated Arbitrator was communicated to the
first to be nominated Arbitrator, the third Arbitrator shall be nominated by the International
Court of Arbitration in accordance with Article 1.4 of the ICC Rules. The seat of the arbitration
shall be in Geneva, Switzerland. The arbitration proceedings shall be conducted, and the award
shall be rendered in writing, in the English language. No party shall be entitled to commence
proceedings before the courts of any jurisdiction, including England and Wales, in connection with
the conduct of any arbitration proceedings, provided that the parties shall be free to
commence proceedings before such courts for the purposes of enforcing any arbitral award.

     The Arbitrators shall apportion the costs of the arbitration (including any administrative
costs and fees of the Arbitrators and fees of experts hired by the Arbitrators, but excluding any
fees of counsel or other experts of the Claimant or the Respondent) as part of their arbitral
award. Among other remedies otherwise available to them, such Arbitrators shall be authorized to
order injunctive relief or the specific performance of any provision contained herein or in any
Ancillary Agreement. Any award rendered by the Arbitrators shall be final and binding upon the
parties to such arbitration, and judgment upon such award, including any costs of arbitration
referred to above, together with interest, may be entered in accordance with applicable Laws in any
court of competent jurisdiction.

     (d) Confidentiality. All arbitration proceedings under this Article XVIII shall
be confidential and the Arbitrators may issue appropriate protective orders to safeguard the
Confidential Information of any Party or Merial Venture Company. Except as required by Laws, none
of the parties to the arbitration proceedings shall make (or request any Arbitrator or permit any
Merial Venture Company to make) any public announcement with respect to the proceedings or
decisions of the Arbitrators without the

252

 

prior written consent of the other party or parties thereto. The existence of any dispute
submitted to arbitration, and the award of the Arbitrators, shall be kept in strict confidence,
except as required in connection with the enforcement of such award or as otherwise required by
applicable Laws.

SECTION 18.3. Interim Equitable Relief

     (a) Notwithstanding the provisions of Section 18.1 and Section 18.2, each of the Parties, to
the extent allowed by Article 8.5 of the ICC Rules, may initiate legal proceedings in a court of
competent jurisdiction, as provided in Section 18.3(b), in respect of a dispute that is an
Arbitrable Matter hereunder, solely for the purpose of seeking interim relief, and prior to the
time the file is transmitted to the Arbitrators, preserving the status quo and preventing
irreparable harm that would befall the Party initiating such proceedings, Merial or any other
Merial Venture Company in the absence of such relief.

     (b) Each of the Parties consents to jurisdiction and venue, and expressly waives any objection
thereto, in any court of competent jurisdiction in connection with the proceedings for interim
equitable relief contemplated in Section 18.3(a).

SECTION 18.4. Tolling of Breach Period

     From the date of mailing of the Dispute Notice and until (i) sixty (60) days after the date of
the Arbitrators’ award, or (ii) if neither the Claimant nor the Respondent delivers an Arbitration
Request to the other with respect to such Arbitrable Matter, 60 days after the date of mailing of
the Dispute Notice, the running of any sixty (60) day period referred to in Section 16.3(a)(ii)(C)
with respect to any alleged material breach (a “Breach Period”) shall be suspended as to such
alleged material breach.

253

 

ARTICLE XIX

MISCELLANEOUS

SECTION 19.1. Expenses

     Except as otherwise expressly provided herein or therein, each Party shall bear its own
expenses in connection with the negotiation and execution of, and the Closing and performance
under, this Agreement and the Ancillary Agreements. For the avoidance of doubt, the Parties
acknowledge that each of RP and Merck will bear the legal, accounting and banking fees and
commissions incurred by (or on behalf of) any members of the RP Group or the Merck Group or their
respective Merial Venture Businesses in connection with the negotiation of this Agreement and the
Ancillary Agreements and with the formation of the Merial Venture and the preparation and
consummation of the Closing.

SECTION 19.2. Notices

     Notices and other communications provided for herein shall be in writing and shall be
delivered by registered mail, by hand or overnight courier service as follows:

     (a)  If to Rhône-Poulenc or any Subsidiary thereof, to:

Rhône-Poulenc S.A.

25 Quai Paul Doumer

92408 Courbevoie Cedex

France

Attention:   Corporate Secretary

Facsimile:   (33 1) 47.68.11.33

with a copy to:

Institut Mérieux S.A.

17 rue Bourgelat

69002 Lyon

France

Attention:   General Counsel

Facsimile:   (33 4) 72.73.70.61

254

 

     (b)  If to Merck or any Subsidiary thereof, to:

Merck & Co., Inc.

One Merck Drive

P.O. Box 100

Whitehouse Station, New Jersey 08889

Attention:   General Counsel

Facsimile:   (908) 735-1244

     (c)  If to Merial, to:

Registered Office, London, England

Attention:   General Counsel

with a copy to Merck, Rhône-Poulenc and Institut Mérieux at the addresses specified
above.

     All notices and other communications given to any Party in accordance with the provisions of
this Agreement or any such Ancillary Agreement shall be deemed to have been given ten days after
the date of mailing if sent by registered mail, or on the date of receipt if delivered by hand or
overnight courier service, in each case delivered or sent to such Party as provided in this Section
19.2 or in accordance with the latest unrevoked direction from such Party (which direction shall
have been given in accordance with this Section 19.2). In the event any notice is given pursuant
to any Ancillary Agreement, a copy will also be provided to the head of the applicable operating
division of the Party to which the notice is addressed.

SECTION 19.3. Confidentiality

     (a) General. Except as expressly set forth in this Section 19.3, each Party
shall, and shall cause its Affiliates and its and their officers, directors, employees, agents and
subcontractors (collectively, “Agents”) to, keep confidential and not disclose to any other person,
nor use for any purpose other than the purposes of this Agreement or any Ancillary Agreement or
Future Agreement, any and all information received from another Party, its Affiliates or any of
their respective Agents, as a result of negotiating, entering into or performing this Agreement or
any Ancillary Agreement or Future Agreement (all such information being “Confidential
Information”), other than information which:

255

 

     (i) is or hereafter becomes generally available to the trade or public (other
than through disclosure by the receiving person or any Affiliate or Agent thereof);

     (ii) is disclosed to the receiving person or any Affiliate or Agent thereof by a
Third Party who has the right to disclose such information;

     (iii) was or is independently known to, or developed by or on behalf of, the
receiving person or any of its Affiliates, without reliance on information which is
otherwise Confidential Information hereunder;

     (iv) is submitted by the receiving person to Public Authorities to facilitate the
issuance of marketing approvals (or to maintain such approvals) for a Merial Venture
Product, provided that reasonable measures shall be taken to assure confidential treatment
of such information and provided further that such information shall remain
Confidential Information for all other purposes unless subparagraphs (i) through (iii)
above otherwise apply; or

     (v) based on such person’s good faith judgment with the advice of counsel, is
otherwise required by a Public Authority to be disclosed in compliance with applicable Laws,
provided that such person shall use reasonable efforts to obtain assurance that
confidential treatment will be accorded such information, and provided further
that such information shall remain Confidential Information for all other
purposes unless subparagraphs (i) through (iv) above otherwise apply.

     Each Party shall be entitled, in addition to any other right or remedy it may have, to an
injunction, without the posting of any bond or other security, enjoining or restraining any other
person, as appropriate, from any violation or threatened violation of this Section 19.3, and no
Party shall, or permit any of its Subsidiaries to, object to the entry of any such injunction.

256

 

     (b) Use of Confidential Information. No Party shall, or permit any of its
Subsidiaries to, except as contemplated or otherwise permitted under any Ancillary
Agreement or any Future Agreement:

     (i) use any Confidential Information in its own businesses except as necessary
to the fulfillment of the rights and obligations of the Parties under this Agreement, any
Ancillary Agreement and any Future Agreement;

     (ii) assign, license, sublicense, market, transfer or loan, directly or
indirectly, any Confidential Information except as necessary to the fulfillment of the
rights and obligations of the Parties under this Agreement, any Ancillary Agreement and any
Future Agreement; or

     (iii) permit any Confidential Information to be used or exploited by any RP
Company or Merck Company or by any of their respective Agents for their benefit or the
benefit of any relationships with customers of such RP Company or Merck Company.

     (c) Protection of Confidential Information. Each Party shall, and shall cause
its Subsidiaries to, deal with Confidential Information so as to protect it from disclosure
with a degree of care not less than that used by it in dealing with its own information
intended to remain exclusively within its knowledge and shall take reasonable steps to
minimize the risk of disclosure of Confidential Information which shall include ensuring
that only its Affiliates and its and their Agents who have a bona fide “need to know” such
Confidential Information for purposes permitted or contemplated by this Agreement, any
Ancillary Agreement or any Future Agreement shall have access thereto. Each Party
shall, and shall cause its Subsidiaries to, notify all of its Affiliates and its and their
respective Agents who have access to Confidential Information of its confidentiality and
the care therefor required, and shall obtain from any Third Party (other than attorneys
and accountants for such Party or its Affiliates), who is permitted access to such
Confidential Information in accordance with this Section 19.3, an agreement of
confidentiality incorporating the restrictions set forth herein.

257

 

     (d) Survival of Obligations. The obligations set forth in this Section 19.3 shall
survive the expiration, termination or assignment of this Agreement, any Ancillary Agreement or any
Future Agreement; the obligations set forth in this Section 19.3 shall terminate seven (7) years
after the termination of this Agreement pursuant to a Dissolution.

     (e) Exceptions to Confidentiality. Notwithstanding anything in this Agreement to the
contrary, in connection with any proposed Transfer of the Merial Venture or of either Principal’s
Merial Venture Interest pursuant to Article XVI or Section 17.2, RP and/or Merck, as the case may
be, may disclose, and may permit its Subsidiaries and its and their Agents to disclose, to any
prospective purchaser and to any Investment Bank or other financial advisor retained by RP or
Merck, as the case may be, or the prospective purchaser in connection with such proposed Transfer,
such Confidential Information of the type that is customarily provided to prospective purchasers or
as may reasonably be requested by the recipient; provided, however, that prior to
the receipt of any such Confidential Information concerning the Merial Venture or the Merial
Venture Business, the recipient shall have entered into a written confidentiality agreement
incorporating the terms of this Section 19.3.

     (f) No Impairment of Other Confidentiality Provisions. Nothing in this Section 19.3
shall limit, expand, modify or otherwise affect any rights or obligations of the parties to any
Ancillary Agreement, Future Agreement or license or similar agreement. Accordingly, and without
limiting the generality of the foregoing, the Parties hereto expect that the confidentiality of
certain scientific or technical information may be governed by more stringent provisions in such
Ancillary Agreements, Future Agreements or license or similar agreements.

SECTION 19.4. Governing Law

     The LLC Agreement shall be construed in accordance with and governed by the Laws of the State
of Delaware. The Association Documents and this Agreement shall be construed in accordance with
and governed by the Laws of England and Wales. In the

258

 

event of any inconsistency between the terms of this Agreement and the provisions of the
Association Documents, the terms of this Agreement shall prevail as between the Parties.

SECTION 19.5. Decisions of the Parties

     Any decision or action expressly required by the terms of this Agreement to be made or taken
by the Parties or by agreement of the Parties or any of them (other than by vote in the Merial
Board of Directors or Members’ Meeting) shall be made or taken only by means of a writing signed on
behalf of each Party by (i) the Chairman, President, chief executive officer or chief operating
officer of such Party, or (ii) any such other officer or employee of such Party as the chief
executive officer of such Party shall have previously designated in writing to the other Parties as
being authorized to bind such Party with respect to the matters set forth in such writing.

SECTION 19.6. Successors and Assigns

     (a) This Agreement shall be binding upon and inure to the benefit of the Parties (upon such
Party’s execution hereof) and their respective successors and permitted assigns.

     (b) Except as set forth in Article XVII, no Party hereto shall assign this Agreement or any of
its rights or obligations hereunder without the prior written consent of each of the other Parties.

SECTION 19.7. Waiver; Amendment

     No provision of this Agreement may be waived except by a writing signed by the Party entitled
to the benefit thereof, and no such waiver of any provision hereof in one instance shall constitute
a waiver of any other provision or of such provision in any other instance. No omission, delay or
failure on the part of any Party in exercising any rights hereunder will constitute a waiver of
such rights or of any other rights hereunder. Neither this Agreement nor any provision hereof may
be waived, amended or modified

259

 

except pursuant to an agreement or agreements in writing entered into by each Party, which
instrument shall specifically indicate that it is the desire of the Parties to waive, amend or
modify this Agreement.

SECTION 19.8. Severability

     In the event any one or more of the provisions contained in this Agreement should be held
invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions contained herein shall not in any way be affected or impaired thereby, unless
the absence of the invalidated provision materially and adversely affects the substantive rights of
the Parties. To the extent permitted by applicable law, each Party waives any provision of law
which renders any provision hereof invalid, illegal or unenforceable in any respect. Each
Principal acknowledges and agrees that if any provision of this Agreement shall be adjudged by any
Public Authority of competent jurisdiction to be void or unenforceable but would be valid if part
of the wording thereof were to be deleted, the said provision shall apply within the jurisdiction
of that court or competent authority with such modifications as are necessary to make it valid and
effective.

SECTION 19.9. Counterparts

     This Agreement may be executed in two or more counterparts, each of which shall constitute an
original but all of which when taken together shall constitute but one instrument.

SECTION 19.10. Terms Generally

     The definitions in this Agreement shall apply equally to both the singular and plural
forms of the terms defined.

     Whenever the context may require, any pronoun shall include the corresponding masculine,
feminine, neuter, singular and plural forms.

260

 

     The words “include”, “includes” and “including” shall be deemed to be followed by the phrase
“without limitation”.

     The terms “hereof”, “herein” and words of similar import shall be deemed to refer to this
Agreement as a whole and not to any particular provision, paragraph, Section or Article hereof.

     All references herein to Articles, Sections, Exhibits and Schedules shall be deemed references
to Articles and Sections of, and Exhibits and Schedules to, this Agreement unless the context
requires otherwise.

     All Exhibits and Schedules referred to herein (whether appended hereto at the time of
execution hereof or delivered subsequently to such execution pursuant to the terms hereof) form an
integral part of this Agreement and are deemed incorporated herein and shall be included in any
reference to “this Agreement”, “hereof”, “herein” and words of similar import, and such Exhibits
and Schedules referred to in any Article or Section form an integral part of such Article or
Section and are deemed incorporated therein and shall be included in any reference to such Article
or Section as if set out therein in full.

     A reference in any representation or warranty to any Law includes any amendment, modification
or successor thereto enacted or promulgated prior to the Closing Date; all other references to Laws
include amendments, modifications or successors to such Laws enacted or promulgated at any time.

     A reference to any person includes its permitted successors and permitted assigns.

     Except as otherwise expressly provided herein, all references herein to $ or dollars shall be
deemed to refer to U.S. dollars and all terms of an accounting or financial nature relating to the
Merial Venture shall be construed in accordance with U.S. GAAP, as in effect from time to time.
All references herein to FF are to French francs.

SECTION 19.11. Headings

261

 

     Article and Section headings and the Table of Contents used herein are for convenience of
reference only, are not part of this Agreement and are not to affect the construction of, or to be
taken into consideration in interpreting, this Agreement.

SECTION 19.12. Entire Agreement

     This Agreement, the Association Documents, the LLC Agreement and the Ancillary Agreements set
forth the entire agreement and understanding between the Parties as to the subject matter hereof
and merge, cancel and supersede all prior memoranda of intent, memoranda of terms, and other
documents heretofore executed by or exchanged, circulated or discussed between the Parties with
respect to the subject matter hereof unless any such other written agreement by its terms
specifically overrides this Section 19.12. None of the Parties shall be bound by any conditions,
definitions, warranties, understandings, representations, covenants or agreements with respect to
such subject matter other than as expressly provided in this Agreement, the Association Documents,
the LLC Agreement and the Ancillary Agreements or as fully set forth in a written instrument dated
after the date hereof signed by a representative of the Party to be bound thereby.

     It is further agreed that:

          (a) no Party has entered into this Agreement in reliance upon any representation,
warranty or undertaking of any other Party or its Affiliates or representatives which is not
expressly set out or referred to in this Agreement, the Articles of Association, the LLC
Agreement or the Ancillary Agreements;

          (b) a Party may claim in contract for breach of the representations, warranties, agreements or
other undertakings under this Agreement but shall have no, and no Party shall claim in any
proceeding that it has any, other claim or remedy under this Agreement in respect of any
misrepresentation (whether negligent or otherwise, and whether made prior to, and/or in, this
Agreement) or untrue statement made by any other Party or its Affiliates or representatives; and

262

 

          (c) this Section 19.12 shall not exclude any liability for fraudulent misrepresentation.

SECTION 19.13. Publicity

     No Party shall, without the prior written consent of the other Parties, issue any press
release or make any other public announcement or furnish any statement to any Third Party
concerning the terms and conditions of this Agreement or any Ancillary Agreement or the
Transactions, except for (i) disclosures made in compliance with Section 19.3(a) or 19.3(e), (ii)
disclosures made on a confidential basis to attorneys, consultants and accountants retained to
represent such Party in connection with the Transactions, and (iii) occasional, brief comments by
the respective officers of RP and Merck consistent with the press release issued jointly by RP and
Merck on December 19, 1996 and such other guidelines for public statements as may be mutually
agreed by RP and Merck in connection with interviews with analysts or members of the press. In
addition, after consultation with counsel, each Party in its own right may make such further
announcements and disclosure, if any, as may be required by applicable Laws, in which case the
Party making the announcement or disclosure will use its best efforts to give advance notice to,
and discuss such announcement or disclosure with, the other Parties. Once any information is
publicly disclosed in accordance with this Section 19.13, it shall no longer be considered
Confidential Information.

SECTION 19.14. No Third Party Beneficiaries

     Except as otherwise provided expressly herein or, with respect to the Ancillary Agreements,
therein, (i) nothing in this Agreement is intended to confer on any person other than the Parties
or their respective successors or permitted assigns, any rights or obligations under or by reason
of this Agreement or any Ancillary Agreements, and (ii) there are no Third Party beneficiaries to
this Agreement or any Ancillary Agreement except for the rights under Article XIV hereof of the
Merial Venture Companies and of the Subsidiaries of either Principal and of Indemnified Parties as
described therein.

263

 

SECTION 19.15. Enforcement of Judgments

     Each Party is fully cognizant, and agrees and acknowledges, that any arbitral award made pursuant to Section 18.2 may include the imposition of mandatory injunctive relief and/or an award of monetary penalties, and hereby irrevocably consents to the recognition and enforcement by any Public Authority of competent jurisdiction of any such arbitral award.

SECTION 19.16. Ancillary Agreements

     The parties hereto acknowledge that certain provisions of this Agreement are incorporated by reference in, or by their terms otherwise apply to, the Ancillary Agreements, and agree that such provisions shall be given full effect in interpreting and enforcing the Ancillary Agreements.

SECTION 19.17. References to Master Agreement

     All references in the Ancillary Agreements to the “Master Agreement” or to the “Master Merial Venture Agreement, dated as of May 23, 1997” (or similar terminology) shall be deemed to refer to this Agreement (as it may be amended from time to time).

264

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their
respective authorized officers as of the day and year first above written.

[Signatures omitted]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]